0000012208-20-000012.txt : 20200302 0000012208-20-000012.hdr.sgml : 20200302 20200302075345 ACCESSION NUMBER: 0000012208-20-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-RAD LABORATORIES, INC. CENTRAL INDEX KEY: 0000012208 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 941381833 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07928 FILM NUMBER: 20674243 BUSINESS ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 BUSINESS PHONE: 5107247000 MAIL ADDRESS: STREET 1: 1000 ALFRED NOBEL DRIVE CITY: HERCULES STATE: CA ZIP: 94547 FORMER COMPANY: FORMER CONFORMED NAME: BIO RAD LABORATORIES INC DATE OF NAME CHANGE: 19920703 10-K 1 a10k123119.htm 10-K 12.31.19 Document
false--12-31FY2019000001220826713000202050000.00010.00010.00010.000180000000200000008000000020000000248842655096421249660355089532247047725095504248358045089532.101P6YP3YP8YP9YP7YP0YP3YP5YP6YP8YP8YP6YP0YP8Y00.00010.0001750000075000000000P12YP3Y56000000000P5YP5Y001794939171302310 0000012208 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassBMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2020-02-24 0000012208 us-gaap:CommonClassBMember 2020-02-24 0000012208 us-gaap:CommonClassBMember 2019-06-30 0000012208 us-gaap:CommonClassAMember 2019-06-30 0000012208 2019-12-31 0000012208 2018-12-31 0000012208 us-gaap:CommonClassBMember 2019-12-31 0000012208 us-gaap:CommonClassAMember 2018-12-31 0000012208 us-gaap:CommonClassAMember 2019-12-31 0000012208 us-gaap:CommonClassBMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2018-12-31 0000012208 bio:TreasuryClassBMember 2019-12-31 0000012208 bio:TreasuryClassBMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2019-12-31 0000012208 2017-01-01 2017-12-31 0000012208 2018-01-01 2018-12-31 0000012208 2016-12-31 0000012208 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2019-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000012208 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:CommonStockMember 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2019-12-31 0000012208 us-gaap:TreasuryStockMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000012208 2018-01-01 0000012208 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2019-12-31 0000012208 srt:MinimumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000012208 naics:ZZ541714 2019-12-31 0000012208 srt:MinimumMember bio:ReagentRentalEquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember bio:ReagentRentalEquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000012208 2019-01-01 2019-03-31 0000012208 2019-03-04 0000012208 2019-10-01 2019-12-31 0000012208 2019-10-01 0000012208 2019-07-01 2019-09-30 0000012208 2019-08-02 0000012208 2018-10-01 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2019-01-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2019-01-01 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-07-01 2019-09-30 0000012208 bio:DistributorMember 2019-10-01 2019-12-31 0000012208 bio:DistributorMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-12-31 0000012208 bio:DistributorMember 2019-01-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-01-01 2019-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:LifeScienceMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:LifeScienceMember 2019-12-31 0000012208 us-gaap:LicensingAgreementsMember 2019-12-31 0000012208 us-gaap:TradeNamesMember 2019-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2019-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000012208 bio:KnowHowMember 2019-12-31 0000012208 bio:CellsorterMember us-gaap:DevelopedTechnologyRightsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:DiaMedMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-08-02 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-08-02 0000012208 bio:CellsorterMember us-gaap:NoncompeteAgreementsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 us-gaap:TradeNamesMember 2019-08-02 0000012208 bio:BiotestAGMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-08-02 0000012208 bio:PasteurSanofiDiagnosicsS.A.Member bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 bio:KnowHowMember 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000012208 us-gaap:TradeNamesMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000012208 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 bio:KnowHowMember 2019-01-01 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2019-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2019-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2019-04-30 0000012208 us-gaap:LineOfCreditMember 2019-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2019-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0000012208 us-gaap:ForeignCountryMember 2019-12-31 0000012208 bio:NetofprepaidtaxesMember 2019-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2019-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2018-01-01 2018-12-31 0000012208 bio:TaxCutsandJobsActMember 2019-01-01 2019-12-31 0000012208 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 bio:TaxCutsandJobsActMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2019-01-01 2019-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 bio:OperatingleaseobligationsMember 2018-12-31 0000012208 bio:OperatingleaseassetsMember 2018-12-31 0000012208 bio:OperatingleaseassetsMember 2019-12-31 0000012208 bio:OperatingleaseobligationsMember 2019-12-31 0000012208 2018-11-30 0000012208 2018-11-01 2018-11-30 0000012208 2019-06-30 0000012208 2019-11-30 0000012208 2019-08-31 0000012208 2019-05-31 0000012208 2019-06-01 2019-06-30 0000012208 2019-08-01 2019-08-31 0000012208 2019-05-01 2019-05-31 0000012208 2019-11-01 2019-11-30 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassAMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:ParentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000012208 us-gaap:ParentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:ParentMember 2019-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2019-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2019-01-01 2019-12-31 0000012208 country:US 2019-12-31 0000012208 2019-02-26 2019-02-26 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2019-12-31 0000012208 srt:EuropeMember 2018-01-01 2018-12-31 0000012208 srt:EuropeMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 srt:AmericasMember 2019-01-01 2019-12-31 0000012208 srt:AmericasMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2019-01-01 2019-12-31 0000012208 srt:EuropeMember 2019-01-01 2019-12-31 0000012208 srt:AsiaPacificMember 2019-01-01 2019-12-31 0000012208 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000012208 country:US 2018-01-01 2018-12-31 0000012208 srt:AmericasMember 2017-01-01 2017-12-31 0000012208 srt:EuropeMember 2018-12-31 0000012208 srt:AmericasMember 2018-12-31 0000012208 srt:AmericasMember 2019-12-31 0000012208 country:US 2019-12-31 0000012208 srt:AsiaPacificMember 2018-12-31 0000012208 srt:EuropeMember 2019-12-31 0000012208 country:US 2018-12-31 0000012208 srt:AsiaPacificMember 2019-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2019-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2018-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:FacilityClosingMember 2018-12-01 2019-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2019-01-01 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2018-06-01 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember 2019-01-01 2019-12-31 0000012208 bio:FinanceLeaseMember 2019-12-31 0000012208 2019-04-01 2019-06-30 0000012208 2018-01-01 2018-03-31 0000012208 2018-04-01 2018-06-30 0000012208 2018-07-01 2018-09-30 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM
10-K
(Mark One)
 
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the year ended
December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from ___________________________ to _________________________________
 
Commission file number
1-7928
 
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
94-1381833
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
1000 Alfred Nobel Drive,
Hercules,
California
 
94547
(Address of principal executive offices)
 
(Zip Code)
 
 
Registrant's telephone number, including area code
(510)
724-7000 
Securities registered pursuant to Section 12(b) of the Act:
 
 
 
Title of Each Class
Trading Symbols
Name of Each Exchange on Which Registered
Class A Common Stock Par Value $0.0001 per share
BIO
New York Stock Exchange
Class B Common Stock Par Value $0.0001 per share
BIOb
New York Stock Exchange
 
Securities registered pursuant to Section 12(g) of the Act:  NONE
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
☐
Yes
 ☒
No
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
☐
Yes
☒
No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
☒
Yes
¨ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 
☒
Yes
¨ No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
 
 
 
 
 
Large accelerated filer
☒
 
 
Accelerated filer
☐
Non-accelerated file
☐
 
 
Smaller reporting company
☐
 
 
 
 
Emerging growth company
☐
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
☐
Yes
☒   No
As of June 30, 2019, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the Registrant's Class A Common Stock held by non-affiliates was approximately $6,613,310,960 and the aggregate market value of the registrant's Class B Common Stock held by non-affiliates was approximately $67,954,565.

As of February 24, 2020, there were 24,839,715 shares of Class A Common Stock and 5,085,621 shares of Class B Common Stock outstanding.
Documents Incorporated by Reference
 
 
 
Document
 
 
Form 10-K Parts 
(1)
Definitive Proxy Statement to be mailed to stockholders in connection with the
 
 
 
 
 
 
 
 
 
 
 
registrant's 2020 Annual Meeting of Stockholders (specified portions)
 
 
 III





BIO-RAD LABORATORIES, INC.

FORM 10-K DECEMBER 31, 2019

TABLE OF CONTENTS



2


INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

Other than statements of historical fact, statements made in this Annual Report include forward-looking statements, such as statements with respect to our future financial performance, operating results, plans and objectives that involve risk and uncertainties.  Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions.  Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements.  We have based these forward-looking statements on our current expectations and projections about future events.  However, actual results may differ materially from those currently anticipated depending on a variety of risk factors including but not limited to those identified under “Item 1A, Risk Factors” of this Annual Report. We caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

PART I.

ITEM 1.  BUSINESS

General

Founded in 1952 and incorporated in 1957, Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” and “our”) was initially engaged in the development and production of specialty chemicals used in biochemical, pharmaceutical and other life science research applications.  We entered the field of clinical diagnostics with the development of our first test kit based on separation techniques and materials developed for life science research.  Through internal research and development efforts and acquisitions we have expanded into various markets.  Today, Bio-Rad manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

As we broadened our product lines, we also expanded our geographical market.  We have direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts are supplemented by distributors and agents.

Description of Business

Business Segments

Today, Bio-Rad operates in two industry segments designated as Life Science and Clinical Diagnostics.  Both segments operate worldwide.  Our Life Science segment and our Clinical Diagnostics segment generated 38% and 61%, respectively, of our net sales for the year ended December 31, 2019. We generated approximately 39% of our consolidated net sales for the year ended December 31, 2019 from U.S. sales and approximately 61% from sales in our remaining worldwide markets.

For a description of business and financial information on industry and geographic segments, see Note 14 of Item 8 of Part II of this report.

3



Life Science Segment

Our Life Science segment is at the forefront of discovery, creating advanced tools to answer complex biological questions.  We are a leader in the life sciences market and develop, manufacture and market approximately 6,000 reagents, apparatus and laboratory instruments that serve a global customer base. Many of our products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting.  We focus on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cellular biology and food safety.  We estimate that the worldwide market that our portfolios can address for products in these selected segments of our addressable markets is approximately $9 billion. Our principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories.

Clinical Diagnostics Segment

Our Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.  Our products currently address specific niches within the in vitro diagnostics (IVD) test market, and we seek to focus on the higher margin, higher growth segments of this market.

We supply more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. We estimate that the worldwide sales for products in the markets we serve were approximately $12 billion. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. Our products consist of reagents, instruments and software, typically provided to our customers as an integrated package to allow them to generate reproducible test results. Revenue in this business is highly recurring, as laboratories typically standardize test methodologies, which are dependent on a particular supplier’s equipment, reagents and consumable products. An installed base of diagnostic test systems therefore typically creates an ongoing source of revenue through the sale of test kits for each sample analyzed on an installed system.  Our principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories.

Raw Materials and Components

We utilize a wide variety of chemicals, biological materials, electronic components, machined metal parts, optical parts, computing and peripheral devices.  Most of these materials and components are available from numerous sources, and generally we have not experienced difficulty in securing adequate supplies. However, in certain instances we acquire components and materials from a sole supplier. Due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials.

Patents, Trademarks and Licenses

We own over 2,000 U.S. and international patents and numerous trademarks.  We also hold licenses under U.S. and foreign patents owned by third parties and pay royalties on the sales of certain products under the licenses.  We view these patents, trademarks and license agreements as valuable assets; however, we believe that our ability to develop and manufacture our products depends primarily on our knowledge, technology and special skills rather than our patent, trademark and licensing positions.

4



Seasonal Operations and Backlog

Our business is not inherently seasonal.  However, the European custom of concentrating vacation during the summer months usually tempers third quarter sales volume and operating income.

For the most part, we operate in markets characterized by short lead times and the absence of significant backlogs. Management has concluded that backlog information is not material to our business as a whole.

Sales and Marketing

We conduct our worldwide operations through an extensive direct sales force, employing approximately 920 direct sales and sales management personnel around the world. Our sales force typically consists of experienced industry professionals with scientific training, and we maintain a separate specialist sales force for each of our segments. We believe that this direct sales approach allows us to sell a broader range of our products that creates more brand awareness and long-term relationships with our customers.

We also use a range of sales and marketing intermediaries (SMIs) in our international markets. The types of SMIs we utilize are distributors, agents, brokers and resellers. We have programs and policies in place with our SMIs that require compliance with all applicable laws, including adhering to our anti-corruption standards to ensure a transparent sale to our customers.

Our customer base is broad and diversified. Our worldwide customer base includes (1) prominent university and research institutions; (2) hospital, public health and commercial laboratories; (3) other leading diagnostic manufacturers; and (4) leading companies in the biotechnology, pharmaceutical, chemical and food industries. There has been no single customer that accounted for more than three percent of our total net sales.  Our sales are affected by a number of external factors.  For example, a number of our customers, particularly in the Life Science segment, are substantially dependent on government grants and research contracts for their funding.  

Most of our international sales are generated by our wholly-owned international subsidiaries and their branch offices.  Certain of these subsidiaries also have manufacturing facilities.  Bio-Rad’s international operations are subject to certain risks common to foreign operations in general, such as changes in governmental regulations, import restrictions and foreign exchange fluctuations.  

Competition

The markets served by our product groups are highly competitive.  Our competitors range in size from start-ups to large multinational corporations with significant resources and reach.  We seek to compete primarily in market segments where our products and technology offer customers specific advantages over the competition.

Because of the breadth of its product lines, our Life Science segment does not face the same competitors for all of its products.  Major competitors in this market include Becton Dickinson, GE Biosciences, Merck Millipore and Thermo Fisher Scientific. We compete primarily based on meeting performance specifications and offering complete solutions.
Major competitors of our Clinical Diagnostics segment include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMérieux, Ortho Clinical Diagnostics, Tosoh, Immucor and DiaSorin. We compete in our customer segments by providing high quality products, broad product portfolios and outstanding customer support.

5


Research and Development
We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff. Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future. Our research teams are continuously developing new products and new applications for existing products. In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.

Regulatory Matters

The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of our products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration (FDA) and in other jurisdictions by state and foreign government authorities.  FDA regulations require that some new products have pre-marketing clearance or approval by the FDA and require certain products to be manufactured in accordance with FDA’s “good manufacturing practice” regulations, to be extensively tested and to be properly labeled to disclose test results and performance claims and limitations. After a product that is subject to FDA regulation is placed on the market, numerous regulatory requirements apply, including, for example, the requirement that we comply with recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA enforces these requirements by inspection and market surveillance. The FDA has authority to take various administrative and legal actions against us for our, or our products’, failure to comply with relevant legal or regulatory requirements, including issuing warning letters, initiating product seizures, requesting or requiring product recalls or withdrawals, and other civil or criminal sanctions, among other things.

We are also subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and imprisonment.

Sales of our products will depend, in part, on the extent to which our products or diagnostic tests using our products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for certain medical products and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls and restrictions on reimbursement. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our products or diagnostic tests using our products, or a decision by a third-party payor to not cover our products could reduce or eliminate utilization of our products and have a material adverse effect on our sales, results of operations and financial condition. In addition, healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures.

As a multinational manufacturer and distributor of sophisticated instrumentation, we must meet a wide array of electromagnetic compatibility and safety compliance requirements to satisfy regulations in the United States, the European Union and other jurisdictions.  

6



Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liabilities and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations could also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties.

These regulatory requirements vary widely among countries.

Employees

At December 31, 2019, Bio-Rad had approximately 8,120 employees.  Approximately seven percent of our approximately 3,180 U.S. employees are covered by a collective bargaining agreement, which will expire on November 14, 2023.  Many of our non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.  We consider our employee relations to be generally good.

Available Information

Bio-Rad files annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended.  The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Bio-Rad, that file electronically with the SEC.  The public can obtain any documents that we file with the SEC at http://www.sec.gov.

Bio-Rad’s website address is www.bio-rad.com.  We make available, free of charge through our website, our Form 10-Ks, 10-Qs and 8-Ks, and any amendments to these forms, as soon as reasonably practicable after filing with the SEC. The information on our website is not part of this Annual Report on Form 10-K.



ITEM 1A. RISK FACTORS

In evaluating our business and whether to invest in any of our securities, you should carefully read the following risk factors in addition to the other information contained in this Annual Report.  We believe that any of the following risks could have a material effect on our business, results of operations or financial condition, our industry or the trading price of our common stock.  We operate in a continually changing business environment, and new risks and uncertainties emerge from time to time. We cannot predict these new risks and uncertainties, nor can we assess the extent to which any such new risks and uncertainties or the extent to which the risks and uncertainties set forth below may adversely affect our business, results of operations, financial condition, our industry or the trading price of our common stock.

7



Our international operations expose us to additional costs and legal and regulatory risks, which could have a material adverse effect on our business, results of operations and financial condition.

We have significant international operations. We have direct distribution channels in over 35 countries outside the United States, and in 2019 our foreign entities generated 61% of our net sales. Compliance with complex foreign and U.S. laws and regulations that apply to our international operations increases our cost of doing business. These numerous and sometimes conflicting laws and regulations include, among others, data privacy requirements (including the requirements for compliance with the EU General Data Protection Regulation, which went into effect May 25, 2018), labor relations laws, tax laws, anti-competition regulations, import and trade restrictions, tariffs, duties, quotas and other trade barriers, export requirements, U.S. laws such as the Foreign Corrupt Practices Act and other U.S. federal laws and regulations established by the office of Foreign Asset Control, foreign laws such as the UK Bribery Act 2010 or other foreign laws which prohibit corrupt payments to governmental officials or certain payments or remunerations to customers. In addition, changes in laws or regulations potentially could be disruptive to our operations and business relationships in the affected regions. For example, the United Kingdom's withdrawal from the European Union (commonly referred to as “Brexit”) could disrupt the free movement of goods, services and people between the United Kingdom and the European Union and result in increased regulatory, legal, labor and tax complexities.

Given the high level of complexity of the foreign and U.S. laws and regulations that apply to our international operations, there is a risk that we may inadvertently breach some provisions, for example, through fraudulent or negligent behavior of individual employees, our failure to comply with certain formal documentation requirements, or otherwise. Our success depends, in part, on our ability to anticipate these risks and manage these challenges through policies, procedures and internal controls. However, we have a dispersed international sales organization, and we use distributors and agents in many of our international operations. This structure makes it more difficult for us to ensure that our international selling operations comply with laws and regulations, and our global policies and procedures.

Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Violations of laws and regulations also could result in prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, or our business, results of operations and financial condition. See also our risk factors regarding government regulations and regarding global economic conditions below.

The industries and market segments in which we operate are highly competitive, and we may not be able to compete effectively.

The life science and clinical diagnostics markets are each highly competitive. Some of our competitors have merged, and some of our competitors have greater financial resources than we do, making them better equipped to license technologies and intellectual property from third parties or to fund research and development, manufacturing and marketing efforts. Moreover, competitive and regulatory conditions in many markets in which we operate restrict our ability to fully recover, through price increases, higher costs of acquired goods and services resulting from inflation and other drivers of cost increases. Many public tenders have become more competitive due to governments lengthening the commitments of their public tenders to multiple years, which reduce the number of tenders in which we can participate annually. Because the value of these multiple-year tenders is so high, our competitors have been more aggressive with their pricing. Our failure to compete effectively and/or pricing pressures resulting from competition could adversely affect our business, results of operations and financial condition.

8



We may not be able to grow our business because of our failure to develop new or improved products.

Our future growth depends in part on our ability to continue to improve our product offerings and develop and introduce new product lines and extensions that integrate technological advances. In particular, we may not be able to keep up with changes in the clinical diagnostics industry, such as the trend toward molecular diagnostics or point-of-care tests. If we are unable to integrate technological advances into our product offerings or to design, develop, manufacture and market new product lines and extensions successfully and in a timely manner, our business, results of operations and financial condition will be adversely affected. We have experienced product launch delays in the past, and may do so in the future. We cannot assure you that our product and process development efforts will be successful or that new products we introduce will achieve market acceptance. Failure to launch successful new products or improvements to existing products may cause our products to become obsolete, which could harm our business, results of operations and financial condition.

Breaches of our information systems could have a material adverse effect on our business and results of operations.

We have experienced and expect to continue to experience attempts by computer programmers and hackers to attack and penetrate our layered security controls, like the December 2019 Cyberattack that is further discussed in Item 7 of this Annual Report. Through our sales and eCommerce channels, we collect and store confidential information that customers provide to, among other things, purchase products or services, enroll in promotional programs and register on our web site. We also acquire and retain information about suppliers and employees in the normal course of business. Such information on our systems includes personally identifiable information and, in limited instances, protected health information. We also create and maintain proprietary information that is critical to our business, such as our product designs and manufacturing processes. Despite recent initiatives to improve our technology systems, such as our enterprise resource planning implementation and the centralization of our global information technology organization, we could experience a significant data security breach. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and often are not recognized until launched against a target, we may not be able to anticipate all of these techniques or to implement adequate preventive measures. Computer hackers have attempted to penetrate and will likely continue to attempt to penetrate our and our vendors’ information systems and, if successful, could misappropriate confidential customer, supplier, employee or other business information, such as our intellectual property. Third parties could also gain control of our systems and use them for criminal purposes while appearing to be us. As a result, we could lose existing customers, have difficulty attracting new customers, be exposed to claims from customers, financial institutions, payment card associations, employees and other persons, have regulatory sanctions or penalties imposed, incur additional expenses or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Our operations and ability to process sales orders, particularly through our eCommerce channels, could also be disrupted, as they were in the December 2019 Cyberattack. Any significant breakdown, intrusion, interruption, corruption, or destruction of our systems, as well as any data breaches, could have a material adverse effect on our business and results of operations. See also our risk factors regarding our information technology systems and our enterprise resource planning system (ERP) implementation below.

If our information technology systems are disrupted, or if we fail to successfully implement, manage and integrate our information technology and reporting systems, our business, results of operations and financial condition could be harmed.

Our information technology (IT) systems are an integral part of our business, and a serious disruption of our IT systems could have a material adverse effect on our business, results of operations and financial condition. We depend on our IT systems to process orders, manage inventory and collect accounts receivable.  Our IT systems also allow us to efficiently purchase products from our suppliers and ship products to our customers on a timely basis, maintain cost-effective operations and provide customer service.  We may experience disruption of our IT systems due to redundancy issues with our network servers. We cannot assure you that our contingency plans will allow us to operate at our current level of efficiency.


9


Our ability to implement our business plan in a rapidly evolving market requires effective planning, reporting and analytical processes.  We expect that we will need to continue to improve and further integrate our IT systems, reporting systems and operating procedures by training and educating our employees with respect to these improvements and integrations on an ongoing basis in order to effectively run our business.  We may suffer interruptions in service, loss of data or reduced functionality when we upgrade or change systems. If we fail to successfully manage and integrate our IT systems, reporting systems and operating procedures, it could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our data security above and ERP implementation and events beyond our control below.

We are subject to foreign currency exchange fluctuations, which could have a material adverse effect on our results of operations and financial condition.

As stated above, a significant portion of our operations and sales are outside of the United States. When we make purchases and sales in currencies other than the U.S. dollars, we are exposed to fluctuations in foreign currencies relative to the U.S. dollar that may adversely affect our results of operations and financial condition. Our international sales are largely denominated in local currencies. As a result, the strengthening of the U.S. dollar negatively impacts our consolidated net sales expressed in U.S. dollars. Conversely, when the U.S. dollar weakens, our expenses at our international sites increase. In addition, the volatility of other currencies may negatively impact our operations outside of the United States and increase our costs to hedge against currency fluctuations. We cannot assure you that future shifts in currency exchange rates will not have a material adverse effect on our results of operations and financial condition.

Our reported financial results may be materially affected by changes in the market value of our investment in Sartorius AG.
Changes in the market value of our investment in Sartorius AG may continue to materially impact our Consolidated Statements of Income and other financial statements. A decline in the market value of our investment in Sartorius AG could result in significant losses due to write-downs in the value of the equity securities. An increase in the market value of our investment in Sartorius AG could result in a significant and favorable impact to net income independent of the actual operating performance of our business. For example, our net income for 2019 was significantly and favorably impacted by recognition, on the income statement, of an increase in the fair market value of equity securities of $2,031.0 million, primarily related to the holdings of our investment in Sartorius AG. Net income for 2018 was also significantly and favorably impacted by recognition, on the income statement, of an increase in the fair market value of equity securities of $606.2 million, primarily related to the holdings of our investment in Sartorius AG.

Our share price may change significantly based upon changes in the market valuation of Sartorius AG, and such change may be unrelated to the actual performance of our business. Non-operating income for a period may be significantly impacted by the timing of dividends paid by Sartorius AG, particularly in comparison to prior year periods.

We may incur losses in future periods due to write-downs in the value of financial instruments.
We have positions in a variety of financial instruments including asset backed securities and other similar instruments. Financial markets are volatile and the markets for these securities can be illiquid.  The value of these securities will continue to be impacted by external market factors including default rates, changes in the value of the underlying property, such as residential or commercial real estate, rating agency actions, the prices at which observable market transactions occur and the financial strength of various entities, such as financial guarantors who provide insurance for the securities. Should we need to convert these positions to cash, we may not be able to sell these instruments without significant losses due to current debtor financial conditions or other market considerations.

10



We also have positions in equity securities, including our investment in Sartorius AG. Financial markets are volatile and the markets for these equity securities can be illiquid as well. A decline in the market value of our investments in equity securities that we own could result in significant losses due to write-downs in the value of the equity securities. In addition, if we need to convert these positions to cash, we may not be able to sell these equity securities without significant losses.

We may experience difficulties implementing our new global enterprise resource planning system.

We are engaged in a multi-year implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. For example, we experienced system implementation issues in our Clinical Diagnostics segment during our first deployment that impacted invoicing and caused an increase in accounts receivable. In our second deployment, we experienced delays in manufacturing and logistics, which adversely impacted our sales. In our third deployment in Western Europe in April 2017, we experienced system implementation issues impacting the timing of payment of vendor invoices and resulting in delays in product availability and shipments. We also experienced lower productivity levels related to the April 2017 go-live of the ERP in Western Europe, which adversely impacted our sales during the second and third quarters of 2017. We expect to implement the remaining smaller phases of the ERP platform over the next few years. In addition, our efforts to centralize various business processes and functions within our organization in connection with our ERP implementation may continue to disrupt our operations and negatively impact our business, results of operations and financial condition.

Recent and planned changes to our organizational structure and executive management team could negatively impact our business.

We made significant changes to our organizational structure over the past few years. In 2016, we began implementing the reorganization of the structure of our European organization, and we have continued implementing this reorganization in 2017, 2018 and 2019. The Board of Directors appointed a new Chief Financial Officer effective April 6, 2019 and a new Chief Operating Officer effective April 22, 2019. At the beginning of 2020, we appointed a new executive to head our Clinical Diagnostics segment, and we restructured this segment based on functional groups rather than product line divisions. These changes may have unintended consequences, such as distraction of our management and employees, business disruption, attrition of our workforce, inability to attract or retain key employees, and reduced employee morale or productivity.

Violations of the U.S. Foreign Corrupt Practices Act or similar anti-corruption laws could have a material adverse effect on our business, results of operations and financial condition.

As further discussed above in our risk factor concerning our international operations, we have significant international operations which expose us to additional costs and legal and regulatory risks, including the risk of violating anti-corruption laws such as the U.S. Foreign Corrupt Practices Act (FCPA) or similar anti-corruption laws. As previously disclosed, we entered into a non-prosecution agreement (NPA) with the U.S. Department of Justice (DOJ) and the Securities and Exchange Commission (SEC) and consented to the entry of an Order by the SEC (SEC Order), effective November 3, 2014, which actions resolved both the DOJ and the SEC investigations into our violations of the FCPA. Any future violations of the FCPA could result in more punitive actions by the SEC and DOJ and/or could harm our reputation with customers, either of which could materially adversely affect our business, results of operations and financial condition.


11


Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline.

Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements.  

As previously discussed in Item 9A "Controls and Procedures" of our Annual Report for the period ended December 31, 2017, and Item 4 "Controls and Procedures" of our 2018 Form 10-Qs, management identified a material weakness in our internal control over financial reporting. During the fourth quarter of 2017 and throughout 2018, management conducted an extensive remediation plan to address its material weakness, and management concluded that the material weakness had been remediated as of December 31, 2018. However, we cannot assure you that additional deficiencies or material weaknesses in our internal control over financial reporting will not be identified in the future.

Material weaknesses have adversely affected us in the past and could affect us in the future, and the results of our periodic management evaluations and annual auditor attestation reports regarding the effectiveness of our internal control over financial reporting required by Section 404 of the Sarbanes-Oxley Act of 2002.  Any failure to maintain or implement new or improved internal controls, or any difficulties that we may encounter in their maintenance or implementation, could result in additional significant deficiencies or material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations.  This could cause us to lose public confidence, and could cause the trading price of our common stock to decline.  For further information regarding our controls and procedures, see Part II, Item 9A of this Annual Report on Form 10-K.

Risks relating to intellectual property rights may negatively impact our business.

We rely on a combination of copyright, trade secret, patent and trademark laws and third-party nondisclosure agreements to protect our intellectual property rights and products. However, we cannot assure you that our intellectual property rights will not be challenged, invalidated, circumvented or rendered unenforceable, or that meaningful protection or adequate remedies will be available to us. For instance, unauthorized third parties have attempted to copy our intellectual property, reverse engineer or obtain and use information that we regard as proprietary, or have developed equivalent technologies independently, and may do so in the future. Additionally, third parties have asserted patent, copyright and other intellectual property rights to technologies that are important to us, and may do so in the future. If we are unable to license or otherwise access protected technology used in our products, or if we lose our rights under any existing licenses, we could be prohibited from manufacturing and marketing such products. From time to time, we also must enforce our patents or other intellectual property rights or defend ourselves against claimed infringement of the rights of others through litigation. As a result, we could incur substantial costs, be forced to redesign our products, or be required to pay damages or royalties to an infringed party. Any of the foregoing matters could adversely impact our business, results of operations and financial condition.

12



Global economic and geopolitical conditions could adversely affect our operations.

In recent years, we have been faced with very challenging global economic conditions. A deterioration in the global economic environment may result in decreased demand for our products, increased competition, downward pressure on the prices for our products and longer sales cycles. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply in the future. We have also experienced delays in collecting receivables in certain countries in Western Europe, and we may experience similar delays in these and other countries or regions experiencing liquidity problems. In addition, a slowing of growth in the Chinese economy and in emerging markets, especially those oil-producing countries that would be affected by a decline in oil prices, could adversely affect our business, results of operations or financial condition. There is also uncertainty surrounding the impact that Brexit will have on European and worldwide economic conditions and the stability of global financial markets, and a negative effect from any of these things could adversely affect our business, results of operations or financial condition. Additionally, the United States and other countries, such as China and India, recently have imposed tariffs on certain goods. While tariffs imposed by other countries on U.S. goods have not yet had a significant impact on our business, further escalation of tariffs or other trade barriers could adversely impact our profitability and/or our competitiveness. In addition, the geopolitical situation in locations such as the Middle East could adversely affect our business in such locations. See also our risk factors regarding our international operations above and regarding government regulations below.

Reductions in government funding and the capital spending programs of our customers could have a material adverse effect on our business, results of operations or financial condition.

Our customers include universities, clinical diagnostics laboratories, government agencies, hospitals and pharmaceutical, biotechnology and chemical companies.  The capital spending programs of these institutions and companies have a significant effect on the demand for our products.  Such programs are based on a wide variety of factors, including the resources available to make such purchases, the availability of funding from grants by governments or government agencies, the spending priorities for various types of equipment and the policies regarding capital expenditures during industry downturns or recessionary periods.  If government funding to our customers were to decrease, or if our customers were to decrease or reallocate their budgets in a manner adverse to us, our business, results of operations or financial condition could be materially and adversely affected.

Changes in the healthcare industry could have an adverse effect on our business, results of operations and financial condition.

There have been, and will continue to be, significant changes in the healthcare industry in an effort to reduce costs. These changes include:

•
The trend towards managed care, together with healthcare reform of the delivery system in the United States and efforts to reform in Europe, has resulted in increased pressure on healthcare providers and other participants in the healthcare industry to reduce selling prices.  Consolidation among healthcare providers and consolidation among other participants in the healthcare industry has resulted in fewer, more powerful groups, whose purchasing power gives them cost containment leverage.  In particular, there has been a consolidation of laboratories and a consolidation of blood transfusion centers. These industry trends and competitive forces place constraints on the levels of overall pricing, and thus could have a material adverse effect on our gross margins for products we sell in clinical diagnostic markets.

13



•
Third party payors, such as Medicare and Medicaid in the United States, have reduced their reimbursements for certain medical products and services. Our Clinical Diagnostics business is impacted by the level of reimbursement available for clinical tests from third party payors. In the United States payment for many diagnostic tests furnished to Medicare fee-for-service beneficiaries is made based on the Medicare Clinical Laboratory Fee Schedule (CLFS), a fee schedule established and adjusted from time to time by the Centers for Medicare and Medicaid Services (CMS). Some commercial payors are guided by the CLFS in establishing their reimbursement rates. Laboratories and clinicians may decide not to order or perform certain clinical diagnostic tests if third party payments are inadequate, and we cannot predict whether third party payors will offer adequate reimbursement for tests utilizing our products to make them commercially attractive. Legislation, such as the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (PPACA) and the Middle Class Tax Relief and Job Creation Act of 2012, has reduced the payments for clinical laboratory services paid under the CLFS. In addition, the Protecting Access to Medicare Act of 2014 (PAMA) has made significant changes to the way Medicare will pay for clinical laboratory services, which has further reduced reimbursement rates.

To the extent that the healthcare industry seeks to address the need to contain costs stemming from reform measures such as those contained in the PPACA and the PAMA, or in future legislation, by limiting the number of clinical tests being performed or the amount of reimbursement available for such tests, our business, results of operations and financial condition could be adversely affected.  If these changes in the healthcare markets in the United States and Europe continue, we could be forced to alter our approach in selling, marketing, distributing and servicing our products.

We are subject to substantial government regulation, and any changes in regulation or violations of regulations by us could adversely affect our business, prospects, results of operations or financial condition.

Some of our products (primarily our Clinical Diagnostic products), production processes and marketing are subject to U.S. federal, state and local, and foreign regulation, including by the FDA in the United States and its foreign counterparts.  The FDA regulates our Clinical Diagnostic products as medical devices, and we are subject to significant regulatory clearances or approvals to market our Clinical Diagnostic products and other requirements including, for example, recordkeeping and reporting requirements, such as the FDA’s medical device reporting regulations and reporting of corrections and removals. The FDA has broad regulatory and enforcement powers. If the FDA determines that we have failed to comply with applicable regulatory requirements, it can impose a variety of enforcement actions ranging from public warning letters, fines, injunctions, consent decrees and civil penalties to suspension or delayed issuance of approvals, seizure or recall of our products, total or partial shutdown of production, withdrawal of approvals or clearances already granted, and criminal prosecution.

The FDA can also require us to repair, replace or refund the cost of devices that we manufactured or distributed.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our products or impact our ability to modify our currently approved or cleared products on a timely basis. Changes in the FDA’s review of certain clinical diagnostic products referred to as laboratory developed tests, which are tests developed by a single laboratory for use only in that laboratory, could affect some of our customers who use our Life Science instruments for laboratory developed tests. In the past, the FDA has chosen to not enforce applicable regulations and has not reviewed such tests for approval. However, the FDA has issued draft guidance that it may begin enforcing its medical device requirements, including premarket submission requirements, to such tests. Any delay in, or failure to receive or maintain, clearance or approval for our products could prevent us from generating revenue from these products and adversely affect our business operations and financial results. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products.

14



Many foreign governments have similar rules and regulations regarding the importation, registration, labeling, sale and use of our products. Such agencies may also impose new requirements that may require us to modify or re-register products already on the market or otherwise impact our ability to market our products in those countries. For example, in April 2017 the European Parliament voted to enact final regulations that include broad changes regarding in vitro diagnostic devices and medical devices, which will require us to modify or re-register some products and will result in additional costs. In addition, Russia has enacted more stringent medical product registration and labeling regulations, China has enacted stricter labeling requirements, and we expect other countries, such as Brazil and India, to impose more regulations that impact our product registrations. Brexit also will likely result in additional regulatory requirements associated with goods sold in the United Kingdom and will likely result in additional complexities and possible delays with respect to goods, raw materials and personnel moving between the United Kingdom and the European Union. In addition, new government administrations may interpret existing regulations or practices differently. For example, the Mexican health regulatory agency COFEPRIS in 2019 cited Bio-Rad’s Mexican subsidiary for operating practices that had been endorsed by a prior administration, which has impacted our ability to conduct our Clinical Diagnostics business in Mexico. Due to these evolving and diverse requirements, we face uncertain product approval timelines, additional time and effort to comply, as well as the potential for reduced sales and/or fines for noncompliance. Increasing protectionism in such countries also impedes our ability to compete with local companies. For example, we may not be able to participate in certain public tenders in Russia because of increasing measures to restrict access to such tenders for companies without local manufacturing capabilities. Such regulations could adversely affect our business, results of operations and financial condition. See also our risk factors regarding our international operations and regarding global economic and geopolitical conditions above.

We are also subject to government regulation of the use and handling of a number of materials and controlled substances.  The U.S. Drug Enforcement Administration establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements for controlled substances pursuant to the Controlled Substances Act of 1970. Failure to comply with present or future laws and regulations could result in substantial liability to us, suspension or cessation of our operations, restrictions on our ability to expand at our present locations or require us to make significant capital expenditures or incur other significant expenses.

We cannot assure you that we will be able to integrate acquired companies, products or technologies into our company successfully, or we may not be able to realize the anticipated benefits from the acquisitions.

As part of our overall business strategy, we pursue acquisitions of and investments in complementary companies, products and technologies. In order to be successful in these activities, we must, among other things:
•
assimilate the operations and personnel of acquired companies;
•
retain acquired business customers;
•
minimize potential disruption to our ongoing business;
•
retain key technical and management personnel;
•
integrate acquired companies into our strategic and financial plans;
•
accurately assess the value of target companies, products and technologies;
•
comply with new regulatory requirements;
•
harmonize standards, controls, procedures and policies;
•
minimize the impact to our relationships with our employees and customers; and
•
assess, document and remediate any deficiencies in disclosure controls and procedures and internal control over financial reporting.

The benefits of any acquisition may prove to be less than anticipated and may not outweigh the costs reported in our financial statements.  Completing any potential future acquisitions could cause significant diversion of our management’s time and resources.  If we acquire new companies, products or technologies, we may be required to assume contingent liabilities or record impairment charges for goodwill and other intangible assets over time. Goodwill and non-amortizable intangible assets are subject to impairment testing, and potential periodic goodwill impairment charges, amortization expenses related to certain intangible assets, and other write-offs could harm our

15


operating results. Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. If the results forecast in our impairment tests are not achieved, or business trends vary from the assumptions used in forecasts, or external factors change detrimentally, future impairment losses may occur. For example, as we previously discussed in Item 7 of our Annual Report for the period ended December 31, 2017, one reporting unit, whose goodwill was primarily from the acquisitions of Biotest AG and DiaMed Holding AG, had excess fair value over book value of only 8% at December 31, 2017. The goodwill allocated to this reporting unit as of December 31, 2017 was $263.6 million. We impaired all the goodwill related to this reporting unit for the year ended December 31, 2018 because assumptions utilized in our 2017 forecast did not materialize.

We cannot assure you that we will successfully overcome these risks or any other problems we encounter in connection with any acquisitions, and any such acquisitions could adversely affect our business, results of operations and financial condition.

Product quality and liability issues could harm our reputation and negatively impact our business, results of operations and financial condition.

We must adequately address quality issues associated with our products, including defects in our engineering, design and manufacturing processes, as well as defects in third-party components included in our products. Our instruments, reagents and consumables are complex, and identifying the root cause of quality issues, especially those affecting reagents or third-party components, is difficult. We may incur significant costs and expend substantial time in researching and remediating such issues. Quality issues could also delay our launching or manufacturing of new products. In addition, quality issues, unapproved uses of our products, or inadequate disclosure of risks related to our products, could result in product recalls or product liability or other claims being brought against us. These issues could harm our reputation, impair our relationship with existing customers and harm our ability to attract new customers, which could negatively impact our business, results of operations and financial condition.

Lack of key personnel could hurt our business.

Our products are very technical in nature. In general, only highly qualified and well-trained scientists have the necessary skills to develop, market and sell our products, and many of our manufacturing positions require very specialized knowledge and skills.  In addition, the global nature of our business also requires that we have sophisticated and experienced staff to comply with increasingly complex international laws and regulations. We face intense competition for these professionals from our competitors, customers, marketing partners and other companies throughout our industry. In particular, the job market in Northern California, where many of our employees are located, is very competitive. If we do not offer competitive compensation and benefits, we may fail to retain or attract a sufficient number of qualified personnel, which could impair our ability to properly run our business.

In some cases we rely on temporary personnel or consultants, and we may do so in the future. Such temporary personnel or consultants may lack the knowledge and/or specific skills necessary for our business, require time to train without benefiting us through extended employment and increase our costs. In addition, as noted above, our strategic initiatives, such as our internal restructuring and ERP implementation, may be burdensome and disruptive and lead to employee dissatisfaction and attrition. Also, loss, including retirement, of long-term personnel may negatively impact our ability to conduct our business.

16



A reduction or interruption in the supply of components and raw materials could adversely affect our manufacturing operations and related product sales.

The manufacture of many of our products requires the timely delivery of sufficient amounts of quality components and materials. We manufacture our products in numerous manufacturing facilities around the world. We acquire our components and materials from many suppliers in various countries. We work closely with our suppliers to ensure the continuity of supply but we cannot guarantee these efforts will always be successful. Further, while we seek to diversify our sources of components and materials, in certain instances we acquire components and materials from a sole supplier. In addition, due to the regulatory environment in which we operate, we may be unable to quickly establish additional or replacement sources for some components or materials. If our supply is reduced or interrupted or of poor quality, and we are unable to develop alternative sources for such supply, our ability to manufacture our products in a timely or cost-effective manner could be adversely affected, which would adversely affect our ability to sell our products.

Natural disasters, terrorist attacks, acts of war or other events beyond our control may cause damage or disruption to us and our employees, facilities, information systems, security systems, vendors and customers, which could significantly impact our business, results of operations and financial condition.

We have significant manufacturing and distribution facilities, including in the western United States, France, Switzerland, Germany and Singapore.  In particular, the western United States has experienced a number of earthquakes, wildfires, floods, landslides and other natural disasters in recent years.  These occurrences could damage or destroy our facilities which may result in interruptions to our business and losses that exceed our insurance coverage. In addition, electricity outages, strikes or other labor unrest at any of our sites or surrounding areas could cause disruption to our business.

Acts of terrorism, bioterrorism, violence or war, or public health issues such as the outbreak of a contagious disease like the 2019-Novel Coronavirus (COVID-19) could also affect the markets in which we operate, our business operations and strategic plans. Political unrest may affect our sales in certain regions, such as in Southeast Asia, the Middle East and Eastern Europe. Any of these events could adversely affect our business, results of operations and financial condition.

We may have higher than anticipated tax liabilities.

We are subject to income taxes in the United States and many foreign jurisdictions. We report our results of operations based on our determination of the amount of taxes owed in various tax jurisdictions in which we operate. The determination of our worldwide provision for income taxes and other tax liabilities requires estimation, judgment and calculations where the ultimate tax determination may not be certain. Our determination of our tax liabilities is subject to review or examination by tax authorities in various tax jurisdictions. Tax authorities have disagreed with our judgment in the past and may disagree with positions we take in the future resulting in assessments of additional taxes. Any adverse outcome of such review or examination could have a negative impact on our operating results and financial condition.

Economic and political pressures to increase tax revenues in various jurisdictions may make resolving tax disputes more difficult. For example, in recent years, the tax authorities in Europe have disagreed with our tax positions related to hybrid debt, research and development credits, transfer pricing and indirect taxes, among others. We regularly assess the likelihood of the outcome resulting from these examinations to determine the adequacy of our provision for income taxes. Although we believe our tax estimates are reasonable, the final determination of tax audits and any related litigation could be materially different from our historical income tax provisions and accruals.

The results from various tax examinations, audits and litigation may differ from the liabilities recorded in our financial statements and could materially and adversely affect our financial results and cash flows in the periods in which those determinations are made.

17



Changes in tax laws or rates, changes in the interpretation of tax laws or changes in the jurisdictional mix of our earnings could adversely affect our financial position and results of operations.

On December 22, 2017, the U.S. enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”) which made a number of substantial changes to how the United States imposes income tax on multinational corporations. The U.S Treasury, Internal Revenue Service and other standard setting bodies continue to issue guidance and interpretation relating to the Tax Act.  As future guidance is issued, we may make adjustments to amounts previously reported that could materially impact our financial statements.

Our global operations subject us to income and other taxes in the U.S. and in numerous foreign jurisdictions, each with different tax schemes and tax rates.  In addition to the changes in tax laws and the interpretation of tax laws and tax rates in these jurisdictions, the jurisdictional mix of our earnings in countries with differing statutory tax rates can have a significant impact on our effective tax rate from period to period.

The tax effect of our investment in Sartorius AG and the jurisdictional mix of our earnings could continue to materially affect our financial results and cash flow.

In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Co-operation and Development’s project on “Base Erosion and Profit Shifting” (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate.  These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.

Our reported financial results may be materially affected by changes in accounting principles generally accepted in the United States.
Generally accepted accounting principles in the United States, or U.S. GAAP, are subject to interpretation by the Financial Accounting Standards Board, or FASB, the U.S. Securities and Exchange Commission, or SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.

For example, in January 2016, the FASB issued Accounting Standards Update No. (ASU) 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Amendments under ASU 2016-01, among other items, require that all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting), such as our investment in Sartorius AG, will be measured at fair value through earnings. The impact of adoption of ASU 2016-01 in the first quarter of 2018 materially impacted our Condensed Consolidated Statements of Income due to our investment in Sartorius AG, and this impact may continue in future periods.

Also for example, in February 2016, the FASB issued ASU 2016-02, "Leases," which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our consolidated financial statements.

18



Environmental, health and safety regulations and enforcement proceedings may negatively impact our business, results of operations and financial condition.

Our operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissions to air and discharges to water, as well as handling and disposal practices for solid, hazardous and medical wastes.  In addition to environmental laws that regulate our operations, we are also subject to environmental laws and regulations that create liability and clean-up responsibility for spills, disposals or other releases of hazardous substances into the environment as a result of our operations or otherwise impacting real property that we own or operate.  The environmental laws and regulations also subject us to claims by third parties for damages resulting from any spills, disposals or releases resulting from our operations or at any of our properties. We must also comply with various health and safety regulations in the United States and abroad in connection with our operations.

We may in the future incur capital and operating costs to comply with currently existing laws and regulations, and possible new statutory enactments, and these expenditures may be significant.  We have incurred, and may in the future incur, fines related to environmental matters and/or liability for costs or damages related to spills or other releases of hazardous substances into the environment at sites where we have operated, or at off-site locations where we have sent hazardous substances for disposal.  We cannot assure you, however, that such matters or any future obligations to comply with environmental or health and safety laws and regulations will not adversely affect our business, results of operations or financial condition.

Our debt may restrict our future operations.

We have substantial debt and have the ability to incur additional debt. As of December 31, 2019, we had approximately $439.8 million of outstanding indebtedness, primarily consisting of the 4.875% Notes due in December 2020 as further discussed in Note 5 of the Consolidated Financial Statements. In addition, we have a revolving credit facility that provides for up to $200.0 million, $0.2 million of which has been utilized for domestic standby letters of credit. Our incurrence of substantial amounts of debt may have important consequences.  For instance, it could:

•
make it more difficult for us to satisfy our financial obligations, including those relating to our outstanding debt;
•
require us to dedicate a substantial portion of our cash flow from operations to the payment of interest and principal due under our debt, which will reduce funds available for other business purposes;
•
increase our vulnerability to general adverse economic and industry conditions;
•
limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;
•
place us at a competitive disadvantage compared with some of our competitors that have less debt; and
•
limit our ability to obtain additional financing required to fund working capital and capital expenditures and for other general corporate purposes.

Our existing credit facility and the terms of our other debt instruments, including agreements we may enter in the future, contain or will contain covenants imposing significant restrictions on our business.  These restrictions may affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities as they arise.  These covenants place restrictions on our ability to, among other things: incur additional debt; acquire other businesses or assets through merger or purchase; create liens; make investments; enter into transactions with affiliates; sell assets; in the case of some of our subsidiaries, guarantee debt; and declare or pay dividends, redeem stock or make other distributions to stockholders. Our existing credit facility also requires that we comply with certain financial ratios, including a maximum consolidated leverage ratio test and a minimum consolidated interest coverage ratio test.


19


Our ability to comply with these covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions.  The breach of any of these restrictions could result in a default.  An event of default under our debt agreements would permit some of our lenders to declare all amounts borrowed from them to be due and payable, together with accrued and unpaid interest. In addition, acceleration of our other indebtedness may cause us to be unable to make interest payments on our outstanding notes and repay the principal amount of our outstanding notes or may cause the future subsidiary guarantors, if any, to be unable to make payments under the guarantees.

We are subject to healthcare laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to healthcare regulation and enforcement by both the U.S. federal government and the U.S. states and foreign governments in which we conduct our business. These healthcare laws and regulations include, for example:

•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for or to induce either the referral of an individual for, or the purchase order or recommendation of, any item or services for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs;

•
U.S. federal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the U.S. federal government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;

•
the U.S. Physician Payment Sunshine Act, which requires certain manufacturers of drugs, biologics, devices and medical supplies to record any transfers of value to U.S. physicians and U.S. teaching hospitals;

•
the Health Insurance Portability and Accountability Act ("HIPAA"), as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and

•
state or foreign law equivalents of each of the U.S. federal laws above, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers.

These laws will continue to impose administrative, cost and compliance burdens on us. The shifting compliance environment and the need to build and maintain robust systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may violate one or more of these requirements. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business, results of operations and financial condition.

20



Regulations related to “conflict minerals” could adversely impact our business.
As part of the Dodd-Frank Wall Street Reform and Consumer Protection Act, the SEC adopted disclosure requirements regarding the use of certain minerals, known as conflict minerals, which are mined from the Democratic Republic of Congo (DRC) and adjoining countries, as well as procedures regarding a manufacturer's efforts to identify the sourcing of such minerals and metals produced from those minerals. In March and April 2017, the European Parliament and the European Council formally approved a conflict minerals regulation, and the requirements will become effective starting in January 2021. We have incurred, and will continue to incur, additional costs in order to comply with the SEC’s disclosure requirements. In addition, we might incur further costs due to possible changes to our products, processes, or sources of supply as a consequence of our due diligence activities. As our supply chain is complex, we may not be able to sufficiently verify the origins of the specified minerals used in our products through our due diligence procedures, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as “DRC conflict free”, which could place us at a competitive disadvantage if we do not do so. We filed our report for the calendar year 2018 with the SEC on May 3, 2019.

Risks related to our common stock
 
A significant majority of our voting stock is held by the Schwartz family, which could lead to conflicts of interest.
We have two classes of voting stock: Class A Common Stock and Class B Common Stock. With a few exceptions, holders of Class A and Class B Common Stock vote as a single class.  When voting as a single class, each share of Class A Common Stock is entitled to one-tenth of a vote, while each share of Class B Common Stock has one vote. In the election or removal of directors, the classes vote separately and the holders of Class A Common Stock are entitled to elect 25% of the Board of Directors, with holders of Class B Common Stock electing the remaining directors.

As a result of the Schwartz family's ownership of our Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for our company.  The Schwartz family may exercise its control over us according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of our company.


ITEM 1B.  UNRESOLVED STAFF COMMENTS
None.

21




 
ITEM 2.  PROPERTIES

We own our corporate headquarters located in Hercules, California.  The principal manufacturing and research locations for each segment are as follows:

 
 
 
Segment
Location
Owned/Leased
 
 
 
Life Science
Greater San Francisco Bay Area, California
Owned/Leased
 
Singapore, Singapore
Leased
 
Oxford, England
Leased
 
 
 
Clinical
 
 
Diagnostics
Greater San Francisco Bay Area, California
Owned/Leased
 
Irvine, California
Leased
 
Greater Seattle Area, Washington
Leased
 
Lille, France
Owned
 
Greater Paris Area, France
Leased
 
Nazareth-Eke, Belgium
Leased
 
Cressier, Switzerland
Owned/Leased
 
Dreieich, Germany
Owned/Leased

Most manufacturing and research facilities also house administration, sales and distribution activities.  In addition, we lease office and warehouse facilities in a variety of locations around the world.  The facilities are used principally for sales, service, distribution and administration for both segments.

ITEM 3.  LEGAL PROCEEDINGS  

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On

22


February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24, 2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on our 2019 results of operations and is now closed.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

 
ITEM 4.  MINE SAFETY DISCLOSURES  

Not applicable.

23



PART II.


ITEM 5.   MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Information Concerning Common Stock

Bio-Rad’s Class A and Class B Common Stock are listed on the New York Stock Exchange with the ticker symbols BIO and BIOb, respectively.

On February 24, 2020, we had 209 holders of record of Class A Common Stock and 103 holders of record of Class B Common Stock.  Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. This new authorization superseded the prior authorization of up to $18.0 million of Bio-Rad's common stock and has no expiration.

The following table contains information on the shares of our common stock that we purchased or otherwise acquired during the three months ended December 31, 2019, as required by the Securities and Exchange Commission rules.
Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Maximum Number (or Approximate Dollar Value) of Shares that May yet be Purchased Under the Plans or Programs (in millions)
October 1 to October 31, 2019
—

 
$
—

—

 
$
181.1

November 1 to November 30, 2019
22,343

Class A
$
358.04

22,343

Class A
$
173.1

December 1 to December 31, 2019
—

 
$
—

—

 
$
173.1



See Item 12 of Part III of this report for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans.

24



Stock Performance Graph

The following graph compares the cumulative stockholder returns over the past five years for our Class A Common Stock, the S&P 400 MidCap Index and a selected peer group, assuming $100 invested on December 31, 2014, and reinvestment of dividends if paid:             
    
    chart-d7753823a7d35527837a01.jpg        
(1)  The Peer Group consists of the following public companies: Danaher, Becton Dickinson, Thermo Fisher Scientific, Meridian Bioscience and PerkinElmer. Companies in our peer group reflect our participation in two different markets: life science research products and clinical diagnostics. No single public or private company has a comparable mix of products which serve the same markets. In many cases, only one division of a peer-group company competes in the same market as we do. Collectively, however, our peer group reflects products and markets similar to those of Bio-Rad.

This stock performance graph shall not be deemed incorporated by reference by any general statement incorporating by reference into any filing under the Securities Act or the Exchange Act, and shall not otherwise be deemed filed under these Acts.


25



ITEM 6.  SELECTED FINANCIAL DATA

BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
Selected Financial Data
 
 
 
 
 
 
(In thousands, except per share data)
 
 
 
 
 
 
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
2016
 
2015
 
 
 
 
 
 
 
 
 
 
 
Net sales
 
$
2,311,659

 
$
2,289,415

 
$
2,160,153

 
$
2,068,172

 
$
2,019,441

Cost of goods sold
 
1,054,663

 
1,066,264

 
972,450

 
929,744

 
897,771

Gross profit
 
1,256,996

 
1,223,151

 
1,187,703

 
1,138,428

 
1,121,670

Selling, general and administrative expense
 
824,625

 
834,783

 
806,790

 
814,697

 
761,990

Research and development expense
 
202,710

 
199,196

 
250,157

 
205,708

 
192,972

Impairment losses on goodwill and long-lived assets
 
—

 
292,513

 
11,506

 
62,305

 
—

Interest expense
 
23,416

 
23,962

 
23,014

 
23,380

 
21,692

Foreign currency exchange losses, net
 
2,245

 
2,861

 
9,128

 
4,542

 
10,249

Change in fair market value of equity securities
 
(2,030,987
)
 
(606,230
)
 
—

 
—

 
—

Other (income) expense, net
 
(26,094
)
 
(36,593
)
 
(10,697
)
 
(13,764
)
 
(11,080
)
Income before income taxes
 
2,261,081

 
512,659

 
97,805

 
41,560

 
145,847

(Provision for) benefit from income taxes
 
(502,406
)
 
(147,045
)
 
24,444

 
(15,560
)
 
(36,608
)
Net income
 
$
1,758,675

 
$
365,614

 
$
122,249

 
$
26,000

 
$
109,239

 
 
 
 
 
 
 
 
 
 
 
Basic earnings per share
 
$
58.93

 
$
12.25

 
$
4.12

 
$
0.88

 
$
3.74

Diluted earnings per share
 
$
58.27

 
$
12.10

 
$
4.07

 
$
0.88

 
$
3.71

Cash dividends paid per common share
 
$
—

 
$
—

 
$
—

 
$
—

 
$
—

Total assets
 
$
8,008,859

 
$
5,611,068

 
$
4,273,012

 
$
3,850,504

 
$
3,709,718

Long-term debt, net of current maturities
 
$
13,579

 
$
438,937

 
$
434,581

 
$
434,186

 
$
433,883



ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion should be read in conjunction with the information contained in our consolidated financial statements and the accompanying notes which are an integral part of the statements.

Overview.  We are a multinational manufacturer and worldwide distributor of our own life science research and clinical diagnostics products.  Our business is organized into two primary segments, Life Science and Clinical Diagnostics, with the mission to provide scientists with specialized tools needed for biological research and clinical diagnostics.  

We sell more than 9,000 products and services to a diverse client base comprised of scientific research, healthcare, education and government customers worldwide. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

We manufacture and supply our customers with a range of reagents, apparatus and equipment to separate complex chemical and biological materials and to identify, analyze and purify components.  Because our customers require standardization for their experiments and test results, much of our revenues are recurring.  

26



We are impacted by the support of many governments for both research and healthcare. The current global economic outlook is still uncertain as the need to control government social spending by many governments limits opportunities for growth. Adding to this uncertainty was the referendum in the United Kingdom to withdraw from the European Union. Approximately 39% of our 2019 consolidated net sales are derived from the United States and approximately 61% are derived from international locations, with Europe being our largest international region. The international sales are largely denominated in local currencies such as the Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. As a result, our consolidated net sales expressed in dollars benefit when the U.S. dollar weakens and suffer when the dollar strengthens.  When the U.S. dollar strengthens, we benefit from lower cost of sales from our own international manufacturing sites as well as non-U.S. suppliers, and from lower international operating expenses. We regularly discuss our changes in revenue and expense categories in terms of both changing foreign exchange rates and in terms of a currency neutral basis, if notable, to explain the impact currency has on our results.

Cyberattack

As we previously disclosed on December 9, 2019 on a Form 8-K filed with the Securities and Exchange Commission (SEC), we detected a cyberattack on our network on the evening of December 5, 2019 PST and immediately took affected systems offline as part of our comprehensive response to contain the activity (“December 2019 Cyberattack”). The virus was targeted at Windows-based systems and did not attack our global ERP system (SAP) and other non-Windows-based systems.  Critical systems were back online within a few days of the incident. As part of our in-depth investigation into this incident, we engaged outside cyber security experts to assist us with investigation and remediation efforts.  To date, we have found no evidence of unauthorized transfer or misuse of personal data, and there is no indication at this point that customer systems were affected. We anticipate some ongoing expenses relating to this incident will continue into the first half of 2020.  

We have insurance coverage for costs resulting from cyberattacks. At this time, we expect that our losses from this incident will exceed our insurance coverage.  We have not recorded any estimated proceeds resulting from an insurance claim regarding this incident since covered expenses as a result of this incident are still not yet quantified and, in any case, disputes over the extent of insurance coverage for claims are not uncommon. We did not pay a ransom in connection with this incident.

Acquisitions

In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. As of December 31, 2019, the preliminary allocation of the payments was $3.4 million to customer relationships, a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets.

In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill. We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations.


27


In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles. We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.

The above acquisitions are immaterial to Bio-Rad taken as a whole for the periods presented.

Restructuring Costs for European and North American Reorganization

In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, United States and Canada, and is expected to be incurred through 2020. We recorded $25.3 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2019. The liability of $25.3 million as of December 31, 2019 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $4.8 million, in Selling, general and administrative expense of $14.4 million and in Research and development expense of $6.1 million in the Consolidated Statements of Income for the year ended December 31, 2019.

Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million and $3.9 million and exit costs of zero and $0.2 million for the years ended December 31, 2019 and 2018, respectively. From December 2018 to December 31, 2019, total expenses were $4.0 million.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.3) million and $1.7 million for the years ended December 31, 2019 and 2018, respectively. From June 2018 to December 31, 2019, total expenses were $1.4 million. This restructuring plan was completed in November 2019.


Critical Accounting Policies and Estimates

The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP).  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and contingencies as of the date of the financial statements and reported amounts of revenues and expenses during the reporting periods.  We evaluate our estimates on an on-going basis.  We base our estimates on historical experience and on other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. However, future events may cause us to change our assumptions and estimates, which may require adjustment. Actual results could differ from these estimates. We have determined that for the periods reported in this Annual Report on Form 10-K the following accounting policies and estimates are critical in understanding our financial condition and results of operations.

28



Accounting for Income Taxes.  Management is required to make estimates related to our income tax provision in each of the jurisdictions in which we operate.  This process involves estimating our current tax exposures, as well as making judgments regarding the recoverability of deferred tax assets in each jurisdiction. Deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Management assesses the likelihood that the deferred tax assets will be recovered from future taxable income and to the extent management believes that recovery is not likely, a valuation allowance must be established.  To the extent management establishes a valuation allowance or increases this allowance in a period, an increase to expense within the Provision for income taxes in the Consolidated Statements of Income may result.

As of December 31, 2019 and 2018, we recorded a valuation allowance of $67.2 million and $70.8 million, respectively, due to uncertainties related to our ability to utilize deferred tax assets in some jurisdictions. The valuation allowance is based on management’s current estimates of taxable income for the jurisdictions in which we operate and the period over which the deferred tax assets will be recoverable.  In the event that actual results differ from these estimates, or these estimates are adjusted in future periods, an additional valuation allowance may need to be established, which would increase the tax provision, lowering income and impacting our financial position. Should realization of these deferred tax assets for which a valuation allowance has been provided occur, the provision for income taxes may decrease, raising income and positively impacting Bio-Rad’s financial position.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense. Our overall effective tax rate is subject to fluctuations because of changes in the geographic mix of earnings, changes to statutory tax rates and tax laws, and because of the impact of various tax audits and assessments, as well as generation of tax credits.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.

Valuation of Business Acquisitions, Goodwill and Long-lived Assets.  Upon the consummation of a business combination, we use multiple analyses to determine the fair market value of the consideration of assets acquired and liabilities assumed. Once the fair market value of the acquired business is determined, any residual value between fair market value and the consideration is defined as goodwill.

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses, which could include contingent consideration. Contingent consideration is an obligation of the acquirer to transfer additional assets or equity interest to the former owners of an acquiree as part of the exchange for control of the acquiree if specified future events occur or conditions are met. Contingent consideration is reported at fair value each reporting period until the contingency is resolved. Any changes in fair value are recognized in earnings, which could become volatile over time depending on the facts and circumstances.


29


Goodwill amounts are assigned to reporting units at the time of acquisition and are adjusted for any subsequent significant transfers of business between reporting units. We assess the impairment of goodwill annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We perform the impairment tests of goodwill at our reporting unit level, which is one level below our operating segments. A goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.

We use a projected discounted cash flow model to determine the fair value of a reporting unit. This discounted cash flow method for determining goodwill may be different from the fair value that would result from an actual transaction between a willing buyer and a willing seller. Projections such as discounted cash flow models are inherently uncertain and accordingly, actual future cash flows may differ materially from projected cash flows. Management judgment is required in developing the assumptions for the discounted cash flow model. These assumptions include revenue growth rates, profit margins and discount rates. In addition, for some diagnostic units where they supply reagent rental equipment, capital expenditures can have a significant impact. We estimate future cash flows using current and longer-term financial forecasts. These forecasts take into account the current economic environment. The discount rates used are compiled using independent sources, current trends in similar businesses and other observable market data. Changes to these rates might result in material changes in the valuation and determination of the recoverability of goodwill. For example, an increase in the discount rate used to discount cash flows will decrease the computed fair value.

Impairment tests are highly sensitive to changes in assumptions and minor changes to assumptions could result in impairment losses. Our forecasts utilized in our 2019 impairment test assumed, among other things, sales growth from executing our sales and marketing programs, new product introductions, successful product development and timely registration of our products when required, while controlling costs to manufacture and service our equipment at the customer site. In addition, external factors, such as competitive pricing in the market, currency, inflation rates, cost of capital, and forecasted tax rates could affect the determination of fair value of our reporting units. Our impairment tests resulted in excessive fair value over book value ranging from 75% to more than 400% for our various reporting units. If the initiatives mentioned above do not achieve the desired results, or external factors change detrimentally, future impairment losses may occur.

To validate the reasonableness of the reporting unit fair values, we reconcile the aggregate fair values of the reporting units to the enterprise market capitalization. In performing the reconciliation we may, depending on the volatility of the market value of our stock price, use either the stock price on the valuation date or the average stock price over a range of dates around the valuation date.

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We assess the impairment of long-lived assets (including identifiable intangibles) whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In addition to the required quantitative review, we also review quarterly qualitative factors that we consider important, which could trigger an impairment review and include:

•
significant reporting unit under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

30



When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method. Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets. We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If this is the case, an impairment loss would be recognized. The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

In conjunction with our annual valuation of goodwill, there were no impairment losses in 2019. In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc.

In 2017, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A. and with our 2013 acquisition of AbD Serotec in the amounts of $2.8 million and $8.7 million, respectively.

All the impairments above were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Revenue Recognition. We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.

31


Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.

Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.

Valuation of Inventories.   We value inventory at the lower of the actual cost to purchase and/or manufacture the inventory, or the current estimated net realizable value of the inventory.  We review inventory quantities on hand and reduce the cost basis of excess and obsolete inventory based primarily on an estimated forecast of product demand, production requirements and the quality, efficacy and potency of raw materials.  This review is done on a quarterly basis or, if warranted by the circumstances, more frequently.  In addition, our industry is characterized by technological change, frequent new product development and product obsolescence that could result in an increase in the amount of obsolete inventory quantities on hand.  Our estimates of future product demand may prove to be inaccurate, and if too high, we may have overstated the carrying value of our inventory. In the future, if inventory is determined to be overvalued, we would be required to write down the value of inventory to market and recognize such costs in our cost of goods sold at the time of such determination.  Therefore, although we make efforts to ensure the accuracy of our forecasts of future product demand and perform procedures to safeguard overall inventory quality, any significant unanticipated changes in demand, technological developments, regulations, storage conditions, or other economic or environmental factors affecting biological materials, could have a significant impact on the value of our inventory and reported results of operations.

32




Results of Operations - Sales, Gross Margins and Expenses - Incorporating by Reference the Results of Operations - Sales, Gross Margins and Expenses from our Annual Report on Form 10-K for the fiscal year ended December 31, 2018

The following shows cost of goods sold, gross profit, expense items and net income as a percentage of net sales:

 
 
 
2019
 
2018
Net sales
100.0
%
 
100.0
%
Cost of goods sold
45.6

 
46.6

Gross profit
54.4

 
53.4

Selling, general and administrative expense
35.7

 
36.5

Research and development expense
8.8

 
8.7

Impairment losses on goodwill and long-lived assets
—

 
12.8

Net income
76.1

 
16.0


Net sales

Net sales (sales) in 2019 were $2.31 billion, an increase of 1.0% compared to $2.29 billion in 2018. Excluding the impact of foreign currency exchange rate fluctuations, 2019 sales increased by approximately 3.3% compared to 2018. Currency neutral sales increased in all regions.

The Life Science segment sales in 2019 were $885.9 million, an increase of 2.8% compared to 2018.  On a currency neutral basis, sales increased 4.6% compared to 2018. The currency neutral sales increase was primarily driven by growth in our Droplet Digital™ PCR, Food Safety and Process Media product lines. Currency neutral sales increases occurred mostly in the Americas and Europe. Sales in Asia were most impacted by the December 2019 Cyberattack .

The Clinical Diagnostics segment sales in 2019 were $1.41 billion, relatively flat compared to 2018. On a currency neutral basis, sales increased 2.8% compared to 2018. The currency neutral sales in 2018 benefited from a one-time $6.0 million receipt for the resolution of a dispute involving a licensed patent. Excluding the one-time receipt last year, we saw currency neutral sales growth across all three regions, primarily in the Americas and Asia. Product lines that contributed to the growth included Quality Controls, Blood Typing, Immunology and Diabetes. Management expects sales growth in Europe to continue to be challenging due to government initiatives to contain healthcare spending, along with increased competition.

Gross margin

Consolidated gross margins were 54.4% in 2019 compared to 53.4% in 2018. Life Science segment gross margins in 2019 increased when compared to 2018 by approximately 2.7 percentage points primarily due to $7.4 million and $1.5 million of cost of sales benefits in 2019 from escrow releases related to 2011 and 2017 acquisitions within the Life Science group, respectively, and product mix, as well as a decrease in service costs. Clinical Diagnostics segment gross margins in 2019 were flat compared to 2018. Unfavorable manufacturing costs included restructuring costs, lower absorption, and higher service costs primarily associated with a larger installed base. These costs were primarily offset by lower excess and obsolete inventory related costs, logistics costs, and royalty expenses. The gross margin in 2018 benefited from a one-time receipt of $6.0 million for the resolution of a dispute involving a licensed patent, partially offset by a restructuring charge related to a manufacturing facility closure. 

33



Selling, general and administrative expense

Consolidated selling, general and administrative expenses (SG&A) decreased to $824.6 million or 35.7% of sales in 2019 compared to $834.8 million or 36.5% of sales in 2018, an overall decrease of $10.2 million.  Decreases to SG&A primarily were related to lower professional fees of $27.7 million, lower bad debt of $14.6 million and lower travel of $8.6 million. Decreases in SG&A were partially offset primarily by increases in employee related expenses of $40.8 million, which included higher expenses associated with the restructuring plans in 2019 compared to those in 2018.

Research and development expense

Research and development expense increased to $202.7 million or 8.8% of sales in 2019 compared to $199.2 million or 8.7% of sales in 2018.  Life Science segment research and development expense increased in 2019 from 2018, primarily driven by additional spending for personnel, outside consultants and supplies that were related to new product innovation within the Droplet Digital PCR product line. Clinical Diagnostics segment research and development expense decreased in 2019 from 2018 primarily from lower spending due to the timing of projects that led to lower outside professional services expense and lower supplies expense, partially offset by the restructuring plan in the fourth quarter of 2019.

Impairment losses on goodwill and long-lived assets

In conjunction with our annual valuation of goodwill, there were no impairment losses in 2019. In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations.

Results of Operations – Non-operating

Interest expense

Interest expense in 2019 was $23.4 million, a slight decrease compared to 2018 of $24.0 million.

Foreign currency exchange gains and losses

Foreign currency exchange gains and losses consist primarily of foreign currency transaction gains and losses on intercompany net receivables and payables and the change in fair value of our forward foreign exchange contracts used to manage our foreign currency exchange risk.  Net foreign currency exchange losses for 2019 and 2018 were $2.2 million and $2.9 million, respectively.  The 2019 and 2018 net foreign currency exchange losses were attributable to market volatility, the result of the estimating process inherent in the timing of shipments and payments of intercompany debt, and the cost of hedging. All years are affected by the economic hedging program we employ to hedge our intercompany receivables and payables denominated in foreign currencies.

34



Change in fair market value of equity securities

Change in fair market value of equity securities were gains of $2,031.0 million for 2019 compared to $606.2 million for 2018, primarily resulting from the recognition of holding gains on our investment in Sartorius AG.

Other (income) expense, net

Other (income) expense, net includes investment and dividend income, interest income on our cash and cash equivalents, short-term investments and long term marketable securities.  Other (income) expense, net in 2019 decreased to $26.1 million of income compared to $36.6 million of income in 2018. Other income, net decreased primarily due to a land sale of $4.1 million and a divestiture of a product line of $5.1 million that both occurred in 2018, and higher other-than-temporary impairment losses on equity method investments that were recorded in light of the investees' financial condition in 2019.

Effective tax rate

Our effective tax rate was 22.2% and 28.7% in 2019 and 2018, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. Our effective tax rate may be impacted in the future, either favorably or unfavorably, by many factors including, but not limited to, changes in the geographic mix of earnings, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe the resolution of our uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

As of December 31, 2019, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.8 million. Substantially all such amounts will impact our effective income tax rate.

Comparison of the Year Ended December 31, 2018 to the Year Ended December 31, 2017

Refer to Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations located in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed on April 16, 2019, for the discussion of the comparison of the fiscal year ended December 31, 2018 to the fiscal year ended December 31, 2017, the earliest of the three fiscal years presented in the Consolidated Statements of Operations.
 

35




Liquidity and Capital Resources

Bio-Rad operates and conducts business globally, primarily through subsidiary companies established in the markets in which we trade.  Goods are manufactured in a small number of locations, and are then shipped to local distribution facilities around the world.  Our product mix is diversified, and certain products compete largely on product efficacy, while others compete on price.  Gross margins are generally sufficient to exceed normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.  In addition to the annual positive cash flow from operating activities, additional liquidity is readily available via the sale of short-term investments and access to our domestic $200.0 million unsecured Credit Agreement that we entered into in April 2019, and to a lesser extent international lines of credit. Borrowings under the 2019 Credit Agreement are available on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the 2019 Credit Agreement as of December 31, 2019; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability.  The 2019 Credit Agreement matures in April 2024. In total under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had approximately $207.5 million available for borrowing and usage as of December 31, 2019, which was reduced by approximately $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations. Management believes that this availability, together with cash flow from operations, will be adequate to meet our current objectives for operations, research and development, capital additions for manufacturing and distribution, plant and equipment, information technology systems and an acquisition of reasonable proportion to our existing total available capital. However, we have outstanding $425.0 million principal amount of Senior Notes that are due in December 2020 (4.875% Notes). We are currently assessing the repayment of the 4.875% Notes and believe we have adequate resources to repay or finance this obligation.
 
At December 31, 2019, we had available $1,114.6 million in cash, cash equivalents and short-term investments, of which approximately 21% was held in our foreign subsidiaries. We believe that our holdings of cash, cash equivalents and short-term investments in the U.S. and in our foreign subsidiaries are sufficient to meet both the current and long-term needs of our global operations. The amount of funds held in the United States can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and foreign cash flows (both inflows and outflows).

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. 

Demand for our products and services could change more dramatically than in previous years based on activity, funding, reimbursement constraints and support levels from government, universities, hospitals and private industry, including diagnostic laboratories.  The need for certain sovereign nations with large annual deficits to curtail spending, and international trade disputes and increased regulation, could lead to slower growth of, or even a decline in, our business. Sovereign nations either delaying payment for goods and services or renegotiating their debts could impact our liquidity.

36




Cash Flows from Operations

Net cash provided by operations was $457.9 million and $285.5 million in 2019 and 2018, respectively.  The net increase between 2019 and 2018 of $172.4 million primarily resulted from:

•
lower cash paid to suppliers that included value added tax refunds of approximately $53 million in 2019,
•
lower income tax payments in 2019 compared to 2018, and
•
higher investment income received, partially offset by
•
lower comparative cash received from customers in 2019 was primarily due to higher collections in 2018 subsequent to the ERP implementation in 2017, and
•
forward foreign exchange contracts had lower net proceeds in 2019 compared to 2018.

Cash flows from operations during the first quarter have historically had larger payments for royalties, fourth quarter sales commissions to third parties and annual employee bonuses, and we expect this pattern to recur in the first quarter of 2020.

Cash Flows from Investing Activities

Net cash used in investing activities was $208.9 million and $187.0 million for 2019 and 2018, respectively. The net increase between 2019 and 2018 of $21.9 million was primarily due to payments for acquisitions in 2019, and to a lesser extent proceeds for a divestiture of a product line in 2018 as discussed below. These were partially offset primarily by lower capital expenditures in 2019 than in 2018 as discussed below, and for sales of marketable securities and investments that increased by $27.6 million in 2019 compared to 2018. Other items that affected cash flows from investing activities are further discussed below.

Our investment objective is to maintain liquidity to meet anticipated operational and other corporate requirements in which capital is preserved and increased through investing in low risk, high quality securities with commensurate returns, consistent with our risk tolerance level.

During the first quarter of 2019, we received $7.4 million from an escrow release related to an acquisition from 2011 within the Life Science Group. During the first quarter of 2018, we received $7.0 million for a divestiture of a product line and $4.1 million for a land sale.

In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. The acquisition does not meet the significant or material subsidiary test. The purchase price allocation is preliminary as additional time is required to complete the valuation of assets acquired and liabilities assumed.

In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition does not meet the significant or material subsidiary test.

In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition does not meet the significant or material subsidiary test.

The above acquisitions are immaterial to Bio-Rad taken as a whole for the periods presented.


37


We continue to review possible acquisitions, including early stage businesses, to expand both our Life Science and Clinical Diagnostics segments. We routinely meet with the principals or brokers of the subject companies.  However, it is not certain at this time that any of these discussions will advance to completion.

Capital expenditures in 2019 totaled $98.5 million, compared to $129.8 million in 2018. Capital expenditures represent the addition and replacement of production machinery and research equipment, ongoing manufacturing and facility additions for expansion, regulatory, environmental and compliance. Also included in capital expenditures are investments in business systems and data communication upgrades and enhancements, including the remaining phases of the global enterprise resource planning (ERP) platform.  All periods include equipment placed with Clinical Diagnostics segment customers who then contract to purchase our reagents for use. Capital expenditures were lower in 2019 than in 2018 primarily due to implementing smaller phases of the ERP platform. In addition in 2018, we made an investment in two office buildings and adjacent land in the greater San Francisco Bay Area, California.

Cash Flows from Financing Activities
    
Net cash used in financing activities was $22.8 million compared to $48.7 million in 2019 and 2018, respectively. Net cash used in financing activities was lower in 2019 than 2018 primarily due to lower repurchases of our common stock in 2019 than in 2018 of $20.9 million.

We have outstanding 4.875% Notes of $425.0 million, which are due in December 2020. We are currently assessing the repayment of the 4.875% Notes and believe we have adequate resources to repay or finance this obligation.
We believe the current cash is sufficient to meet normal operating costs, and funding for research and development of new products, as well as routine outflows of capital expenditures, interest and taxes.
 
Treasury Shares

During 2019, 137,748 shares of our Class A treasury stock and 917 shares of our Class B treasury stock, with an aggregate total cost of $38.7 million, were reissued to fulfill annual grants to employees under our restricted stock program, and to fulfill our Employee Stock Purchase Plan purchases.  Upon reissuing the Class A and B treasury stock under our restricted stock program, a loss of $8.4 million was incurred as they were reissued at a lower price than their average cost, which reduced Retained earnings while $24.9 million reduced Additional paid-in-capital.  These reissuances for the restricted stock program did not require cash payments or receipts and therefore did not affect liquidity.  Upon fulfilling our Employee Stock Purchase Plan purchases, a loss of $1.6 million was incurred as they were issued at a lower price than the average cost, which reduced Retained earnings and resulted in net proceeds of $3.8 million.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have had or are reasonably likely to have a current or future material effect on our financial condition, results of operations or liquidity.

Contractual Obligations
The following summarizes certain of our contractual obligations as of December 31, 2019 and the effect such obligations are expected to have on our cash flows in future periods (in millions):


38


 
 
Payments Due by Period
 
 
 
 
Less
Than
 
1-3
 
3-5
 
More
than
Contractual Obligations
 
Total
 
One Year
 
Years
 
Years
 
5 Years
Long-term debt, including current portion (1)
 
$
440.4

 
$
426.8

 
$
3.1

 
$
0.8

 
$
9.7

Interest payments (1)
 
28.8

 
20.1

 
1.7

 
1.4

 
5.6

Operating lease obligations (2)
 
255.4

 
41.0

 
64.4

 
46.3

 
103.7

Purchase obligations (3)
 
35.8

 
34.0

 
1.3

 
0.3

 
0.2

Long-term liabilities (4)
 
118.4

 
5.2

 
17.3

 
7.6

 
88.3

 
 
 
 
 
 
 
 
 
 
 
(1) These amounts represent expected cash payments, including finance lease obligations, which are included in our December 31, 2019 Consolidated Balance Sheet. Our debt is fixed and primarily consists of the 4.875% Notes. See Note 5 of the Consolidated Financial Statements for additional information about our debt.
 
 
 
(2) Operating lease obligations are described in Note 16 of the Consolidated Financial Statements.
 
 
 
(3) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms.  Purchase obligations exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad.
 
 
 
(4) These amounts primarily represent recognized long-term obligations for other post-employment benefits mostly due in more than 5 years, and long-term deferred revenue. Excluded from this table are tax liabilities for uncertain tax positions and contingencies in the amount of $47.6 million.  We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded from the table above.  See Note 6 of the Consolidated Financial Statements for additional information about our income taxes.
 
 
 

Recent Accounting Pronouncements Adopted and to be Adopted

See Note 1 to the consolidated financial statements for recent accounting pronouncements adopted and to be adopted.


ITEM 7A.  QUANTITIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Financial Risk Management

The main goal of Bio-Rad’s financial risk management program is to reduce the variance in expected cash flows arising from unexpected foreign exchange rate and interest rate changes.  Financial exposures are managed through operational means and by using various financial instruments, including cash and liquid resources, borrowings, and forward and spot foreign exchange contracts.  No derivative financial instruments are entered into for the purpose of trading or speculation.  Company policy requires that all derivative positions are undertaken to manage the risks arising from underlying business activities.  These derivative transactions do not qualify for hedge accounting treatment.  Derivative instruments used in these transactions are valued at fair value and changes in fair value are included in reported earnings.

Foreign Exchange Risk.  We operate and conduct business in many countries and are exposed to movements in foreign currency exchange rates.  We face transactional currency exposures that arise when we enter into transactions denominated in currencies other than U.S. dollars.  Additionally, our consolidated net equity is impacted by the conversion of the net assets of our international subsidiaries for which the functional currency is not the U.S. dollar.

39



Foreign currency exposures are managed on a centralized basis.  This allows for the netting of natural offsets and lowers transaction costs and net exposures.  Where possible, we seek to manage our foreign exchange risk in part through operational means, including matching same-currency revenues to same-currency costs, and same-currency assets to same-currency liabilities.  Moreover, weakening in one currency can often be offset by strengthening in another currency.  Foreign exchange risk is also managed through the use of forward foreign exchange contracts. Positions are primarily in Euro, Swiss Franc, Japanese Yen, Chinese Yuan and British Sterling. The majority of forward contracts are for periods of 90 days or less. We record the change in value of our foreign currency receivables and payables as a Foreign exchange (gain) loss on our Consolidated Statements of Income along with the change in fair market value of the forward exchange contract used as an economic hedge of those assets or liabilities.

Our forward contract holdings at year-end were analyzed to determine their sensitivity to fluctuations in foreign currency exchange rates.  All other variables were held constant.  Market risk associated with derivative holdings is the potential change in fair value of derivative positions arising from an adverse movement in foreign exchange rates.  A decline of 10% on quoted foreign exchange rates would result in an approximate net-present-value loss of $25 million on our derivative position as of December 31, 2019.  This impact of a change in exchange rates excludes the offset derived from the change in value of the underlying assets and liabilities, which could reduce the adverse effect significantly.

Interest Rate Risk of Debt Instruments.  Bio-Rad centrally manages the short-term cash surpluses and shortfalls of its subsidiaries.  Our holdings of variable rate debt instruments at year-end were analyzed to determine their sensitivity to movements in interest rates.  Due to the relatively small amount of short-term variable rate debt we have outstanding, there would not be a material impact to earnings or cash flows if interest rates moved adversely by 10%.  Our long-term debt consists primarily of fixed-rate instruments, and is thus insulated from interest rate changes.  As of December 31, 2019, the overall interest rate risk associated with our debt was not significant.




ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 
 
 
Index to Consolidated Financial Statements
 
 
Page
 
 
 
Reports of Independent Registered Public Accounting Firm
 
41-43
Consolidated Balance Sheets at December 31, 2019 and 2018
 
44-45
Consolidated Statements of Income for each of the three years in the period ended
 
 
December 31, 2019
 
46
Consolidated Statements of Comprehensive Income for each of the three years in the period
 
 
December 31, 2019
 
47
Consolidated Statements of Cash Flows for each of the three years in the period ended
 
 
December 31, 2019
 
48
Consolidated Statements of Changes in Stockholders’ Equity for each of the three years
 
 
in the period ended December 31, 2019
 
49
Notes to Consolidated Financial Statements
 
50-92
 
 
 



40


Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio-Rad Laboratories, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Bio-Rad Laboratories, Inc. and subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of income, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three‑year period ended December 31, 2019, and the related notes and financial statement schedule (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 28, 2020 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.
 
Changes in Accounting Principle
As discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for leases effective January 1, 2019 due to the adoption of Accounting Standard Update (ASU) 2016-02, Leases, and related accounting standard updates.

Also as discussed in Note 1 to the consolidated financial statements, the Company has changed its method of accounting for revenue recognition effective January 1, 2018, due to the adoption of Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers.

Also as discussed in Note 1 to the consolidated financial statements, the Company changed its method of accounting for equity instruments effective January 1, 2018 due to the adoption of ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities and ASU 2018-03, Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities.

Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

41


Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

Assessment of Lease Term for Reagent Rental Arrangements

As discussed in Note 1 to the consolidated financial statements, the Company earns revenue from reagent rental agreements with its customers. Each agreement generally includes lease elements subject to the lease accounting standards and non-lease elements subject to the revenue accounting standards. The classification of the lease component as an operating or sales-type lease can impact the timing of revenue recognition and cost attributable to the underlying lease elements. While most reagent rental arrangements contain an option for a lessee to extend and the option for the lessee to cancel or both, the period in which the contract is enforceable is generally short, and the lease term has been limited to the noncancellable period. The revenue allocated to the reagent rental lease elements is approximately 3% of total revenue and it is included as part of Net Sales in the Consolidated Statement of Income.
We identified the assessment of the lease term for the reagent rental agreements, including the impact from any associated contractual termination penalties, as a critical audit matter. The Company’s determination of lease classification as operating or sales-type lease is primarily dependent on the initial determination of the lease term. The Company’s process is based on the manual examination of a high volume of agreements that are negotiated individually across the world with diverse terms. Testing the determination of the lease term, including consideration of contractual termination penalties, required a high degree of auditor judgment to design and execute the audit procedures.
The primary procedures we performed to address the critical audit matter included the following. We tested certain internal controls over the Company’s process for determining the lease term, including consideration of contractual termination penalties. We assessed the Company’s policies for determining that the lease term of its reagent rental arrangements were in accordance with U.S generally accepted accounting principles. Additionally, for a selection of reagent rental agreements, we read the underlying contract, and compared relevant terms within the contract to the Company’s determination of lease term analysis.


/s/ KPMG LLP
We have served as the Company's auditor since 2013.
 
Santa Clara, California
February 28, 2020

42


Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Bio‑Rad Laboratories, Inc.:

Opinion on Internal Control Over Financial Reporting
We have audited Bio-Rad Laboratories, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of income, comprehensive income, changes in stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes and financial statement schedule (collectively, the consolidated financial statements), and our report dated February 28, 2020 expressed an unqualified opinion on those consolidated financial statements.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP
Santa Clara, California
February 28, 2020

43




BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(In thousands, except share data)
 
December 31,
 
2019
 
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
660,672

 
$
431,526

Short-term investments
453,973

 
413,270

Restricted investments
5,560

 
5,560

Accounts receivable, less allowance for doubtful accounts of $20,205 at 2019 and $26,713 at 2018
392,672

 
392,443

 
 
 
 
Inventories:
 
 
 
Raw materials
109,570

 
108,008

Work in process
146,131

 
145,051

Finished goods
298,306

 
330,756

Total inventories
554,007

 
583,815

 
 
 
 
Prepaid expenses
102,331

 
187,249

Other current assets
10,940

 
9,615

Total current assets
2,180,155

 
2,023,478

 
 
 
 
Property, plant and equipment:
 
 
 
   Land and improvements
25,215

 
25,185

   Buildings and leasehold improvements
341,598

 
331,563

   Equipment
1,015,359

 
970,081

     Total property, plant and equipment
1,382,172

 
1,326,829

Less: accumulated depreciation and amortization
(882,833
)
 
(818,139
)
Property, plant and equipment, net
499,339

 
508,690

 
 
 
 
Operating lease right-of-use assets
201,868

 
—

Goodwill, net
264,131

 
219,770

Purchased intangibles, net
145,525

 
133,123

Other investments
4,638,205

 
2,655,709

Other assets
79,636

 
70,298

Total assets
$
8,008,859

 
$
5,611,068

 
 
 
 

The accompanying notes are an integral part of these consolidated financial statements.

 44



BIO-RAD LABORATORIES, INC.
Consolidated Balance Sheets
(continued)
(In thousands, except share data)

 
December 31,
 
2019
 
2018
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
  Accounts payable
$
107,014

 
$
122,450

  Accrued payroll and employee benefits
180,084

 
143,510

  Current maturities of long-term debt
426,172

 
493

  Income taxes payable
8,763

 
27,513

  Other taxes payable
27,522

 
28,675

  Current operating lease liabilities
35,365

 
—

  Deferred revenue
33,735

 
26,936

  Other current liabilities
86,840

 
101,218

Total current liabilities
905,495

 
450,795

 
 
 
 
Long-term debt, net of current maturities
13,579

 
438,937

Deferred income taxes
997,787

 
553,239

Operating lease liabilities
176,018

 
—

Other long-term liabilities
160,923

 
147,766

Total liabilities
2,253,802

 
1,590,737

 
 
 
 
Commitments and contingent liabilities


 


 
 
 
 
Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value, 7,500,000 shares authorized; issued and outstanding - none
—

 
—

  Class A common stock, $0.0001 par value; 80,000,000 shares authorized; shares issued - 24,966,035 and 24,884,265 at 2019 and 2018, respectively; shares outstanding - 24,835,804 and 24,704,772 at 2019 and 2018, respectively
2

 
2

  Class B common stock, $0.0001 par value; 20,000,000 shares authorized; shares issued - 5,089,532 and 5,096,421 at 2019 and 2018, respectively; shares outstanding - 5,089,532 and 5,095,504 at 2019 and 2018, respectively
1

 
1

Additional paid-in capital
410,020

 
394,342

  Class A treasury stock at cost, 130,231 shares at 2019 and 179,493 shares at 2018
(38,397
)
 
(49,040
)
  Class B treasury stock at cost, 0 shares at 2019 and 917 shares at 2018
—

 
(89
)
Retained earnings
5,470,779

 
3,722,073

Accumulated other comprehensive loss
(87,348
)
 
(46,958
)
Total stockholders’ equity
5,755,057

 
4,020,331

Total liabilities and stockholders’ equity
$
8,008,859

 
$
5,611,068

 
 
 
 



The accompanying notes are an integral part of these consolidated financial statements.

 45



BIO-RAD LABORATORIES, INC.
Consolidated Statements of Income
(In thousands, except per share data)


 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
 
Net sales
$
2,311,659

 
$
2,289,415

 
$
2,160,153

 
Cost of goods sold
1,054,663

 
1,066,264

 
972,450

 
Gross profit
1,256,996

 
1,223,151

 
1,187,703

 
Selling, general and administrative expense
824,625

 
834,783

 
806,790

 
Research and development expense
202,710

 
199,196

 
250,157

 
Impairment losses on goodwill and long-lived assets
—

 
292,513

 
11,506

 
Income (loss) from operations
229,661

 
(103,341
)
 
119,250

 
Interest expense
23,416

 
23,962

 
23,014

 
Foreign currency exchange losses, net
2,245

 
2,861

 
9,128

 
Change in fair market value of equity securities
(2,030,987
)
 
(606,230
)
 
—

 
Other (income) expense, net
(26,094
)
 
(36,593
)
 
(10,697
)
 
Income before income taxes
2,261,081

 
512,659

 
97,805

 
(Provision for) benefit from income taxes
(502,406
)
 
(147,045
)
 
24,444

 
Net income
$
1,758,675

 
$
365,614

 
$
122,249

 
 
 
 
 
 
 
 
Basic earnings per share:
 
 
 
 
 
 
Net income per basic share
$
58.93

 
$
12.25

 
$
4.12

 
Weighted average common shares - basic
29,843

 
29,836

 
29,655

 
 
 
 
 
 
 
 
Diluted earnings per share:
 
 
 
 
 
 
Net income per diluted share
$
58.27

 
$
12.10

 
$
4.07

 
Weighted average common shares - diluted
30,184

 
30,228

 
30,034

 

The accompanying notes are an integral part of these consolidated financial statements. 


46


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Comprehensive Income
(In thousands)


 
Year Ended December 31,
 
2019
 
2018
 
2017
Net income
$
1,758,675

 
$
365,614

 
$
122,249

Other comprehensive (loss) income:
 
 
 
 
 
Foreign currency translation adjustments
(36,953
)
 
(112,857
)
 
76,050

Foreign other post-employment benefits adjustments, net of income taxes
(7,363
)
 
7,549

 
(3,767
)
Net unrealized holding gains (losses) on available-for-sale (AFS) investments, net of income taxes and effect of adoption of ASU 2018-02*
3,926

 
(1,187
)
 
248,745

Other comprehensive (loss) income, net of income taxes
(40,390
)
 
(106,495
)
 
321,028

Comprehensive income
$
1,718,285

 
$
259,119

 
$
443,277


*ASU 2018-02, "Reclassification of Certain Tax effects from Accumulated Other Comprehensive Income," as disclosed in our December 31, 2017 Form 10-K


The accompanying notes are an integral part of these consolidated financial statements.



47


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Cash Flows
(In thousands)
 
Year Ended December 31,
 
2019
 
2018
 
2017
Cash flows from operating activities:
 
 
 
 
 
Cash received from customers
$
2,311,925

 
$
2,326,310

 
$
2,093,948

Cash paid to suppliers and employees
(1,818,575
)
 
(1,989,685
)
 
(1,916,119
)
Interest paid, net
(22,330
)
 
(22,703
)
 
(22,224
)
Income tax payments, net
(45,081
)
 
(62,414
)
 
(52,136
)
Investment proceeds and miscellaneous receipts, net
31,673

 
26,383

 
18,392

Proceeds from (payments for) forward foreign exchange contracts, net
285

 
7,603

 
(17,724
)
Net cash provided by operating activities
457,897

 
285,494

 
104,137

Cash flows from investing activities:
 
 
 
 
 
Capital expenditures
(98,532
)
 
(129,825
)
 
(111,332
)
Proceeds from dispositions of property, plant and equipment
129

 
4,315

 
86

Proceeds from divestiture of a product line
—

 
6,964

 
—

(Payments for) proceeds from acquisitions and long-term investment
(79,386
)
 
266

 
(76,645
)
Recovery of (payments for) purchases of intangible assets
8,818

 
(3
)
 
(3,795
)
Payments for purchases of restricted investment
—

 
—

 
(1,000
)
Payments for purchases of marketable securities and investments
(371,450
)
 
(371,019
)
 
(282,656
)
Proceeds from sales of marketable securities and investments
104,632

 
77,029

 
97,523

Proceeds from maturities of marketable securities and investments
226,900

 
225,295

 
202,247

Net cash used in investing activities
(208,889
)
 
(186,978
)
 
(175,572
)
Cash flows from financing activities:
 
 
 
 
 
Net payments on line-of-credit arrangements and notes payable
—

 
—

 
(36
)
Payments on long-term borrowings
(643
)
 
(2,961
)
 
(316
)
Payments for credit agreement renewal fees
(486
)
 
—

 
—

Proceeds from issuances of common stock for share-based compensation
13,113

 
14,133

 
14,604

Tax payments from net share settlement
(8,096
)
 
(8,862
)
 
(7,310
)
Proceeds from reissuances of treasury stock for shared-based compensation, net
3,831

 
—

 
—

Payments for purchases of treasury stock
(28,000
)
 
(48,912
)
 
(2,920
)
Payments of contingent consideration
(2,477
)
 
(2,078
)
 
(3,681
)
Net cash (used in) provided by financing activities
(22,758
)
 
(48,680
)
 
341

Effect of foreign exchange rate changes on cash
2,237

 
(655
)
 
(1,094
)
Net increase (decrease) in cash, cash equivalents and restricted cash
228,487

 
49,181

 
(72,188
)
Cash, cash equivalents and restricted cash at beginning of year
434,164

 
384,983

 
457,171

Cash, cash equivalents and restricted cash at end of year
$
662,651

 
$
434,164

 
$
384,983


The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that agrees to the same amounts shown in the Consolidated Statements of Cash Flows (in thousands):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Cash and cash equivalents
$660,672
 
$431,526
 
$383,824
Restricted cash included in Other current assets
93

 
111

 
882

Restricted cash included in Other assets
1,886

 
2,527

 
277

Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows
$662,651
 
$434,164
 
$384,983
These restricted cash items are primarily related to performance guarantees.
The accompanying notes are an integral part of these consolidated financial statements.

48


BIO-RAD LABORATORIES, INC.
Consolidated Statements of Changes in Stockholders’ Equity
(In thousands)
 
 
Common
Stock
 
Additional Paid-in Capital
 
Treasury Stock
 
Retained
Earnings
 
Accumulated Other Comprehensive Income
 
Total Stockholders' Equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2016
 
$
3

 
$
332,911

 
$
(101
)
 
$
1,828,581

 
$
417,766

 
$
2,579,160

Net income
 
—

 
—

 
—

 
122,249

 
—

 
122,249

Effect of adoption of ASU 2016-09*
 
—

 
391

 
—

 
(256
)
 
—

 
135

Other comprehensive income, net of tax
 
—

 
—

 
—

 
—

 
200,893

 
200,893

Effect of adoption of ASU 2018-02**
 
—

 
—

 
—

 
(120,135
)
 
120,135

 
—

Issuance of common stock
 
—

 
4,490

 
—

 
—

 
—

 
4,490

Stock compensation expense
 
—

 
23,439

 
—

 
—

 
—

 
23,439

Purchase of treasury stock
 
—

 
—

 
(2,920
)
 
—

 
—

 
(2,920
)
Reissuance of treasury stock
 
—

 
—

 
2,804

 


 


 
2,804

Balance at December 31, 2017
 
3

 
361,231

 
(217
)
 
1,830,439

 
738,794

 
2,930,250

Effect of adoption of ASU 2016-01 and ASU 2018-03***
 
—

 
—

 
—

 
1,543,747

 
(679,257
)
 
864,490

Effect of adoption of ASU 2016-16****
 
—

 
—

 
—

 
(17,591
)

 
 
(17,591
)
Effect of adoption of ASC 606*****
 
—

 
—

 
—

 
(136
)
 
—

 
(136
)
Net income
 
—

 
—

 
—

 
365,614

 
—

 
365,614

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
(106,495
)
 
(106,495
)
Issuance of common stock
 
—

 
5,271

 
—

 
—

 
—

 
5,271

Stock compensation expense
 
—

 
27,840

 
—

 
—

 
—

 
27,840

Purchase of treasury stock
 
—

 
—

 
(48,912
)
 
—

 
—

 
(48,912
)
Balance at December 31, 2018
 
3

 
394,342

 
(49,129
)
 
3,722,073

 
(46,958
)
 
4,020,331

Net income
 
—

 
—

 
—

 
1,758,675

 
—

 
1,758,675

Other comprehensive loss, net of tax
 
—

 
—

 
—

 
—

 
(40,390
)
 
(40,390
)
Issuance of common stock
 
—

 
5,017

 
—

 
—

 
—

 
5,017

Stock compensation expense
 
—

 
35,593

 
—

 
—

 
—

 
35,593

Purchase of treasury stock
 
—

 
—

 
(28,000
)
 
—

 
—

 
(28,000
)
Reissuance of treasury stock
 
—

 
(24,932
)
 
38,732

 
(9,969
)
 
—

 
3,831

Balance at December 31, 2019
 
$
3

 
$
410,020

 
$
(38,397
)
 
$
5,470,779

 
$
(87,348
)
 
$
5,755,057


* ASU 2016-09, "Improvements to Employee Shared-Based Payment Accounting," as disclosed in our December 31, 2017 Form 10-K
** ASU 2018-02,"Reclassification of Certain Tax effects from Accumulated Other Comprehensive Income," as disclosed in our
December 31, 2017 Form 10-K
*** ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities, and ASU 2018-03, "Technical Corrections and Improvements to Financial Instruments - Recognition and Measurement of Financial Assets and Financial Liabilities," as disclosed in our December 31, 2018 Form 10-K
**** ASU 2016-16, "Intra-Entity Transfers of Assets Other Than Inventory," as disclosed in our December 31, 2018 Form 10-K
***** See Note 1, "Significant Accounting Policies" under "Revenue Recognition"

The accompanying notes are an integral part of these consolidated financial statements.

49


 
BIO-RAD LABORATORIES, INC.
Notes to Consolidated Financial Statements


1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2019 and 2018 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

50



Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 10-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years.

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of December 31, 2019. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of December 31, 2019.


51


ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

52



When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard.


53


We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.

In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.

54


Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.
As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  As a result, our lease income is heavily variable in nature.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.

Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% and 5% of total revenue for 2019 and 2018, respectively, and is included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.

55


Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.8 million at December 31, 2019 was primarily driven by $33.1 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $24.6 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2019
 
2018
January 1
 
$
10.1

 
$
18.7

Provision for warranty
 
9.9

 
25.5

Actual warranty costs
 
(11.0
)
 
(34.1
)
December 31
 
$
9.0

 
$
10.1



Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.

Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

56



Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Forfeitures are recognized as they occur.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Basic weighted average shares outstanding
 
29,843

 
29,836

 
29,655

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
341

 
392

 
379

Diluted weighted average common shares
 
30,184

 
30,228

 
30,034

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
98

 
84

 
13



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

57



The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Pronouncements Adopted

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of December 31, 2019, we capitalized $3.1 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet.

In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."

Recent Accounting Pronouncements to be Adopted

In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption.


58


In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements, however due to the generally short duration of our customers' trade receivables, we do not expect ASU 2016-13 to have a material impact.



2.    ACQUISITIONS

In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

As of December 31, 2019, the preliminary allocation of the payments was $3.4 million to customer relationships; a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets.

59



In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill.

We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations.

In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles.

We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.


3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions):


60


 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
42.9

 
$
—

 
$
42.9

Time deposits
31.2

 
10.0

 
—

 
41.2

Asset-backed securities
—

 
0.1

 
—

 
0.1

Money market funds
69.9

 
—

 
—

 
69.9

Total cash equivalents (a)
101.1

 
53.0

 
—

 
154.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
4,664.4

 
—

 
—

 
4,664.4

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
204.5

 
—

 
204.5

U.S. government sponsored agencies
—

 
106.1

 
—

 
106.1

Foreign government obligations
—

 
4.7

 
—

 
4.7

Other foreign obligations
—

 
3.1

 
—

 
3.1

Municipal obligations
—

 
11.6

 
—

 
11.6

Asset-backed securities
—

 
72.9

 
—

 
72.9

Total available-for-sale investments (c)
—

 
402.9

 
—

 
402.9

Forward foreign exchange contracts (d)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
4,771.1

 
$
456.8

 
$
—

 
$
5,227.9

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

     Contingent consideration (f)
—

 
—

 
4.9

 
4.9

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
4.9

 
$
5.9


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):


61


 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents (a)
59.6

 
88.1

 
—

 
147.7

Restricted investment:
5.6

 
—

 
—

 
5.6

Equity securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

 Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
Short-term investments
$
51.0

 
$
40.2

Other investments
4,613.4

 
2,632.7

        Total
$
4,664.4

 
$
2,672.9



The year-to-date unrealized gains on our equity securities still held as of December 31, 2019 were $2,031.1 million and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income.

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2019
 
December 31, 2018
 
 
 
 
Short-term investments
$
402.8

 
$
373.0

Other investments
0.1

 
0.2

Total
$
402.9

 
$
373.2




62



(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Other current liabilities
$
3.3

 
$
3.2

Other long-term liabilities
1.6

 
5.2

   Total
$
4.9

 
$
8.4



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2019, we paid $1.4 million and $1.1 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $13.9 million. The contingent consideration was accrued at its estimated fair value of $4.3 million as of December 31, 2019.

During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is due in the second quarter of 2020. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of December 31, 2019.

The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions):

December 31, 2018
$
8.4

Analytical flow cytometer platform:
 
Payment of sales milestone
(2.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(1.6
)
 
 
Foreign distributor earn-outs:
 
Acquisition of foreign distributor
$
0.6

December 31, 2019
$
4.9



63



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2019. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
      Discount rate
11.1
%
 
 
      Cost of debt
3.9
%


To estimate the fair value of Level 2 debt securities, our primary pricing provider used Reuters as of December 31, 2019 and Securities Evaluations as of December 31, 2018 as the primary pricing sources. Our pricing process allowed us to select a hierarchy of pricing sources for securities held. If Reuters or Securities Evaluations did not price a Level 2 security that we held, then the pricing provider utilized our custodian supplied pricing as the secondary pricing source.

For all commercial paper as of December 31, 2019, our primary pricing provider used its leading pricing source in the hierarchy to determine pricing.

Our primary pricing provider performed daily reasonableness testing of the Reuters and Securities Evaluations prices. Price changes of 5% or greater were investigated and resolved. In addition, we performed a quarterly testing of the Reuters and Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% were investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2019
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
203.2

 
$
1.4

 
$
(0.1
)
 
$
204.5

Municipal obligations
11.5

 
0.1

 
—

 
11.6

Asset-backed securities
72.7

 
0.2

 
(0.1
)
 
72.8

U.S. government sponsored agencies
105.6

 
0.7

 
(0.2
)
 
106.1

Foreign government obligations
4.7

 
—

 
—

 
4.7

  Other foreign obligations
3.1

 
—

 
—

 
3.1

 
400.8

 
2.4

 
(0.4
)
 
402.8

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.1

 
—

 
—

 
0.1

 
0.1

 
—

 
—

 
0.1

Total
$
400.9

 
$
2.4

 
$
(0.4
)
 
$
402.9



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2019 by contractual maturity date (in millions):


64


 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
174.5

 
$
174.6

Mature in one to five years
164.2

 
165.2

Mature in more than five years
62.2

 
63.1

Total
$
400.9

 
$
402.9



Available-for-sale investments consist of the following (in millions):
 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2019
 
December 31, 2018
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
19.9

 
$
117.9

Fair value of investments in a loss position less than 12 months
$
97.8

 
$
193.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.1

 
$
1.8

Gross unrealized losses for investments in a loss position less than 12 months
$
0.3

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2019 or at December 31, 2018.

65



As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2019 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2019
Contracts maturing in January through March 2020 to sell foreign currency:
 
Notional value
$
52.0

Unrealized gain
$
0.3

Contracts maturing in January through March 2020 to purchase foreign currency:
 
Notional value
$
269.1

Unrealized loss
$
(0.3
)


The estimated fair value of our current maturities of long-term debt, excluding leases, as of December 31, 2019 and long-term-debt, excluding all lease and current maturities, as of December 31, 2018 that is not recognized at fair value in the Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
December 31, 2019
 
December 31, 2018
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Total current maturities long-term debt, excluding leases
$
424.4

 
$
435.5

 
2
 
$
—

 
$
—

 
2
Total long-term debt, excluding leases
and current maturities
$
—

 
$
—

 
2
 
$
423.7

 
$
435.8

 
2


Included in Other Investments in the Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $0.3 million and $0.6 million as of December 31, 2019 and December 31, 2018, respectively.

66



We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2019. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of December 31, 2019, due to the adoption of ASU 2016-01 and ASU 2018-03 as of January 1, 2018, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange.


4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2019
 
 
2018
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.5

 
$
320.5

 
$
555.0

 
 
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
192.7

 
27.1

 
219.8

 
 
198.8

 
307.3

 
506.1

Acquisitions
 
15.6

 
28.7

 
44.3

 
 
—

 
—

 
—

Divestiture
 
—

 
—

 
—

 
 
—

 
(1.4
)
 
(1.4
)
Impairment
 
—

 
—

 
—

 
 
(5.9
)
 
(276.1
)
 
(282.0
)
Currency fluctuations
 
—

 
—

 
—

 
 
(0.2
)
 
(2.7
)
 
(2.9
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
250.1

 
349.2

 
599.3

 
 
234.5

 
320.5

 
555.0

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(41.8
)
 
(293.4
)
 
(335.2
)
Goodwill, net
 
$
208.3

 
$
55.8

 
$
264.1

 
 
$
192.7

 
$
27.1

 
$
219.8



In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded $3.4 million of Customer relationships, a definite-lived intangible assets.

In conjunction with the purchase of all the issued and outstanding membership interests of Exact Diagnostics, LLC in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog.

In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset.

In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

67



In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
 
December 31, 2019
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
6.36
 
$
107.2

 
$
(74.3
)
 
$
32.9

Know how
5.71
 
188.5

 
(162.6
)
 
25.9

Developed product technology
8.31
 
144.2

 
(93.9
)
 
50.3

Licenses
8.74
 
76.0

 
(44.4
)
 
31.6

Tradenames
8.50
 
6.4

 
(3.6
)
 
2.8

Covenants not to compete
6.01
 
3.2

 
(1.4
)
 
1.8

Other
—
 
0.1

 
(0.1
)
 
—

     Total definite-lived intangible assets
 
 
525.6

 
(380.3
)
 
145.3

In-process research and development
 
 
0.2

 
—

 
0.2

     Total purchased intangible assets
 
 
$
525.8

 
$
(380.3
)
 
$
145.5


 
December 31, 2018
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
3.98
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
6.64
 
190.6

 
(159.8
)
 
30.8

Developed product technology
8.34
 
130.4

 
(86.6
)
 
43.8

Licenses
9.72
 
76.3

 
(40.9
)
 
35.4

Tradenames
3.42
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7.01
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1



In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

68



Amortization expense related to purchased intangible assets for the years ended December 31, 2019, 2018 and 2017 was $23.5 million, $28.3 million and $30.8 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2020, 2021, 2022, 2023, 2024 and thereafter is $23.5 million, $22.8 million, $19.6 million, $18.7 million, $16.6 million, and $44.1 million, respectively.


5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $207.5 million available for borrowing and usage as of December 31, 2019, which was reduced by $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(0.6
)
 
(1.3
)
Long-term debt less unamortized discount and debt issuance costs
424.4

 
423.7

Finance leases and other debt
15.4

 
—

Capital leases and other debt
—

 
15.7

 
439.8

 
439.4

Less current maturities
(426.2
)
 
(0.5
)
Long-term debt
$
13.6

 
$
438.9



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2019. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In April 2019, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2019; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2019. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.035% at December 31, 2019.


69


The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2019.

Maturities of long-term debt at December 31, 2019 were as follows: 2020 - $426.8 million; 2021 - $1.6 million; 2022 - $1.5 million; 2023 - $0.4 million; 2024 - $0.4 million; and thereafter - $9.7 million.


6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U.S.
 
$
1,034.0

 
$
363.4

 
$
72.8

International
 
1,227.1

 
149.3

 
25.0

Income before taxes
 
$
2,261.1

 
$
512.7

 
$
97.8



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
13.0

 
$
8.8

 
$
6.7

State
 
4.4

 
2.2

 
3.4

International
 
23.5

 
30.5

 
32.0

Current tax expense
 
40.9

 
41.5

 
42.1

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
409.7

 
114.0

 
(69.8
)
State
 
24.4

 
6.6

 
4.3

International
 
16.1

 
0.3

 
(19.3
)
Deferred tax expense (benefit)
 
450.2

 
120.9

 
(84.8
)
Non-current tax expense (benefit)
 
11.3

 
(15.4
)
 
18.3

Provision for (benefit from) income taxes
 
$
502.4

 
$
147.0

 
$
(24.4
)



The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:


70


 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U. S. statutory tax rate
 
21.0
 %
 
21.0
 %
 
35.0
 %
Impact of foreign operations
 
(9.7
)
 
(4.1
)
 
6.0

Research tax credits
 
(0.2
)
 
(0.7
)
 
(3.8
)
Nontaxable subsidies
 
(0.1
)
 
(0.2
)
 
(2.2
)
Goodwill impairment
 
—

 
5.6

 
1.2

Share-based compensation
 
(0.1
)
 
(1.0
)
 
(5.3
)
Nondeductible executive compensation
 
0.1

 
0.2

 
2.0

U.S. taxation of foreign income
 
10.3

 
15.5

 
2.7

Acquisition-related
 
—

 
(0.2
)
 
10.1

U.S. tax reform
 
—

 
(9.6
)
 
(71.0
)
State taxes
 
1.0

 
1.7

 
2.9

Other
 
(0.1
)
 
0.5

 
(2.6
)
Provision for (benefit from) income taxes
 
22.2
 %
 
28.7
 %
 
(25.0
)%


On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.

Our effective income tax rate was 22.2%, 28.7% and (25.0)% in 2019, 2018 and 2017, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act.

Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):


71


 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
23.9

 
$
21.7

Other post-employment benefits, vacation and other reserves
 
23.0

 
23.0

Tax credit and net operating loss carryforwards
 
83.7

 
75.3

Lease obligations
 
48.6

 
—

Other
 
26.0

 
27.1

    Total gross deferred tax assets
 
205.2

 
147.1

Valuation allowance
 
(67.2
)
 
(70.8
)
       Total deferred tax assets
 
138.0

 
76.3

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
38.4

 
40.1

Lease assets
 
46.4

 
—

Investments and intangible assets
 
1,001.4

 
540.6

        Total deferred tax liabilities
 
1,086.2

 
580.7

Net deferred tax liabilities
 
$
(948.2
)
 
$
(504.4
)


The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2019, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by $3.6 million in 2019.

As of December 31, 2019, our foreign and California net operating loss carryforwards were approximately $239.0 million and $52.7 million, respectively. Of our foreign net operating losses, $124.7 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of December 31, 2019, our California research tax credit carryforwards were approximately $35.7 million and may be carried forward indefinitely.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):

72


 
 
2019
 
2018
 
2017
Unrecognized tax benefits – January 1
 
$
29.8

 
$
54.9

 
$
21.1

Additions to tax positions related to prior years
 
7.6

 
0.6

 
1.3

Reductions to tax positions related to prior years
 
(0.7
)
 
(20.2
)
 
(1.0
)
Additions to tax positions related to the current year
 
3.0

 
4.6

 
34.8

Settlements
 
—

 
(6.8
)
 
(0.2
)
Lapse of statute of limitations
 
(0.4
)
 
(1.1
)
 
(3.4
)
Currency translation
 
(0.1
)
 
(2.2
)
 
2.3

Unrecognized tax benefits – December 31
 
$
39.2

 
$
29.8

 
$
54.9



Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2019, 2018 and 2017, respectively was $11.2 million, $9.5 million and $10.9 million. Bio-Rad accrued interest and penalties of $1.7 million, $(1.4) million, and $(0.9) million in 2019, 2018, and 2017, respectively. The total unrecognized tax benefits and interest and penalties of $50.4 million in 2019 was partially offset by deferred tax assets of $1.4 million and prepaid taxes of $5.4 million, for a net amount of $43.6 million.

As of December 31, 2019, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.


7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):

73


 
Class A Shares
 
Class B Shares
Balance at January 1, 2017
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096

B to A conversions
24

 
(24
)
Issuance of common stock
58

 
18

Balance at December 31, 2019
24,966

 
5,090


Treasury Shares

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1

May 1, 2019 - May 31, 2019
25,421

$
291.70

218,571

$
193.7

June 1, 2019 - June 30, 2019
25,977

$
292.01

244,548

$
186.1

August 1, 2019 - August 31, 2019
14,745

$
339.05

259,293

$
181.1

November 1, 2019 - November 30, 2019
22,343

$
358.04

281,636

$
173.1

 
 
 
 
 


In 2019, we used 118,910 of the repurchased shares in connection with the vesting of restricted stock units and 19,755 shares in connection with ESPP stock purchases. The Credit Agreement may limit our ability to repurchase our stock.



74



8.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive income (loss), net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)
Other comprehensive (loss) income, before reclassifications
(36.5
)
(10.0
)
4.8

(41.7
)
Amounts reclassified from Accumulated other comprehensive income
—

1.5

(0.4
)
1.1

Income tax effects
(0.4
)
1.1

(0.5
)
0.2

Other comprehensive (loss) income, net of income taxes
(36.9
)
(7.4
)
3.9

(40.4
)
Balances as of December 31, 2019
$
(72.4
)
$
(22.2
)
$
7.2

$
(87.4
)


The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2019
2018
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(1.5
)
$
(2.4
)
 
Selling, general and administrative expense
 
Net holding gains (losses) on equity securities and available for sale investments
 
$
0.4

$
(0.3
)
 
Other (income) expense, net
 


Reclassification adjustments are calculated using the specific identification method.



75



9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have two equity award plans for officers and certain other employees: the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2007 Plan.

The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 2,095,049 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2019, there were 1,507,489 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2019, 2018 and 2017, we recognized share-based compensation expense of $35.6 million, $27.8 million and $23.4 million, respectively.  The income tax benefit related to share-based compensation expense was $5.6 million, $4.4 million and $5.8 million for 2019, 2018 and 2017, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2019, 2018 and 2017 was $5.4 million, $5.4 million, and $6.3 million, respectively.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur.

76



Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
 
 
 
Granted
 
34,672

 
$
328.48

 
 
 
 
Exercised
 
(55,490
)
 
$
98.00

 
 
 
 
Forfeited/expired
 
(8,300
)
 
$
231.71

 
 
 
 
Outstanding, December 31, 2019
 
344,522

 
$
162.23

 
4.76
 
$
71.6

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2019
 
94,172

 
$
273.93

 
8.45
 
$
9.1

Exercisable, December 31, 2019
 
250,350

 
$
120.22

 
3.46
 
$
62.5




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2019, 2018 and 2017 was approximately $12 million, $8 million and $10 million, respectively.

Cash received from stock options exercised during 2019, 2018 and 2017 was $2.6 million, $0.5 million and $1.6 million, respectively.  

As of December 31, 2019, there was $7.0 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Expected volatility
 
22
%
 
22
%
 
20
%
Risk-free interest rate
 
1.69
%
 
2.85
%
 
1.87
%
Expected life (in years)
 
7.5

 
7.6

 
7.2

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
93.96

 
$
105.94

 
$
58.65



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.


77


The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2018
 
474,400

 
$
235.58

 
 
 
 
Granted
 
174,782

 
$
332.38

 
 
 
 
Vested
 
(134,525
)
 
$
206.44

 
 
 
 
Forfeited
 
(44,715
)

$
243.76

 
 
 
 
Outstanding, December 31, 2019
 
469,942

 
$
279.14

 
2.08
 
$
173.9



The total fair value of restricted stock units vested in 2019, 2018 and 2017 was $44.8 million, $40.0 million and $27.7 million, respectively. As of December 31, 2019, there was approximately $119.5 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 3 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2019
 
 
 
2018
 
 
 
2017
Expected volatility
31
%
 
 
 
27
%
 
 
 
19
%
Risk-free interest rate
2.25
%
 
 
 
1.82
%
 
 
 
0.83
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.24

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
60.39

 
 
 
$
55.04

 
 
 
$
38.86



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 58,717 shares for $14.3 million, 63,464 shares for $13.6 million and 74,409 shares for $13.0 million under the 2011 ESPP to employees in 2019, 2018 and 2017, respectively.  At December 31, 2019, 599,531 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.

78





10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Interest and investment income
 
$
(30.5
)
 
$
(26.6
)
 
$
(19.1
)
Net realized gains on investments
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Other expense
 
0.1

 
—

 
1.5

Other (income) expense, net
 
$
(26.1
)
 
$
(36.6
)
 
$
(10.7
)


Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition in the first and fourth quarters of 2019.



79


11. SUPPLEMENTAL CASH FLOW INFORMATION
The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net income
 
$
1,758.7

 
$
365.6

 
$
122.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
134.2

 
138.1

 
148.7

Reduction in the carrying amount of right-of-use assets
 
40.3

 
—

 
—

Share-based compensation
 
35.6

 
27.8

 
23.4

Gains on dispositions of securities
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Changes in fair market value of equity securities
 
(2,031.0
)
 
(606.2
)
 
—

Losses on dispositions of fixed assets
 
1.2

 
2.0

 
8.1

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Payments for operating lease liabilities
 
(38.6
)
 
—

 
—

Changes in fair value of contingent consideration
 
(1.6
)
 
(6.2
)
 
(18.1
)
Decrease (increase) in accounts receivable, net
 
1.6

 
59.7

 
(64.1
)
Decrease (increase) in inventories, net
 
24.2

 
(12.9
)
 
(47.7
)
Decrease (increase) in other current assets
 
61.8

 
(15.3
)
 
(35.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
10.6

 
(45.6
)
 
7.8

Decrease in income taxes payable
 
(4.2
)
 
(20.9
)
 
(22.4
)
Increase (decrease) in deferred income taxes
 
450.2

 
120.9

 
(82.0
)
(Increase) decrease in other long term assets
 
(1.7
)
 
1.1

 
2.3

Increase (decrease) in other long term liabilities
 
13.4

 
(10.0
)
 
38.1

Impairment losses on goodwill and long-lived assets
 
—

 
292.5

 
11.5

Other
 
(1.1
)
 
4.9

 
5.1

Net cash provided by operating activities
 
$
457.9

 
$
285.5

 
$
104.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
Purchased property, plant and equipment
 
$
8.1

 
$
5.7

 
$
—

Purchased marketable securities and investments
 
$
1.4

 
$
0.8

 
$
2.8

Sold marketable securities and investments
 
$
1.3

 
$
—

 
$
0.3





80


12. COMMITMENTS AND CONTINGENT LIABILITIES

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $16.1 million, $15.9 million and $16.0 million in 2019, 2018 and 2017, respectively.

Purchase Obligations

As of December 31, 2019, we had purchase obligations that have not been recognized on our balance sheet of $35.8 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2019 are as follows: 2020 - $34.0 million, 2021 - $1.0 million, 2022 - $0.2 million, 2023 - $0.2 million, 2024 - $0.2 million and after 2024 - $0.2 million.

Long-Term Liabilities

As of December 31, 2019, we had obligations that have been recognized on our balance sheet of $118.4 million, which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded.

The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of December 31, 2019 were as follows: 2020 - $5.2 million, 2021 - $12.8 million, 2022 - $4.5 million, 2023 - $4.3 million, 2024 - $3.3 million and after 2024 - $88.3 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.2 million of standby letters of credit/guarantees with financial institutions as of December 31, 2019.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2019 and 2018 of $81.5 million and $70.4 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):


81


Change in benefit obligation:
2019
2018
Benefit obligation at beginning of year
$137.3
$136.6
Service cost
6.9

7.5

Interest cost
1.5

1.1

Plan participants' contributions
3.5

3.1

Actuarial (gain) loss
11.9

(5.4
)
Gross benefits paid
(2.1
)
(3.1
)
Plan amendments
0.2

(0.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
(1.6
)
(2.0
)
 
 
 
Benefit obligation at end of year
153.8

137.3

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
66.9

61.7

Actual return on plan assets
0.9

0.3

Employer contributions
4.7

4.0

Plan participants' contributions
3.8

3.1

Gross benefits paid
(0.8
)
(1.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
0.6

(0.7
)
 
 
 
Fair value of plan assets at end of year
72.3

66.9

 
 
 
Under funded status of plans
$(81.5)
$(70.4)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(80.4
)
(69.3
)
 
 
 
Net liability, end of fiscal year
$(81.5)
$(70.4)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2019
2018
2017
Service costs
$6.9
$7.5
$6.5
Interest costs
1.5

1.1

1.1

Expected returns on plan assets
(1.2
)
(1.1
)
(1.1
)
Amortization of actuarial losses
1.0

1.3

1.4

Amortization of prior service costs
—

0.1

—

Settlements
0.9

—

1.2

 
 
 
 
Net periodic benefit costs
$9.1
$8.9
$9.1
 
 
 
 


Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


82



 
2019
2018
Discount rate
0.5
%
1.1
%
Compensation rate increase
1.7
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2019
2018
2017
Discount rate
1.1
%
0.8
%
0.9
%
Expected long-term rate of return on plan assets
1.8
%
1.8
%
1.9
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2019 and 2018 was $3.5 million and $3.1 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2019, approximately seven percent of Bio-Rad's approximately 3,180 U.S. employees were covered by a collective bargaining agreement, which will expire on November 14, 2023.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.


13.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24,

83


2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on our 2019 results of operations and is now closed.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2019, 2018, and 2017 and for the years then ended is as follows (in millions):


84


 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2019
 
$
885.9

 
$
1,412.0

 
$
13.8

 
2018
 
861.7

 
1,411.8

 
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2019
 
$
7.4

 
$
15.9

 
$
0.1

 
2018
 
7.2

 
16.7

 
0.1

 
2017
 
7.0

 
14.9

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2019
 
$
29.4

 
$
71.7

 
$
0.9

 
2018
 
34.1

 
72.0

 
0.5

 
2017
 
36.2

 
80.2

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2019
 
$
72.1

 
$
148.5

 
$
(1.5
)
 
2018
 
28.7

 
(145.7
)
 
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
 
 
 
 
 
 
 
Segment assets
2019
 
$
496.1

 
$
1,075.8

 
$
9.2

 
2018
 
450.2

 
949.0

 
5.9

 
 
 
 
 
 
 
 
Capital expenditures
2019
 
$
16.6

 
$
58.9

 
$
0.6

 
2018
 
36.7

 
60.5

 
0.5




Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements).

Segment assets at December 31, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 16 to the consolidated financial statements).

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Total segment profit (loss)
$
219.1

 
$
(116.8
)
 
$
106.3

Foreign currency exchange losses, net
(2.2
)
 
(2.9
)
 
(9.1
)
Net corporate operating, interest and other expense not allocated to segments
(12.9
)
 
(10.4
)
 
(10.1
)
Change in fair market value of equity securities
2,031.0

 
606.2

 
—

Other income (expense), net
26.1

 
36.6

 
10.7

Consolidated income before income taxes
$
2,261.1

 
$
512.7

 
$
97.8




85


The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2019
 
2018
Total segment assets
 
$
1,581.1

 
$
1,405.1

Cash and other current assets
 
1,233.5

 
1,047.2

Property, plant and equipment, net, and operating lease right-of-use
 

 

  assets, excluding segment specific balances
 
66.8

 
79.9

Goodwill, net
 
264.1

 
219.8

Other long-term assets
 
4,863.4

 
2,859.1

Total assets
 
$
8,008.9

 
$
5,611.1



Other long-term assets at December 31, 2019 increased from December 31, 2018 balance due to increase in fair market value of equity securities (see Note 3 to the consolidated financial statements).

The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Europe
 
$
770.3

 
$
792.0

 
$
758.5

Asia
 
505.0

 
495.5

 
461.3

United States
 
899.1

 
863.6

 
800.2

Other (primarily Canada and Latin America)
 
137.3

 
138.3

 
140.0

Total net sales
 
$
2,311.7

 
$
2,289.4

 
$
2,160.2


The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2019
 
2018
Europe
 
$
198.3

 
$
129.1

Asia
 
51.5

 
20.7

United States
 
468.7

 
369.2

Other (primarily Canada and Latin America)
 
12.7

 
11.1

Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes
 
$
731.2

 
$
530.1




Prior year amounts have been adjusted to exclude Other investments.


86




15.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, were incurred through and completed in December 2019. We recorded approximately $(0.1) million, $(0.2) million and $0.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2019, 2018 and 2017, respectively. From May 2016 to December 31, 2019, total expenses were $12.7 million. The amounts recorded were reflected in Cost of goods sold of $(0.1) million, $(0.1) million and $(0.2) million, and in Selling, general and administrative expense of zero, $(0.1) million and $0.7 million in the Consolidated Statements of Income for the years ended December 31, 2019, 2018 and 2017, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2019
 
2018
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.2
)
Cash payments
 
(0.3
)
 
(0.5
)
 
(0.8
)
 
(1.5
)
 
(2.9
)
 
(4.4
)
Reserve transferred to European and North American Reorganization restructuring costs reserve (see below)
 
(0.3
)
 
(0.4
)
 
(0.7
)
 
—

 
—

 
—

Foreign currency translation gains
 
—

 
—

 
—

 
—

 
(0.1
)
 
(0.1
)
Balance as of December 31
 
$
—

 
$
—

 
$
—

 
$
0.6

 
$
1.0

 
$
1.6




Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded restructuring charges and adjustments related to severance and employee benefits of less than $(0.1) million, $0.4 million and $11.0 million and asset write-offs and exit costs of zero, $(0.1) million and $10.1 million for the years ended December 31, 2019, 2018 and 2017, respectively. From December 2017 to December 31, 2019, total expenses were $21.4 million. This restructuring plan was completed in December 2019.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.3) million and $1.7 million for the years ended December 31, 2019 and 2018, respectively. From June 2018 to December 31, 2019, total expenses were $1.4 million. This restructuring plan was completed in November 2019.

87



In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million and $3.9 million and exit costs of zero and $0.2 million for the years ended December 31, 2019 and 2018, respectively. From December 2018 to December 31, 2019, total expenses were $4.0 million.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of $(0.3) million, $5.4 million and $2.3 million, in Selling, general and administrative expense of zero, $0.4 million and $3.3 million, and in Research and development expense of $(0.1) million, $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2019, 2018 and 2017, respectively. The liability of $3.2 million as of December 31, 2019 consisted of $1.8 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2019
 
2018
Balance as of January 1
 
$
11.5

 
$
14.1

Charged to expense
 
—

 
5.8

Adjustment to expense
 
(0.4
)
 
0.3

Cash payments
 
(7.7
)
 
(8.4
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
Balance as of December 31
 
$
3.2

 
$
11.5



Restructuring Costs for European and North American Reorganization

In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy.
The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. We recorded $25.3 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2019. The liability of $25.3 million as of December 31, 2019 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $4.8 million, in Selling, general and administrative expense of $14.4 million and in Research and development expense of $6.1 million in the Consolidated Statements of Income for the year ended December 31, 2019.

The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):


88


 
 
2019
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
—

 
$
—

 
$
—

Charged to expense
 
6.2

 
19.1

 
25.3

Cash payments
 
(0.4
)
 
(0.7
)
 
(1.1
)
Reserve transferred from European Reorganization restructuring costs reserve (see above)
 
0.3

 
0.4

 
0.7

Foreign currency translation losses
 
0.1

 
0.3

 
0.4

Balance as of December 31
 
$
6.2

 
$
19.1

 
$
25.3




16.    LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 19 years, which includes our determination to exercise renewal options.

The components of lease expense were as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Operating lease cost
$
51.4

 
 
Finance lease cost:
 
  Amortization of right-to-use assets
$
0.6

  Interest on lease liabilities
0.9

        Total finance lease cost
$
1.5

 
 
Sublease income
$
3.0


The sublease is for a building with a term that ends in 2025, with no options to extend or renew.

Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments.

Historically, our short-term leases, reflecting leases with a lease term of one year or less, are predominantly comprised of leases with a lease term of one month or less, which are not significant. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial.

Supplemental cash flow information related to leases was as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
  Operating cash flows from operating leases
$
47.2

  Operating cash flows from finance leases
$
0.9

  Financing cash flows from finance leases
$
0.6

 
 
Right-of-use assets obtained in exchange for lease obligations:
 
  Operating leases
$
28.7

  Finance leases
$
0.2




89


Supplemental balance sheet information related to leases was as follows (in millions):
 
December 31, 2019
 
 
Operating Leases
 
  Operating lease right-of-use assets
$
201.9

 
 
  Current operating lease liabilities
$
35.4

  Operating lease liabilities
176.0

     Total operating lease liabilities
$
211.4


 
December 31, 2019
 
 
Finance Leases
 
  Property, plant and equipment, gross
$
11.4

  Less: accumulated depreciation and amortization
(4.2
)
      Property, plant and equipment, net
$
7.2

 
 
  Current maturities of long-term debt and notes payable
$
0.5

  Long-term debt, net of current maturities
11.2

      Total finance lease liabilities
$
11.7


 
December 31, 2019
 
 
Weighted Average Remaining Lease Term
 
  Operating leases - in years
9

  Finance leases - in years
18

 
 
Weighted Average Discount Rate
 
  Operating leases
4.2
%
  Finance leases
6.5
%


Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,

Operating Leases
 
Finance Leases
 
 
 
 
2020
$
41.0

 
$
1.1

2021
35.8

 
1.3

2022
28.6

 
1.2

2023
24.5

 
1.1

2024
21.8

 
1.1

Thereafter
103.7

 
15.2

   Total lease payments
255.4

 
21.0

Less imputed interest
(44.0
)
 
(9.3
)
    Total
$
211.4

 
$
11.7



The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over.


90


As of December 31, 2019, we have an additional lease for a facility in Texas that has not commenced of $1.6 million. The operating lease will commence in either the second or third quarter of 2020 with a lease term of four years.

Operating and Capital Lease Commitments Under ASC 840, Leases

Rents and Leases

Rental expense under operating leases was $47.4 million and $43.6 million in 2018 and 2017, respectively.  Leases were principally for facilities and automobiles.
 
Annual future minimum lease payments at December 31, 2018 under operating leases were as follows: 2019 - $44.4 million; 2020 - $37.8 million; 2021 - $27.4 million; 2022 - $19.7 million; 2023 - $13.9 million; and 2024 and beyond - $25.6 million.

The total minimum rentals to be received in the future for the sublease as of December 31, 2018 were $17.8 million and ends in 2025.

Maturities of our capital lease obligations at December 31, 2018 were as follows: 2019 - $0.5 million; 2020 - $0.2 million; 2021 - $0.5 million; 2022 - $0.4 million; 2023 - $0.4 million; and thereafter - $9.9 million.


17. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2019 and 2018 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2019
 
 
 
 
 
 
 
 
Net sales
 
$
554.0

 
$
572.6

 
$
560.6

 
$
624.5

Gross profit
 
311.8

 
307.8

 
307.0

 
330.4

Net income (loss)
 
865.2

 
598.8

 
(258.8
)
 
553.5

Basic earnings (loss) per share
 
$
29.03

 
$
20.08

 
$
(8.68
)
 
$
18.50

Diluted earnings (loss) per share
 
$
28.74

 
$
19.86

 
$
(8.68
)
 
$
18.31

 
 
 
 
 
 
 
 
 
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)


91



As a result of the net losses for the three months ended September 30, 2019 and December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effects were anti-dilutive. Financial data for the fourth quarter of 2019 were negatively affected by the December 2019 Cyberattack, and restructuring costs for the European and North American reorganization, and are described in Item 7 and Note 15 to the consolidated financial statements, respectively. These negative effects were offset by a $646.0 million increase in fair market value of equity securities. The net losses for the three months ended September 30, 2019 and December 31, 2018 were primarily due to a $390.6 million and $814.1 million decrease in fair market value of equity securities, respectively. These changes in fair market value of equity securities mostly consisted of holding gains or losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of $292.5 million (see Note 4 to the consolidated financial statements).


ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Not applicable.


92





ITEM 9A.  CONTROLS AND PROCEDURES

(a)
Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures”, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Subject to the limitations noted above, our management, with the participation of our CEO and CFO, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the year covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective to meet the objective for which they were designed and operate at the reasonable assurance level.

(b) Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company as defined in Rule 13a-15(f) or 15(d)-15(f) of the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles, and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our consolidated financial statements.

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2019 using the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this assessment and those criteria, management concluded that our internal control over financial reporting was effective as of December 31, 2019. Our internal control over financial reporting has been audited by KPMG, LLP, an independent registered public accounting firm, as stated in their report, which appears in Part II, Item 8 of this Form 10-K.

93



(c) Changes in Internal Control over Financial Reporting

Management continuously reviews disclosure controls and procedures, and internal control over financial reporting, and accordingly may, from time to time, make changes aimed at enhancing their effectiveness to ensure that its systems evolve with its business. There were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the year ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(d) Inherent Limitations on Effectiveness of Internal Controls

Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

ITEM 9B.  OTHER INFORMATION

None.


PART III.

ITEM 10.  DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad’s definitive proxy statement to be mailed to stockholders in connection with our 2020 annual meeting of stockholders (the “2020 Proxy Statement”) under “Election of Directors,” “Committees of the Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance.”

Bio-Rad’s Board of Directors has determined that each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K.  Each of Jeffrey L. Edwards, Gregory K. Hinckley and Melinda Litherland is also an “independent” director, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 303A.02 of the New York Stock Exchange (NYSE) Listed Company Manual.

We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, controller and all other employees and is available through the Corporate Governance section of our website (www.bio-rad.com).  We will also provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at “Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA  94547.” We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on the Corporate Governance section of our website (www.bio-rad.com).

94




ITEM 11.  EXECUTIVE COMPENSATION

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2020 Proxy Statement under “Compensation Discussion and Analysis,” “Summary Compensation Table,” “Grants of Plan-Based Awards,” “Outstanding Equity Awards at Fiscal Year-End,” “Option Exercises and Stock Vested Table,” “Pension Benefits,” “Nonqualified Deferred Compensation Plans,” “Potential Payments on Termination or Change in Control,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and "Pay Ratio Disclosure.”  In addition, the information from a portion of the 2020 Proxy Statement under “Compensation Committee Report” is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.


ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2020 Proxy Statement under “Principal and Management Stockholders.”

Equity Compensation Plan Information as of December 31, 2019
Plan category
 
Number of securities
to be issued
upon exercise of outstanding options,
warrants and rights
 
Weighted-average exercise price of
outstanding options,
warrants and rights
 
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
 
 
(a)
 
(b)(3)
 
(c)
Equity compensation plans approved by
 
 
 
 
 
 
 
 
security holders (1)
 
814,464

 
$
162.23

 
2,107,020

 
(2)
Equity compensation plans not approved by
 
 
 
 
 
 
 
 
security holders
 
—

 
—

 
—

 
 
Total
 
814,464

 
$
162.23

 
2,107,020

 
 

(1)
Consists of the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan, the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, and the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(2)
Consists of 1,507,489 shares available under the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan and 599,531 shares available under the Bio-Rad Laboratories, Inc. 2011 Employee Stock Purchase Plan.
(3)
Excludes Restricted Stock Units.


ITEM 13.  CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2020 Proxy Statement under “Transactions with Related Persons” and “Committees of the Board of Directors.”


ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required to be furnished by this item is incorporated by reference from a portion of the 2020 Proxy Statement under “Report of the Audit Committee of the Board of Directors.”

95




PART IV.

ITEM 15.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
 
 
 
(a)1
Index to Financial Statements – See Item 8 of Part II of this report “Financial Statements and
 
Supplementary Data" on page 40 for a list of financial statements.
 
 
 
2
Schedule II Valuation and Qualifying Accounts
 
 
 
 
All other financial statement schedules are omitted because they are not required or the required information is included in the consolidated financial statements or the notes thereto.
 

BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2019, 2018, and 2017
(in thousands)

Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 

(Credited) Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2019
 
$
26,713

 
$
(1,240
)
 
$
(5,268
)
 
$
20,205

2018
 
$
25,549

 
$
11,527

 
$
(10,363
)
 
$
26,713

2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2019
 
$
70,769

 
$
—

 
$
(3,579
)
 
$
67,190

2018
 
$
66,356

 
$
4,413

 
$
—

 
$
70,769

2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356



 
 
 
3.
Index to Exhibits
 
 
 
 
The exhibits listed below in the accompanying Index to Exhibits are filed or incorporated by reference as part of this report.
 
 
 


96




 
BIO-RAD LABORATORIES, INC.
INDEX TO EXHIBITS ITEM 15(a)3 - NOT UPDATED
 
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed under the Securities Exchange Act of 1934.”
 
Exhibit No.
 
 
 
3.1

 
 
3.1.1

 
 
3.2

 
 
4.1

 
 
4.2

 
 
 
10.1

 
 
10.2

 
 
10.2.1

 
 
10.3

 
 
10.4

 
 
10.4.1

 
 
 
10.4.2




97


 
 
10.7

 
 
10.8

 
 
10.9

 
 
10.10

 
 
10.11

 
 
 
10.12

 
 
 
 
Exhibit No.
 
 
 
21.1

 
 
23.1

 
 
31.1

 
 
31.2

 
 
32.1

 
 
 
32.2

 
 
 
101.INS
The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Labels Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
104
Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
 
(1
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended
 
December 31, 2010.
 
 
(2
)
Incorporated by reference to Exhibit 3.1 to Bio-Rad’s Form 8-K filing, dated October 27, 2017.
 
 
(3
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form 8-K filing, dated December 9, 2010.

98


 
 
(4
)
Incorporated by reference to the Exhibit 10.1 to Bio-Rad’s 8-K filing, dated April 16, 2019.
 
 
(5
)
Incorporated by reference to Exhibit 10.9 to Bio-Rad's June 30, 2011 Form 10-Q filing, dated August 4, 2011.
 
 
(6
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017
 
 
(7
)
Incorporated by reference to Exhibit 10.6 to Bio-Rad’s September 30, 1997 Form 10-Q filing, dated
 
November 13, 1997.
 
 
(8
)
Incorporated by reference to Exhibit 4.1 to Bio-Rad’s Form S-8 filing, dated July 30, 2007.
 
 
(9
)
Incorporated by reference to Exhibit 10.8.1 to Bio-Rad’s September 30, 2009 Form 10-Q filing, dated
 
November 4, 2009.
 
 
(10
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s March 31, 2014 Form 10-Q filing, dated May 8, 2014.
 
 
(11
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated May 9, 2017

 
 
(12
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017

 
 
(13
)
Incorporated by reference to Exhibit 10.2 to Bio-Rad’s Form 10-Q filing, dated November 9, 2017

 
 
(14
)
Incorporated by reference to the Exhibit10.1 to Bio-Rad’s 8-K filing, dated April 2, 2019
 
 
(15
)
Incorporated by reference to the Exhibit10.1 to Bio-Rad’s 8-K filing, dated April 22, 2019
 
 
(16
)
Incorporated by reference to the Exhibit10.1 to Bio-Rad’s 8-K filing, dated August 23, 2019
 
 
(17
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated August 7, 2017.
 
 
(18
)
Incorporated by reference to Exhibit 10.1 to Bio-Rad’s Form 10-Q filing, dated November 7, 2014.
 
 
(19
)
Incorporated by reference to the Exhibits to Bio-Rad’s Form 10-K filing for the fiscal year ended December 31, 2014.


Item 16. FORM 10-K SUMMARY

Not applicable.

99




SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.
 
 
By:
/s/ Ilan Daskal
 
Ilan Daskal

 
Executive Vice President, Chief Financial Officer
 
 
Date:
February 28, 2020

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
 
 
Principal Executive Officer:
Chairman of the Board, President
 
/s/ Norman Schwartz
and Chief Executive Officer
February 28, 2020
(Norman Schwartz)
 
 
 
 
 
Principal Financial Officer:
 
 
/s/ Ilan Daskal
Executive Vice President,
 
(Ilan Daskal)
Chief Financial Officer
February 28, 2020
 
 
 
Principal Accounting Officer:
 
 
/s/ James R. Stark
Vice President, Corporate Controller
February 28, 2020
(James R. Stark)
 
 
 
 
 
Other Directors:
 
 
/s/ Jeffrey L. Edwards
Director
February 28, 2020
(Jeffrey L. Edwards)
 
 
 
 
 
/s/ Gregory K. Hinckley
Director
February 28, 2020
(Gregory K. Hinckley)
 
 
 
 
 
/s/ Melinda Litherland
Director
February 28, 2020
(Melinda Litherland)
 
 
 
 
 
/s/ Arnold A. Pinkston
Director
February 28, 2020
(Arnold A. Pinkston)
 
 
 
 
 
/s/ Alice N. Schwartz
Director
February 28, 2020
(Alice N. Schwartz)
 
 

100
 EX-4.1 2 ex41123119.htm EXHIBIT 4.1 12.31.19 Exhibit


Exhibit 4.1


DESCRIPTION OF BIO-RAD LABORATORIES, INC.
CLASS A AND CLASS B COMMON STOCK

The following description of Bio-Rad Laboratories, Inc.’s (“Bio-Rad’s”) Class A Common Stock and Class B Common Stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”), the complete text of Bio-Rad’s Restated Certificate of Incorporation and Certificate of Amendment to Restated Certificate of Incorporation (together, the “certificate of incorporation”), filed as Exhibits 3.1 and 3.1.1, respectively, to Bio-Rad’s Annual Report on Form 10-K, and the complete text of Bio-Rad’s Amended and Restated Bylaws (the “bylaws”), filed as Exhibit 3.2 to Bio-Rad’s Annual Report on Form 10-K. We encourage you to read the DGCL and our certificate of incorporation and bylaws carefully.
Class A and Class B Common Stock
General
Our certificate of incorporation authorizes 80,000,000 shares of Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), and 20,000,000 shares of Class B Common Stock, par value $0.0001 per share (the “Class B Common Stock”). Except as set forth in the certificate of incorporation and summarized below, the shares of Class A and Class B Common Stock are identical in all respects and have equal rights and privileges.
Dividends
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of Class A and Class B Common Stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. Declaration and payment of any dividend are subject to the discretion of the board of directors. The time and amount of dividends are dependent upon our financial condition, operations, cash requirements and availability, debt repayment obligations, capital expenditure needs, restrictions in our debt instruments, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors the board of directors may consider relevant.
Dividends may be paid in cash or in shares of Class A or Class B Common Stock. Cash dividends may be paid to holders of Class A Common Stock without paying any cash dividend to holders of Class B Common Stock, but no cash dividend may be paid to holders of Class B Common Stock unless a cash dividend of at least an equal amount is paid to holders of Class A Common Stock. For any dividend in shares of Class A or Class B Common Stock, the same number of shares shall be paid in respect of each outstanding share of Class A or Class B Common Stock. If no shares of Class A Common Stock have been issued or are outstanding, a dividend of shares of Class A Common Stock may be paid to holders of Class B Common Stock. Otherwise, a dividend of shares of Class A Common Stock may be paid to holders of Class A Common Stock and a dividend of shares of Class B Common Stock may be paid to holders of Class B Common Stock.
Voting Rights
Holders of Class B Common Stock shall have exclusive voting power, except as may be provided to holders of any then outstanding preferred stock and except as follows:
•
With respect to the election of directors, the holders of Class A Common Stock voting as a separate class are entitled to elect 25% of the authorized number of members of the board of directors and, if such 25% is not a whole number, then the holders of Class A Common Stock are entitled to elect the nearest higher whole number of directors. The holders of Class B Common Stock voting as a separate class are entitled to elect the remaining directors.


1



•
The holders of Class A Common Stock are entitled to vote as a separate class on the removal, with or without cause, of any director elected by the holders of Class A Common Stock. Similarly, the holders of Class B Common Stock are entitled to vote as a separate class on the removal, with or without cause, of any director elected by the holders of Class B Common Stock. Any director may be removed for cause by the vote of the holders of Class A and Class B Common Stock voting as a single class, in which event the holders of Class A Common Stock shall have 1/10th vote per share and the holders of Class B Common Stock shall have one vote per share.

•
The holders of Class A Common Stock and the holders of Class B Common Stock are entitled to vote as separate classes on such other matters as may be required by law or the certificate of incorporation to be submitted to such holders voting as separate classes.

•
In all matters not specified above, the holders of Class A and Class B Common Stock shall vote together as a single class, in which event the holders of Class A Common Stock shall have 1/10th vote per share and the holders of Class B Common Stock shall have one vote per share.

•
Any vacancy in the office of a director elected by the holders of Class A Common Stock may be filled by a vote of such holders voting as a separate class, and any vacancy in the office of a director elected by the holders of Class B Common Stock may be filled by a vote of such holders voting as a separate class. In the absence of a stockholder vote, any vacancy may be filled by the remaining directors as provided in the bylaws.

•
If on the record date for any stockholder meeting at which directors are to be elected, the number of issued and outstanding shares of Class A Common Stock is less than 10% of the aggregate number of issued and outstanding shares of Class A and Class B Common Stock, the holders of Class A Common Stock will not have the rights to elect directors set forth above. In such case, all directors to be elected at such meeting will be elected by holders of Class A and Class B Common Stock voting as a single class, where the holders of Class A Common Stock shall have 1/10th vote per share and the holders of Class B Common Stock shall have one vote per share.

•
If no shares of Class B Common Stock are issued and outstanding, then the holders of Class A Common Stock shall have exclusive voting power on all matters.
Conversion
Each holder of record of Class B Common Stock may at any time or from time to time, in such holder’s sole discretion and at such holder’s option, convert any whole number or all of such holder’s shares of Class B Common Stock into fully paid and non-assessable shares of Class A Common Stock on a one-for-one basis, subject to adjustment as set forth in the certificate of incorporation. No fraction of a share of Class A Common Stock will be issued for any share of Class B Common Stock; however, Bio-Rad will pay in cash to such holder the pro rata fair market value of any such fraction.
Liquidation
In the event of Bio-Rad’s liquidation, dissolution or winding up, holders of Class A and Class B Common Stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.



2



Rights and Preferences
Holders of Class A and Class B Common Stock have no preemptive, subscription, conversion (other than the conversion rights with respect to the Class B Common Stock described above) or other rights, and there are no redemption or sinking fund provisions applicable to our Class A and Class B Common Stock. The rights, preferences and privileges of the holders of Class A and Class B Common Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate in the future.
Fully Paid and Nonassessable
All outstanding shares of Class A and Class B Common Stock are fully paid and non-assessable.
Preferred Stock
The board of directors is authorized, subject to limitations prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. The board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. The board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Class A or Class B Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of Bio-Rad and might adversely affect the market price of the Class A and/or Class B Common Stock and the voting and other rights of the holders of the Class A and Class B Common Stock.
Anti-Takeover Effects of Provisions
Some provisions of Delaware law and the certificate of incorporation and bylaws could make the following transactions difficult: acquisition by means of a tender offer; acquisition by means of a proxy contest or otherwise; or removal of incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in the best interests of Bio-Rad, including transactions that might result in a premium over the market price for shares of Class A and/or Class B Common Stock.
These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control to first negotiate with Bio-Rad’s board of directors. We believe that the benefits of protection to Bio-Rad’s potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure Bio-Rad outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
Delaware Anti-Takeover Statute
Section 203 of the DGCL prohibits persons deemed “interested stockholders” from engaging in a “business combination” with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock and a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our Class A and/or Class B Common Stock.

3



Dual Class Common Stock
As described above, our certificate of incorporation provides for a dual class common stock structure pursuant to which holders of our Class B Common Stock have the ability to control the outcome of most matters requiring stockholder approval, even if they own significantly less than a majority of the shares of the outstanding Class A and Class B Common Stock, including the election of directors and significant corporate transactions, such as a merger or other sale of the company or its assets. As a result of the Schwartz family’s ownership of the Class A and Class B Common Stock, they are able to elect a majority of our directors, effect fundamental changes in our direction and control matters affecting us, including the determination of business opportunities that may be suitable for Bio-Rad. The Schwartz family may exercise its control over Bio-Rad according to interests that are different from other investors’ or debtors’ interests. In particular, this concentration of ownership and voting power may have the effect of delaying or preventing a change in control of Bio-Rad.

Undesignated Preferred Stock
The ability to authorize undesignated preferred stock will make it possible for the board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of Bio-Rad. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of Bio-Rad.
Requirements for Advance Notification of Stockholder Nominations and Proposals
The bylaws sets forth advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.
Choice of Forum
The bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, the certificate of incorporation or bylaws; or any action asserting a claim against Bio-Rad that is governed by the internal affairs doctrine. Although the bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.
Limitations of Liability and Indemnification Matters
The certificate of incorporation and bylaws contain provisions that limit the liability of the directors and officers for monetary damages to the fullest extent permitted by Delaware law. Consequently, directors and officers are not personally liable to Bio-Rad or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:
•
any breach of the director’s or officer’s duty of loyalty to Bio-Rad or its stockholders;

•
any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

•
unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or

•
any transaction from which the director or officer derived an improper personal benefit.


4



Each of the certificate of incorporation and bylaws provides that we are required to indemnify the directors and officers, in each case to the fullest extent permitted by Delaware law. The bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered into agreements to indemnify the directors, executive officers and other employees as determined by the board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding to the fullest extent permitted by applicable law. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. Bio-Rad also maintains directors’ and officers’ liability insurance.
The limitation of liability and indemnification provisions in the certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against the directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against the directors and officers, even though an action, if successful, might benefit Bio-Rad and its stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage.
Transfer Agent
The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar’s address is c/o Shareholder Services, 462 South 4th Street, Suite 1600, Louisville KY 40202.
Listing
Our Class A Common Stock is listed on the New York Stock Exchange (“NYSE”) under the symbol “BIO.” Our Class B Common Stock is listed on the NYSE under the symbol “BIOb.”

5

 EX-21.1 3 ex211123119.htm EXHIBIT 21.1 12.31.19 Exhibit


Exhibit 21.1
LISTING OF SUBSIDIARIES
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories Pty Ltd
 
Australia
Bio-Rad Laboratories Ges.m.b.H.
 
Austria
DiaMed Österreich GmbH
 
Austria
Bio-Rad Laboratories NV
 
Belgium
Research Specialties for Laboratories NV
 
Belgium
DiaMed Benelux NV
 
Belgium
Bio-Rad Laboratórios Brasil Ltda.
 
Brazil
DiaMed Latino-América S.A.
 
Brazil
Bio-Rad Laboratories (Rishon), Inc.
 
California, USA
(f/k/a Bio-Rad Laboratories (Israel), Inc.)
 
 
Bio-Rad Pacific Limited
 
California, USA
Bio-Rad Laboratories (Canada) Limited
 
Canada
Bio-Rad Laboratories (Shanghai) Co., Ltd.
 
China
Bio-Rad (Shanghai) Life Science Research & Development Co., Ltd.
 
China
Wuxi BioCanal Nano Technology Co. Ltd.
 
China
Bio-Rad spol. s r.o.
 
Czech Republic
Bio-Rad Export LLC
 
Delaware, USA
Bio-Rad Holdings, LLC
 
Delaware, USA
Bio-Rad QL, Inc.
 
Delaware, USA
GnuBIO Inc.
 
Delaware, USA
Raindance Techologies, Inc.
 
Delaware, USA
Bio-Rad Denmark ApS
 
Denmark
Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy)
 
Finland
Bio-Rad France Holding
 
France
Bio-Rad Innovations
 
France
Bio-Rad Laboratories SAS
 
France
Bio-Rad France
 
France
Bio-Rad
 
France
Bio-Rad Services France
 
France
DiaMed France SA
 
France
Bio-Rad 1
 
France
Bio-Rad Laboratories GmbH
 
Germany
Bio-Rad Germany Holding GmbH
 
Germany
DiaMed Diagnostika Deutschland GmbH
 
Germany
Bio-Rad Medical Diagnostics GmbH
 
Germany
Bio-Rad AbD Serotec GmbH
 
Germany
Bio-Rad Laboratories Logistik GmbH
 
Germany
 
 
 

1


LISTING OF SUBSIDIARIES - continued
 
 
 
 
 
JURISDICTION OF
SUBSIDIARY
 
ORGANIZATION
 
 
 
Bio-Rad Laboratories M.EPE
 
Greece
Bio-Rad China Ltd.
 
Hong Kong
Bio-Rad Hungary Trading LLC
 
Hungary
IMV Medical Information Division, Inc.
 
Illinois, USA
Bio-Rad Laboratories (India) Private Limited
 
India
Bio-Rad Haifa Ltd.
 
Israel
Bio-Rad Laboratories S.r.l.
 
Italy
Bio-Rad Laboratories K.K.
 
Japan
Bio-Rad Korea Ltd.
 
Korea
Bio-Rad Luxembourg S.à r.l.
 
Luxembourg
International Marketing Ventures, Ltd.
 
Maryland, USA
Bio-Rad, S.A.
 
Mexico
Bridger Technologies, Inc.
 
Montana, USA
Bio-Rad Laboratories B.V.
 
The Netherlands
Bio-Rad Norway AS
 
Norway
Bio-Rad Polska Sp. z o.o.
 
Poland
Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios, Lda
 
Portugal
Bio-Rad Laboratorii OOO
 
Russia
Bio-Rad Laboratories (Singapore) Pte Ltd
 
Singapore
Bio-Rad Laboratories (Pty) Ltd
 
South Africa
Bio-Rad Laboratories, S.A.
 
Spain
Distribudora de Analítica para la Medicina Ibérica, S.A.U.
 
Spain
Bio-Rad Laboratories AB
 
Sweden
Bio-Rad Europe GmbH
 
Switzerland
Bio-Rad IHC Europe GmbH
 
Switzerland
DiaMed Holding GmbH
 
Switzerland
DiaMed (Schweiz) GmbH
 
Switzerland
DiaMed GmbH
 
Switzerland
Bio-Rad Laboratories AG
 
Switzerland
Bio-Rad Laboratories Ltd.
 
Thailand
DiaMed S.E.A. Limited
 
Thailand
Bio-Rad Middle East FZ-LLC
 
United Arab Emirates
Bio-Rad Laboratories Limited
 
United Kingdom
DiaMed (G.B.) Ltd
 
United Kingdom
Bio-Rad AbD Serotec Ltd
 
United Kingdom
Bio-Rad Services UK Limited
 
United Kingdom
Bio-Metrics (U.K.) Limited
 
United Kingdom
Raindance Technologies Limited
 
United Kingdom
Respiratory Diagnostics, Inc.
 
Washington, USA


2
 EX-23.1 4 ex231123119.htm EXHIBIT 23.1 12.31.19 Exhibit


Exhibit 23.1



Consent of Independent Registered Public Accounting Firm




The Board of Directors
Bio-Rad Laboratories, Inc.:

We consent to the incorporation by reference in the registration statement on Forms S-8 (Nos. 333-220219, 333-144962, 333-133507, 333-124187, 333-53335, 333-53337, 333-179876, 333-197979, and 333-206885) of Bio-Rad Laboratories, Inc. of our reports dated February 28, 2020, with respect to the consolidated balance sheets of Bio-Rad Laboratories, Inc. as of December 31, 2019 and 2018, the related consolidated statements of income, comprehensive income, changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes and financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2019, which reports appear in the December 31, 2019 annual report on Form 10-K of Bio-Rad Laboratories, Inc.

Our report refers to a change in the accounting method for lease recognition in 2019, a change in the accounting for revenue recognition in 2018, and a change in the accounting method for equity instruments in 2018.



/s/ KPMG LLP

Santa Clara, California
February 28, 2020



EX-31.1 5 ex311123119.htm EXHIBIT 31.1 CEO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.1

Certification of Chief Executive Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Norman Schwartz, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
February 28, 2020
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer



 EX-31.2 6 ex312123119.htm EXHIBIT 31.2 CFO SECTION 302 CERTIFICATION Exhibit


Exhibit 31.2

Certification of Chief Financial Officer Required By
Exchange Act Rules 13a-14(a) and 15d-14(a)

I, Ilan Daskal, certify that:

1.
I have reviewed this annual report on Form 10-K of Bio-Rad Laboratories, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report fairly present, in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:
February 28, 2020
 
/s/ Ilan Daskal
 
 
 
Ilan Daskal, Executive Vice President,
 
 
 
   Chief Financial Officer


 EX-32.1 7 ex321123119.htm EXHIBIT 32.1 CEO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.1




Certification of Periodic Report


I, Norman Schwartz, Chief Executive Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Saran's-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:
February 28, 2020
 
/s/ Norman Schwartz
 
 
 
Norman Schwartz, Chairman of the Board, President and
 
 
 
    Chief Executive Officer


The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.


 EX-32.2 8 ex322123119.htm EXHIBIT 32.2 CFO SECTION 906 CERTIFICATION Exhibit


Exhibit 32.2




Certification of Periodic Report


I, Ilan Daskal, Chief Financial Officer of Bio-Rad Laboratories, Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:


(1)
the Annual Report on Form 10-K of the Company for the year ended December 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:
February 28, 2020
 
/s/ Ilan Daskal
 
 
 
Ilan Daskal, Executive Vice President,
 
 
 
   Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Annual Report or as a separate disclosure document.



 EX-101.SCH 9 bio-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2114100 - Disclosure - 10. Other Income and Expenses link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - 10. Other Income and Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - 10. Other Income and Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - 11. Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - 12. Commitments & Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - 12. Commitments & Contingent Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - 13. Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - 14. Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - 14. Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - 14. Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2425402 - Disclosure - 15. Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2125100 - Disclosure - 15. Restructuring Costs (Notes) link:presentationLink link:calculationLink link:definitionLink 2325301 - Disclosure - 15. Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2427402 - Disclosure - 16. Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2127100 - Disclosure - 16. Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 2327301 - Disclosure - 16. Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2128100 - Disclosure - 17. Quarterly Financial Data link:presentationLink link:calculationLink link:definitionLink 2428402 - Disclosure - 17. Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 2328301 - Disclosure - 17. Quarterly Financial Data (Tables) link:presentationLink link:calculationLink link:definitionLink 2429402 - Disclosure - 18. Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2129100 - Disclosure - 18. Subsequent Event (Notes) link:presentationLink link:calculationLink link:definitionLink 2329301 - Disclosure - 18. Subsequent Event (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - 1. Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401406 - Disclosure - 1. Significant Accounting Policies Details (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - 2. Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - 2. Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - 3. Fair Value Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - 3. Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - 3. Fair Value Measurements Available-for-Sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - 3. Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - 3. Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - 6. Income Taxes link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - 6. Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - 6. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - 7. Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - 9. Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - 9. Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - 9. Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2130100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns link:presentationLink link:calculationLink link:definitionLink 2430402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) link:presentationLink link:calculationLink link:definitionLink 2330301 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Schedule II - Valuation and Qualifying Accounts (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bio-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bio-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bio-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Information regarding industry segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Reconciliation of segment profit to consolidated income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Assets from Segment to Consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Net sales and assets to external customers by geographic area Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Statement [Line Items] Statement [Line Items] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Cash received from customers Proceeds from Customers Cash paid to suppliers and employees Payments to Suppliers and Employees Interest paid, net Interest Paid, Including Capitalized Interest, Operating and Investing Activities Income tax payments, net Income Taxes Paid, Net Investment proceeds and miscellaneous receipts, net Proceeds from Other Operating Activities Proceeds from (payments for) forward foreign exchange contracts, net Proceeds from derivative instruments, operating activities Proceeds from derivative instruments, operating activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from dispositions of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Proceeds from divestiture of a product line Proceeds from Sale of Productive Assets Payments for (proceeds from) acquisitions and long-term investment Payments for (Proceeds from) Investments Recovery of (payments for) purchases of intangible assets Payments for (Proceeds from) Productive Assets Payments for purchases of restricted investment Payments to Acquire Restricted Investments Payments for purchases of marketable securities and investments Payments to Acquire Investments Proceeds from sales of marketable securities and investments Proceeds from Sale of Available-for-sale Securities Proceeds from maturities of marketable securities and investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net (payments) borrowings on line-of-credit arrangements and notes payable Proceeds from (Repayments of) Lines of Credit Payments on long-term borrowings Repayments of Long-term Debt Payments for credit agreement renewal fees Payments of Debt Issuance Costs Proceeds from Issuances of common stock for shared-based compensation Proceeds from Issuance or Sale of Equity Tax payments from net share settlement Payment, Tax Withholding, Share-based Payment Arrangement Proceeds from reissuances of treasury stock for shared-based compensation, net Proceeds from (Repurchase of) Equity Payments for purchases of treasury stock Payments for Repurchase of Common Stock Payments of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted Cash included in Other current assets Restricted Cash, Current Restricted Cash included in Other assets Restricted Cash, Noncurrent Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Restructuring Costs [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] GERMANY GERMANY Restructuring Plan [Axis] Restructuring Plan [Axis] Restructuring Plan [Domain] Restructuring Plan [Domain] European Reorganization [Member] European Reorganization [Member] European Reorganization [Member] Facility Closing [Member] Facility Closing [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] Termination of a Diagnostics Research and Development Project [Member] European and North American Reorganization [Member] European and North American Reorganization [Member] European and North American Reorganization [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accounts Payable and Accrued Liabilities [Member] Accounts Payable and Accrued Liabilities [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] Life Science [Member] Life Science [Member] Life Sciences [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Clinical Diagnostics [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance [Member] Employee Severance [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Operating Income (Expense) [Member] Other Operating Income (Expense) [Member] Cost of Goods and Service Benchmark [Member] Cost of Goods and Service Benchmark [Member] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses [Member] Research and Development Expense [Member] Research and Development Expense [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve, Accrual Adjustment Restructuring Reserve, Accrual Adjustment Restructuring Charges Restructuring Charges Document Fiscal Year Focus Document Fiscal Year Focus Restructuring Reserve Restructuring Reserve Payments for Restructuring Payments for Restructuring Restructuring Reserve, Translation and Other Adjustment Restructuring Reserve, Translation and Other Adjustment Restructuring Reserve, Foreign Currency Translation (Gain) Loss Restructuring Reserve, Foreign Currency Translation Gain (Loss) Income Tax Disclosure [Abstract] Income Tax Contingency [Table] Income Tax Contingency [Table] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Operating lease obligations [Member] Operating lease obligations [Member] Operating lease obligations [Member] Operating lease assets [Member] Operating lease assets [Member] Operating lease assets [Member] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Axis] Fines and penalties [Domain] Fines and penalties [Domain] [Domain] for Fines and penalties [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Axis] Net of prepaid taxes [Domain] Net of prepaid taxes [Domain] [Domain] for Net of prepaid taxes [Axis] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Net of prepaid taxes [Member] Dividends [Axis] Dividends [Axis] Dividends [Domain] Dividends [Domain] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Acquisition-related Costs [Member] Acquisition-related Costs [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Foreign Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Limitations On Use Limitations On Use [Member] Limitations On Use [Member] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Axis] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Domain] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Including accrued interest and penalties [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] Tax Cuts and Jobs Act [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Income Taxes [Line Items] Income Tax Contingency [Line Items] Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Prepaid Taxes Prepaid Taxes U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic International Income (Loss) from Continuing Operations before Income Taxes, Foreign Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest U.S. Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) International Current Foreign Tax Expense (Benefit) Current Income Tax Expense (Benefit) Current Income Tax Expense (Benefit) U.S. Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) International Deferred Foreign Income Tax Expense (Benefit) Deferred tax benefit Deferred Income Tax Expense (Benefit) Non-current tax expense (benefit) Non Current Income Tax Expense Non Current Income Tax Expense Provision for income taxes Income Tax Expense (Benefit) U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Impact of foreign operations Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Foreign dividends, net Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Nontaxable subsidies Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent Tax settlements and changes to unrecognized tax benefits Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Goodwill impairment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Domestic manufacturing deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Fines and penalties Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent Prior period adjustments Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Other reconciling items Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent U.S. tax reform Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Provision for income taxes Effective Income Tax Rate Reconciliation, Percent Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Tax Cuts and Jobs Act, Income Tax Expense, Composition Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act Bad debt, inventory and warranty accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves Legal reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Other post-employment benefits, vacation and other reserves Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other Tax credit and net operating loss carryforwards Deferred Tax Assets, Tax Credit Carryforwards Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Liabilities, Leasing Arrangements Other Deferred Tax Assets, Other Total gross deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Total deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Investments and intangible assets Deferred Tax Liabilities, Other Finite-Lived Assets Total deferred tax liabilities Deferred Tax Liabilities, Gross Net deferred tax liabilities Deferred Tax Liabilities, Net Unrecognized tax benefits period start Unrecognized Tax Benefits Additions to tax positions related to prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions to tax positions related to prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Additions to tax positions related to the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation Acquisitions Unrecognized Tax Benefits, Increase Resulting from Acquisition Currency translation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation Unrecognized tax benefits period end Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Operating Loss Carryforwards, Expiration Dates Operating Loss Carryforwards, Expiration Date Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries Tax Credit Carryforward, Amount Tax Credit Carryforward, Amount Tax Credit Carryforward, Limitations on Use Tax Credit Carryforward, Limitations on Use Deferred Tax Assets, Tax Credit Carryforwards, Research Deferred Tax Assets, Tax Credit Carryforwards, Research Operating Loss Carryforward, Valuation Allowance Operating Loss Carryforwards, Valuation Allowance Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforward With No Expiration Date Operating Loss Carryforwards Operating Loss Carryforwards Other Tax Expense (Benefit) Other Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Segment Reporting Information, Profit (Loss) [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Foreign Currency Gain (Loss) [Member] Foreign Currency Gain (Loss) [Member] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments [Member] Operating Segments [Member] Segment Reconciling Items [Member] Segment Reconciling Items [Member] Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Goodwill, Impairment Loss Goodwill, Impairment Loss Unrealized Gain on Securities Unrealized Gain on Securities Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign currency translation adjustments [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Other Postretirement Benefit Plan [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Net Unrealized Investment Gain (Loss) [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Parent [Member] Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Debt Disclosure [Abstract] Principal components of long-term debt [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Quarterly Financial Data [Abstract] Schedule of Quarterly Financial Data [Table Text Block] Quarterly Financial Information [Table Text Block] Segment Information Segment Reporting Disclosure [Text Block] Stockholders' Equity Attributable to Parent [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Treasury Stock [Text Block] Treasury Stock [Text Block] Class of Treasury Stock [Table Text Block] Class of Treasury Stock [Table Text Block] Schedule of Stock by Class [Table Text Block] Schedule of Stock by Class [Table Text Block] Legal Proceedings [Abstract] -- None. No documentation exists for this element. -- Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost Total Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Mature in less than one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Mature in one to five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Mature in more than five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value Estimated Fair Value Debt Securities, Available-for-sale Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure Goodwill and Intangible Assets Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Short-term Investments [Member] Other Investments [Member] Other Investments [Member] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Foreign Government Obligations [Member] Debt Security, Government, Non-US [Member] Time Deposits [Member] Bank Time Deposits [Member] US Government Sponsored Agencies [Member] US Treasury and Government [Member] Money Market Funds [Member] Commercial Paper [Member] Commercial Paper [Member] Cash Equivalents [Member] Cash Equivalents [Member] Domestic Time Deposit [Member] Certificates of Deposit [Member] Asset-backed Securities [Member] Asset-backed Securities [Member] Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Foreign Government Debt [Member] Foreign Government Debt [Member] Money Market Funds [Member] Corporate Debt Securities [Member] Corporate Debt Securities [Member] Municipal Obligations [Member] Municipal Bonds [Member] Marketable Equity Securities [Member] Equity Securities [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Securities, FV-NI, Unrealized Gain Equity Securities, FV-NI, Unrealized Gain Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted Investments, at Fair Value Restricted Investments, at Fair Value Equity Securities, FV-NI Equity Securities, FV-NI Debt Securities, Available-for-sale Forward foreign exchange contracts, Asset Foreign Currency Contract, Asset, Fair Value Disclosure Financial Assets Carried at Fair Value Assets, Fair Value Disclosure Forward foreign exchange contracts, Liability Foreign Currency Contracts, Liability, Fair Value Disclosure Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Other Income and Expenses [Abstract] Other Income and Other Expense Disclosure Other Income and Other Expense Disclosure [Text Block] Notes Payable and Long-term Debt Long-term Debt [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform [Member] Analytical Flow Cytometer Platform Pasteur Sanofi Diagnosics S.A. [Member] Pasteur Sanofi Diagnosics S.A. [Member] Pasteur Sanofi Diagnosics S.A. [Member] DiaMed [Member] DiaMed [Member] DiaMed [Member] Biotest AG [Member] Biotest AG [Member] Biotest AG [Member] Goodwill [Line Items] Goodwill [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill [Roll Forward] Goodwill period start Goodwill, Gross Accumulated impairment loss period start Goodwill, Impaired, Accumulated Impairment Loss Goodwill, net period start Goodwill Goodwill, Acquired During Period Goodwill, Acquired During Period Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit Currency fluctuations Goodwill, Foreign Currency Translation Gain (Loss) Goodwill period end Accumulated impairment loss period end Goodwill, net period end Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Other Long-term Investments [Member] Other Long-term Investments [Member] Financial Instruments [Domain] Debt Securities [Member] Debt Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale, Amortized Cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Axis] Other Comprehensive Income Location [Domain] Other Comprehensive Income Location [Domain] Restructuring and Related Costs [Table Text Block] Restructuring and Related Costs [Table Text Block] Equity [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Measurement Frequency [Axis] Fair Value, Recurring [Member] Price Change Debt Security Price Change Debt Security Price Change Debt Security Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Tolerable variance Level 2 debt security pricing Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Gross unrealized losses for investments in a loss position 12 months or more Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Gross unrealized losses for investments in a loss position less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Estimate of Fair Value, Fair Value Disclosure [Member] Estimate of Fair Value Measurement [Member] Carrying (Reported) Amount, Fair Value Disclosure [Member] Reported Value Measurement [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Equity Securities without Readily Determinable Fair Value, Amount Equity Securities without Readily Determinable Fair Value, Amount Debt, Current Debt, Current Short-term Debt, Fair Value Short-term Debt, Fair Value Other Investments Other Investments Total long-term debt, excluding leases and current maturities Long-term Debt, Fair Value Investment ownership percentage Investment ownership percentage Investment ownership percentage Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Axis] Retirement Plan Tax Status [Domain] Retirement Plan Tax Status [Domain] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Axis] Retirement Plan Funding Status [Domain] Retirement Plan Funding Status [Domain] Retirement Plan Name [Axis] Retirement Plan Name [Axis] Retirement Plan Name [Domain] Retirement Plan Name [Domain] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] Industry Sector [Axis] Industry Sector [Axis] Industry Sector [Domain] Industry Sector [Domain] Investment Objective [Axis] Investment Objective [Axis] Investment Objective [Domain] Investment Objective [Domain] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Service Cost Defined Benefit Plan, Service Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Interest Cost Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Amount Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Employer Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Contributions by Plan Participant Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Benefits Paid Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Payment for Settlement Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Current Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan, Noncurrent Liability, Defined Benefit Plan Liability, Defined Benefit Plan Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Gain (Loss) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Document and Entity Information -- None. No documentation exists for this element. -- Entities [Table] Entities [Table] Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Entity Registrant Name Entity Registrant Name Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Fiscal Period Focus Document Fiscal Period Focus Entity Public Float Entity Public Float Document Annual Report Document Annual Report Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Interactive Data Current Entity Interactive Data Current Supplemental Cash Flow Information [Abstract] Other Significant Noncash Transactions [Table] Other Significant Noncash Transactions [Table] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction [Axis] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transaction, Name [Domain] Other Significant Noncash Transactions [Line Items] Other Significant Noncash Transactions [Line Items] Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Depreciation and amortization Depreciation, Depletion and Amortization Reduction in the carrying amount of right-of-use assets Depreciation, Amortization and Accretion, Net Share-based compensation Share-based Payment Arrangement, Noncash Expense Gains on disposition of securities Debt and Equity Securities, Gain (Loss) Other than Temporary Impairment Losses on Investments Other than Temporary Impairment Losses, Investments Changes in fair market value of equity securities Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss Losses on dispositions of fixed assets Gain (Loss) on Disposition of Property Plant Equipment Gain on sale of land Gain (Loss) on Disposition of Assets Gain on divestiture of product line Gain (Loss) on Disposition of Other Assets Payments for operating lease liabilities Operating Lease, Payments, Use Changes in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Decrease (increase) in accounts receivable, net Increase (Decrease) in Accounts Receivable Decrease (increase) in inventories, net Increase (Decrease) in Inventories Decrease (increase) in Other Current Assets Increase (Decrease) in Other Current Assets Increase (decrease) in accounts payable and other current liabilities Increase (Decrease) in Accounts Payable and Other Operating Liabilities Decrease in Income Taxes Payable Increase (Decrease) in Income Taxes Payable Increase (decrease) in deferred income taxes Increase (Decrease) in Deferred Income Taxes (Increase) decrease in other long term assets Increase (Decrease) in Other Noncurrent Assets Increase (decrease) in Other Long Term Liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net Impairment losses on goodwill and long-lived assets Asset Impairment Charges Increase (Decrease) in Other Operating Assets and Liabilities, Net Increase (Decrease) in Other Operating Assets and Liabilities, Net Noncash purchased property, plant and equipment Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash Purchased Marketable Securities and Investments Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Accounts Receivable Acquired Noncash or Part Noncash Acquisition, Accounts Receivable Acquired Commitments and Contingencies Disclosure [Abstract] Contribution expense Deferred Compensation Arrangement with Individual, Contributions by Employer Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table] Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Nature of Error [Axis] Nature of Error [Axis] Nature of Error [Domain] Nature of Error [Domain] Quantifying Misstatement in Current Year Financial Statements [Line Items] Quantifying Misstatement in Current Year Financial Statements [Line Items] Net sales Revenue from Contract with Customer, Including Assessed Tax Operating Income (Loss) Operating Income (Loss) Cost of Goods and Services Sold Cost of Goods and Services Sold Gross profit Gross Profit Selling, general and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Unrealized Loss on Securities Unrealized Loss on Securities Earnings Per Share, Basic Earnings Per Share, Basic Earnings Per Share, Diluted Earnings Per Share, Diluted Income Tax Expense (Benefit) Accounting Policies [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Employee Location [Axis] Employee Location [Axis] Employee Location [Axis] Employee Location [Domain] Employee Location [Domain] [Domain] for Employee Location [Axis] 541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member] 541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2016-16 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Capitalized Cloud Computing Arrangements Capitalized Cloud Computing Arrangements Capitalized Cloud Computing Arrangements Entity Number of Employees Entity Number of Employees Deferred Tax Assets, Net, Noncurrent Deferred Tax Assets, Net, Noncurrent Interest expense Interest Expense Other assets Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent Restricted investments Restricted Investments, Current Retained earnings Retained Earnings (Accumulated Deficit) Prepaid Taxes Deferred Income Tax Assets, Net Deferred Income Tax Assets, Net Investments Investments Other (income) expense, net Other Nonoperating Income (Expense) Deferred Tax Assets, Gross Deferred Income Tax Expense (Benefit) Restricted Cash Restricted Cash Reconciliation of Assets from Segment to Consolidated [Table] Reconciliation of Assets from Segment to Consolidated [Table] Other Current Assets [Member] Other Current Assets [Member] Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] -- excludes segment specific gross machinery and equipment and operating lease right-of-use assets Goodwill [Member] Goodwill [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Segment Reporting, Asset Reconciling Item [Line Items] Segment Reporting, Asset Reconciling Item [Line Items] Total assets Assets Basis of Presentation Consolidation, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Short-term Restricted Investments Short-term Restricted Investments [Policy Text Block] Short-term Restricted Investments [Policy Text Block] Available-for-sale Investments Marketable Securities, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Accounts Receivable [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Lessor, Leases Lessor, Leases [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Revenue Recognition, Leases Revenue Recognition, Leases [Policy Text Block] Revenue Recognition, Deferred Revenue Revenue Recognition, Deferred Revenue [Policy Text Block] Warranty Standard Product Warranty, Policy [Policy Text Block] Shipping and Handling Shipping and Handling Cost, Policy [Policy Text Block] Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Forward Foreign Exchange Contracts Derivatives, Policy [Policy Text Block] Share-based Compensation Plans Share-based Payment Arrangement [Policy Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restructuring and Related Activities Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Treasury Class-A [Member] Treasury Class-A [Member] Treasury Class A [Member] Treasury Class B [Member] Treasury Class B [Member] Treasury Class B [Member] Shares, Issued Shares, Issued Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, Conversion of Convertible Securities Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Treasury Stock, Shares, Acquired Treasury Stock, Shares, Acquired Common Stock, Voting Rights Common Stock, Voting Rights Election Percentage for Board of Directors Election Percentage for Board of Directors Election Percentage for Board of Directors Income Statement [Abstract] Scenario [Axis] Gross Profit Income from operations Foreign exchange losses, net Foreign Currency Transaction Gain (Loss), before Tax Unrealized Gain on Securities Other (income) expense, net Income before income taxes Provision for income taxes Net Income (Loss) Attributable to Parent Basic earnings per share: Earnings Per Share, Basic [Abstract] Weighted average common shares - basic Weighted Average Number of Shares Outstanding, Basic Diluted earnings per share: Earnings Per Share, Diluted [Abstract] Weighted average common shares - diluted Weighted Average Number of Shares Outstanding, Diluted accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] accumulated other comprehensive income [Text Block] Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Unsecured Debt [Member] Finance Lease Obligations [Member] Finance Lease Obligations [Member] Finance Lease Obligations [Member] Capital Lease Obligations [Member] Line of Credit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% due 2020 [Member] Senior Notes 4.875% [Member] Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Finance Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Capital Leases and Other Debt [Member] Performance Guarantee [Member] Performance Guarantee [Member] Standby Letters of Credit [Member] Standby Letters of Credit [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Unsecured Debt Unsecured Debt Long-term debt Long-term Debt Other Long-term Debt Other Long-term Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Long-term Debt and Lease Obligation, Including Current Maturities Long-term Debt and Lease Obligation, Including Current Maturities Debt and Lease Obligation Debt and Lease Obligation Other Long-term Debt, Current Other Long-term Debt, Current Long-term Debt and Lease Obligation Long-term Debt and Lease Obligation Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Face amount of debt sold Debt Instrument, Face Amount Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Maturities of Long-term Debt [Abstract] Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Two Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Three Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Four Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Long-term Debt, Maturities, Repayments of Principal after Year Five Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Long-term Line of Credit Line of Credit, Current Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Interest Rate at Period End Line of Credit Facility, Interest Rate at Period End Letters of Credit Outstanding, Amount Letters of Credit Outstanding, Amount Basic weighted average shares outstanding Effect of potentially dilutive stock options and restricted stock awards Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares Anti-dilutive shares excluded from the computation of diluted EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Software [Member] Computer Software, Intangible Asset [Member] Building and Building Improvements [Member] Building and Building Improvements [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Reagent Rental Equipment [Member] Equipment [Member] Equipment [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Restricted Cash and Cash Equivalents Restricted Cash and Cash Equivalents Other assets Other Assets, Noncurrent Equipment Machinery and Equipment, Gross Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Segments, Geographical Areas [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Europe [Member] Europe [Member] Asia [Member] Asia Pacific [Member] UNITED STATES UNITED STATES Other (primarily Canada and Latin America) [Member] Americas [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Net sales Revenue from Contract with Customer, Excluding Assessed Tax Other assets, property, plant and equipment, net and Operating lease right-of-use assets Long-Lived Assets Movement in Standard Product Warranty Accrual [Roll Forward] Warranty accrual, beginning of period Standard and Extended Product Warranty Accrual Provision for warranty Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Actual warranty costs Standard and Extended Product Warranty Accrual, Decrease for Payments Warranty accrual, end of period Leases [Abstract] Leases of Lessee Disclosure [Text Block] Leases of Lessee Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other post-employment benefits adjustments, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Net unrealized holding gains on available-for-sale investments, net of tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Comprehensive income attributable to Bio-Rad Comprehensive Income (Loss), Net of Tax, Attributable to Parent Lease, Cost [Table Text Block] Lease, Cost [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Cash Flow Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block] Commitments and Contingent Liabilities Commitments and Contingencies Disclosure [Text Block] SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] SEC Schedule, 12-09, Allowance, Credit Loss [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Valuation Allowances and Reserves, Balance Period Start SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Other SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired Valuation Allowances and Reserves, Balance Period End Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Axis] Contract with Customer, Duration [Domain] Contract with Customer, Duration [Domain] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Revenue Allocation Percent To Lease Elements Deferred Revenue Deferred Revenue Deferred Revenue, Period Increase (Decrease) Deferred Revenue, Period Increase (Decrease) Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Obligations and Funded Status [Abstract] Obligations and Funded Status [Abstract] Schedule of Net Benefit Costs [Table Text Block] Schedule of Net Benefit Costs [Table Text Block] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Defined Contribution Plan Disclosures [Table Text Block] Defined Benefit Plan, Assumptions [Table Text Block] Defined Benefit Plan, Assumptions [Table Text Block] Share-based Payment Arrangement, Noncash Expense [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Exercise Price Range [Axis] Exercise Price Range [Domain] Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis] Award Type [Axis] Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain] Award Type [Domain] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] Stock Option and Award Plans [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] 2011 Employee Stock Purchase Plan [Member] Stock Options [Member] Share-based Payment Arrangement, Option [Member] Employee Stock [Member] Employee Stock [Member] Stock Options [Member] Employee Stock [Member] Stock Award Plans [Member] Stock Award Plans [Member] Stock Award Plans [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Incentive Award Plan 2017 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted Average Remaining Contractual Term (in years) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (in millions) - Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options - Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Granted - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options Exercised - Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options Granted Term Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Options Forfeitured/expired - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Options - Shares Vested and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options Vested and Expected to Vest - Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Weighted Average Exercise Price - Options Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in years) - Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options Exercisable Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Options, Exercises in Period, Total Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Cash Received from Exercise of Stock Options Proceeds from Stock Options Exercised Share-based Payment Arrangement, Exercise of Option, Tax Benefit Share-based Payment Arrangement, Exercise of Option, Tax Benefit Total unrecognized compensation cost from stock options Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options Number Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Stock Issued During Period, Shares, Employee Stock Purchase Plans Stock Issued During Period, Shares, Employee Stock Purchase Plans Options Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Employee Contribution Rate - Maximum Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount Employee Purchase Price Discount from Market Price Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Share-based Compensation Expense Share-based Payment Arrangement, Expense Share-based Payment Arrangement, Expense, Tax Benefit Share-based Payment Arrangement, Expense, Tax Benefit Weighted average fair value of options granted, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Weighted average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options - Shares Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Options - Shares Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options - Shares Forfeitures/expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding end of period Business Combinations [Abstract] Business Combination Disclosure [Text Block] Business Combination Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common Stock [Member] Common Stock [Member] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Preferred stock par value Preferred Stock, Par or Stated Value Per Share Preferred stock authorized Preferred Stock, Shares Authorized Preferred stock issued Preferred Stock, Shares Issued Preferred stock outstanding Preferred Stock, Shares Outstanding Common stock par value Common Stock, Par or Stated Value Per Share Common stock authorized Common Stock, Shares Authorized Common stock issued Common Stock, Shares, Issued Common stock outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Derivative [Table] Derivative [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to purchase foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Forward foreign exchange contract to sell foreign currency [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Gain (loss) on foreign currency derivative instruments not designated as hedging instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Derivative, Notional Amount Derivative, Notional Amount U.S. and international components of income before taxes [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Provision for income taxes [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of deferred tax assets and liabilities [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of income tax years currently under audit or open to examinations [Table Text Block] Summary of Income Tax Examinations [Table Text Block] Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block] Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block] Statement of Financial Position [Abstract] Deferred Tax Asset [Domain] Deferred Tax Asset [Domain] Deferred Revenue [Domain] Deferred Revenue [Domain] Common Class A [Member] Common Class B [Member] ASSETS: Assets [Abstract] Short-term investments Short-term Investments Accounts receivable, less allowance for doubtful accounts Accounts Receivable, after Allowance for Credit Loss, Current Inventories: Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total inventories Inventory, Net Prepaid expenses Prepaid Expense, Current Other current assets Other Assets, Current Total current assets Assets, Current Property, plant and equipment: Property, Plant and Equipment, Gross [Abstract] Land and improvements Land Buildings and leasehold improvements Buildings and Improvements, Gross Total property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Goodwill, net Purchased intangibles, net Intangible Assets, Net (Excluding Goodwill) Other investments Long-term Investments Long-term deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Total assets LIABILITIES AND STOCKHOLDERS' EQUITY: Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued payroll and employee benefits Employee-related Liabilities, Current Current maturities of long-term debt Notes and Loans Payable, Current Income taxes payable Accrued Income Taxes, Current Other taxes payable Taxes Payable, Current Current operating lease liabilities Operating Lease, Liability, Current Accrued royalties Accrued Royalties, Current Deferred revenue Deferred Revenue, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, net of current maturities Operating lease liabilities Operating Lease, Liability, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingent liabilities Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Preferred stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Treasury Stock, Value Treasury Stock, Value Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Class of Treasury Stock [Table] Class of Treasury Stock [Table] Treasury Class-A [Member] Restricted Stock Units (RSUs) [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Treasury Stock Acquired, Average Cost Per Share Treasury Stock Acquired, Average Cost Per Share Stock Issued During Period, Shares, Treasury Stock Reissued Stock Issued During Period, Shares, Treasury Stock Reissued All Other Segments [Member] Other Segments [Member] Number Of Products And Services Number Of Products And Services Number Of Products And Services Segment profit Payments to Acquire Property, Plant, and Equipment Debt Securities, Available-for-sale [Table Text Block] Debt Securities, Available-for-sale [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Schedule of Derivative Instruments [Table Text Block] Financial assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of available-for-sale investments Available-for-sale Securities [Table Text Block] Summary of investments with gross unrealized losses and the associated fair value Schedule of Unrealized Loss on Investments [Table Text Block] Summary of amortized cost and estimated fair value of debt securities by contractual maturity date Investments Classified by Contractual Maturity Date [Table Text Block] Estimated fair value of financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In Process Research and Development [Member] In Process Research and Development [Member] CellSorter [Member] CellSorter [Member] CellSorter [Member] [Member] Acquired Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer Relationships [Member] Customer Relationships [Member] Know how [Member] Know How [Member] Know how [Member] Developed Technology Rights [Member] Developed Technology Rights [Member] Licensing Agreements [Member] Licensing Agreements [Member] Trade Names [Member] Trade Names [Member] Noncompete Agreements [Member] Noncompete Agreements [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Future Amortization Expense, Year One Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months Future Amortization Expense, Year Two Finite-Lived Intangible Assets, Amortization Expense, Year Two Future Amortization Expense, Year Three Finite-Lived Intangible Assets, Amortization Expense, Year Three Future Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Four Future Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Amortization Expense, after Year Five Finite-Lived Intangible Assets, Net [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Net Carrying Amount Finite-Lived Intangible Assets, Net Amortization [Abstract] Amortization expense Amortization of Intangible Assets Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of Intangible Assets, Finite-lived Intangible Assets, Net (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Intangible Assets, Gross (Excluding Goodwill) Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill, Purchase Accounting Adjustments Goodwill, Purchase Accounting Adjustments Goodwill Business Combination, Consideration Transferred, Liabilities Incurred Business Combination, Consideration Transferred, Liabilities Incurred Restricted Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total unrecognized compensation cost from restricted stock Nonvested shares - Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Units Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units - Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units - Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Weighted Average Grant Date Fair Value - Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Line of Credit [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Member] Reclassification out of Accumulated Other Comprehensive Income [Member] Selling, general and administrative expense Realized Investment Gains (Losses) Realized Investment Gains (Losses) SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Schedule of other income (expense), net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Statement of Stockholders' Equity [Abstract] Additional Paid-in Capital [Member] Treasury Stock [Member] Treasury Stock [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Total Bio Rad [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Net income Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect Issuance of common stock Proceeds from Issuance of Common Stock Stock compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption Treasury Stock, Value, Acquired, Cost Method Treasury Stock, Value, Acquired, Cost Method Stock Issued During Period, Value, Treasury Stock Reissued Stock Issued During Period, Value, Treasury Stock Reissued Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Balance Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Subsequent Events [Text Block] Subsequent Events [Text Block] Stock Options Activity Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Stock Options Outstanding Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Stock Options Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Resticted Stock Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Schedule of Weighted Average Number of Shares Schedule of Weighted Average Number of Shares [Table Text Block] Changes to goodwill by segment Schedule of Goodwill [Table Text Block] Schedule of Finite-Lived Intangible Assets by Major-Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lease Type [Axis] Lease Type [Axis] Lease Type [Axis] Property Subject to or Available for Operating Lease [Domain] Property Subject to or Available for Operating Lease [Domain] Finance Lease [Member] Finance Lease [Member] Finance Lease [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Unrecorded Unconditional Purchase Obligation Other Commitment Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Deferred Tax Assets, Other U.S. Operating Leases, Rent Expense, Net Operating Leases, Rent Expense, Net Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Finance Lease, Liability, Payments, Remainder of Fiscal Year Finance Lease, Liability, Payments, Due Next Twelve Months Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Property, Plant and Equipment, Gross Operating Lease, Payments Operating Lease, Payments Capital Leases, Future Minimum Payments Due in Three Years Capital Leases, Future Minimum Payments Due in Three Years Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating Leases, Future Minimum Payments, Due in Two Years Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Operating Lease, Cost Operating Lease, Cost Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Right-of-Use Asset, Amortization Finance Lease, Interest Expense Finance Lease, Interest Expense Finance Lease Cost Finance Lease Cost Finance Lease Cost Sublease Income Sublease Income Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Four Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases, Future Minimum Payments, Due Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Capital Leases, Future Minimum Payments Due, Next Twelve Months Capital Leases, Future Minimum Payments Due, Next Twelve Months Capital Leases, Future Minimum Payments Due in Two Years Capital Leases, Future Minimum Payments Due in Two Years Capital Leases, Future Minimum Payments Due in Four Years Capital Leases, Future Minimum Payments Due in Four Years Capital Leases, Future Minimum Payments Due in Five Years Capital Leases, Future Minimum Payments Due in Five Years Capital Leases, Future Minimum Payments Due Thereafter Capital Leases, Future Minimum Payments Due Thereafter Finance Lease, Interest Payment on Liability Finance Lease, Interest Payment on Liability Finance Lease, Principal Payments Finance Lease, Principal Payments Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Current operating lease liabilities Current maturities of long-term debt and notes payable Finance Lease, Liability, Current Finance Lease, Liability, Noncurrent Finance Lease, Liability, Noncurrent Operating Lease, Liability Operating Lease, Liability Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Finance Lease, Liability, Payments, Due Year Two Finance Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Finance Lease, Liability, Payments, Due Year Three Finance Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Finance Lease, Liability, Payments, Due Year Four Finance Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Finance Lease, Liability, Payments, Due Year Five Finance Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, Payments, Due after Year Five Finance Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Payments, Due Finance Lease, Liability, Payment, Due Finance Lease, Liability, Payment, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability Finance Lease, Liability Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Lessee Operating And Finance Leases Remaining Lease Term Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-term Commitment [Table] Purchase Commitment, Excluding Long-term Commitment [Line Items] Purchase Commitment, Excluding Long-term Commitment [Line Items] Post-Employment Benefits Liability Postemployment Benefits Liability Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Next Twelve Months Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Second Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Third Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fourth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due in Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Recorded Unconditional Purchase Obligation Due after Fifth Year Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation Unrecorded Unconditional Purchase Obligation, Due in Twelve Months Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Two Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Three Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Four Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due within Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Unrecorded Unconditional Purchase Obligation, Due after Five Years Letters of Credit Outstanding Amount Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees Covered By Collective Bargaining Agreements U.S., Percentage Employees covered by collective bargaining agreements, percentage Quarterly Financial Data [Text Block] Quarterly Financial Information [Text Block] Income Taxes [Text Block] Income Tax Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Forecast [Member] Forecast [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Discount rate [Member] Market Price of Risk [Member] Market Price of Risk [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone percentage of annual invoices low [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Sales milestone minimum amount [Member] Cost of debt [Member] Projected Volatility of Sales [Member] [Member] Projected Volatility of Sales [Member] Distributor [Member] Distributor [Member] Distributor [Member] Discount Rate Discount Rate Discount Rate Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Business Acquisition, Contingent Consideration, Potential Percentage Payout Business Acquisition, Contingent Consideration, Potential Percentage Payout business acquisition contingent consideration percentage payout Interest and investment income Investment Income, Interest and Dividend Net realized gains on investments Other-than-temporary impairment losses on investments Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Gain on divestiture of product line Other Expense Other Nonoperating Expense Other (income) expense, net Loss Contingency, Damages Sought, Value Loss Contingency, Damages Sought, Value Litigation Settlement Interest Litigation Settlement Interest Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency Accrual, Period Increase (Decrease) Loss Contingency, Damages Awarded, Value Loss Contingency, Damages Awarded, Value Disclosure of Compensation Related Costs, Share-based Payments Share-based Payment Arrangement [Text Block] EX-101.PRE 13 bio-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 chart-d7753823a7d35527837a01.jpg STOCK PERFORMANCE GRAPH begin 644 chart-d7753823a7d35527837a01.jpg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end XML 15 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
15. Restructuring Costs (Notes)
 12 Months Ended
Dec. 31, 2019
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, were incurred through and completed in December 2019. We recorded approximately $(0.1) million, $(0.2) million and $0.5 million in restructuring charges and adjustments related to severance and other employee benefits for the years ended December 31, 2019, 2018 and 2017, respectively. From May 2016 to December 31, 2019, total expenses were $12.7 million. The amounts recorded were reflected in Cost of goods sold of $(0.1) million, $(0.1) million and $(0.2) million, and in Selling, general and administrative expense of zero, $(0.1) million and $0.7 million in the Consolidated Statements of Income for the years ended December 31, 2019, 2018 and 2017, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2019
 
2018
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.2
)
Cash payments
 
(0.3
)
 
(0.5
)
 
(0.8
)
 
(1.5
)
 
(2.9
)
 
(4.4
)
Reserve transferred to European and North American Reorganization restructuring costs reserve (see below)
 
(0.3
)
 
(0.4
)
 
(0.7
)
 
—

 
—

 
—

Foreign currency translation gains
 
—

 
—

 
—

 
—

 
(0.1
)
 
(0.1
)
Balance as of December 31
 
$
—

 
$
—

 
$
—

 
$
0.6

 
$
1.0

 
$
1.6




Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures

In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded restructuring charges and adjustments related to severance and employee benefits of less than $(0.1) million, $0.4 million and $11.0 million and asset write-offs and exit costs of zero, $(0.1) million and $10.1 million for the years ended December 31, 2019, 2018 and 2017, respectively. From December 2017 to December 31, 2019, total expenses were $21.4 million. This restructuring plan was completed in December 2019.

In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.3) million and $1.7 million for the years ended December 31, 2019 and 2018, respectively. From June 2018 to December 31, 2019, total expenses were $1.4 million. This restructuring plan was completed in November 2019.

In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges and adjustments related to severance and employee benefits of $(0.1) million and $3.9 million and exit costs of zero and $0.2 million for the years ended December 31, 2019 and 2018, respectively. From December 2018 to December 31, 2019, total expenses were $4.0 million.

Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of $(0.3) million, $5.4 million and $2.3 million, in Selling, general and administrative expense of zero, $0.4 million and $3.3 million, and in Research and development expense of $(0.1) million, $0.3 million and $15.5 million in the Consolidated Statements of Income for the years ended December 31, 2019, 2018 and 2017, respectively. The liability of $3.2 million as of December 31, 2019 consisted of $1.8 million recorded in Accrued payroll and employee benefits, $0.2 million recorded in Other current liabilities, and $1.2 million recorded in Other long-term liabilities in the Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2019
 
2018
Balance as of January 1
 
$
11.5

 
$
14.1

Charged to expense
 
—

 
5.8

Adjustment to expense
 
(0.4
)
 
0.3

Cash payments
 
(7.7
)
 
(8.4
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
Balance as of December 31
 
$
3.2

 
$
11.5



Restructuring Costs for European and North American Reorganization

In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy.
The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. We recorded $25.3 million of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2019. The liability of $25.3 million as of December 31, 2019 was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $4.8 million, in Selling, general and administrative expense of $14.4 million and in Research and development expense of $6.1 million in the Consolidated Statements of Income for the year ended December 31, 2019.

The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):

 
 
2019
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
—

 
$
—

 
$
—

Charged to expense
 
6.2

 
19.1

 
25.3

Cash payments
 
(0.4
)
 
(0.7
)
 
(1.1
)
Reserve transferred from European Reorganization restructuring costs reserve (see above)
 
0.3

 
0.4

 
0.7

Foreign currency translation losses
 
0.1

 
0.3

 
0.4

Balance as of December 31
 
$
6.2

 
$
19.1

 
$
25.3

XML 16 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.
Cash and Cash Equivalents
Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.
Short-term Restricted Investments
Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2019 and 2018 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.
Available-for-sale Investments
Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).
Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.
Accounts Receivable
Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.
Inventory
Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.
Property, Plant and Equipment
Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 10-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years.
Leases
Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of December 31, 2019. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of December 31, 2019.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.
Lessor, Leases
Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."
Goodwill
Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  
Long-Lived Assets
Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.
Income Taxes
Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.
Revenue Recognition
Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.

In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.
Revenue Recognition, Leases
Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.
As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  As a result, our lease income is heavily variable in nature.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.

Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% and 5% of total revenue for 2019 and 2018, respectively, and is included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).
Revenue Recognition, Deferred Revenue Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.8 million at December 31, 2019 was primarily driven by $33.1 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $24.6 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018.
Warranty
We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2019
 
2018
January 1
 
$
10.1

 
$
18.7

Provision for warranty
 
9.9

 
25.5

Actual warranty costs
 
(11.0
)
 
(34.1
)
December 31
 
$
9.0

 
$
10.1
Shipping and Handling
Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.
Research and Development Expense

Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  
Foreign Currency

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.
Forward Foreign Exchange Contracts

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  
Share-based Compensation Plans

Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Forfeitures are recognized as they occur.  These plans are described more fully in Note 9.
Earnings Per Share

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Basic weighted average shares outstanding
 
29,843

 
29,836

 
29,655

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
341

 
392

 
379

Diluted weighted average common shares
 
30,184

 
30,228

 
30,034

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
98

 
84

 
13
Fair Value of Financial Instruments

Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).
New Accounting Pronouncements
Recent Accounting Pronouncements Adopted

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of December 31, 2019, we capitalized $3.1 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet.

In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."

Recent Accounting Pronouncements to be Adopted

In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption.

In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements, however due to the generally short duration of our customers' trade receivables, we do not expect ASU 2016-13 to have a material impact.
XML 17 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies Revenue Recognition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2018
Disaggregation of Revenue [Line Items]        
Cost of Goods and Services Sold $ 1,054,663 $ 1,066,264 $ 972,450  
Retained earnings $ 5,470,779 $ 3,722,073    
Revenue Allocation Percent To Lease Elements 3.00% 5.00%    
Deferred Revenue $ 45,800 $ 37,300    
Deferred Revenue, Period Increase (Decrease) 33,100      
Deferred Revenue, Revenue Recognized $ 24,600      
Accounting Standards Update 2014-09 [Member]        
Disaggregation of Revenue [Line Items]        
Retained earnings       $ 100
XML 18 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]      
Restricted investments $ 5,560 $ 5,560  
Retained earnings 5,470,779 3,722,073  
Other assets 79,636 70,298  
Prepaid Taxes 5,400    
Equipment 1,015,359 970,081  
Deferred income taxes 997,787 553,239  
Income Tax Expense (Benefit) $ (502,406) $ (147,045) $ 24,444
Minimum [Member] | Software [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 3 years    
Minimum [Member] | Building and Building Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 10 years    
Minimum [Member] | Reagent Rental Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 1 year    
Minimum [Member] | Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 3 years    
Maximum [Member] | Software [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 12 years    
Maximum [Member] | Building and Building Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 39 years    
Maximum [Member] | Reagent Rental Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 5 years    
Maximum [Member] | Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property, Plant and Equipment, Useful Life 12 years    
XML 19 R60.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
7. Stockholders' Equity (Details) - shares
 1 Months Ended 12 Months Ended
Nov. 30, 2019
Aug. 31, 2019
Jun. 30, 2019
May 31, 2019
Nov. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Class of Stock [Line Items]                  
Treasury Stock, Shares, Acquired 22,343 14,745 25,977 25,421 178,911        
Common Class A [Member]                  
Class of Stock [Line Items]                  
Shares, Issued           24,966,000 24,884,000 24,679,000 24,454,000
Stock Issued During Period, Shares, Conversion of Convertible Securities           (24,000) (30,000) (34,000)  
Stock Issued During Period, Shares, New Issues           58,000 175,000 191,000  
Common Stock, Voting Rights           .10      
Election Percentage for Board of Directors           25.00%      
Common Class B [Member]                  
Class of Stock [Line Items]                  
Shares, Issued           5,090,000 5,096,000 5,108,000 5,124,000
Stock Issued During Period, Shares, Conversion of Convertible Securities           (24,000) (30,000) (34,000)  
Stock Issued During Period, Shares, New Issues           18,000 18,000 18,000  
Common Stock, Voting Rights           1      
Election Percentage for Board of Directors           75.00%      
XML 20 R64.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
9. Share-based Compensation (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Payment Arrangement, Exercise of Option, Tax Benefit $ 5,400,000 $ 5,400,000 $ 6,300,000
Share-based Compensation Expense 35,600,000 27,800,000 23,400,000
Share-based Payment Arrangement, Expense, Tax Benefit $ 5,600,000 $ 4,400,000 5,800,000
2011 Employee Stock Purchase Plan [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 1,300,000    
Stock Option and Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Authorized 2,095,049    
Number of Shares Available for Grant 1,507,489    
Stock Options [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted Average Remaining Contractual Term (in years) - Outstanding 4 years 9 months 3 days    
Aggregate Intrinsic Value (in millions) - Outstanding $ 71.6    
Options - Weighted-Average Exercise Price $ 162.23 $ 138.81  
Options Granted - Weighted Average Exercise Price 328.48    
Options Exercised - Weighted Average Exercise Price $ 98.00    
Options Granted Term P10Y    
Options Forfeitured/expired - Weighted Average Exercise Price $ 231.71    
Options - Shares Vested and Expected to Vest 94,172    
Options Vested and Expected to Vest - Weighted Average Exercise Price $ 273.93    
Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years) 8 years 5 months 12 days    
Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions) $ 9.1    
Weighted Average Exercise Price - Options Exercisable $ 120.22    
Weighted Average Remaining Contractual Term (in years) - Exercisable 3 years 5 months 15 days    
Options Exercisable Aggregate Intrinsic Value (in millions) $ 62.5    
Options, Exercises in Period, Total Intrinsic Value 12,000,000 $ 8,000,000 10,000,000
Cash Received from Exercise of Stock Options 2,600,000 $ 500,000 $ 1,600,000
Total unrecognized compensation cost from stock options $ 7,000,000.0    
Options Number Exercisable 250,350    
Options Vesting Period 5 years    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 20.00%    
Weighted average fair value of options granted, period for recognition 3 years    
Expected Volatility 22.00% 22.00% 20.00%
Risk Free Interest Rate 1.69% 2.85% 1.87%
Expected life (in years) 7 years 6 months 7 years 7 months 6 days 7 years 2 months 12 days
Expected dividend $ 0 $ 0 $ 0
Weighted average fair value of options granted $ 93.96 $ 105.94 $ 58.65
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]      
Outstanding beginning of period 373,640    
Options - Shares Granted 34,672    
Options - Shares Exercised (55,490)    
Options - Shares Forfeitures/expired (8,300)    
Outstanding end of period 344,522 373,640  
Employee Stock [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of Shares Available for Grant 599,531    
Cash Received from Exercise of Stock Options $ 14,300,000 $ 13,600,000 $ 13,000,000.0
Stock Issued During Period, Shares, Employee Stock Purchase Plans 58,717 63,464 74,409
Employee Contribution Rate - Maximum 10.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount $ 25,000    
Employee Purchase Price Discount from Market Price 85.00%    
Expected Volatility 31.00% 27.00% 19.00%
Risk Free Interest Rate 2.25% 1.82% 0.83%
Expected life (in years) 2 months 26 days 2 months 26 days 2 months 26 days
Expected dividend $ 0 $ 0 $ 0
Expected dividend yield 0.00%    
Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased $ 60.39 $ 55.04 $ 38.86
Stock Award Plans [Member] | Incentive Award Plan 2017 [Member]      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Options Vesting Period 5 years    
XML 21 R68.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. Commitments & Contingent Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Post-Employment Benefits Liability $ 3.5 $ 3.1
Recorded Unconditional Purchase Obligation 118.4  
Recorded Unconditional Purchase Obligation Due in Next Twelve Months 5.2  
Recorded Unconditional Purchase Obligation Due in Second Year 12.8  
Recorded Unconditional Purchase Obligation Due in Third Year 4.5  
Recorded Unconditional Purchase Obligation Due in Fourth Year 4.3  
Recorded Unconditional Purchase Obligation Due in Fifth Year 3.3  
Recorded Unconditional Purchase Obligation Due after Fifth Year 88.3  
Unrecorded Unconditional Purchase Obligation 35.8  
Unrecorded Unconditional Purchase Obligation, Due in Twelve Months 34.0  
Unrecorded Unconditional Purchase Obligation, Due within Two Years 1.0  
Unrecorded Unconditional Purchase Obligation, Due within Three Years 0.2  
Unrecorded Unconditional Purchase Obligation, Due within Four Years 0.2  
Unrecorded Unconditional Purchase Obligation, Due within Five Years 0.2  
Unrecorded Unconditional Purchase Obligation, Due after Five Years 0.2  
Letters of Credit Outstanding Amount $ 4.2  
Employees Covered By Collective Bargaining Agreements U.S., Percentage 7.00%  
UNITED STATES    
Purchase Commitment, Excluding Long-term Commitment [Line Items]    
Entity Number of Employees 3,180  
ZIP 22 0000012208-20-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000012208-20-000012-xbrl.zip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�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
XML 24 R56.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Mar. 04, 2019
Goodwill [Line Items]            
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill           $ 200
Goodwill [Roll Forward]            
Goodwill period start   $ 555,000 $ 559,300 $ 555,000 $ 559,300  
Accumulated impairment loss period start   (335,200) (53,200) (335,200) (53,200)  
Goodwill, net period start   219,770 506,100 219,770 506,100  
Goodwill, Acquired During Period $ 28,700 15,600   44,300 0  
Goodwill, Written off Related to Sale of Business Unit       0 (1,400)  
Goodwill, Impairment Loss       0 282,000  
Currency fluctuations       0 (2,900)  
Goodwill period end       599,300 555,000  
Accumulated impairment loss period end       (335,200) (335,200)  
Goodwill, net period end       264,131 219,770  
Life Science [Member]            
Goodwill [Roll Forward]            
Goodwill period start   234,500 234,700 234,500 234,700  
Accumulated impairment loss period start   (41,800) (35,900) (41,800) (35,900)  
Goodwill, net period start   192,700 198,800 192,700 198,800  
Goodwill, Acquired During Period       15,600 0  
Goodwill, Written off Related to Sale of Business Unit       0 0  
Goodwill, Impairment Loss       0 5,900  
Currency fluctuations       0 (200)  
Goodwill period end       250,100 234,500  
Accumulated impairment loss period end       (41,800) (41,800)  
Goodwill, net period end       208,300 192,700  
Clinical Diagnostics [Member]            
Goodwill [Roll Forward]            
Goodwill period start   320,500 324,600 320,500 324,600  
Accumulated impairment loss period start   (293,400) (17,300) (293,400) (17,300)  
Goodwill, net period start   $ 27,100 307,300 27,100 307,300  
Goodwill, Acquired During Period       28,700 0  
Goodwill, Written off Related to Sale of Business Unit     $ (1,400) 0 (1,400)  
Goodwill, Impairment Loss       0 276,100  
Currency fluctuations       0 (2,700)  
Goodwill period end       349,200 320,500  
Accumulated impairment loss period end       (293,400) (293,400)  
Goodwill, net period end       $ 55,800 27,100  
Pasteur Sanofi Diagnosics S.A. [Member] | Clinical Diagnostics [Member]            
Goodwill [Roll Forward]            
Goodwill, Impairment Loss         18,100  
DiaMed [Member] | Clinical Diagnostics [Member]            
Goodwill [Roll Forward]            
Goodwill, Impairment Loss         247,200  
Biotest AG [Member] | Clinical Diagnostics [Member]            
Goodwill [Roll Forward]            
Goodwill, Impairment Loss         $ 10,800  
XML 25 R79.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
18. Subsequent Event (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Subsequent Event [Line Items]      
Business Combination, Consideration Transferred $ 4.2 $ 60.0 $ 20.0
XML 26 R75.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Information Segment Information by Geographical Location (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]      
Net sales $ 2,311.7 $ 2,289.4 $ 2,160.2
Other assets, property, plant and equipment, net and Operating lease right-of-use assets 731.2 530.1  
Europe [Member]      
Segment Reporting Information [Line Items]      
Net sales 770.3 792.0 758.5
Other assets, property, plant and equipment, net and Operating lease right-of-use assets 198.3 129.1  
Asia [Member]      
Segment Reporting Information [Line Items]      
Net sales 505.0 495.5 461.3
Other assets, property, plant and equipment, net and Operating lease right-of-use assets 51.5 20.7  
UNITED STATES      
Segment Reporting Information [Line Items]      
Net sales 899.1 863.6 800.2
Other assets, property, plant and equipment, net and Operating lease right-of-use assets 468.7 369.2  
Other (primarily Canada and Latin America) [Member]      
Segment Reporting Information [Line Items]      
Net sales 137.3 138.3 $ 140.0
Other assets, property, plant and equipment, net and Operating lease right-of-use assets $ 12.7 $ 11.1  
XML 27 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
13. Legal Proceedings Legal Proceedings (Details) - USD ($)
 12 Months Ended
Feb. 26, 2019
Dec. 31, 2018
Legal Proceedings [Abstract]    
Loss Contingency, Damages Sought, Value   $ 10,920,000
Litigation Settlement Interest   $ 141,608
Subsequent Event [Line Items]    
Loss Contingency Accrual, Period Increase (Decrease) $ (2,960,000)  
Loss Contingency, Damages Awarded, Value $ 7,960,000  
XML 28 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:      
Cash received from customers $ 2,311,925 $ 2,326,310 $ 2,093,948
Cash paid to suppliers and employees (1,818,575) (1,989,685) (1,916,119)
Interest paid, net (22,330) (22,703) (22,224)
Income tax payments, net (45,081) (62,414) (52,136)
Investment proceeds and miscellaneous receipts, net 31,673 26,383 18,392
Proceeds from (payments for) forward foreign exchange contracts, net 285 7,603 (17,724)
Net cash provided by operating activities 457,897 285,494 104,137
Cash flows from investing activities:      
Capital expenditures (98,532) (129,825) (111,332)
Proceeds from dispositions of property, plant and equipment 129 4,315 86
Proceeds from divestiture of a product line 0 6,964 0
Payments for (proceeds from) acquisitions and long-term investment (79,386) 266 (76,645)
Recovery of (payments for) purchases of intangible assets (8,818) 3 3,795
Payments for purchases of restricted investment 0 0 (1,000)
Payments for purchases of marketable securities and investments (371,450) (371,019) (282,656)
Proceeds from sales of marketable securities and investments 104,632 77,029 97,523
Proceeds from maturities of marketable securities and investments 226,900 225,295 202,247
Net cash used in investing activities (208,889) (186,978) (175,572)
Cash flows from financing activities:      
Net (payments) borrowings on line-of-credit arrangements and notes payable 0 0 (36)
Payments on long-term borrowings (643) (2,961) (316)
Payments for credit agreement renewal fees (486) 0 0
Proceeds from Issuances of common stock for shared-based compensation 13,113 14,133 14,604
Tax payments from net share settlement (8,096) (8,862) (7,310)
Proceeds from reissuances of treasury stock for shared-based compensation, net 3,831 0 0
Payments for purchases of treasury stock (28,000) (48,912) (2,920)
Payments of contingent consideration (2,477) (2,078) (3,681)
Net cash (used in) provided by financing activities (22,758) (48,680) 341
Effect of foreign exchange rate changes on cash 2,237 (655) (1,094)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 228,487 49,181 (72,188)
Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 434,164 384,983 457,171
Cash and cash equivalents 660,672 431,526 383,824
Restricted Cash included in Other current assets 93 111 882
Restricted Cash included in Other assets 1,886 2,527 277
Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $ 662,651 $ 434,164 $ 384,983
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements
3. FAIR VALUE MEASUREMENTS

We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:

•
Level 1: Quoted prices in active markets for identical instruments
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
42.9

 
$
—

 
$
42.9

Time deposits
31.2

 
10.0

 
—

 
41.2

Asset-backed securities
—

 
0.1

 
—

 
0.1

Money market funds
69.9

 
—

 
—

 
69.9

Total cash equivalents (a)
101.1

 
53.0

 
—

 
154.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
4,664.4

 
—

 
—

 
4,664.4

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
204.5

 
—

 
204.5

U.S. government sponsored agencies
—

 
106.1

 
—

 
106.1

Foreign government obligations
—

 
4.7

 
—

 
4.7

Other foreign obligations
—

 
3.1

 
—

 
3.1

Municipal obligations
—

 
11.6

 
—

 
11.6

Asset-backed securities
—

 
72.9

 
—

 
72.9

Total available-for-sale investments (c)
—

 
402.9

 
—

 
402.9

Forward foreign exchange contracts (d)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
4,771.1

 
$
456.8

 
$
—

 
$
5,227.9

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

     Contingent consideration (f)
—

 
—

 
4.9

 
4.9

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
4.9

 
$
5.9


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents (a)
59.6

 
88.1

 
—

 
147.7

Restricted investment:
5.6

 
—

 
—

 
5.6

Equity securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

 Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
Short-term investments
$
51.0

 
$
40.2

Other investments
4,613.4

 
2,632.7

        Total
$
4,664.4

 
$
2,672.9



The year-to-date unrealized gains on our equity securities still held as of December 31, 2019 were $2,031.1 million and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income.

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2019
 
December 31, 2018
 
 
 
 
Short-term investments
$
402.8

 
$
373.0

Other investments
0.1

 
0.2

Total
$
402.9

 
$
373.2




(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Other current liabilities
$
3.3

 
$
3.2

Other long-term liabilities
1.6

 
5.2

   Total
$
4.9

 
$
8.4



During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020. The sales milestones could potentially range from $0 to an unlimited amount. In the first and third quarters of 2019, we paid $1.4 million and $1.1 million, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of $13.9 million. The contingent consideration was accrued at its estimated fair value of $4.3 million as of December 31, 2019.

During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is due in the second quarter of 2020. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of December 31, 2019.

The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions):

December 31, 2018
$
8.4

Analytical flow cytometer platform:
 
Payment of sales milestone
(2.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(1.6
)
 
 
Foreign distributor earn-outs:
 
Acquisition of foreign distributor
$
0.6

December 31, 2019
$
4.9



The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2019. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
      Discount rate
11.1
%
 
 
      Cost of debt
3.9
%


To estimate the fair value of Level 2 debt securities, our primary pricing provider used Reuters as of December 31, 2019 and Securities Evaluations as of December 31, 2018 as the primary pricing sources. Our pricing process allowed us to select a hierarchy of pricing sources for securities held. If Reuters or Securities Evaluations did not price a Level 2 security that we held, then the pricing provider utilized our custodian supplied pricing as the secondary pricing source.

For all commercial paper as of December 31, 2019, our primary pricing provider used its leading pricing source in the hierarchy to determine pricing.

Our primary pricing provider performed daily reasonableness testing of the Reuters and Securities Evaluations prices. Price changes of 5% or greater were investigated and resolved. In addition, we performed a quarterly testing of the Reuters and Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% were investigated and resolved.

Available-for-sale investments consist of the following (in millions):

 
December 31, 2019
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
203.2

 
$
1.4

 
$
(0.1
)
 
$
204.5

Municipal obligations
11.5

 
0.1

 
—

 
11.6

Asset-backed securities
72.7

 
0.2

 
(0.1
)
 
72.8

U.S. government sponsored agencies
105.6

 
0.7

 
(0.2
)
 
106.1

Foreign government obligations
4.7

 
—

 
—

 
4.7

  Other foreign obligations
3.1

 
—

 
—

 
3.1

 
400.8

 
2.4

 
(0.4
)
 
402.8

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.1

 
—

 
—

 
0.1

 
0.1

 
—

 
—

 
0.1

Total
$
400.9

 
$
2.4

 
$
(0.4
)
 
$
402.9



The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2019 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
174.5

 
$
174.6

Mature in one to five years
164.2

 
165.2

Mature in more than five years
62.2

 
63.1

Total
$
400.9

 
$
402.9



Available-for-sale investments consist of the following (in millions):
 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2



The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2019
 
December 31, 2018
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
19.9

 
$
117.9

Fair value of investments in a loss position less than 12 months
$
97.8

 
$
193.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.1

 
$
1.8

Gross unrealized losses for investments in a loss position less than 12 months
$
0.3

 
$
0.8



The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at December 31, 2019 or at December 31, 2018.

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of December 31, 2019 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income.

The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2019
Contracts maturing in January through March 2020 to sell foreign currency:
 
Notional value
$
52.0

Unrealized gain
$
0.3

Contracts maturing in January through March 2020 to purchase foreign currency:
 
Notional value
$
269.1

Unrealized loss
$
(0.3
)


The estimated fair value of our current maturities of long-term debt, excluding leases, as of December 31, 2019 and long-term-debt, excluding all lease and current maturities, as of December 31, 2018 that is not recognized at fair value in the Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues.

The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
December 31, 2019
 
December 31, 2018
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Total current maturities long-term debt, excluding leases
$
424.4

 
$
435.5

 
2
 
$
—

 
$
—

 
2
Total long-term debt, excluding leases
and current maturities
$
—

 
$
—

 
2
 
$
423.7

 
$
435.8

 
2


Included in Other Investments in the Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $0.3 million and $0.6 million as of December 31, 2019 and December 31, 2018, respectively.

We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of December 31, 2019. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of December 31, 2019, due to the adoption of ASU 2016-01 and ASU 2018-03 as of January 1, 2018, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
7. Stockholders' Equity
 12 Months Ended
Dec. 31, 2019
Stockholders' Equity Attributable to Parent [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]
7.    STOCKHOLDERS' EQUITY

Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect 25% of the Board of Directors and Class B stockholders are entitled to elect 75% of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.

Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2017
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096

B to A conversions
24

 
(24
)
Issuance of common stock
58

 
18

Balance at December 31, 2019
24,966

 
5,090


Treasury Shares

In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to $250.0 million of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1

May 1, 2019 - May 31, 2019
25,421

$
291.70

218,571

$
193.7

June 1, 2019 - June 30, 2019
25,977

$
292.01

244,548

$
186.1

August 1, 2019 - August 31, 2019
14,745

$
339.05

259,293

$
181.1

November 1, 2019 - November 30, 2019
22,343

$
358.04

281,636

$
173.1

 
 
 
 
 


In 2019, we used 118,910 of the repurchased shares in connection with the vesting of restricted stock units and 19,755 shares in connection with ESPP stock purchases. The Credit Agreement may limit our ability to repurchase our stock.
XML 31 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2019
Feb. 24, 2020
Jun. 30, 2019
Entity Registrant Name BIO-RAD LABORATORIES, INC.    
Document Type 10-K    
Document Period End Date Dec. 31, 2019    
Amendment Flag false    
Entity Central Index Key 0000012208    
Current Fiscal Year End Date --12-31    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Shell Company false    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Document Annual Report true    
Document Transition Report false    
Entity File Number 1-7928    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 94-1381833    
Entity Address, Address Line One 1000 Alfred Nobel Drive,    
Entity Address, City or Town Hercules,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94547    
City Area Code (510)    
Local Phone Number 724-7000     
Entity Interactive Data Current Yes    
Common Class A [Member]      
Entity Common Stock, Shares Outstanding   24,839,715  
Entity Public Float     $ 6,613,310,960
Title of 12(b) Security Class A Common Stock Par Value $0.0001 per share    
Trading Symbol BIO    
Security Exchange Name NYSE    
Common Class B [Member]      
Entity Common Stock, Shares Outstanding   5,085,621  
Entity Public Float     $ 67,954,565
Title of 12(b) Security Class B Common Stock Par Value $0.0001 per share    
Trading Symbol BIOb    
Security Exchange Name NYSE    
XML 32 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
2. Acquisitions
 12 Months Ended
Dec. 31, 2019
Business Combinations [Abstract]  
Business Combination Disclosure [Text Block]
2.    ACQUISITIONS

In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million, which included cash payments at closing, net of closing cash, of $3.6 million, and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

As of December 31, 2019, the preliminary allocation of the payments was $3.4 million to customer relationships; a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets.

In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately $60.0 million. Cash payments at closing, net of closing cash, were $59.7 million. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

The final allocation of the payments was $26.8 million to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, $4.2 million to acquired net assets, and $28.7 million to goodwill.

We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations.

In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately $20.0 million. Cash payments, net of closing cash, consisted of $4.0 million paid in November 2018 and the remaining $16.0 million paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.

The final allocation of the payments was $15.6 million to goodwill that included workforce and time-to-market advantage, $5.5 million to definite-lived intangibles, $0.2 million to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of $1.3 million related to the purchased intangibles.

We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
11. Supplemental Cash Flow Information
 12 Months Ended
Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]  
Cash Flow, Supplemental Disclosures [Text Block]
11. SUPPLEMENTAL CASH FLOW INFORMATION
The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net income
 
$
1,758.7

 
$
365.6

 
$
122.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
134.2

 
138.1

 
148.7

Reduction in the carrying amount of right-of-use assets
 
40.3

 
—

 
—

Share-based compensation
 
35.6

 
27.8

 
23.4

Gains on dispositions of securities
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Changes in fair market value of equity securities
 
(2,031.0
)
 
(606.2
)
 
—

Losses on dispositions of fixed assets
 
1.2

 
2.0

 
8.1

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Payments for operating lease liabilities
 
(38.6
)
 
—

 
—

Changes in fair value of contingent consideration
 
(1.6
)
 
(6.2
)
 
(18.1
)
Decrease (increase) in accounts receivable, net
 
1.6

 
59.7

 
(64.1
)
Decrease (increase) in inventories, net
 
24.2

 
(12.9
)
 
(47.7
)
Decrease (increase) in other current assets
 
61.8

 
(15.3
)
 
(35.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
10.6

 
(45.6
)
 
7.8

Decrease in income taxes payable
 
(4.2
)
 
(20.9
)
 
(22.4
)
Increase (decrease) in deferred income taxes
 
450.2

 
120.9

 
(82.0
)
(Increase) decrease in other long term assets
 
(1.7
)
 
1.1

 
2.3

Increase (decrease) in other long term liabilities
 
13.4

 
(10.0
)
 
38.1

Impairment losses on goodwill and long-lived assets
 
—

 
292.5

 
11.5

Other
 
(1.1
)
 
4.9

 
5.1

Net cash provided by operating activities
 
$
457.9

 
$
285.5

 
$
104.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
Purchased property, plant and equipment
 
$
8.1

 
$
5.7

 
$
—

Purchased marketable securities and investments
 
$
1.4

 
$
0.8

 
$
2.8

Sold marketable securities and investments
 
$
1.3

 
$
—

 
$
0.3
XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 496 657 1 true 127 0 false 4 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.bio-rad.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 6 false false R7.htm 1005000 - Statement - Consolidated Statements of Comprehensive Income Sheet http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 7 false false R8.htm 2101100 - Disclosure - 1. Significant Accounting Policies Sheet http://www.bio-rad.com/role/A1SignificantAccountingPolicies 1. Significant Accounting Policies Notes 8 false false R9.htm 2102100 - Disclosure - 2. Acquisitions Sheet http://www.bio-rad.com/role/A2Acquisitions 2. Acquisitions Notes 9 false false R10.htm 2103100 - Disclosure - 3. Fair Value Measurements Sheet http://www.bio-rad.com/role/A3FairValueMeasurements 3. Fair Value Measurements Notes 10 false false R11.htm 2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 4. Intangible Assets, Goodwill and Other Notes 11 false false R12.htm 2106100 - Disclosure - 5. Notes Payable and Long-Term Debt Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 5. Notes Payable and Long-Term Debt Notes 12 false false R13.htm 2108100 - Disclosure - 6. Income Taxes Sheet http://www.bio-rad.com/role/A6IncomeTaxes 6. Income Taxes Notes 13 false false R14.htm 2109100 - Disclosure - 7. Stockholders' Equity Sheet http://www.bio-rad.com/role/A7StockholdersEquity 7. Stockholders' Equity Notes 14 false false R15.htm 2111100 - Disclosure - 8. Accumulated Other Comprehensive Income Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome 8. Accumulated Other Comprehensive Income Notes 15 false false R16.htm 2112100 - Disclosure - 9. Share-based Compensation Sheet http://www.bio-rad.com/role/A9ShareBasedCompensation 9. Share-based Compensation Notes 16 false false R17.htm 2114100 - Disclosure - 10. Other Income and Expenses Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 10. Other Income and Expenses Notes 17 false false R18.htm 2115100 - Disclosure - 11. Supplemental Cash Flow Information Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 11. Supplemental Cash Flow Information Notes 18 false false R19.htm 2116100 - Disclosure - 12. Commitments & Contingent Liabilities Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities 12. Commitments & Contingent Liabilities Notes 19 false false R20.htm 2121100 - Disclosure - 13. Legal Proceedings Sheet http://www.bio-rad.com/role/A13LegalProceedings 13. Legal Proceedings Notes 20 false false R21.htm 2124100 - Disclosure - 14. Segment Reporting Sheet http://www.bio-rad.com/role/A14SegmentReporting 14. Segment Reporting Notes 21 false false R22.htm 2125100 - Disclosure - 15. Restructuring Costs (Notes) Notes http://www.bio-rad.com/role/A15RestructuringCostsNotes 15. Restructuring Costs (Notes) Notes 22 false false R23.htm 2127100 - Disclosure - 16. Leases (Notes) Notes http://www.bio-rad.com/role/A16LeasesNotes 16. Leases (Notes) Notes 23 false false R24.htm 2128100 - Disclosure - 17. Quarterly Financial Data Sheet http://www.bio-rad.com/role/A17QuarterlyFinancialData 17. Quarterly Financial Data Notes 24 false false R25.htm 2130100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns Schedule II - Valuation and Qualifying Accoutns Notes 25 false false R26.htm 2201201 - Disclosure - 1. Significant Accounting Policies (Policies) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies 1. Significant Accounting Policies (Policies) Policies http://www.bio-rad.com/role/A1SignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - 1. Significant Accounting Policies (Tables) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 1. Significant Accounting Policies (Tables) Tables http://www.bio-rad.com/role/A1SignificantAccountingPolicies 27 false false R28.htm 2303301 - Disclosure - 3. Fair Value Measurements (Tables) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsTables 3. Fair Value Measurements (Tables) Tables http://www.bio-rad.com/role/A3FairValueMeasurements 28 false false R29.htm 2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables) Sheet http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables 4. Intangible Assets, Goodwill and Other (Tables) Tables http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther 29 false false R30.htm 2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 5. Notes Payable and Long-Term Debt (Tables) Tables http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt 30 false false R31.htm 2308301 - Disclosure - 6. Income Taxes (Tables) Sheet http://www.bio-rad.com/role/A6IncomeTaxesTables 6. Income Taxes (Tables) Tables http://www.bio-rad.com/role/A6IncomeTaxes 31 false false R32.htm 2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Sheet http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables) Tables 32 false false R33.htm 2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables) Tables 33 false false R34.htm 2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) Tables 34 false false R35.htm 2312301 - Disclosure - 9. Share-based Compensation (Tables) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationTables 9. Share-based Compensation (Tables) Tables http://www.bio-rad.com/role/A9ShareBasedCompensation 35 false false R36.htm 2314301 - Disclosure - 10. Other Income and Expenses (Tables) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 10. Other Income and Expenses (Tables) Tables http://www.bio-rad.com/role/A10OtherIncomeAndExpenses 36 false false R37.htm 2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 11. Supplemental Cash Flow Information (Tables) Tables http://www.bio-rad.com/role/A11SupplementalCashFlowInformation 37 false false R38.htm 2316301 - Disclosure - 12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables 12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables) Tables 38 false false R39.htm 2324301 - Disclosure - 14. Segment Reporting (Tables) Sheet http://www.bio-rad.com/role/A14SegmentReportingTables 14. Segment Reporting (Tables) Tables http://www.bio-rad.com/role/A14SegmentReporting 39 false false R40.htm 2325301 - Disclosure - 15. Restructuring Costs (Tables) Sheet http://www.bio-rad.com/role/A15RestructuringCostsTables 15. Restructuring Costs (Tables) Tables http://www.bio-rad.com/role/A15RestructuringCostsNotes 40 false false R41.htm 2327301 - Disclosure - 16. Leases (Tables) Sheet http://www.bio-rad.com/role/A16LeasesTables 16. Leases (Tables) Tables http://www.bio-rad.com/role/A16LeasesNotes 41 false false R42.htm 2328301 - Disclosure - 17. Quarterly Financial Data (Tables) Sheet http://www.bio-rad.com/role/A17QuarterlyFinancialDataTables 17. Quarterly Financial Data (Tables) Tables http://www.bio-rad.com/role/A17QuarterlyFinancialData 42 false false R43.htm 2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails 1. Significant Accounting Policies Property, Plant and Equipment (Details) Details 43 false false R44.htm 2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails 1. Significant Accounting Policies Warranty rollforward (Details) Details 44 false false R45.htm 2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails 1. Significant Accounting Policies Earnings per share (Details) Details 45 false false R46.htm 2401406 - Disclosure - 1. Significant Accounting Policies Details (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails 1. Significant Accounting Policies Details (Details) Details http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables 46 false false R47.htm 2401407 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details) Sheet http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails 1. Significant Accounting Policies Revenue Recognition (Details) Details 47 false false R48.htm 2402401 - Disclosure - 2. Acquisitions (Details) Sheet http://www.bio-rad.com/role/A2AcquisitionsDetails 2. Acquisitions (Details) Details http://www.bio-rad.com/role/A2Acquisitions 48 false false R49.htm 2403402 - Disclosure - 3. Fair Value Measurements (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsDetails 3. Fair Value Measurements (Details) Details http://www.bio-rad.com/role/A3FairValueMeasurementsTables 49 false false R50.htm 2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details) Details 50 false false R51.htm 2403404 - Disclosure - 3. Fair Value Measurements Available-for-Sale Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails 3. Fair Value Measurements Available-for-Sale Investments (Details) Details 51 false false R52.htm 2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details) Details 52 false false R53.htm 2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) Details 53 false false R54.htm 2403407 - Disclosure - 3. Fair Value Investments (Details) Sheet http://www.bio-rad.com/role/A3FairValueInvestmentsDetails 3. Fair Value Investments (Details) Details 54 false false R55.htm 2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details) Sheet http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails 3. Fair Value Measurements Contingent Consideration (Details) Details 55 false false R56.htm 2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details) Details 56 false false R57.htm 2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Sheet http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) Details 57 false false R58.htm 2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details) Notes http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails 5. Notes Payable and Long-Term Debt (Details) Details http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables 58 false false R59.htm 2408402 - Disclosure - 6. Income Taxes (Details) Sheet http://www.bio-rad.com/role/A6IncomeTaxesDetails 6. Income Taxes (Details) Details http://www.bio-rad.com/role/A6IncomeTaxesTables 59 false false R60.htm 2409402 - Disclosure - 7. Stockholders' Equity (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityDetails 7. Stockholders' Equity (Details) Details http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables 60 false false R61.htm 2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details) Sheet http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails 7. Stockholders' Equity Treasury Shares (Details) Details 61 false false R62.htm 2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables 62 false false R63.htm 2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Sheet http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) Details http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables 63 false false R64.htm 2412402 - Disclosure - 9. Share-based Compensation (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationDetails 9. Share-based Compensation (Details) Details http://www.bio-rad.com/role/A9ShareBasedCompensationTables 64 false false R65.htm 2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details) Sheet http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails 9. Share-based Compensation Restricted Stock (Details) Details 65 false false R66.htm 2414402 - Disclosure - 10. Other Income and Expenses (Details) Sheet http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails 10. Other Income and Expenses (Details) Details http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables 66 false false R67.htm 2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details) Sheet http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails 11. Supplemental Cash Flow Information (Details) Details http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables 67 false false R68.htm 2416402 - Disclosure - 12. Commitments & Contingent Liabilities (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails 12. Commitments & Contingent Liabilities (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables 68 false false R69.htm 2416403 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails 12. Commitments & Contingent Liabilities Period Expense (Details) Details 69 false false R70.htm 2416404 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details) Sheet http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails 12. Commitments & Contingent Liabilities Pensions (Details) Details http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables 70 false false R71.htm 2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details) Sheet http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails 13. Legal Proceedings Legal Proceedings (Details) Details 71 false false R72.htm 2424402 - Disclosure - 14. Segment Reporting (Details) Sheet http://www.bio-rad.com/role/A14SegmentReportingDetails 14. Segment Reporting (Details) Details http://www.bio-rad.com/role/A14SegmentReportingTables 72 false false R73.htm 2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails 14. Segment Information Segment Profit Reconciliation (Details) Details 73 false false R74.htm 2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails 14. Segment Information Segment Asset Reconciliation (Details) Details 74 false false R75.htm 2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details) Sheet http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails 14. Segment Information Segment Information by Geographical Location (Details) Details 75 false false R76.htm 2425402 - Disclosure - 15. Restructuring Costs (Details) Sheet http://www.bio-rad.com/role/A15RestructuringCostsDetails 15. Restructuring Costs (Details) Details http://www.bio-rad.com/role/A15RestructuringCostsTables 76 false false R77.htm 2427402 - Disclosure - 16. Leases (Details) Sheet http://www.bio-rad.com/role/A16LeasesDetails 16. Leases (Details) Details http://www.bio-rad.com/role/A16LeasesTables 77 false false R78.htm 2428402 - Disclosure - 17. Quarterly Financial Data (Details) Sheet http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails 17. Quarterly Financial Data (Details) Details http://www.bio-rad.com/role/A17QuarterlyFinancialDataTables 78 false false R79.htm 2429402 - Disclosure - 18. Subsequent Event (Details) Sheet http://www.bio-rad.com/role/A18SubsequentEventDetails 18. Subsequent Event (Details) Details 79 false false R80.htm 2430402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details) Sheet http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails Schedule II - Valuation and Qualifying Accoutns (Details) Details http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns 80 false false R9999.htm Uncategorized Items - a10k123119.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - a10k123119.htm Cover 81 false false All Reports Book All Reports a10k123119.htm bio-20191231.xsd bio-20191231_cal.xml bio-20191231_def.xml bio-20191231_lab.xml bio-20191231_pre.xml ex211123119.htm ex231123119.htm ex311123119.htm ex312123119.htm ex321123119.htm ex322123119.htm ex41123119.htm chart-d7753823a7d35527837a01.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/naics/2017-01-31 true true XML 35 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
11. Supplemental Cash Flow Information (Tables)
 12 Months Ended
Dec. 31, 2019
Supplemental Cash Flow Information [Abstract]  
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
11. SUPPLEMENTAL CASH FLOW INFORMATION
The reconciliation of net income to net cash provided by operating activities is as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Net income
 
$
1,758.7

 
$
365.6

 
$
122.2

Adjustments to reconcile net income
 
 

 
 

 
 

to net cash provided by operating activities
 
 

 
 

 
 

Depreciation and amortization
 
134.2

 
138.1

 
148.7

Reduction in the carrying amount of right-of-use assets
 
40.3

 
—

 
—

Share-based compensation
 
35.6

 
27.8

 
23.4

Gains on dispositions of securities
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Changes in fair market value of equity securities
 
(2,031.0
)
 
(606.2
)
 
—

Losses on dispositions of fixed assets
 
1.2

 
2.0

 
8.1

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Payments for operating lease liabilities
 
(38.6
)
 
—

 
—

Changes in fair value of contingent consideration
 
(1.6
)
 
(6.2
)
 
(18.1
)
Decrease (increase) in accounts receivable, net
 
1.6

 
59.7

 
(64.1
)
Decrease (increase) in inventories, net
 
24.2

 
(12.9
)
 
(47.7
)
Decrease (increase) in other current assets
 
61.8

 
(15.3
)
 
(35.7
)
Increase (decrease) in accounts payable
 


 


 


and other current liabilities
 
10.6

 
(45.6
)
 
7.8

Decrease in income taxes payable
 
(4.2
)
 
(20.9
)
 
(22.4
)
Increase (decrease) in deferred income taxes
 
450.2

 
120.9

 
(82.0
)
(Increase) decrease in other long term assets
 
(1.7
)
 
1.1

 
2.3

Increase (decrease) in other long term liabilities
 
13.4

 
(10.0
)
 
38.1

Impairment losses on goodwill and long-lived assets
 
—

 
292.5

 
11.5

Other
 
(1.1
)
 
4.9

 
5.1

Net cash provided by operating activities
 
$
457.9

 
$
285.5

 
$
104.1

 
 
 
 
 
 
 
Non-cash investing activities:
 
 
 
 
 
 
Purchased property, plant and equipment
 
$
8.1

 
$
5.7

 
$
—

Purchased marketable securities and investments
 
$
1.4

 
$
0.8

 
$
2.8

Sold marketable securities and investments
 
$
1.3

 
$
—

 
$
0.3
XML 36 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]
Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive income (loss), net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)
Other comprehensive (loss) income, before reclassifications
(36.5
)
(10.0
)
4.8

(41.7
)
Amounts reclassified from Accumulated other comprehensive income
—

1.5

(0.4
)
1.1

Income tax effects
(0.4
)
1.1

(0.5
)
0.2

Other comprehensive (loss) income, net of income taxes
(36.9
)
(7.4
)
3.9

(40.4
)
Balances as of December 31, 2019
$
(72.4
)
$
(22.2
)
$
7.2

$
(87.4
)
XML 37 R53.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Price Change Debt Security 5.00%  
Tolerable variance Level 2 debt security pricing 1.00%  
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value $ 19.9 $ 117.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value 97.8 193.0
Gross unrealized losses for investments in a loss position 12 months or more 0.1 1.8
Gross unrealized losses for investments in a loss position less than 12 months $ 0.3 $ 0.8
XML 38 R57.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Oct. 01, 2019
Aug. 02, 2019
Mar. 04, 2019
Acquired Finite-Lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles         $ 3,400 $ 26,800 $ 5,500
Finite-Lived Intangible Assets, Gross $ 493,100 $ 525,600 $ 493,100        
Future Amortization Expense, Year One   23,500          
Future Amortization Expense, Year Two   22,800          
Future Amortization Expense, Year Three   19,600          
Future Amortization Expense, Year Four   18,700          
Future Amortization Expense, Year Five   16,600          
Finite-Lived Intangible Assets, Amortization Expense, after Year Five   44,100          
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (360,000) (380,300) (360,000)        
Net Carrying Amount 133,100 145,300 133,100        
Amortization [Abstract]              
Amortization expense   23,500 28,300 $ 30,800      
Impairment losses on goodwill and long-lived assets 292,500 0 292,513 $ 11,506      
Intangible Assets, Net (Excluding Goodwill) 133,123 145,525 $ 133,123        
Intangible Assets, Gross (Excluding Goodwill)   $ 525,800          
Customer Relationships [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           16,100  
Finite-Lived Intangible Assets, Remaining Amortization Period   6 years 3 years        
Finite-Lived Intangible Assets, Gross 88,700 $ 107,200 $ 88,700        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (68,300) (74,300) (68,300)        
Net Carrying Amount 20,400 $ 32,900 $ 20,400        
Know how [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Remaining Amortization Period   5 years 6 years        
Finite-Lived Intangible Assets, Gross 190,600 $ 188,500 $ 190,600        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (159,800) (162,600) (159,800)        
Net Carrying Amount 30,800 $ 25,900 $ 30,800        
Developed Technology Rights [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           8,100  
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 8 years        
Finite-Lived Intangible Assets, Gross 130,400 $ 144,200 $ 130,400        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (86,600) (93,900) (86,600)        
Net Carrying Amount 43,800 $ 50,300 $ 43,800        
Licensing Agreements [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 9 years        
Finite-Lived Intangible Assets, Gross 76,300 $ 76,000 $ 76,300        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (40,900) (44,400) (40,900)        
Net Carrying Amount 35,400 $ 31,600 $ 35,400        
Trade Names [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           2,500  
Finite-Lived Intangible Assets, Remaining Amortization Period   8 years 3 years        
Finite-Lived Intangible Assets, Gross 3,900 $ 6,400 $ 3,900        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (3,300) (3,600) (3,300)        
Net Carrying Amount 600 $ 2,800 $ 600        
Noncompete Agreements [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Finite-Lived Intangible Assets, Remaining Amortization Period   6 years 7 years        
Finite-Lived Intangible Assets, Gross 3,200 $ 3,200 $ 3,200        
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization (1,100) (1,400) (1,100)        
Net Carrying Amount $ 2,100 $ 1,800 $ 2,100        
Other Intangible Assets [Member]              
Acquired Finite-Lived Intangible Assets [Line Items]              
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles           $ 100  
Finite-Lived Intangible Assets, Remaining Amortization Period   0 years 0 years        
Finite-Lived Intangible Assets, Gross   $ 100          
Finite-Lived Intangible Assets, Net [Abstract]              
Accumulated Amortization   (100)          
Net Carrying Amount   0          
Life Science [Member] | CellSorter [Member] | Developed Technology Rights [Member]              
Amortization [Abstract]              
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)     $ 8,800        
Life Science [Member] | CellSorter [Member] | Noncompete Agreements [Member]              
Amortization [Abstract]              
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)     $ 1,700        
In Process Research and Development [Member]              
Amortization [Abstract]              
Indefinite-lived Intangible Assets (Excluding Goodwill)   $ 200          
EXCEL 39 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

X,. L L(C0"OK;T1[&OB8?/$(!^YK$%PC'^Y(<(DE M@>TU-T 36ST,1P);/10'HQV(VQ(@OD0&_G?.@3L 1-=(B'L Q)=(&-LE4ZNO MEBC,$GJ%P9)Q_7#G <1Z"!OAH+@+4'*%?A1W 0H7Z->!SOZ#F6V!",QGS-*O M@X5G%AB-Z4=QYZ&V\S VTGX4=P%ZS>6&XBY +[G>T,_O-PB$1LQN*F]PT2UX MM6NFCMI9BV,I]45OL-M/-O=47Y2-_86:>-KYY)VF'9=^I-4N*VOG24AU#6\N MRULA)%=IDEN5X%Y-:/TBYUNI7R/U7K5C2KN0XM"-8%X_!\[^ U!+ P04 M" "T/F)0,VYT\8$" !0"0 &0 'AL+W=OZ:O0B/AK3WB>)WAY%S?6=;$5CO]E+57-C MI^J0Z%8)OO-%=96D"-&DYF43+^=^;:.62W'1 MHW'DK#Q)^>PFWW:+&#E%HA);XRBX?9S%6E258[(Z_O2D\?!.5S@>O[)_\>:M MF2>NQ5I6O\N=.2YB%D<[L>>GRCS(RU?1&R)QU+O_+LZBLG"GQ+YC*ROM/Z/M M21M9]RQ62LU?NF?9^.>EYW\M@PO2OB ="G#^WX*L+\BN"I).F;?ZF1N^G"MY MB53W:[7<_2GP?6;#W+I%GYW_SKK5=O6\Q(CB>7)V3#UHU8'2$2A]BUB'"$H' M2&(5##)24$;JZ^E;&2G,D($,F6?(1@S%ETG@(0X@Q4ER9"7&$8JN' MP7IR4$\>Z,&(3&1"0 9R0R849*#O9])!\I%73)@UBZXR 7 Y(F/<&STS4,\, MR(1F, ,#&=@-F10@0_%^)D7H-,+5/*@F V*PH)G.!&QJ''6T]D0D.N EQ?DLNI+&GI+^+-M+:80E17>6[FBO-\.D$GOCAC,[5MT9 MWTV,;/O[2S)ELNP2EX"=LXK409UGD%7^JG>9'H]0;_FIQ8@?^D\M?IZ=:K?R. M99>7O&IR43DUWR_=1_R0$1-@$+]S?FUZ]XY.Y46(5[WXMENZ2"OB!=]*3<'4 MY<(WO"@TD]+QUY*ZW9DZL'__SO[%)*^2>6$-WXCB3[Z3QZ6;N,Z.[]FYD,_B M^I7;A$+7L=E_YQ=>*+A6HL[8BJ(QG\[VW$A16A8EI61O[36OS/5J^=_#X !B M T@7@*-/ Z@-H!\!P:J- MV#( AB/D$5AU"*H.IZI1E(QDMR",>B?%%'OC/@&PD")OYFF(0#T1I&>F#S'( M$-_1R01D2&[H9 *4)$8>'96DA05]5#HJ6P91A8D7PI)34')Z2QO3Z4$X32:: M(1A)Y]JH<9!S($!1C&8X9MP'W]%*#+K+(R8W--."^FT*43@JBP4-ZA*DH3?" M92 NPMZ,'6'8CS"]I:,6-?S)X;&D#00CJ&<[0T6POV' X!":,1L,NPT.[^DH M[! 8L(AI1Z-IQDG:?XAM92!<1+WQ_PN(0[->BV%KPO%-38VA!RB9_$M .!JE MLYI@L\. VZ%X[L<.NP].[V@K@0V# (8Q::L%#;V)QA,+@W$3J\LL+NS#@AF3 M(K!)$7Q+3RTJ'7CJI*,0"D^,U^]-;R6O#V8R;IRM.%=2ST"]W6[Z?B1Z^AOM MK]54WL[0'S3M2/^#U8>\:IP7(=5L:2; O1"2*Y'(4]4ZJK>(;E'PO=2WL;JO MVU&Z74AQLJ\)?O>NLOH/4$L#!!0 ( +0^8E!;_#&PO=V]R:W-H965T%]NUWM_WO(-OG'W5 ,3U]\ M7;^\%M47X_O;M]5+]F=6_/7V95]^&I][>5IOL]UAG>\&^^SY;OA9W"R%L%6+ MH^3O=?9QN/A[4,WE6YY_KS[\]G0W3"J3LDWV6%1]K,I?/[))MME4796&_-OT M.CP/6C6\_/O4^_PX^W(VWU:';))O_ED_%:]W0S<8V,$T#PS7)-@TLMT':-$BY#5S3P 4-QO7E M.%[?Z:I8W=_N\X_!OKY'WU95*(@;5]Y!C]67QQOF^+_R$A_*;W_1>-RRN=Y2S3O!]GI(9CT MI*NPMBV9=B5"!9.>10>:1Q6+J&)Y3='RAH)W@3HVMQ?-M72X PT[T,<.U.7X M:7 3 0DQA(%#F$[[\IJGN <+>[#\6::P@Q29X()YUB)_%.V.HD_)*(B7"10% M%W7:%24C@^UUT%Z'[/7!K>,ZHP@Y(OSJX3 >#..2P"VU2%].)O!)K1#)I26C M,.2 R(["F*M%AAYK'E4LHHKEM1FUO%99B]";(+^)D+U)=\;EO1+<=1,HTR-- M6$0L!@)9U%D-!+0H#2T2;/] 1'\6$EFC0FMD],9J)*'!@K &(U(H9 WE7TQ) MH?D$$IB" F(P9%"CHF?<.(8EFQ(R8H41&+["(O\1.!.8OR+MX3^,1 &9V/&? MB]]4CN<[($LHO K,5P$!2Z4[RX;M.8CI(1(>.Z^2UL&\R*PP0(AXEIH.$ M= A7'1FG@P1T2#KK#E+)<,6>Q8>;QR6+N&1Y5=)V'\:9A#@+%Y]&%5XI%;H0 MR025JT@,1]E-$,'BTZBB%FFV?S!G)>)L9_%I5%=OKVN2MB48G!*"DR"(Q."4 M/< I,3@E"YR21<5)5-:V"&-1LO).&4\\@23$N 1YIPZG-8N/-8]+%G')\JJD MO=_#RX%BY9X*YY[!;GP"97+D"8OPZJ)8N:?"2X<.+6+GG@JO+HJ5>ZKXZJ)Z MY9Z*V)Y#6!/QJS!>58_<4V$F*IA[!OO)F>H"C\B2%0:>@L"C[B8,/-4#> H# M3[& IZYEBNUA,,44HECHU(D"_"$S<(UC7J.8]X2U&D>I%GR_:AQ:&H56QZ^Z M5]QH'#<:Q4W'MQID+XJBER;.OU#RXBEK<7AIT\.W.'0T"IVN;RT+HDAVF6FU M#<)QJ.&1F0\-2J,<;20M8\R(\@Z.:(TBNI,P:)";J##3GR"5$.'2.(6R;N+ M&G/.4BU8JF5,U?8G1I>&"5B81&B KD]IY[@(RAQU@&4PX@Q,:\)EV^"T)KS$ MA(P( (.!:5!:XPD_&TQ,(_E@,)B$!I(P!(.);??:0V$4&H3"#G0-V,>9$$%3 MI)*D/<1S Y2U>*H/S%73X]&!P20TK(<'YAH)V\-@QAG.F?_$P%.ICOZ"S#DL#E8+TYOP EAXZ!2 :HI4PE#G M*A:'OD6A[ZD^<$S;'IL'B\/0P@.5+Q M(TK./'&,:S%%;(]]C<6$L*PLR$)"A.>=+-6IN>8B*E MG)QEFJ*M%#T4#OT4A+Y(B!3+X=!W/4+?X=!WK'3$Q9Z3U=< R1+JOG0X$ATG M:YDVJLNB"$'XW^%H=2 9$0G5!PY7UR,9<3@,'>_ 64MKJ.92VUA$SG@]S7FR!4^VC,K:GL)0<@A*G>,$AX@C* PXHC *YD#A MPP;7Y]F]P\!Q\(PD/)%P\'B7"&&/L>3!V8=(B 798R[Y'L>['I/$ H\SUV$!Y' MC^>LUP\>1(^EXM03E85PN::*AA*JSJ['@ETN1D0G<,D.)WV2!;.F2J42HO(M M816WG&3D8/6B<9)=6S5X7@2C$25\":M, MY23C/3PI;VEB,%85RDG&.[<2"5&@ET"Z$.<3Y;U/]-*G1B\ABO02%F%.LC94 M/3UQHKPN8162G&3T:*=PB]9OS$X:?[6K.7/(!:^[9506U @3.&76+1.%RU3I M(UF2S*Q)[K,)$E3%,;/D&!44T\%-%12CBN+R+J=Z(7C4JZ:8*BIF5A4WLN"U M!7+>!&=@)7#GA/PD:]VLX5/#.5:%EWU\\3;4-MN_'-^6.PP>\_==4;TU<_'M M^96\S[)ZFRKX_D'<3.OWZGYU4[_G]\=J_[+>'0;?\J+(MW?5&U7/>5YDI9') MJ'3;:[9Z.G_89,]%]6=U&K2O7Z^K/Q3YVUW][N#X_ +C_?]02P,$% @ MM#YB4+P*IYT+!@ &UL ME9IA;]M&#(;_BN'OJ76\XYT4) %J!\,&;$#0H=MG-5$2H[;E24K2_?M)LNK: MY,MB^1+',N]>4B(?47>Z>JN;K^US576S;]O-KKV>/W?=_G*Q:.^?JVW9?JCW MU:[_Y;%NMF77?VV>%NV^J!HP6?ZVKM_;D_]D0RI>Z_CI\^>WA>IX-'E6;ZKX; MIBC[C]=J56TVPTR]'_],D\Z/FL/ T_^_S_[+&'P?S)>RK5;UYN_U0_=\/<_G MLX?JL7S9=)_JMU^K*2">SZ;H?Z]>JTUO/GC2:]S7FW;\.[M_:;MZ.\W2N[(M MOQT^U[OQ\^WP2RJF87@ 30/H.,#%GP[PTP#_8T#XZ8 P#0ABP.(0RGAN;LNN MO+EJZK=9<[B\^W+((G<9^K-_/QP<3_;X6W]ZVO[HZXUS67ZU>!UFFHR6!R,Z M-3I:+/KICQJ$-):DAM.YP$I;Q'AN,$\3S2 L\0X QAG,&? MS% 4(I+EP89'F]U!)6895F&HPDK%]8X*&6AD7)0(92*:048353341R.<60&K MY*R@$_0F*6]28.',P2:8D\$;AY'EO/(J5SYY)469RV,N M7=)VUK7 ]',:?_TI4K>* -*=S,N.$>@@W@H9$2LI-H4P!!VB($F@3%9G,85@ M2F'".8VX7LI)*0"O9%+)82PYQ"52.:K!1,F."C/'(>B0ETFAJI4RL0H8>@0@@Y)O$U6IT*%*82A0P@Z).E&@"5FGA,&"6F0]$H2):01 MX([43'G"#$":]Z<\T)._TP)0A1PLM&B30ES!N'QXSPB!%>,&+E M-2-,&'G,"(\8X5D*:4;80I@1'C'"1RFD&5&8B>>-YR/$""\9X34C;"&,"(\0 MX64CX34BS/SV&! > <(74D@#@G(3$!X#PB- !/G4YC4@[ S'>/ :#X6*"#01 M[*/*3FUF^8+YX0$_,GF?]!H?+L5,-HXK8&=Y@R'C-61RY8Q&S$6>4ZY8! U= M?IH]YPL&F$A M*+RLO16PXRR/A>41)E= Y JR"9VLSI8IG-V%!F,-",$KR"X46[&AA.D5$+V" M.M/0*AE*&%X!PDL"&5M9]8#I%5!SPQ*302_->#:[PX#A%%!SPZKT )V\J83! M$U!WPZKV0'>3VTN#F">,>,(RTUGSQ*YRQD!A!!26> YR [*6"]&!&!9O0P>@S)O MMCF,2<&( 2S[#P;/06PG($8%(U1$M0Z.GH/8A#IC5C!B192L8+!@8J^=,H8% M(UA$"0L&[4<(IE;$M(B(%E'2(FI:7!0F R/&142XB!(7D]7YDK"9@Q'C(B)< M1./>&C$(XGLV@R*N\(@J7&Y;+;&5<7^.N,(CJO"3!=[S.8SMGOB>B'%)1EB2 M*F)M%=C8J8NX'B.L1\M97&BQ>$? "1=0@AL=$N();728"$JX@)(N(/7TDO3= M]B*87$VX?-+_:-^3OM?::_@)EU@">Q=DY'W"%9;">RXAKIT$MQ(D;R>KL^VW ML^;L\+@"S.1)69QLO&^KYFE\J:&=W=GQQXB,-&_?B^-)=WAY> M?_@QS>%MC#_*YFF]:V=?ZJZKM^/F_6-==U7O8?:A]^VY*A^.7S;58S?\.[C> M'-Z".'SIZOWTAL?B^)K)S7]02P,$% @ M#YB4'+E90_[! XA8 !D M !X;"]W;W)K&ULC9A=3^LX$(;_2M5[$H]C.S8J ME2A0Z,=*Z*QV]SI00ZO3-MTDP-E_OTX:2CLSX;07M G/C%][9OPU^,B+G^72 M^ZKW:[/>EE?]957M+N.X?%[Z359&^\F*35>&Q>(W+7>&S16.T6<=2 M"!-OLM6V/QPT[QZ+X2!_J]:KK7\L>N7;9I,5_XW\.O^XZD/_\\6/U>NRJE_$ MP\$N>_5_^NJOW6,1GN*#E\5JX[?E*M_V"O]RU;^&RSF8VJ A_E[YC_+H=Z_N MRE.>_ZP?)HNKOJ@5^;5_KFH76?AZ]S=^O:X]!1W_MD[[AS9KP^/?G]['3>=# M9YZRTM_DZW]6BVIYU;?]WL*_9&_KZD?^\>#;#NE^K^W]W+_[=0M ;)EX'ZUD"U M!NI< ]T:Z',-3&M@SC5(6X/T7 /;&MAS#5QKX,XU /$9.?%E8KXW.00;SF[E M,]P@D4F\3ZPF4V^S*AL.BORC5^R+;9?5-0V7P2HXK]\VN=_\,V1K&=Z^#P%2 M,8C?:UGK9P0PDMD-);RB"==YP7 M.&7&E#'F%+FGB-/VE'G@&'?*3)BFM$9#^]NAF?U>\)PBD"1\A!(^59+&@SE- ME8X@*]Z%:EPDQRY4@I)MS^B&V>[[HHS D9Y23(I$.)NBH6'<"2,3Y&Y.,<'W M3/,]T[1G"4J]T9Y1QU*D(CE\HXD4'2235&>P5!+LCL&T(L,YII@!XS!VSWA3 M&C#VP&G3Q-N$TP9D0*9TW&0"8' MS1A.6J< U=.>$IDZIXRDEI0T(K8U"QSCC.&&E0 MZL\IY](Z]WGAEA=NN1''TX8%)&P./(,YB*1X, SC'EGZ%4)+I6HHY#%=!3E5(&RZ:GB LMI!)XY\*!80T1BN0P!:4*GP[Q M'><#8 X(B<.)8FA3]8:>S,N4([L$WA7@#0[#03AT&=2[^.@*:>.+U^:RM.P] MYV_;JN[5T=O#A>RUK*^@T/L17$Z >3^M+W";*ZLO]_O;WS^RXG6U+7M/>57E MF^9VZB7/*Q_4BRCH7OIL<7A8^Y>J_IF&W\7^UG7_4.6[]D8Y/EQK#_\'4$L# M!!0 ( +0^8E!H6*%Z\0$ -X$ 9 >&PO=V]R:W-H965T&B];&U#9A^_?U M;5E"T+Y@S_B<,Q<\SD;&7T0#(+U72CIQ\!LI^SU"HFB 8K%A/73JI&*<8JE, M7B/1<\"E(5&"HB#8(HK;SL\SX[OP/&.#)&T'%^Z)@5+,_QV!L/'@A_Z;X[FM M&ZD=*,]Z7,-/D+_Z"U<6FE3*ED(G6M9Y'*J#_Q3NSXG&&\#O%D8QVWNZDBMC M+]KX5A[\0"<$! JI%;!:;G "0K202N.OT_2GD)HXW[^I?S&UJUJN6,")D3]M M*9N#_\GW2JCP0.0S&[^"JR?U/5?\=[@!47"=B8I1,"+,URL&(1EU*BH5BE_M MVG9F'>U)FCK:.B%RA&@BA!\38D>(WPG)AX3$$9(% =E23&_.6.(\XVSTN/V[ M/=:7*-PGJON%=IIFFS/5'J&\MSP,=VF&;EK)@8X6%,U R2Z9,$@%F*)$:U&. MT8- =!_B](A(@^ >:4B?(GU+%OZC M&EX[:^\R=O)_8%ZWG?"N3*H[:&Y*Q9@$E6&P4O"9J>M/P_4$L#!!0 ( +0^8E#5U.5T_ ( &D+ 9 >&PO=V]R M:W-H965T"U>*4'_A/+G^='ALU"GJ675'Q MNBU$[35\O_3OX6X#B0XPB-\%O[:#=T];>1;B10^^[99^J!7QDF^EILC5X\(? M>%EJ)J7CKR7U^S5UX/#]C?V+,:_,/.*KA6HM;8BK(UO][VW$I1618EI0R7RT:A,PH1ECN4IBK$H=L\(AJ+A MS"E)4EDG9LH3ES-4Y3C??,18J0U0[5FF%;G:JVSZ9XDD+E':HI" MLK!!N$99&&F&$"\X(:9Z)DR!'CA :SR MI-3)@$4-EP*(2>*D (5!0F<4X84,II5L_FX#7LL *V:3VVU10[E$G;_(-8_ MXIBZYP^#11&;*6N US5@G[GB%C7*?$Q8Z@I'8!!&S*W&&"[-,C*C'*^G@!94 M]\);U+#RDY"$L:L<@4TSL\%@H\QTPH-!OU'QYF!ZN=;;BG,M];_V8+;O%^^) M[E><^;7N(TT?\T[3-:$_\N90U*WW+*3JADS/LA="&PO=V]R:W-H965TY"6@,IK83IO^^MF$H$^Y4\X*W<][Z/3*B8N6*CT49R)[ ?1HBUI& L]+2$N;SJT*.[<3 M5<$OBC4=[(0C+VU+Q9\'8'PH7=]]F7ALSK4R$Z0J>GJ&[Z!^]#NA1V1V.38M M=++AG2/@5+H?_,TV-WHK^-G (!=]QY#L.7\R@R_'TO5,(&!P4,:!ZN8*6V#, M&.D8OR=/=][2%"[[+^Z?++MFV5,)6\Y^-4=5EV[F.DX M-RDT3O<>!,VJMSN$C%V\E%1VGI\]@VG6V'<27)IC*\()@*@G\%Z7\+ MPJD@G MT6 ,_)K.H'ZFB52'XX(CQ8?74O!/^)M0W\V F[;VS:YI6ZMEKY?M9 M7)"K<9I$#Z@H>2W:CJ+@M2B=143'F+,$:); .H1+ASS+4(%P9!%Y^P[+6 MZ)C9#'BA" T4(48(;Q*A!_ ZBM08A&D71@N@N2?,@ M?ILH00,EJ\VB/,,-4M0@Q=+>(F&BW+M!2M=(?IB\R9.A<3)L)Q]WR%&'_#U MF&@%E*_>NCL_C7-_C406G[RYTB>%_51/G"O0KMZ]-JSU"3\/ M&)R4Z::Z+\9S;APHWD]'.)G_(]5?4$L#!!0 ( +0^8E!:#G_(H>T (V^ M P 4 >&PO:W*Z@L(CW8@S M$2.20'==L[+R^N3ORG(;[;+T;[OD(M]EVW__;C"8#;^+OJY76?GOWSULMYL7 M/_Y8SA^2=5SV\DV2P3?+O%C'6_BSN/^QW!1)O"@?DF2[7OTX[/=/?US':?;= M[W]7IK__W?;WK_+Y;IUDVRC.%M%EMDVW3]%5QBVD>1:=1)]N7D6=H^/?_;C] M_>]^Q)?XQ<$P>I=GVX<2WEHDB^K7KY)Y+QH-NM&P/YA5OWR=W/6BX1B_'/:K M7_YAE\&;_>8W980?D_NTW!8QC/M]O$ZJ3[V\NC[Y>/XJ>GO^\OKC^>WUQZO+ MFVYT]?ZB5QNF3O_V:5-K9M _^6/K"Q^2(LUQR1;1JWA;>U?G___]K__5-(]S M:&-![;Q>Q??5;Y?QJJRU*%._@)>*> 6;M$B^1G],GJK/]?&_P7#8GU:_N=@5 M!769EG-HX2])7+2._^1D,#P9#5H&<;E.BOLTNX_>%/GC]B&ZR->;.*L-19Z^ M6<>K5?1R5Z994I9M#STD\-#^AEZGJZ2(+F"X]WE1>^AM7-PGT?E\GL!3\,R" MGV];1UF,C\DF+[8XEYMMO-W5AO>7I&W$?\Y7<"+C0L95>^Q]WO+B+S#3D\]9 M_IA%-TE%9!O??_V7UK?/LVP';_-" M59_:%KLZ[;M#!2>T3(F/-+]M]C5ZOUO?U5=@<'(V&]8HV3&J>5Y N\2JNK2! M290#A2"KA'VYR!?UP5VV-'8;?XVN%C#L=)G.F?DU#VDV/AF,IH/I:-32TOEB M40"A=_67Z"T0?G2=5<>"7/Q%N8GGR;]_!VRZ3(HOR7? =?K]Z'RU+( JWN=W MR2IZ5:1?DFX4/=?=!?X%T[\%RJH^^W-2S'>KI.P^UXA;Q ]%_B7-YK4%O#A_ MKHD/>;D%@OG_TTWC#LS&D_%9K55J >ZJQE M#<?2?[Q(< MQ_]IXSG\],TVGW^&E7Z(85#1]6X+RY4M@ 6UO/9A=[=*YW!3Y'%M +?I%LY. MOHP&P\[=,?"3^:Z =VKCE ':$40?@)G\.5[MDNBHW\-+(]H >RUQ6+5NBGA! M//)I?9>O&N[;ZDDW*Z;GOH(7Q3I'">Q MYRFX*)%-EE&1S!/H\&X%/&:%[ INZ_R1Y@YR8+3(=W?;Y6X5Q?)"M:$KZ"/; MYD6:E+69?8P?(Y DX>(!D:;ZY2]Y\1G7@C;F( 4!,27UJW,G^9X!/ I%MG[K1 M9A6+((U;N,%5KRW(6_P:_T_7,.TO2>/6O-RE*SQN)3VY ADA>7'V]^B"[_ M].GJ]B\UXG!'0@+=/"KC>K_"E)HKLD2Y9I?20JZ,(Q M1(X,)P6OBU6>W3,C621WM65!P6J=1-OX:](Z&%Z9O8]HUWEE>U=I?)>N:"QU M]KE,"A1]B@1.=EVV#$_MGH;"H[OGP;?!2A"5X +-:\O6.M34K-9SE+UG(#PU MOS'/3F[/ W@KIDS1?+& J@Z#V+\4S?)23>RDJQ;Y$>@\/]#!WC[52!FXKZQ. MB8_7*'FQ(+T .1,PZ1.X!>;Q)H59U2^S;9RBA@2J3X8\L>%0.#:5,W6 $EDD M#\#U47SKK/*R/)9-:E[(LF%&SRXYK>LA;XJ$TK@.MR#QECM455"<.6F7(-V# M(CR2E+._M7W"TQY!IP-"%-#)0[(%-6@%*W>HY'/^;6)#A4* #HKH2].LJ@_& MNRV(0>G?ZT:GZI,I*M7//I6W"^!VZ]H'&#S5/KK@L>:A!8_L&5>5&EB5V+O+ MI-;VW)RHC=W^XW2+HU?>X]<-$2A-B&097$7_$"YS-T WPF!0$P MNH%S5+OG"SB]J(O"U5;7,58K6)QN!'PM09L8"2:+-_N1#:%$F1%9PKXGD5ZDW#5[=JUU(E_K(!WB$SDLWHI=K6DF"PB=NXQ?8)%CAN1Q* M/B$GT5W36Z_2U6YK;JEO'(F\_LUC632_M^?DDZ[Y&CCUX2HMO;*D5RSU@DQ# M%A(BIV:=EE5+& .]-]\!8ULW6$KI65+68)_+W6:S2N&I0+QM/RCXWCXR!7)# M^906H.4YE?Y9$TV$+ZW3<@X<)LX26!>>RJ:EB0_Z'LVSH]TAU1_C/X]QL<"? MX=%%H0R-3,UMXHD@>P#J?.D"%O'NJ7'IG]LNUFZ>W2Z2OOC<@VRV:[A/PEDN MTG*3LW67".N;-,QJ4S1"[!1;BK&MQ6Z.LFK-:/K[#V9Q8:EM0\;\KR;;MZZ_8+&W)TYCO8N[_:XWV14'] M(EGR""=PV<#LPN5'7Q'*V;3ZV>*_XACX['7Y*GD/LU0/(E^H\'M,4[3 MHR 4PO"8!QQBDGW^_>;W+DF1^F?-:I_ )320BI/"60LNR5IPL!1&!H@6A9&] M'VW:OC&V?!!CBU[WAYD;6A]SQADGT[:.X?KBJD6D;WU'#1/Q-K*ZYFF#H%'P MH ;_+MD^Y#6]@WNA6(9%] I$ 3AQS)M<.Q7*^I@T6T+.%W_=B5 .2U*AX,A3 M<%>U1K]$O)JD6,FU,3F-B\MAT]IK!>.PPWB4%G M>X+745B *P:/PNLX+=PZK]%:=F#'M9"/?7PHH-V: 6@_\U&S _/F^5.$P5?E M2OQ!;J]:K J@)VQ/6).C'557A7USWS'"8[GSQ@P\TTA9]W!,Z&Z-O\3I"E?R M!*[A$Y1TK>BYK^6+A@,-BQRRJ9=I?O(QKI'HH!?=P)K0*<8P&;9S$LG#%LP; MQ(6&1Z+_/+\K20NL,:/KXC[.Q,6&ITYW5EUP']!$#RH)?0#3>\T""YP1L_&O M0(E=Y25J5F1K^[8!XQ2OWKR_>GUU(@?T3F6>[N0/1+8WPWZCB3+VPGT/GV(46-'D.2 M0%R(_NU_3X?#_D_2;9?^'/RD'S\FU4]VI7Z ',)U M?U*T6,PYP"VZXP/--P,=)I0R8<5ZM'8;=%X7[M66U<,EQE!-G#4RF.A3[Z:G MUE!EC5MK& $N)PMB^'GCF*FQN2P"#H<4K!Y>BQAC!H/9K> Q M&.UJ$2U2Z*5@=@[L:&RN2>0[G_^_[ M-ZD77?I%-!W!42IIC9Z;H1B&#Y@7_:K;2(=S(?Q[S.E[@&MZ#Y(A- M8UM9K$:K*N$)I5K.I_N'NJW0<":PQS"V"7H.S!P$)[#A!H I/EX&X8*L4$/3ZDZ"TA(F()!CK\DA1;,H>J9J3J9A$(_2B..L(6-#--Y(0IP.WG(>=_C^ 4F'(A1-RA&V34_WRME M!00H4;EP,.Y6Z3U[NKK1>I>!E+'!L^H$XRZKZ\!*YI_QUC9?\&6&EMF,5J+< MX."1 Y%QJ7)TC_;^,DC M&W8+?].A@S7F.3;%AE0T>!3,BH1#2=!MQ R[)WHEOO"'& X]**^B]W6=A0_. MEYDF+ER-&,,!XFEE:YR^*A/E%O!&J370=(@;_?J+'2DN))XM\HV*D>D6*>*$UX=>*<#&KTC/_PK8^$Z7UG]\7L!BQ.<4_G%??* M\;)'6'[8G44R7]%%+Z*(7S[:"OA\D8*XMO/\X@G)TTD() C J:&-/0'JS>"P MK)'Q%$\D'Q8@_26/I"LJ2GC\(^!;&/8O6+U1%Y@. H?V\E1 MB;G:7NIB":C1ZLFI&S0;G?)1IX1;^CV%2O MGVZHC[=[0E4=6AB%T,B$*,W=VAO @:I4JXE2[AI9C\M07<-O>@R6RP M%U[4$U[4!= J+.-9AT8?5N-*XUWI6AK,O$LST[@OJ$T1+Q785#P?5D= M39='&!<%Z9+$/$HU#2P;:3Z\!=BP'!>+PB[P*-) :4_@].W(=A"; MMBFA"N_NDR1;T++*>/64B." 1X=\U O:9'>[Y-0.4[HG<"9CHE?65%!_U],' MPC9&\4BT$DZ85H.-(U[I7^2H5*NV9"13N+?Q4F0=FPT2;"U?.$+;WT>)S%NE M3_8GDW O7(-8AA.#5PF065$:OL&Q([O"QX'TE$E1_Z06M1U]Y/Q^CD2A2&K^ MGEM1]E]&>4 ^.=,Q+D@O^CE_A!4H0#B- M2F,Q\V32L'&P$K1QCM@?X&K8/LQIB9Y .U^+R4;6DYZ6N^]RA\$3U\\E:; (XI10N9-X[W%;Q:B"U*WZA]"V7SBU!3G% M6[W%S/+,:N!?;CSA'7V'UKEX]?1W[)63'G<9T@E*5!1*(2/NHEB_L&O:C4!" MR?(U[(M1SF7)W##1Z#8X^TD6EA+@0'* ;XNG+C"F$LV'>%CMM6RGZ=XG4CP! MC0VW!73>GMCBX29 FK:3HM#?33(GPD""3"5QT DEE3D:80C&]P@B!]RZL'1+ M)QL1!W:+R.H#9K8\12:_AAHB-N=,/?""$#RZ92AF(<'3CV()T0V+5,R+V=RJ M"3E=F-@=#(>6!,@="'9!S>B=EA;E]B3-NO(;&LW6Y/?!/:;[#28++"U-OB0N M%8<58HG@ 2TF7P%_]"DA'UQPD,M8B?8FC/#B 8]/K06!$Y4.S5#!Y?12U=Y( M)>KN+DC ,=^)$PRV=X'*A'A1.;3?!H]T<0?N):R#XJI\&R2]T(LD.);YD=\!:HL)=EOJR#VSULBV2*,CH MR +51(6:H%=UYFD!*X_1R7/Z8($*<6+D%+V2A4>@H(*7TAW;(#&8D<2Y5W;3 M4K:24!@E"=OH%Z%$(%(3[MC1\$5LCYZWP;21\V'LK1=Y2&41LVGKD\\3@K&E MXW[@\2Q?5,BC.3^K"V)Y=!*-9B0ET *J8*:#I!?9Q)8NG;TY;(0L9;01J5@$ MDN*G5N*"3J'/"7?Y4S7Q:@3?#8;\92]ZR[W_DH0V5[Q:/"&3/4#IFQ0X%DAZ M426QI4%WV9?3U1&GRV0?"L>_\&91__0;&")96F-\(NMT88@!Z!">$T/W.J"V%'F2N(E6<$J M"T.>#Z+SK_(0/Y"2A0#9*6R>+I(HG\CS5>+(U7>8L_>%+C$)@! /F)# :X[[ M Z68STUUIH865<$F12ZT7;5.5>2_?9SET9UV]O#DV1S/V8IW9<.1=I:#PZSN M$S+4B.*&GAU^#F\TH"D6@[G]O2.&M/:J'Z] 9=G"K^=2X@1S;D63B#G+=R>)*2R06 M@&2/XK3K!<6_O)!+3.UBQ+ JE"L.$F$3SXL5]N3_ GN:T#+-B<%BIPD?\01% M^V2A*U6RMUY?Y\CA[(3_BA0/K*.-==]#&);G58DYB?5 MBBL#\T/9,\9S\N]*7X[(O+:'EC0^"XZ?K]16!MW6>J(4J;N079=J"V9!VJ^\ MB52@Y#>TJ9W?7$33\9"$H57R;:-IFN+^$:%Z/4>7&MVN=*1Q *?]TUYT@^Z5 M/;O$;F)T?H.UO==Y$FN?M? MW$U;.@-1Z81>T@ =)8?V=)0M?/8"*H.BL<;BOPTS&\@$K\K.G2 W(9=W(T'! ML$610/ZSV; D4?/];).2J$^9ZKC5P8;^DQ- MU@V+&F[=S*+*3NC9,Z<81B,! 96.T&\>&'>)X#'Y ?A2:OK;RS\NI$"S&[2 MMI/0BW+<7YF3X\*2<5E\"YAF D=Y 9L9A*4TN*HJH^ZQ8/^6$M_$=U85:XJ* M[ZTBO[!8:3-.T11933'%,Z%232'6>'5WY"84OBX\>]-1*51L2"S@#&XMN ^R MLM*Q7228*)9X Z!YTGE;F_MG+P0Q#]5X=:JJ*=E$6O)_B6'D&:[5)-S5L43* MXW^*K8,)HHW3O(9;.2_$Z?;HKV^0YX-G+V^GBZ)=D5[U3: M550OK;"@FK!EQD#$C>R8C,]DXWR&6KV/V'$D9Q9T;%/\E\C7U)@-@X3YI^5# ME<^KLJEN/?6.[EWB;%&G=(Y<%2KA7G@.]='6=VM'9A.7(!7DMWJ! $D46E.] MO^$F;#@)("BPV] 308K4[:Y<.IX[9[QLWJ+2<1@6&\C5Z,P\.]&-B,]B7(?) M(0ZVJ!==+=DCDI9ZN23=AFM1_+2!+,^SKCYH8U_+1NFC26JPD[<1BC[IA$VH MHK;48 Z,Q"^F%G,5/@E!JP3IXK'Q<2LAD!U$ ]CCKVW7NMKKW!8(9>$K>-U0 MB+1D:LI51[R"O-QW29(%9L[V\.!/,B=81YW (<,KDN5*@\9]=%6IVHFYMP72 M@L9-7CDQ^/H8&@W(F%,PW?81!]^P?ZS'M*^6GY\7X9R8IH8.;6KG5!T#+" / M$\T]1>RH<6Y"/JY)%L\UHJR@4$+D(Y*J)%M&48#.$D)1?,V3I8#IX(A1*(8- M$.<#/G?!9;[?/#MHHT*;">5FJV;L#3\2+JA&0[X18:+.3BDA6*A)-_:Z#:*Q M'Y$"V9'(D1[R%%W03=$+$5@XZ)/I9Q9QM*X*/!K6B M%QS9B:-/&WY)=_]CXB^K+EYI,(@=)SI$/O3$>^75SXQ"5<-V=.F+32M>"V^$ M1HQ@?PO)M411!7WAN'*KIVX3E03;07$B3)QM8TW9XNPHB"C1\0W)'N-KA?P6 MSDJ**^KNDPSU%+K"L+TF$G*24O"BDPE!(&,O*R5+QFX"8H.$EXC3,. 3Q_5: ML_XVF3]D)&"O82VV[EK7COC,FAE5CUT;!Q9I"6.@YJC9A\,G$Q2KDXMP0*2\ ME2[]3ID_>OCN82LYJP/]?]&D_STO5OJ0L[6;LRETR?C;@Y# P MYX7.?12& /Z/R*!K/IJ9,4B 5;8=8G0N@ES%QK-/D>ISD< M?$^;H5,-K@YDL*.SN@/N=;DO>X4>]H4E;L8*-\@A, MHSGKNRP:0W XOW -Y>:J^N)VQ:\8XB^)T 6M.49P>\> "DU*3RQCWVSCY=(F MM;[!U6+SW>2\:8+"^214WSUV1 U<9P](U74O<=Z1S<_X2&W0TDV:2#:!R M/.X<\W!DISYYO66!QS.WP!A13L"GD0W/A_-9RSQXE-A^-#+ZR=R(TZ1$''6? MJ-+Y[OSFXKMC]&)0Y#]W0;1XX2*6R7!XH7%QW>]$?B7##C5&QVE;Y'K=:S18 M3(A=0A5Y:>.YQ=Q5)'3A^BWE>(7*I(S(B(]())N>*8R9!7;(]U %%)26L=\; M^'2OIO9MO*B<:+*]@*HH8C,E2T 'XO'QH;CRC ]W-R2> WLFK.WQ4^Y/5,ONIX@P,S<]VS M5KF%"DL67N",;,8JI4YPZ!3%]\%U+/"-73G^Y,:BZ&(7=>V)FG'@0HKS :>A MXL'6)^0P2XUP)#>P=+].4;1Q<888*Z= DBAA^D;Y$+)L0N0HBFC9X$9]5.V* M=2M"KR-U33,5?.YF4\]LW,'[6U(BPW,PCYV*[?(1X$C3*G!?U.&P;WBJJX&E MBP6S\FZ4;.>]8SM4GY=-!V:-4:]T8DQ6GQ&TV#'FUZS2=[[<>A.%4@"+"THD M:SQ)FU72O(KA6>TY# X\$B!B^44*015"85_1WG7FW08Q06Q3X4:I3Q[6 M!!5)2K:1 !*TQFK@OA5O_[I;W+,EE3,>R2:LIEMA3>*0HTR391,'\+L/EVZ. M49?J+/(QCW(^Q ZU))\%9:;"H5XY=J2&0F+3R%-6M4>4T[.$I^R1 0EB5JV7 M+K"\2UI(/N<\BUYTH0*8&Y<;4M"/8>=+7H)8LQM]Q@?%\Y+VPBQ-[N4(D\]0 M._MQI2@33W!TOZ1%GOFEUL9-H,S2,/0C[!W M,@?P C118USZ)BO7C:5-W$CVITEH53A#(<%-GO*>D\ N3;MN'^0#-0*C>QG6 M5(ZP.,[(DTEJ)G%1] ]RCIZ G[#D@ DA2"!.UW.F=C&CWQZV3,TD3@D)95Z[ MD^L4Y%[1/&2%.^(;=A_!&29+X@-+50U[%"XBL$7A0@F;[QS!N;4(Q]:+SDW0 M0M%T#W;9!R5:H<.S9*QQ:8P/EF@_ZCL,8T3:7Q8AH++Z:<5Z:#+@ MY36BD>"T><<-^:^]8"%M)_2QJ3W#CD%CCE&0[#U)ZP>1:! M2$I2Z-M. :.:!(H:!A4K9(SS0:V2[![CC98>S4(P8UBWF/A[&2=#7(&>/BB?EIBKC .S$YGQX_H8(J1<_N90 M3/>-AGSZ;XBKP#+']UE.2<\:R"$)LL(C6"Q@DBG]'6]D/P4!*G=K3BCM2)QI M>5RQ,;#U'[DN&?,9A^"6138_,-0.;%P_)X\FF1*-^/ UXR/,D1;K"JJLWK*A MLJ>!P$J192#F3<&"")&>?$CAKS:Q:$_@+%$: RCX9",7MNOR'TS\="/O8<] MMK=EXEP97'2@+**-O51K+XH,TF4%G+,2N^=B6ZWSPEA7R%CC+KW,.[:[3!,G M1/AXDEGJ\VQ#W\E^8Z!-()OMC3K+V'..< MC5O7#5M,:'R3P6 3=)/-$TW9CR/2!2EQ4=^5)2Q\*)VA852.2*+1%'_14!I) M$Z1%#!N']W+*GV5OIH]L1)@6;(O&4""K%M=!1;L5M!--K3>+PJ/397'84!7F M*U*^F?H1M \BV!LKB&Z=UH< 9Q%D[3@),V86VRHHNI1/'D(8I.1N*"3E M]%X<%@D,+,/]+EWH?:D> 00XA)'AULIZ554Y29P/LW7J:IL-6PI'Y)B,3UYQ M7SD=P47ULC&_54D)8R]DC>JC<08V-34Z><0;Q\5$O$R_)HL?"3IFMS9RJJTHY!;,X#GHN&).W'&"V+%-N-JP?A-[YU24;%+ M\F@&_*-FXFF@)<::^94SN$5[AP:9L9<%E >VZ9MQ$54Y>#*W 81.&2L@B9ID M-:1(W69^<^0Z4S!$O)O0N8Z11SD#^[O0I-J[#2OH]%[%O L"'ZG2GP-JJ\XK!)H!BLK>.-QZWF1[IG//6LNE-KNY.>NS- 59IX !$ MLL"RMMA)]SW*?QO!POE&?C:7:/=9R<(;(E##SI'=D,^' D92B:)W!ZR2HDE[ ML%SM$ )XB\.G"D2HB_.@O^2K'><9N;70BWA!AENZWI>(]+84%:!)ZJFSKFJ2 MM(%'ZOJ<;W<82D3T^8*^7S<3E!8)A-%)(L^O%0&3A:L4P#Y6\E?DAL31&^U! MLM%]XCU.\/X>P6E1&>$E@9NP$;S(3@MVFB,=?7I;LJA-W+N]ZU/W:6:6@UBN MM)?4.)10*-:XJ*K\J\*[^#R5R=ZE-MF2!FL69C'ZGD8]^9[:D?,N'FH83P@+ M6PUPE/DZEA&7%(NG1[S&+YZ%:^RY& P&?GG!E-@@+G7509U1A&SDH,D8, ;- M3NPS,&9;%^SNT'!4$#<89W1VZP:<6P%=*QG11CQ^(B%]0_G%KE,SV7HG@#6\ M3*0PA "Y$CXAX7^BE^$B8W:1+JY #[B'NRR"-)L&..$T[(7=E&ORQ^&Q$2-7 MQHB3+$KYVC\]Q-+7,R8WME#K"Y:T:E_SF6*ZNGNJ8P>*-&5G6VG NU5W3-V?A%K($5W:6D\PJZLH0CH!M&G13.RV#.?%-? M8=3$/A^&1>?1UIUV&Y=52ZL,I6QV@IAAP=UBZA,LPR!L1R$"Z()D&=P(FN^C M1MB#;*^WI IYF8C@!HG3M79,]NJCT5EO9%&SJY@R4V0S1^-);[KO*5#Y8GMO M+ HXJA0Z?30:F3@M0KWIDLP36+WW6[S9?/WD#/;--NPNQTC3KF/89D+)/D?# ML8$%K_M _JXL@Z+6K&"X=]>: 7BF$3NOV9WF(TN]RUC"\K'=.0?K+A*\MKL. MIDT$];SX##,L']*-17MDRXVWU"DAB(K1Y-\A\D3D:H]9%"83F M-J_7>4[5> M]#*%3M):RA%?1"J(.3>B4UM-VBF^4Z0L?6AX@W^#Q>8@>@2XP@)QPO$T:2IL MJ9N?+!H1>EGS=ZG&\0)F'<_=(73=4? U8F1>>.U.SG'UF6Y %*T%Z1FB:MM: MTUWE_CV0[%VF00\]AJG02KKE\0L^:$1FSN 2'44##(2$']/>6116X'53F?7@ MO4EOHH4WC+\7]Z\S&/3ZT7'4&8VAJ6-+UM#P#+Z37FZ '#?J9_D9_J%+\Q=G M;N9XA65!=6RE<>'K09 >3-')32@$A7IG;TE_JF1JR" M1Y=5P@S#FU/=*5$+&DD1=']1,']K;UX 8AU_Q1BI>H T+[LKE7J=7\3)VF?3 MOJ_BBZ-:+1[1<9JZ."/7@XWR7R3HRX)+?HZ";UJJ6*FNN=:07N2D=Z 6I[MT%$=TN5 M-,?*"M$?8Q\#%]0L*$T)0\6IY;( ?E7#DFQBU&TLCF 9V[XZ\HTW4[/B>KNO M3[%O>2&0B_:*I2<5,-_*@A(K"TIE5>&QI1JO&KNRG+UJ-"U9# )=%"=7K 2J@262>*.P M/"9@/)AX6!8LC"Q_OJ@X@R\B0$1#<5K$VX812F;J6O%&&_;#EONJH=>'JW_ MGMG8%-1J@;#AL:V)GJG@M5.L%/!AS=40C'";J(V1.8B C8L*:B=<>LGBOL4C MKP 4&FFBBU4Q_FW%[N'JLWN!VY9R>:)$9SH0LS[\_N3K)?$MY%?''X(*E2Z5 M4:9DGG!@ZS46D7GT"@L@((F>S [3PF)6[*M.$_(IJ:18N%H7K"TY4JA\WU5# MA89KMFUW5\-5;?DH7Z[H-V)"7.KS9:W4)V%-ET$ET*8"J$P4,,[2/*CA0O$C M)5/=HW2<+*K8YC9@CQXY(81.BQ1136$N*Z8N49C4@$ >$[APO?TAC,*@\1C( M,4^89"J7$NJ!':-U5L3/EDFZ=17.:C;<)XY\5DO@AA:4^:XBVQFX._4OSWJ^ M(/ '3,VCFN)8*7+N,[8P@HF+C5O@YSN$._B2+EA(\N6OFDMRJC'YD?0$'+7< MTJ8.@!3%Q9[0@+,E?ZE/(XRW[NY^E:YH# U#W,:?20!&;5*@/DBX<( +"WR7 MDX4<\S*IRE3K5E%0.=#952TKNM&'EBY8,1%)P\60+MK7%H3(^4XS1Y9V71VX"T:_ MG^@2,_/Z55NNH;K:)0.K0;4KLTTUHZ5P$ MCZV9FHI2A8 7N-*FJIY)8""C0AB^4Z4D\47YBEC2DBT1['-E.-04339_V[FD M.:YTY>S;[A858FLB5>]/&AWWHD-CX-!:O M4,'0I!O5%WO?V3$PC E+ (MDF68&X>(AEPK%IEUFI!*X92+$:4!-+[@2CW7O M%MV*6I7$,O6[UM"2>\ML M1.67@#>5;JT#QS[[&*Q:%KHT#$('?R$?/.N^Z#4>OYO+"SU]KRF3Y.-NA6 7 M'-^!4!VCTSH]*2/DY?PV^^"Q,@F?/0=+4TU1Q=%DC5&"?*E27;-;AUE?6OR M._F&U+(G91L^G##JP*S0B_Z$IW0;.S0UF#_T(!]42VDGV0.^*]6RL%(89O)R!>13>Q>'$VHU.ALCWG!@EG@ MDSD:]X;&!2_6!#4/5_+/L')R7E*DCU:HX;_I0?+= X<[->WA (_ZYB.)2()W M)"7'1!5;A47E7U>]8+6BK+D@(R8 +:(AH7E*$&#&KD\5ZCQ*F1QSYU4Q1>4P MI-Q&61 %>E(1D3<.JVU_0P"4 *29%A_C,.J4(L4$D@"(2//)2@W&^4'MZ>QZ M\^@L/N7;M.YX)=W*59R0V%\.)IVV"N)FVCMQ>=E\8T ;%$094[BW&F,L.(X) M%]K"-BZ#J]H,E&IC8KP*2' DZC6LG5!HC$1IO,I[W MXT.^JEI22A_;M.]29W4BP;R4#%FXCUQW'F<],K@^<"0\+1K/LX,/P$@.K-&E MDEXB<+P>,;B+!#VTC=2AL^B9:>LS7I&I('>Y"-K((A3CN1V$XW9,*$M4%JA< M[-_&K-:TL#CY2('N:,DOOZ(4:@B_&[U]>]'$NT[[O;[!R[KX-FY%TL[19-8[ M,VW\O\.Y_W!BW_>^!HFA)%0FPC.X8, NK1_?");[W^2PWSZPVVGU[&$>GH:' MK.GXB!JN'GM;%[OQ['=-34<-ZR1=&6T83VQTQ#*S&6B%\'!P9S>)1=\: '=$]%0.9SD,;)&:VV#;C?M ZXIE=H$ @I9PH4D4ML PG M)G0CGW"ZB;-D5>X]3!;C%CC,.XJE< S&8\=51XW'X1D)B>V/*""5:WR6 DW MY'MTZ91-O&:XA]>T,!@A@H1<-K!I_GTRB)&/Y(M ;:+YUX-'*IK+T>"TX2V_ M'(?QJ[<8BGHSIP"[_\>GZGR*X!$.XU71_RQF-9@8T=N<_\A"J7" &,?>$PFF MZ^1DFY^H.4_-I,!X,$XP%#":Y96R+K"DV8EL3FN$& MM8&)6SY VBD/9(<@P3,[<6D]<.WOT$.+1PBMH.0M:CIUAJ%5];]1SSHMWGG( MU)I6:AY[9;3H=K7TP'9Q!.=7'Z,_G[_]=!F]NSR_^?3Q\MWE^]N;L"8L633" M@D>-H0B!Q\!:@VEI&ZSDXD+8<7PZ^@'IWD0P M$8??$4ML,55>#T $Z7QM=L(7I!2XU@W0*7(L6FV.&-9L%OHA!>(!LGWR09PN M1IM"/E%GOZ=2QEA$.2'$>NS2M&$F7GJGIQ8F,!!#,F@)0T!0!WYDE]4>DM1/ M/SQ*T(8#\W?Q74M;Y"S?/H"^+5C/5&>J# HI:TFW!ZK+)ND.Z8-$M9:74)M(X\!_V]W=YECPYE^(.C=&G&&>OS^A/^I G7?4N1YWX&$8R@-8F(S.>P03C M\#]ZG[FG@0@O^VH7^-DE&:JC&S_PSMUQ-.Z>GHY!PZ^^H9^?JP?V! C^A-!^ M#;WA8BNB.=:L;EJ687\,\D+X%XG;!O05L[;+G*P%]Q((YZ;:/S7KRG]IG)AI MP4)5N3F VF-_9PZ@%M&F-T:F*_S]W2Y+Q5W<\/1@8)::_GB.1,Z&9O_I#][W M>.\J1YWYL9](W[;!?[U^/OBSLS@VQ#D+?N=_D_COF=G%7JA#T+N.QS"40VX[P@_>9[[CH+?&[COZ+2!^]*' M>[CO9 ;G>CJU/&A\!N-I9+XOGN.^9!O'=DU@%_?Y:3]L,_GMONTY$9&/WQS9QT=#:"6SW\ZYLYZ6GP^S=R MTF'W;#1E3GHZJ,@EH^ZPCX?@G\U)^T#+U;^_B9-.04K __\Q3LK#P'8PGW! M1Z_*7&I)*Q=M47D'Y%+VZ #6CV6U#Y*[B84J!O?NL ZJ#+ M+G+3H#F%Q1C[/0AK W0O =L@7LE;<>2$N"/'4%#/Q71@M.R0.0_3["4L18+Z MV6Z1U!:FW*+UXR%9+5IU ?:E#+O]T<"6WD"+85(DQI0G0.T"W:J2*[I00=4& MY7%71N=OV,)3B44Y$$ #S_E^YODOVNAOV&.4Y?!V1$[4;]AEU"EP_]WN]EF7 M8_/&4?&86+H@JD!6^LJ;QYMBD$Y=[(3F>+1'9?C=VCFH MLHK+!<3.^X< >T$CS?!>0!##^1.ZO7 FU6\Q&'57X4%I,71JLU*.(@N9+28J$;7VKT&>T\>9("_[XX_"T<1XAU MM)&T)(=\Z1"&>]$-%4!#NG*H.P^QAN14H=Q,N24?LJT92M7%(&O^J#>K>.CW MDH!6ST,+[+9L#7@_&EMTDY9[K1>1LP^*V ZCMC/FXCR+"K-*!*59"?W=>4 M8+Y]'F9S /O^FV(J'/S\60[Z(OK@-[IR)C@E*PQ[ MN5KG9J]';\A MRBWJX-UT['1&&X2HE('H9B&)-X4L'I%Z5=]+ONWV[N??HAVP(!=Y:C-(XCLD M3=U8,<=3'>A&EXEF"1]PK1UP^-O)TSH,%+*IM"5V518IC7,%3E6^T@#RL!11 M4%L!;A(8,^/LX86=M,VV1SY#;O%64S:B3]:!<86=8T8GIE]@6/WSY(IW_?.7 M\$WE!GA!KDZZ^LG:,< [ZGN'QD+&#[P?O@FV0^"@>A>6[ITM]H>XUVI.4E!OX*R)N42_&#(:TY%D:1[T=5S6*1Q1I@M5"E27Y EX:NEOBA2#F;%.::!F;%M7P[9 M6X'Z7RA6LN^P;E$-"KO(PVZKFOOPB%2+F -9!&,^H6B9K21IRSWC"*V=H!3/ M^0-MBZ8FP/L(8%FXXLT"6$9)X/><+<"9EOGJBQ1)#Z*H_3@M;-:O'9X+M>ZC; M,J9M81--*)YPNMUN3;S"IWL*03G4L389C=&>0K)HQ%N\\\6Z,-,I@"BIDGB% MH!NI]1VC^\*+*T;/BPU"+!#D&5(@_SPU#^,C&(2"LA>KP(-3C%P=G*+-PC^W MYN(/<68?/1W",Z>CAH7FE?TGG?#I?^D)'YS2"6?0O@Y&L=$))]=-ZPGWY"GG M=J\7!99T8E] :J5E/N"@3W$#A$%,X;U#O$*C!J\8?C8ZF\#+V !H*J@IL.WS MFP_ML.%P#EL_5UK"WB>TTFAFDQ&H/77_H;541@E"]P60@;6F*\Z6IJ_Y$JL' M:H%UHGP=, ([!#:HX@B<+74PA".5;1]*SG1'PWPTF-'9&0S(1?\MK?DC[]L] MBF;LSAW,<-/>M*P !])^\U@%LQ(Z^ <:;AXV[S=2+R6PUQK.5;FJN(7$:Q$; M:!&N>QI"1?A,44UH8>BLKOT*!=Q\G__S(=WJ#_\/@7:S;1X"[;8- M<=O^NZ.Z_0K,-EB)E$ ,/;*)8H>XBI29L^NH)&3CI;6.VA M6T;XS@\$E\IISUB<)]=LC#:QMK(7XL4I*/:?0X_)+K#)MPJTB8X09\$0G/P8 M"R!J%LHB=O*UVJA=M38LR.Q6:,&R\H[P4##66VLE_6I O,/Q\.YR!FSW@'C_ M#%3.O;(,LJTJKW''OBF"Y#GUV(-?\@FB:CP.+T.=7YJ_-.R+)6M5Z_T%0KPP M>6O$R&2( 4QAT()LCL!US3+>#"[#&9[QD^XM1C7WF/*^[IT:>L Z<1 M-J57"&:QKV?8X@U F$(8P7U>\ +M168_)!3@0A&\SIF=-JJ4YM>?W9#9+ON/ MOB]1D'4Z?8Y(*8R> XW&(]2IAD%LEXL^E!Z>;:Z99%O:Q+Y'%#V&?4_ADZM: M",E5J";L)UWAPJ$XC(XB+%2>FC*V).#6B8/KY*+9@ MT&)QGI.QJ(6\K\O,' MJ->0:"H53,@[JGM;N3&#<6*R7]_ZLZNX&_MX29T>0^<_R5[Y8V;@1:C((3+7 M+_DV2*L-PK@Z[J]C @=YDR=;=HYUHS<)AHH\21&).9O#72%'$A'U^DJ^.PPGO]SK[YY;Q.J7,M9T8_&I?"3("*VFQ*_O*]YHHEL^- MVPK,#+.6F41:)V=SB9$$944_CA] .$&9@-0,27L\EF?^-YNTZ[*WJ>\$3M18"+*+6=-&#VV@8])OKZU>_7+U] M&YV_?Q5=W_Y\^3'Z\.GCQ<_G-Y>OHJOWM^?OWUR]?'L)VW%S>7L370CGLSG) M=[[J,!V0R[0QG([*Y=D:C"3E+.B-,'X&? M@S,2)CN3$7VNXV*)?S!#Y\SP#,30X6 &30UFTQY"K.)+$_*W6#RKB!*_"?UA M/#;A\M6?KU)RH9&=H.T99RP>\,#YQY6?<>L+,K'AV2G9I3O#Z9!JR;CJ#T$! M@-9FV*G4P06@']AH93\-?S [.IR@*7$TGD$#DQGN&>\P[R_O[F^UBZW?A/N( M_KHI&2$G$[*@#D_';.ZD#3[B+3Z23;XBL*R_2KT"CT?E=)<#\"Z>001+0[0Q M Z^)P'.6IKX[#@&W E@C:/^B!=ID#ZR111'Z1R?ZC6A":8!;]"W3#C!5\J7G M7XRX8N%A*$!E_]Q?$,;'X)"%/)J&S[W:@QD#3P\-5@,\?>L 9%0X#!I[&<\_ MPXN_R58 MBYPP*)9A<*5=&K*9/8==Q? C$CU&V[R=PQB L5/\W[)5R^3+%GMOD8=J3/):+#\Y3&) MB_WJZ%^B9@)L!/N40K&CZC/G=Z\0[Q=5&%5"U51+ <[3(.[Z:#@^"T 9CP86 MV(W(:V)"HJO*FKO_4);EL7?-,%DJ-B-"Y5&J-NQQBTQ[YL[WEIIG-T]6%CLU M8VBLJ/AK<-5\55-S>^/@JC/\1T"1!"7$3)_&S[8LRHJ(J0QA*?M-[4MLJ8]Q MYX#-;I3VDE[7UQ03-XW',.T%A52Q3&NQ4">3(I6P$:$1N8^%=3IQRDO$]^?^ M7!%62%I^D]7J%PG9/#D7K?K<%A+^P-I/AZ(WCJ,/>EMPL)>5LH+7,#ZY:KQJ MOO]^7%'EM]/>Z)1*#IY1J$3G;"Q1$B,4#/^(!>\?X/])[VP0#:938.V=P2G[ M]X=X:/9Q]P@D,WAKC$$JG=F(!,T)6E7>PAPRE ?AZA]'9XC)U1F/2(UV1E-V48]&&.\Q0'74! [X6,F]M':$76&TJSK[H@Z MG#28EOY[D!%L+@7:3TGH[IQ.-=8&(V(<%9WV3L=P9:$=K3.8S$C"'R$O?HZ* ML!0%MM29GA(5C$<8D*94-.N=#9&*1D!%?:(RT!7&EHI M!Y26'-G1 /#$;12 MT9FAH@&1W.!0(CF*QK,11QN-"$R3=H[*\C;>[<_"%%;ND7G;F!MNP6GUCAL8 M.;M6>;U!MJA*!BRQS-&]5"*MH&3Z!+=5/?6LBX9CA4*OL?G_23='<"HT%\/D M%>T[QGJETE*H1B/86=0Y$U#,D9&ANZ0C56S1(RO"5"46[ZZ0*<5-T^@X MWY&OAMD^G>/Z?/"-RH2&?9K0<, _AOQCQ#_&*EL42;RDX(RFJ0Z#B1T-9@$ M]M%@&I Q:GLU@.SQN#7QKF8@G/1(32HQ^<=5B*&PN5OTJ[Q*[K;55_"SPRR M+2UOVUK&P5S?7MY$'\[_OHK?7[]^]NGQY&WU"-/=H :P8 M!3H7AN1K>Z(N0<=F#BPC!3V(%,F[IVA%(#LG1 B'XJH*!NRP'"F7Y%>-7 M71I>HV*ZY.DLA?DQ ME:#]'0^0 S]=:*(.^N78=#G=V3+'O<;6GVY(>3JM-]NC8E!/9M M.)W5-S?'+DIV%C*J1F(=CEP6@5X<3 PBU@57[FAYU"-RH95UA-(!_COFZ38X M,3OCX2D;"_N4FU>9%EZ\9%X>CZ9P\S>N-=[*;G=0&^VZ<#^L2 W$20ON &,K MD4'D6ZFV:]J##CJZU_3 L<]1CI[29(57 NXVUP5 23)9\.T]'@ZMMW%+ 0"N M' 8%/,-CX]YL?/J]>,1L1Q@7@Q;*]"O&S,C3UMU_\6XH<3[0P4L M%@E<\%38L]"2D]MJ9S2\)XY+Q-_I-4;?4W_-$E2,OO,.UA:RLUGM*)B&J]53 M(,/GY(2A6S=%LDYW:W81+"7.@%0ZS6\^2"W2BE %UH M,K=@P#[2EG+?979Y!;;A!7R;H&& J)9B9?#\8O!X$'39C4 YN$_0LSEW$0&I M%*WB=%H4(#V:%Y]]-W(B01$0&9*:\Y748DI!;6Z6^WS#12)[X6KAX9GQ+[," MPQ5:MB38VT7M>L*@*%HR:K()MDA40$*X@L15(E+3"=77I%HY7/90(UH)JS5G MWX&4N\%%49Y&LBUN)E]JYPH$0,4 X*BL)"]>61-%MK*,AC'41PQOI+P"Z$4( ML-I>+WJI][4EXEJWN'@J2>>K+P8[C0"",@>]2D&SGRDT&>B'B^AX0V*7+F\T M&S.$-S-_*< GNZ^9SW.7QA$$J*( DN6!,?SNL"FTT,=/J(=B&$,%4+DF-4=LMPW-5T1S2-FNA&NI;+P3)Y,W$HV

"05?[@9J3(-.UH9.C4#68H'[#CFI MB#--P.>@ID".FL+E1H31$)/]TX#F(HR%F^J9!S'3/PV7B4AN"09M50(=RJ 0 M6@!:_@4^XUS7T Q+_.H#"U [ %!+ P04 " "T/F)0$/@1>EP" !># M#0 'AL+W-T>6QE++XE'NS5K1PK+0W1TCL[O_!5)2(EJM:'XML18@36C MO(YAJ53UP?/JM,0,U2>BPEQ' -<.WDWF?AWQQ=C_Y$-'$/@&)^S M& ;S]]#[<^B)KS\/DFUTA)\]$?\8?(2>/PW]"'D$/GT /( >2#PSB5Z[:$F4 M"SZLW10ZAR8CAL$*T1A>(DJ6DIBL'#%"-\X=&D[&I MM,)"HDT0SN"08!M=9"EDAF5?)H"=*XDHSHT<28K2M$I4G@DJ)9@V,H(*P9'5 MT&6TAL:FF-);<]B^Y3OL=0[<&+,D/@1&16?J6;?FL&J^E;Q-<^QM;+@7%U1D M)=2G1D^'V[[9<_A&XIRL;7^=]P(T'545W7RDI. ,N\G\MF"P9\$D0ET=4 I) M[C7/;)54.["$8(6E(NFVYX=$U0*O5;>=UOF^FL/_FF&!.9:(;HO6>__%%$]/ M_UZR/:-CP<^HT5Q$ARCRN8_8/UYZ M>W]O/1)VG@B]%RP;0A7AK=J29!EV>LP;+89?S>./[ES4PTM!XQ5:ZL?^#E_G M9CA'#54W9HHV&,/!_F*$!_-^U*)'Q'"PKW%&&G9N"P[_*)*?4$L#!!0 ( M +0^8E!+!GSJ(@8 .HU / >&PO=V]R:V)O;VLN>&ULQ9O?4]M&$(#_ ME1L_M.E,8UN_#0V922&DGJ$)Q32OG;-TMF^0=,Z=!"%_???.(:R"V?1EZQ? M)]GZ?)+VVUT=K^Z,O5D:3R:NW*A&NK'9JA:VK(QM9 Y3>$-\$1W+>1C\IVNASLV,GEE036DU$^ MA0^\U4XO=:V[^Y-1^+M6(_@6$_0UPCP\_-Y-XK']+]-H5BM=JC-3]HUJN]T\ M6E7[H[=NH[=N)%K9J)/1PRY"MI5XVW9 (^;M[J-@7_]=X-#S:O>].IBQ1UAA MCS5LL/,J\N!\D*?PVM2Z@J-7XG=9R[94(DRY0X Q 1@?#%"\N)0(,B$@D_\1 MDA"+5K<0GL)8*<$9 S7LAX#&"?>CALV(2@C@BH M(UZH9"S.I;;BHZQ[)?Y4TO5V=X9QS)Y207O*2YB.(:YTLEW[XXHWSD$T_%6\ M,Z:ZTW4M,";I%F:Y9&/Q'I(()R[EO?2DWH07IEV_O%:V&6!2AHF8%9./0Y1N ME+B6G]7@)%-.B9BE4L -W)GR9F/J2EGWLW@+-TIWC_$HFT3,.IGY6Q?VZNL0 M!C]T&V5#^+-JHP:WS[W%BVNYQ)B496)FRY )^/"D4X:)F0U#)N #S(1R3<+LFN\2\'"FZV&T M3"C=),RZ>283?QC$F)1N$F;=D!GY\&R3O3)F]]"8.!(EE'X29OT0A8._0#$F MI9^$6S]D\8!K[(323\*M'ZIZ&%Z;E'X2[B+G1]7#$)524,)=Z.Q+T/>&3LI M"7>-\URFON/$G7'*0"EWM8,R]:>D!WM^(\Z-5?A!)^6[R!<5624?S)F_Q"S MZ9-AC$DN%F#V#Z3 WQYZ^K+'A#KHLK?EQA=M&)/R3\;L'Q)S4%%DE'\R9O_0 MW2)4A3)F"SWI%NW19$;Y)V/VSW/MHJ^@> T+Y9^RKJ\ MM,+_"FL/XS3SZP]7?5V?PMB']L)(/QX^X^'?K%[_"U!+ P04 " "T/F)0 M7.6=MH<" !H, &@ 'AL+U]R96QS+W=OFG/LNM^=^F:Y,?^B%UTR_'?KPV M9?HZGLS0[%^;4S*RW:H9YS.JYZ?YS,W+85>-+P=;;7XTXRF5767>+N97/[[F M-J62S>UB'Z8%IEO>A_0_R_?'XWF?OO;[G]?4E0\J_BY0F8^#9#E(Z$%N.6@0 _2Y2"E!\7EH$@/JI>#:GK0XW+0(SW(;H&,6WX2PIJOM05< M6[[7%H!M^6);0+;EFVT!VI:OM@5L6[[;%L!M^7);0+?EVVT!WI:OMP"]A:^W M +UEA6=M]+#-UUN WL+76X#>PM=;@-["UUN WL+76X#>PM=;@-["UUN WL+7 MVP&]'5]O!_1V?+T=T-NML%>"-DOX>CN@M^/K[8#>CJ^W WH[OMX.Z.WX>CN@ MM^/K[8#>CJ^W!WI[OMX>Z.WY>GN@M^?K[8'>?H6];K39S=?; [T]7V\/]/9\ MO3W0V_/U]D!OS]?; [T]7^\ ] Y\O0/0._#U#D#OP-<[ +T#7^\ ] XKO*M$ M+ROY>@>@=^#K'8#>@:]W 'H'OMX!Z!WX>BO06_EZ*]!;^7HKT%OY>BO06_EZ M*]!;^7HKT%M7.&N"#IOP]5:@M_+U5J"W\O56H+?R]8Y [\C7.P*](U_O"/2. M?+TCT#OR]8Y [\C7.P*](U_O"/2.*YP51(<%^7I'H'?DZQV!WI&O=PWTKOEZ MUT#OFJ]W/=,[M\V8#M_+>.Y.^=XE_PS_M&8&=R[OEW3_C-O43]>?*5VF59*Y M?=[];[E-_1-AYA7Y^3=02P,$% @ M#YB4&?]D* G @ 'R\ !, !; M0V]N=&5N=%]4>7!E&ULS=K+;IM % ;@5['85F8\=[>*LTFZ;2,E+S"% M8X,,#)J9I,[;9R 7J9$K)8HM_1MC.,,Y/WCTK7QQ]SA27!SZ;HB;HDEI_,%8 MK!KJ72S]2$.N;'WH72]<2'];X,I'I&GKU%1_:'AN?;X?]J\/^_G[L1?^5HQL/GSM MK9\NAP#)(4%R*) <&B2' &UL4$L! A0#% @ M#YB4&>V<2"^ P $A, !@ M ( !]@@ 'AL+W=OH, !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ M#YB4'E?V+(0! 8A$ !@ ( !B!8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4(#D?YVW 0 T@, !D M ( !]"L 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ M#YB4"_C4!FW 0 T@, !D ( !OC$ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4-P( M$V&W 0 T@, !D ( !B#< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4*U%4 FV 0 T@, !D M ( !4CT 'AL+W=O&PO M=V]R:W-H965T#DPMP$ M -(# 9 " 2U! !X;"]W;W)K&UL4$L! A0#% @ M#YB4/'F"E6W 0 T@, !D ( ! M&T, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ M#YB4*8OO:ZS 0 T@, !D ( !Y$@ 'AL+W=O&PO=V]R:W-H965TQ@$ #<$ 9 " ?A- !X M;"]W;W)K&UL4$L! A0#% @ M#YB4(O>&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4( PP&OH 0 9@4 !D M ( !-U8 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ M#YB4 VD;C>S 0 T@, !D ( !/%P M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MM#YB4#B[AU.X 0 T@, !D ( !*V( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4-(=Z\1Q P A@\ !D M ( !)FX 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ M#YB4-]>0XD-! "Q( !D ( !I78 'AL M+W=O@ >&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB M4#M%&QUG# &5P !D ( !5X$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4$1L*T 3 @ -08 M !D ( !D98 'AL+W=O&PO=V]R:W-H965TQN( M2P( .@' 9 " 4&; !X;"]W;W)K&UL4$L! A0#% @ M#YB4'Z])\,G! )Q4 !D M ( !PYT 'AL+W=O&PO=V]R:W-H965T MG !X;"]W;W)K&UL4$L! A0# M% @ M#YB4&H*AA&L P 1Q( !D ( !M:X 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4!H[ MMR9* P @T !D ( !!KX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4.Q-"VO\!0 DR$ !D M ( !2L@ 'AL+W=O:Q<&PO M=V]R:W-H965T&UL4$L! A0#% @ M#YB4 ?MDAHO!0 ^QH !D ( ! M8=0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ M#YB4-^1 JU=! 018 !D ( ![MX 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M#YB4%O\-R(@" S#@ !D M ( !WO, 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ M#YB4&A8H7KQ 0 W@0 !D ( !J0&PO=V]R:W-H965T&UL4$L! A0#% @ MM#YB4%H.?\BA[0 C;X# !0 ( !4 \! 'AL+W-H87)E9%-T M&UL4$L! A0#% @ M#YB4!#X$7I< @ 7@P T M ( !(_T! 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ M#YB4%SEG;:' @ :# !H ( !^04" 'AL+U]R M96QS+W=O XML 40 R74.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Information Segment Asset Reconciliation (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 8,008,859 $ 5,611,068
Operating Segments [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,581,100 1,405,100
Other Current Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 1,233,500 1,047,200
Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 66,800 79,900
Goodwill [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets 264,100 219,800
Other Noncurrent Assets [Member] | Segment Reconciling Items [Member]    
Segment Reporting, Asset Reconciling Item [Line Items]    
Total assets $ 4,863,400 $ 2,859,100

XML 41 R80.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II - Valuation and Qualifying Accoutns (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) $ 0 $ 4,413 $ (47)
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 70,769 66,356 66,403
Deductions (3,579) 0 0
Valuation Allowances and Reserves, Balance Period End 67,190 70,769 66,356
SEC Schedule, 12-09, Allowance, Credit Loss [Member]      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) (1,240)    
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense   11,527 11,174
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Valuation Allowances and Reserves, Balance Period Start 26,713 25,549 23,367
Deductions (5,268) (10,363) (8,992)
Valuation Allowances and Reserves, Balance Period End $ 20,205 $ 26,713 $ 25,549
XML 42 R70.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. Commitments & Contingent Liabilities Pensions (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]      
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 1.10% 0.80% 0.90%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate 0.50% 1.10%  
Defined Benefit Plan, Benefit Obligation $ 153.8 $ 137.3 $ 136.6
Defined Benefit Plan, Service Cost 6.9 7.5 6.5
Defined Benefit Plan, Interest Cost 1.5 1.1 1.1
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant 3.5 3.1  
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) 11.9 (5.4)  
Defined Benefit Plan, Benefit Obligation, Benefits Paid (2.1) (3.1)  
Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment 0.2 (0.5)  
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement (3.8) 0.0  
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) (1.6) (2.0)  
Defined Benefit Plan, Plan Assets, Amount 72.3 66.9 61.7
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) 0.9 0.3  
Defined Benefit Plan, Plan Assets, Contributions by Employer 4.7 4.0  
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant 3.8 3.1  
Defined Benefit Plan, Plan Assets, Benefits Paid (0.8) (1.5)  
Defined Benefit Plan, Plan Assets, Payment for Settlement (3.8) 0.0  
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) 0.6 (0.7)  
Defined Benefit Plan, Funded (Unfunded) Status of Plan (81.5) (70.4)  
Liability, Defined Benefit Plan, Current (1.1) (1.1)  
Liability, Defined Benefit Plan, Noncurrent (80.4) (69.3)  
Liability, Defined Benefit Plan (81.5) (70.4)  
Defined Benefit Plan, Expected Return (Loss) on Plan Assets (1.2) (1.1) (1.1)
Defined Benefit Plan, Amortization of Gain (Loss) 1.0 1.3 1.4
Defined Benefit Plan, Amortization of Prior Service Cost (Credit) 0.0 0.1 0.0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement 0.9 0.0 1.2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) $ 9.1 $ 8.9 $ 9.1
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase 1.70% 1.80%  
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 1.80% 1.80% 1.90%
XML 43 R78.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
17. Quarterly Financial Data (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Quantifying Misstatement in Current Year Financial Statements [Line Items]                      
Unrealized Gain on Securities $ 646,000               $ 2,030,987 $ 606,230 $ 0
Net sales 624,500 $ 560,600 $ 572,600 $ 554,000 $ 616,900 $ 545,100 $ 575,900 $ 551,500 2,311,659 2,289,415 2,160,153
Operating Income (Loss)                 229,661 (103,341) 119,250
Cost of Goods and Services Sold                 1,054,663 1,066,264 972,450
Gross profit 330,400 307,000 307,800 311,800 332,600 286,700 301,700 302,200 1,256,996 1,223,151 1,187,703
Selling, general and administrative expense                 824,625 834,783 806,790
Research and development expense                 202,710 199,196 250,157
Unrealized Loss on Securities   390,600     814,100            
Net Income (Loss) Attributable to Parent $ 553,500 $ (258,800) $ 598,800 $ 865,200 $ (828,500) $ 269,300 $ 268,000 $ 656,800 $ 1,758,675 $ 365,614 $ 122,249
Earnings Per Share, Basic $ 18.50 $ (8.68) $ 20.08 $ 29.03 $ (27.73) $ 9.02 $ 8.99 $ 22.05 $ 58.93 $ 12.25 $ 4.12
Earnings Per Share, Diluted $ 18.31 $ (8.68) $ 19.86 $ 28.74 $ (27.73) $ 8.89 $ 8.87 $ 21.77 $ 58.27 $ 12.10 $ 4.07
Income Tax Expense (Benefit)                 $ (502,406) $ (147,045) $ 24,444
Impairment losses on goodwill and long-lived assets         $ 292,500       $ 0 $ 292,513 $ 11,506
XML 44 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies
1.SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.

We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.

Short-term Restricted Investments

Short-term restricted investments of $5.6 million at both December 31, 2019 and 2018 represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.

Available-for-Sale Investments

Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis.  Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).

Concentration of Credit Risk

Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions.

The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  

We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.

Accounts Receivable

We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.

Inventory

Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.

Property, Plant and Equipment

Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, 10-39 years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, 1-5 years; and equipment, 3-12 years.

Leases

We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of December 31, 2019. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of December 31, 2019.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components.

Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."

Goodwill

Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.

The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  

Long-Lived Assets

For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:

•
significant under-performance relative to expected, historical or projected future operating results;
•
significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;
•
a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and
•
significant negative industry, legal, regulatory or economic trends.

When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value.

Income Taxes
 
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.

On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.

Revenue Recognition

On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  We recorded a net reduction to opening retained earnings of $0.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard.

We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.

Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service.

At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns.
Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.

In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.

We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.
Reagent Rental Agreements
Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.
As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606.

Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.

Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  As a result, our lease income is heavily variable in nature.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.

Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% and 5% of total revenue for 2019 and 2018, respectively, and is included as part of the Net sales in our Consolidated Statements of Income.
Contract costs:
As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities.
Disaggregation of Revenue:
The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).

Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from $37.3 million at December 31, 2018 to $45.8 million at December 31, 2019 was primarily driven by $33.1 million, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by $24.6 million of revenue recognized that were included in our deferred revenue balance as of December 31, 2018.

We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.

Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2019
 
2018
January 1
 
$
10.1

 
$
18.7

Provision for warranty
 
9.9

 
25.5

Actual warranty costs
 
(11.0
)
 
(34.1
)
December 31
 
$
9.0

 
$
10.1



Shipping and Handling

We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.

Research and Development

Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.

We conduct extensive research and development activities in all areas of our business, employing approximately 780 employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  

Foreign Currency

Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.

Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.

Forward Foreign Exchange Contracts

As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  

Share-Based Compensation Plans

Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Forfeitures are recognized as they occur.  These plans are described more fully in Note 9.

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Basic weighted average shares outstanding
 
29,843

 
29,836

 
29,655

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
341

 
392

 
379

Diluted weighted average common shares
 
30,184

 
30,228

 
30,034

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
98

 
84

 
13



Fair Value of Financial Instruments

For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.

The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).

Recent Accounting Pronouncements Adopted

In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of December 31, 2019, we capitalized $3.1 million of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet.

In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019.

In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."

Recent Accounting Pronouncements to be Adopted

In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption.

In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures.

In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.

In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.

In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements, however due to the generally short duration of our customers' trade receivables, we do not expect ASU 2016-13 to have a material impact.
XML 45 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. Commitments & Contingent Liabilities
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingent Liabilities
12. COMMITMENTS AND CONTINGENT LIABILITIES

Deferred Profit Sharing Retirement Plan

We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was $16.1 million, $15.9 million and $16.0 million in 2019, 2018 and 2017, respectively.

Purchase Obligations

As of December 31, 2019, we had purchase obligations that have not been recognized on our balance sheet of $35.8 million, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad.

The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of December 31, 2019 are as follows: 2020 - $34.0 million, 2021 - $1.0 million, 2022 - $0.2 million, 2023 - $0.2 million, 2024 - $0.2 million and after 2024 - $0.2 million.

Long-Term Liabilities

As of December 31, 2019, we had obligations that have been recognized on our balance sheet of $118.4 million, which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded.

The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of December 31, 2019 were as follows: 2020 - $5.2 million, 2021 - $12.8 million, 2022 - $4.5 million, 2023 - $4.3 million, 2024 - $3.3 million and after 2024 - $88.3 million.

Letters of Credit/Guarantees

In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for $4.2 million of standby letters of credit/guarantees with financial institutions as of December 31, 2019.

Other Post-Employment Benefits
In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at December 31, 2019 and 2018 of $81.5 million and $70.4 million, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.

Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2019
2018
Benefit obligation at beginning of year
$137.3
$136.6
Service cost
6.9

7.5

Interest cost
1.5

1.1

Plan participants' contributions
3.5

3.1

Actuarial (gain) loss
11.9

(5.4
)
Gross benefits paid
(2.1
)
(3.1
)
Plan amendments
0.2

(0.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
(1.6
)
(2.0
)
 
 
 
Benefit obligation at end of year
153.8

137.3

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
66.9

61.7

Actual return on plan assets
0.9

0.3

Employer contributions
4.7

4.0

Plan participants' contributions
3.8

3.1

Gross benefits paid
(0.8
)
(1.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
0.6

(0.7
)
 
 
 
Fair value of plan assets at end of year
72.3

66.9

 
 
 
Under funded status of plans
$(81.5)
$(70.4)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(80.4
)
(69.3
)
 
 
 
Net liability, end of fiscal year
$(81.5)
$(70.4)
 
 
 


Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2019
2018
2017
Service costs
$6.9
$7.5
$6.5
Interest costs
1.5

1.1

1.1

Expected returns on plan assets
(1.2
)
(1.1
)
(1.1
)
Amortization of actuarial losses
1.0

1.3

1.4

Amortization of prior service costs
—

0.1

—

Settlements
0.9

—

1.2

 
 
 
 
Net periodic benefit costs
$9.1
$8.9
$9.1
 
 
 
 


Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2019
2018
Discount rate
0.5
%
1.1
%
Compensation rate increase
1.7
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2019
2018
2017
Discount rate
1.1
%
0.8
%
0.9
%
Expected long-term rate of return on plan assets
1.8
%
1.8
%
1.9
%
 
 
 
 


In some foreign locations we have service award plans that are paid based upon the number of years of employment. Under these plans, the liability at December 31, 2019 and 2018 was $3.5 million and $3.1 million, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.

Concentrations of Labor Subject to Collective Bargaining Agreements

At December 31, 2019, approximately seven percent of Bio-Rad's approximately 3,180 U.S. employees were covered by a collective bargaining agreement, which will expire on November 14, 2023.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements.
XML 46 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net sales $ 2,311,659 $ 2,289,415 $ 2,160,153
Cost of Goods and Services Sold 1,054,663 1,066,264 972,450
Gross Profit 1,256,996 1,223,151 1,187,703
Selling, general and administrative expense 824,625 834,783 806,790
Research and development expense 202,710 199,196 250,157
Impairment losses on goodwill and long-lived assets 0 292,513 11,506
Income from operations 229,661 (103,341) 119,250
Interest expense 23,416 23,962 23,014
Foreign exchange losses, net 2,245 2,861 9,128
Unrealized Gain on Securities (2,030,987) (606,230) 0
Other (income) expense, net (26,094) (36,593) (10,697)
Income before income taxes 2,261,081 512,659 97,805
Provision for income taxes (502,406) (147,045) 24,444
Net Income (Loss) Attributable to Parent $ 1,758,675 $ 365,614 $ 122,249
Basic earnings per share:      
Earnings Per Share, Basic $ 58.93 $ 12.25 $ 4.12
Weighted average common shares - basic 29,843 29,836 29,655
Diluted earnings per share:      
Earnings Per Share, Diluted $ 58.27 $ 12.10 $ 4.07
Weighted average common shares - diluted 30,184 30,228 30,034
XML 47 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
4. Intangible Assets, Goodwill and Other
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure
4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment were as follows (in millions):
 
 
2019
 
 
2018
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.5

 
$
320.5

 
$
555.0

 
 
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
192.7

 
27.1

 
219.8

 
 
198.8

 
307.3

 
506.1

Acquisitions
 
15.6

 
28.7

 
44.3

 
 
—

 
—

 
—

Divestiture
 
—

 
—

 
—

 
 
—

 
(1.4
)
 
(1.4
)
Impairment
 
—

 
—

 
—

 
 
(5.9
)
 
(276.1
)
 
(282.0
)
Currency fluctuations
 
—

 
—

 
—

 
 
(0.2
)
 
(2.7
)
 
(2.9
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
250.1

 
349.2

 
599.3

 
 
234.5

 
320.5

 
555.0

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(41.8
)
 
(293.4
)
 
(335.2
)
Goodwill, net
 
$
208.3

 
$
55.8

 
$
264.1

 
 
$
192.7

 
$
27.1

 
$
219.8



In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded $3.4 million of Customer relationships, a definite-lived intangible assets.

In conjunction with the purchase of all the issued and outstanding membership interests of Exact Diagnostics, LLC in August 2019 (see Note 2, "Acquisitions"), we recorded $28.7 million of goodwill and $26.8 million of definite-lived intangible assets: $16.1 million of Customer relationships, $8.1 million of Developed product technology, $2.5 million of Tradenames and $0.1 million of Backlog.

In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded $15.6 million of goodwill that included workforce and time-to-market advantage, $5.5 million of Developed product technology, a definite-lived intangible asset, and $0.2 million of In-process research and development, an indefinite-lived intangible asset.

In March 2018, we wrote off $1.4 million of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.

In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of $18.1 million, $247.2 million, $10.8 million and $5.9 million, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.

The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
 
December 31, 2019
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
6.36
 
$
107.2

 
$
(74.3
)
 
$
32.9

Know how
5.71
 
188.5

 
(162.6
)
 
25.9

Developed product technology
8.31
 
144.2

 
(93.9
)
 
50.3

Licenses
8.74
 
76.0

 
(44.4
)
 
31.6

Tradenames
8.50
 
6.4

 
(3.6
)
 
2.8

Covenants not to compete
6.01
 
3.2

 
(1.4
)
 
1.8

Other
—
 
0.1

 
(0.1
)
 
—

     Total definite-lived intangible assets
 
 
525.6

 
(380.3
)
 
145.3

In-process research and development
 
 
0.2

 
—

 
0.2

     Total purchased intangible assets
 
 
$
525.8

 
$
(380.3
)
 
$
145.5


 
December 31, 2018
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
3.98
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
6.64
 
190.6

 
(159.8
)
 
30.8

Developed product technology
8.34
 
130.4

 
(86.6
)
 
43.8

Licenses
9.72
 
76.3

 
(40.9
)
 
35.4

Tradenames
3.42
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7.01
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1



In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of $8.8 million and $1.7 million, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.

Amortization expense related to purchased intangible assets for the years ended December 31, 2019, 2018 and 2017 was $23.5 million, $28.3 million and $30.8 million, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, 2020, 2021, 2022, 2023, 2024 and thereafter is $23.5 million, $22.8 million, $19.6 million, $18.7 million, $16.6 million, and $44.1 million, respectively.
XML 48 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
8. Accumulated Other Comprehensive Income
 12 Months Ended
Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
accumulated other comprehensive income [Text Block]
8.    ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):
 
Foreign currency translation adjustments
Foreign other post-employment benefits adjustments
Net unrealized holding gains (losses) on available-for-sale investments
Total Accumulated other comprehensive income (loss)
Balances as of January 1, 2018
$
77.4

$
(22.3
)
$
4.4

$
59.5

Other comprehensive (loss) income, before reclassifications
(112.9
)
6.9

(1.4
)
(107.4
)
Amounts reclassified from Accumulated other comprehensive income
—

2.4

0.3

2.7

Income tax effects
—

(1.8
)
—

(1.8
)
Other comprehensive income (loss), net of income taxes
(112.9
)
7.5

(1.1
)
(106.5
)
Balances as of December 31, 2018
$
(35.5
)
$
(14.8
)
$
3.3

$
(47.0
)
Other comprehensive (loss) income, before reclassifications
(36.5
)
(10.0
)
4.8

(41.7
)
Amounts reclassified from Accumulated other comprehensive income
—

1.5

(0.4
)
1.1

Income tax effects
(0.4
)
1.1

(0.5
)
0.2

Other comprehensive (loss) income, net of income taxes
(36.9
)
(7.4
)
3.9

(40.4
)
Balances as of December 31, 2019
$
(72.4
)
$
(22.2
)
$
7.2

$
(87.4
)


The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2019
2018
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(1.5
)
$
(2.4
)
 
Selling, general and administrative expense
 
Net holding gains (losses) on equity securities and available for sale investments
 
$
0.4

$
(0.3
)
 
Other (income) expense, net
 


Reclassification adjustments are calculated using the specific identification method.
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
10. Other Income and Expenses (Tables)
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
Schedule of other income (expense), net
Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Interest and investment income
 
$
(30.5
)
 
$
(26.6
)
 
$
(19.1
)
Net realized gains on investments
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Other expense
 
0.1

 
—

 
1.5

Other (income) expense, net
 
$
(26.1
)
 
$
(36.6
)
 
$
(10.7
)
XML 50 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)
 12 Months Ended
Dec. 31, 2019
Class of Stock [Line Items]  
Class of Treasury Stock [Table Text Block] The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows:

 
Number of Shares Purchased
Weighted-Average Price per Share
Total Shares Repurchased To Date
Remaining Authorized Value
(in millions)
November 1, 2018 - November 30, 2018
178,911

$
273.39

193,150

$
201.1

May 1, 2019 - May 31, 2019
25,421

$
291.70

218,571

$
193.7

June 1, 2019 - June 30, 2019
25,977

$
292.01

244,548

$
186.1

August 1, 2019 - August 31, 2019
14,745

$
339.05

259,293

$
181.1

November 1, 2019 - November 30, 2019
22,343

$
358.04

281,636

$
173.1

 
 
 
 
 
Schedule of Stock by Class [Table Text Block]
Changes to Bio-Rad's issued common stock shares are as follows (in thousands):
 
Class A Shares
 
Class B Shares
Balance at January 1, 2017
24,454

 
5,124

B to A conversions
34

 
(34
)
Issuance of common stock
191

 
18

Balance at December 31, 2017
24,679

 
5,108

B to A conversions
30

 
(30
)
Issuance of common stock
175

 
18

Balance at December 31, 2018
24,884

 
5,096

B to A conversions
24

 
(24
)
Issuance of common stock
58

 
18

Balance at December 31, 2019
24,966

 
5,090
XML 51 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
16. Leases (Notes)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Leases of Lessee Disclosure [Text Block]
16.    LEASES

We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 19 years, which includes our determination to exercise renewal options.

The components of lease expense were as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Operating lease cost
$
51.4

 
 
Finance lease cost:
 
  Amortization of right-to-use assets
$
0.6

  Interest on lease liabilities
0.9

        Total finance lease cost
$
1.5

 
 
Sublease income
$
3.0


The sublease is for a building with a term that ends in 2025, with no options to extend or renew.

Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments.

Historically, our short-term leases, reflecting leases with a lease term of one year or less, are predominantly comprised of leases with a lease term of one month or less, which are not significant. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial.

Supplemental cash flow information related to leases was as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
  Operating cash flows from operating leases
$
47.2

  Operating cash flows from finance leases
$
0.9

  Financing cash flows from finance leases
$
0.6

 
 
Right-of-use assets obtained in exchange for lease obligations:
 
  Operating leases
$
28.7

  Finance leases
$
0.2



Supplemental balance sheet information related to leases was as follows (in millions):
 
December 31, 2019
 
 
Operating Leases
 
  Operating lease right-of-use assets
$
201.9

 
 
  Current operating lease liabilities
$
35.4

  Operating lease liabilities
176.0

     Total operating lease liabilities
$
211.4


 
December 31, 2019
 
 
Finance Leases
 
  Property, plant and equipment, gross
$
11.4

  Less: accumulated depreciation and amortization
(4.2
)
      Property, plant and equipment, net
$
7.2

 
 
  Current maturities of long-term debt and notes payable
$
0.5

  Long-term debt, net of current maturities
11.2

      Total finance lease liabilities
$
11.7


 
December 31, 2019
 
 
Weighted Average Remaining Lease Term
 
  Operating leases - in years
9

  Finance leases - in years
18

 
 
Weighted Average Discount Rate
 
  Operating leases
4.2
%
  Finance leases
6.5
%


Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,

Operating Leases
 
Finance Leases
 
 
 
 
2020
$
41.0

 
$
1.1

2021
35.8

 
1.3

2022
28.6

 
1.2

2023
24.5

 
1.1

2024
21.8

 
1.1

Thereafter
103.7

 
15.2

   Total lease payments
255.4

 
21.0

Less imputed interest
(44.0
)
 
(9.3
)
    Total
$
211.4

 
$
11.7



The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over.

As of December 31, 2019, we have an additional lease for a facility in Texas that has not commenced of $1.6 million. The operating lease will commence in either the second or third quarter of 2020 with a lease term of four years.

Operating and Capital Lease Commitments Under ASC 840, Leases

Rents and Leases

Rental expense under operating leases was $47.4 million and $43.6 million in 2018 and 2017, respectively.  Leases were principally for facilities and automobiles.
 
Annual future minimum lease payments at December 31, 2018 under operating leases were as follows: 2019 - $44.4 million; 2020 - $37.8 million; 2021 - $27.4 million; 2022 - $19.7 million; 2023 - $13.9 million; and 2024 and beyond - $25.6 million.

The total minimum rentals to be received in the future for the sublease as of December 31, 2018 were $17.8 million and ends in 2025.

Maturities of our capital lease obligations at December 31, 2018 were as follows: 2019 - $0.5 million; 2020 - $0.2 million; 2021 - $0.5 million; 2022 - $0.4 million; 2023 - $0.4 million; and thereafter - $9.9 million.
XML 52 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Schedule of Product Warranty Liability
Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):

 
 
2019
 
2018
January 1
 
$
10.1

 
$
18.7

Provision for warranty
 
9.9

 
25.5

Actual warranty costs
 
(11.0
)
 
(34.1
)
December 31
 
$
9.0

 
$
10.1
Schedule of Weighted Average Number of Shares

The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Basic weighted average shares outstanding
 
29,843

 
29,836

 
29,655

Effect of potentially dilutive stock options
 
 
 
 
 
 
    and restricted stock awards
 
341

 
392

 
379

Diluted weighted average common shares
 
30,184

 
30,228

 
30,034

Anti-dilutive stock options and restricted stock awards
 
 
 
 
 
 
    excluded from the computation of diluted EPS
 
98

 
84

 
13
XML 53 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies Details (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Interest expense   $ 23,416 $ 23,962 $ 23,014  
Selling, general and administrative expense   824,625 834,783 806,790  
Research and development expense   202,710 199,196 250,157  
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)       70,000  
Stockholders' Equity Attributable to Parent $ 5,755,057 5,755,057 4,020,331 2,930,250 $ 2,579,160
Restricted investments 5,560 5,560 5,560    
Retained earnings 5,470,779 5,470,779 3,722,073    
Prepaid Taxes (5,400) (5,400)      
Accumulated other comprehensive (loss) income (87,348) (87,348) (46,958)    
Other (income) expense, net   26,094 36,593 10,697  
Deferred Tax Assets, Gross 205,200 $ 205,200 147,100    
Document Fiscal Year Focus   2019      
Unrealized Gain on Securities 646,000 $ 2,030,987 606,230 0  
Deferred Income Tax Expense (Benefit)   450,200 120,900 (84,800)  
Cost of Goods and Services Sold   1,054,663 1,066,264 $ 972,450  
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase     $ (49,000)    
Adjustments for New Accounting Pronouncement [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Capitalized Cloud Computing Arrangements $ 3,100 $ 3,100      
541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Entity Number of Employees 780 780      
XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
17. Quarterly Financial Data (Tables)
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Data [Abstract]  
Schedule of Quarterly Financial Data [Table Text Block]

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2019
 
 
 
 
 
 
 
 
Net sales
 
$
554.0

 
$
572.6

 
$
560.6

 
$
624.5

Gross profit
 
311.8

 
307.8

 
307.0

 
330.4

Net income (loss)
 
865.2

 
598.8

 
(258.8
)
 
553.5

Basic earnings (loss) per share
 
$
29.03

 
$
20.08

 
$
(8.68
)
 
$
18.50

Diluted earnings (loss) per share
 
$
28.74

 
$
19.86

 
$
(8.68
)
 
$
18.31

 
 
 
 
 
 
 
 
 
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)
XML 56 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. Commitments & Contingent Liabilities Period Expense (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]      
Contribution expense $ 16.1 $ 15.9 $ 16.0
XML 57 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
7. Stockholders' Equity Treasury Shares (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 12 Months Ended
Nov. 30, 2019
Aug. 31, 2019
Jun. 30, 2019
May 31, 2019
Nov. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]              
Treasury Stock, Shares 281,636 259,293 244,548 218,571 193,150    
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 173.1 $ 181.1 $ 186.1 $ 193.7 $ 201.1    
Stock Repurchase Program, Authorized Amount           $ 250.0  
Treasury Stock, Shares, Acquired 22,343 14,745 25,977 25,421 178,911    
Treasury Stock Acquired, Average Cost Per Share $ 358.04 $ 339.05 $ 292.01 $ 291.70 $ 273.39    
Treasury Class-A [Member]              
Equity, Class of Treasury Stock [Line Items]              
Stock Issued During Period, Shares, Treasury Stock Reissued           (118,910)  
Treasury Class B [Member]              
Equity, Class of Treasury Stock [Line Items]              
Treasury Stock, Shares           0 917
Employee Stock [Member]              
Equity, Class of Treasury Stock [Line Items]              
Stock Issued During Period, Shares, Treasury Stock Reissued           (19,755)  
XML 58 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
9. Share-based Compensation Restricted Stock (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)
$ / shares in Units, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value $ 44.8 $ 40.0 $ 27.7
Total unrecognized compensation cost from restricted stock $ 119.5    
Nonvested shares - Weighted Average Grant Date Fair Value $ 279.14 $ 235.58  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]      
Outstanding beginning of period 474,400    
Restricted Stock Units Granted 174,782    
Restricted Stock Units - Vested (134,525)    
Restricted Stock Units - Forfeited (44,715)    
Outstanding end of period 469,942 474,400  
Weighted Average Grant Date Fair Value - Granted $ 332.38    
Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value 206.44    
Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value $ 243.76    
Weighted Average Remaining Contractual Term (in years) 2 years 29 days    
Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions) $ 173.9    
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition 3 years    
XML 59 R76.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
15. Restructuring Costs (Details) - USD ($)
$ in Millions
 12 Months Ended 13 Months Ended 19 Months Ended 25 Months Ended 44 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]              
Document Fiscal Year Focus 2019            
European Reorganization [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment $ (0.1) $ (0.2) $ 0.5        
Restructuring Charges             $ 12.7
Restructuring Reserve 0.0 1.6 6.3 $ 0.0 $ 0.0 $ 0.0 0.0
Payments for Restructuring (0.8) (4.4)          
Restructuring Reserve, Translation and Other Adjustment (0.7) 0.0          
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.0 (0.1)          
European Reorganization [Member] | Cost of Goods and Service Benchmark [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.1) (0.1) (0.2)        
European Reorganization [Member] | Selling, General and Administrative Expenses [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.0 (0.1) 0.7        
European Reorganization [Member] | Life Science [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.0 (0.1)          
Restructuring Reserve 0.0 0.6 2.2 0.0 0.0 0.0 0.0
Payments for Restructuring (0.3) (1.5)          
Restructuring Reserve, Translation and Other Adjustment (0.3) 0.0          
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.0 0.0          
European Reorganization [Member] | Clinical Diagnostics [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.1) (0.1)          
Restructuring Reserve 0.0 1.0 4.1 0.0 0.0 0.0 0.0
Payments for Restructuring (0.5) (2.9)          
Restructuring Reserve, Translation and Other Adjustment (0.4) 0.0          
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.0 (0.1)          
Facility Closing [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges       4.0      
Facility Closing [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.0            
Restructuring Charges   0.2          
Facility Closing [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.1)            
Restructuring Charges   3.9          
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.4) 0.3          
Restructuring Charges 0.0 5.8          
Restructuring Reserve 3.2 11.5 14.1 3.2 3.2 3.2 3.2
Payments for Restructuring (7.7) (8.4)          
Restructuring Reserve, Foreign Currency Translation (Gain) Loss (0.2) (0.3)          
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Cost of Goods and Service Benchmark [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.3)            
Restructuring Charges   5.4 2.3        
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Selling, General and Administrative Expenses [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.0            
Restructuring Charges   0.4 3.3        
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Research and Development Expense [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.1            
Restructuring Charges   0.3 15.5        
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Accounts Payable and Accrued Liabilities [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve 1.8     1.8 1.8 1.8 1.8
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Current Liabilities [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve 0.2     0.2 0.2 0.2 0.2
Termination of a Diagnostics Research and Development Project and a Facility Closure [Member] | Other Noncurrent Liabilities [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve 1.2     1.2 1.2 1.2 1.2
Termination of a Diagnostics Research and Development Project [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges           21.4  
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Other Operating Income (Expense) [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment 0.0 (0.1)          
Restructuring Charges     10.1        
Termination of a Diagnostics Research and Development Project [Member] | Clinical Diagnostics [Member] | Employee Severance [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment (0.1) 0.4          
Restructuring Charges     $ 11.0        
European and North American Reorganization [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 25.3            
Restructuring Reserve 25.3 0.0   25.3 25.3 25.3 25.3
Payments for Restructuring (1.1)            
Restructuring Reserve, Translation and Other Adjustment 0.7            
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.4            
European and North American Reorganization [Member] | Cost of Goods and Service Benchmark [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 4.8            
European and North American Reorganization [Member] | Selling, General and Administrative Expenses [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 14.4            
European and North American Reorganization [Member] | Research and Development Expense [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 6.1            
European and North American Reorganization [Member] | Life Science [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 6.2            
Restructuring Reserve 6.2 0.0   6.2 6.2 6.2 6.2
Payments for Restructuring (0.4)            
Restructuring Reserve, Translation and Other Adjustment 0.3            
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.1            
European and North American Reorganization [Member] | Clinical Diagnostics [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Charges 19.1            
Restructuring Reserve 19.1 0.0   $ 19.1 19.1 $ 19.1 $ 19.1
Payments for Restructuring (0.7)            
Restructuring Reserve, Translation and Other Adjustment 0.4            
Restructuring Reserve, Foreign Currency Translation (Gain) Loss 0.3            
GERMANY | Facility Closing [Member]              
Restructuring Cost and Reserve [Line Items]              
Restructuring Reserve, Accrual Adjustment $ (0.3)            
Restructuring Charges   $ 1.7     $ 1.4    
XML 60 R72.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Reporting (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Segment Reporting Information [Line Items]      
Number Of Products And Services 9,000    
Net sales $ 2,311,700 $ 2,289,400 $ 2,160,200
Interest expense 23,416 23,962 23,014
Depreciation and amortization 134,200 138,100 148,700
Segment profit 229,661 (103,341) 119,250
Total assets 8,008,859 5,611,068  
Payments to Acquire Property, Plant, and Equipment 98,532 129,825 111,332
Life Science [Member]      
Segment Reporting Information [Line Items]      
Net sales 885,900 861,700 785,200
Interest expense 7,400 7,200 7,000
Depreciation and amortization 29,400 34,100 36,200
Segment profit 72,100 28,700 (9,900)
Total assets 496,100 450,200  
Payments to Acquire Property, Plant, and Equipment 16,600 36,700  
Clinical Diagnostics [Member]      
Segment Reporting Information [Line Items]      
Net sales 1,412,000 1,411,800 1,360,800
Interest expense 15,900 16,700 14,900
Depreciation and amortization 71,700 72,000 80,200
Segment profit 148,500 (145,700) 114,800
Total assets 1,075,800 949,000  
Payments to Acquire Property, Plant, and Equipment 58,900 60,500  
All Other Segments [Member]      
Segment Reporting Information [Line Items]      
Net sales 13,800 15,900 14,200
Interest expense 100 100 0
Depreciation and amortization 900 500 0
Segment profit (1,500) 200 $ 1,400
Total assets 9,200 5,900  
Payments to Acquire Property, Plant, and Equipment $ 600 $ 500  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements Available-for-Sale Investments (Details) - USD ($)
$ in Millions
Dec. 31, 2019
Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost $ 400.9  
Debt Securities, Available-for-sale 402.9  
Fair Value, Recurring [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 402.9 $ 373.2
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 204.5 215.0
Fair Value, Recurring [Member] | Municipal Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 11.6 11.0
Fair Value, Recurring [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 72.9 63.3
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 106.1 80.3
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 4.7 3.6
Fair Value, Recurring [Member] | Foreign Government Debt [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 3.1  
Fair Value, Recurring [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 400.9 375.5
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 2.4 0.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.4) (2.6)
Debt Securities, Available-for-sale 402.9 373.2
Fair Value, Recurring [Member] | Short-term Investments [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale 402.8 373.0
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 203.2 216.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 1.4 0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.1) (1.3)
Debt Securities, Available-for-sale 204.5 215.0
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 11.5 11.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.1 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 (0.1)
Debt Securities, Available-for-sale 11.6 11.0
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 72.7 63.5
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.2 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.1) (0.4)
Debt Securities, Available-for-sale 72.8 63.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 105.6 80.9
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.7 0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.2) (0.8)
Debt Securities, Available-for-sale 106.1 80.3
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 4.7 3.6
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale 4.7 3.6
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 3.1  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0  
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0  
Debt Securities, Available-for-sale 3.1  
Fair Value, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 400.8 375.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 2.4 0.3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (0.4) (2.6)
Debt Securities, Available-for-sale 402.8 373.0
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 0.1 0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale 0.1 0.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]    
Debt Securities, Available-for-sale [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 0.1 0.2
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax 0.0 0.0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax 0.0 0.0
Debt Securities, Available-for-sale $ 0.1 $ 0.2
XML 62 R55.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended 37 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2019
Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $ 4.9     $ 4.9 $ 8.4   $ 4.9  
Business Combination, Contingent Consideration, Liability               $ 0.6
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability       (1.6) (6.2) $ (18.1)    
Fair Value, Recurring [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Business Combination, Contingent Consideration, Liability [1] 4.9     4.9 $ 8.4   4.9  
Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Business Combination, Contingent Consideration, Liability 4.3     4.3     4.3  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements   $ (1.1) $ (1.4) (2.5)        
Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense       (1.6)     (13.9)  
Distributor [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0.6     0.6     0.6  
Business Combination, Contingent Consideration, Liability 0.6     0.6     $ 0.6  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements $ (0.7)     $ (1.4)        
Discount rate [Member] | Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Discount Rate       11.10%        
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00%     39.00%     39.00%  
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00%     20.00%     20.00%  
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0     $ 0.0     $ 0.0  
Cost of debt [Member] | Analytical Flow Cytometer Platform [Member]                
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]                
Discount Rate       3.90%        
[1]
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Other current liabilities
$
3.3

 
$
3.2

Other long-term liabilities
1.6

 
5.2

   Total
$
4.9

 
$
8.4
XML 63 R59.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
6. Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Taxes [Line Items]      
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ 3,600    
Prepaid Taxes 5,400    
U.S. 1,034,000 $ 363,400 $ 72,800
International 1,227,100 149,300 25,000
Income before income taxes 2,261,081 512,659 97,805
U.S. Federal 13,000 8,800 6,700
State 4,400 2,200 3,400
International 23,500 30,500 32,000
Current Income Tax Expense (Benefit) 40,900 41,500 42,100
U.S. Federal 409,700 114,000 (69,800)
State 24,400 6,600 4,300
International 16,100 300 (19,300)
Deferred tax benefit 450,200 120,900 (84,800)
Non-current tax expense (benefit) 11,300 (15,400) 18,300
Provision for income taxes $ 502,406 $ 147,045 $ (24,444)
U.S. statutory tax rate 21.00% 21.00% 35.00%
Impact of foreign operations (9.70%) (4.10%) 6.00%
Research tax credits (0.20%) (0.70%) (3.80%)
Nontaxable subsidies (0.10%) (0.20%) (2.20%)
Goodwill impairment 0.00% 5.60% 1.20%
Stock-based compensation (0.10%) (1.00%) (5.30%)
Nondeductible executive compensation 0.10% 0.20% 2.00%
State taxes 1.00% 1.70% 2.90%
Other (0.10%) 0.50% (2.60%)
Provision for income taxes 22.20% 28.70% (25.00%)
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)     $ 70,000
Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase   $ (49,000)  
Bad debt, inventory and warranty accruals $ 23,900 21,700  
Other post-employment benefits, vacation and other reserves 23,000 23,000  
Tax credit and net operating loss carryforwards 83,700 75,300  
Other 26,000 27,100  
Total gross deferred tax assets 205,200 147,100  
Valuation allowance (67,200) (70,800)  
Total deferred tax assets 138,000 76,300  
Property and equipment 38,400 40,100  
Investments and intangible assets 1,001,400 540,600  
Total deferred tax liabilities 1,086,200 580,700  
Net deferred tax liabilities (948,200) (504,400)  
Unrecognized tax benefits period start 29,800 54,900 21,100
Additions to tax positions related to prior years 7,600 600 1,300
Reductions to tax positions related to prior years (700) (20,200) (1,000)
Additions to tax positions related to the current year 3,000 4,600 34,800
Settlements 0 (6,800) (200)
Lapse of statute of limitations (400) (1,100) (3,400)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation     2,300
Currency translation (100) (2,200)  
Unrecognized tax benefits period end 39,200 29,800 54,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued 11,200 9,500 10,900
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 1,700 $ (1,400) $ (900)
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit 2,800    
Foreign Tax Authority [Member]      
Income Taxes [Line Items]      
Operating Loss Carryforward With No Expiration Date $ 124,700    
Domestic Tax Authority [Member]      
Income Taxes [Line Items]      
Other reconciling items 10.30% 15.50% 2.70%
Tax Cuts and Jobs Act [Member]      
Income Taxes [Line Items]      
U.S. tax reform 0.00% (9.60%) (71.00%)
State and Local Jurisdiction [Member]      
Income Taxes [Line Items]      
Operating Loss Carryforwards $ 239,000    
Including accrued interest and penalties [Member]      
Income Taxes [Line Items]      
Other 1,400    
Unrecognized tax benefits period end 50,400    
Research Tax Credit Carryforward [Member] | State and Local Jurisdiction [Member]      
Income Taxes [Line Items]      
Deferred Tax Assets, Tax Credit Carryforwards, Research $ 35,700    
Acquisition-related Costs [Member]      
Income Taxes [Line Items]      
Other reconciling items 0.00% (0.20%) 10.10%
Net of prepaid taxes [Member]      
Income Taxes [Line Items]      
Unrecognized tax benefits period end $ 43,600    
Operating lease obligations [Member]      
Income Taxes [Line Items]      
Other 48,600 $ 0  
Operating lease assets [Member]      
Income Taxes [Line Items]      
Deferred Tax Liabilities, Leasing Arrangements $ 46,400 $ 0  
XML 64 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables)
 12 Months Ended
Dec. 31, 2019
Obligations and Funded Status [Abstract]  
Schedule of Net Benefit Costs [Table Text Block]
Components of Net Periodic Benefit Cost
The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):

 
2019
2018
2017
Service costs
$6.9
$7.5
$6.5
Interest costs
1.5

1.1

1.1

Expected returns on plan assets
(1.2
)
(1.1
)
(1.1
)
Amortization of actuarial losses
1.0

1.3

1.4

Amortization of prior service costs
—

0.1

—

Settlements
0.9

—

1.2

 
 
 
 
Net periodic benefit costs
$9.1
$8.9
$9.1
 
 
 
 
Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]
Obligations and Funded Status
The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):

Change in benefit obligation:
2019
2018
Benefit obligation at beginning of year
$137.3
$136.6
Service cost
6.9

7.5

Interest cost
1.5

1.1

Plan participants' contributions
3.5

3.1

Actuarial (gain) loss
11.9

(5.4
)
Gross benefits paid
(2.1
)
(3.1
)
Plan amendments
0.2

(0.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
(1.6
)
(2.0
)
 
 
 
Benefit obligation at end of year
153.8

137.3

 
 
 
Change in plan assets:
 
 
Fair value of plan assets at beginning year
66.9

61.7

Actual return on plan assets
0.9

0.3

Employer contributions
4.7

4.0

Plan participants' contributions
3.8

3.1

Gross benefits paid
(0.8
)
(1.5
)
Settlements
(3.8
)
—

Change attributable to foreign exchange
0.6

(0.7
)
 
 
 
Fair value of plan assets at end of year
72.3

66.9

 
 
 
Under funded status of plans
$(81.5)
$(70.4)
 
 
 
Amounts recognized in the consolidated balance sheets:
 
 
Current liabilities (Accrued payroll and employee benefits)
$(1.1)
$(1.1)
Noncurrent liabilities (Other long-term liabilities)
(80.4
)
(69.3
)
 
 
 
Net liability, end of fiscal year
$(81.5)
$(70.4)
 
 
 
Defined Benefit Plan, Assumptions [Table Text Block]
Assumptions

The weighted-average assumptions used in computing the benefit obligations are as follows:


 
2019
2018
Discount rate
0.5
%
1.1
%
Compensation rate increase
1.7
%
1.8
%
 
 
 

The weighted-average assumptions used in computing the net periodic benefit costs are as follows:

 
2019
2018
2017
Discount rate
1.1
%
0.8
%
0.9
%
Expected long-term rate of return on plan assets
1.8
%
1.8
%
1.9
%
 
 
 
 
XML 65 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)
 12 Months Ended
Dec. 31, 2019
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]  
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]
The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:
 
 
 
December 31,
 
 
Components of Comprehensive income
 
2019
2018
 
Location
 
Amortization of foreign other post-employment benefit items
 
$
(1.5
)
$
(2.4
)
 
Selling, general and administrative expense
 
Net holding gains (losses) on equity securities and available for sale investments
 
$
0.4

$
(0.3
)
 
Other (income) expense, net
 
XML 66 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
5. Notes Payable and Long-Term Debt (Tables)
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Principal components of long-term debt [Table Text Block]
The principal components of long-term debt are as follows (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(0.6
)
 
(1.3
)
Long-term debt less unamortized discount and debt issuance costs
424.4

 
423.7

Finance leases and other debt
15.4

 
—

Capital leases and other debt
—

 
15.7

 
439.8

 
439.4

Less current maturities
(426.2
)
 
(0.5
)
Long-term debt
$
13.6

 
$
438.9
XML 67 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Balance at Dec. 31, 2016 $ 2,579,160 $ 3 $ 332,911 $ (101) $ 1,828,581 $ 417,766
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 122,249       122,249  
Other comprehensive income, net of tax 200,893         200,893
Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect         (120,135) 120,135
Issuance of common stock 4,490   4,490      
Stock compensation expense 23,439   23,439      
Treasury Stock, Value, Acquired, Cost Method (2,920)     (2,920)    
Stock Issued During Period, Value, Treasury Stock Reissued 2,804     2,804    
Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 135   391   (256)  
Balance at Dec. 31, 2017 2,930,250 3 361,231 (217) 1,830,439 738,794
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 365,614       365,614  
Other comprehensive income, net of tax (106,495)         (106,495)
Issuance of common stock 5,271   5,271      
Stock compensation expense 27,840   27,840      
Treasury Stock, Value, Acquired, Cost Method (48,912)     (48,912)    
Balance at Dec. 31, 2018 4,020,331 3 394,342 (49,129) 3,722,073 (46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Equity Securities without Readily Determinable Fair Value, Amount 600          
Net income 1,758,675       1,758,675  
Other comprehensive income, net of tax (40,390)         (40,390)
Issuance of common stock 5,017   5,017      
Stock compensation expense 35,593   35,593      
Treasury Stock, Value, Acquired, Cost Method (28,000)     (28,000)    
Stock Issued During Period, Value, Treasury Stock Reissued 3,831   (24,932) 38,732 (9,969)  
Balance at Dec. 31, 2019 5,755,057 $ 3 $ 410,020 $ (38,397) $ 5,470,779 $ (87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Equity Securities without Readily Determinable Fair Value, Amount $ 300          
XML 68 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
6. Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes [Text Block]
6. INCOME TAXES

The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U.S.
 
$
1,034.0

 
$
363.4

 
$
72.8

International
 
1,227.1

 
149.3

 
25.0

Income before taxes
 
$
2,261.1

 
$
512.7

 
$
97.8



The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
13.0

 
$
8.8

 
$
6.7

State
 
4.4

 
2.2

 
3.4

International
 
23.5

 
30.5

 
32.0

Current tax expense
 
40.9

 
41.5

 
42.1

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
409.7

 
114.0

 
(69.8
)
State
 
24.4

 
6.6

 
4.3

International
 
16.1

 
0.3

 
(19.3
)
Deferred tax expense (benefit)
 
450.2

 
120.9

 
(84.8
)
Non-current tax expense (benefit)
 
11.3

 
(15.4
)
 
18.3

Provision for (benefit from) income taxes
 
$
502.4

 
$
147.0

 
$
(24.4
)



The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U. S. statutory tax rate
 
21.0
 %
 
21.0
 %
 
35.0
 %
Impact of foreign operations
 
(9.7
)
 
(4.1
)
 
6.0

Research tax credits
 
(0.2
)
 
(0.7
)
 
(3.8
)
Nontaxable subsidies
 
(0.1
)
 
(0.2
)
 
(2.2
)
Goodwill impairment
 
—

 
5.6

 
1.2

Share-based compensation
 
(0.1
)
 
(1.0
)
 
(5.3
)
Nondeductible executive compensation
 
0.1

 
0.2

 
2.0

U.S. taxation of foreign income
 
10.3

 
15.5

 
2.7

Acquisition-related
 
—

 
(0.2
)
 
10.1

U.S. tax reform
 
—

 
(9.6
)
 
(71.0
)
State taxes
 
1.0

 
1.7

 
2.9

Other
 
(0.1
)
 
0.5

 
(2.6
)
Provision for (benefit from) income taxes
 
22.2
 %
 
28.7
 %
 
(25.0
)%


On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of $70 million related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of $49 million.

Our effective income tax rate was 22.2%, 28.7% and (25.0)% in 2019, 2018 and 2017, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a $49 million benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a $70 million benefit recorded as a provisional estimate of the accounting for the Tax Act.

Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.

Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
23.9

 
$
21.7

Other post-employment benefits, vacation and other reserves
 
23.0

 
23.0

Tax credit and net operating loss carryforwards
 
83.7

 
75.3

Lease obligations
 
48.6

 
—

Other
 
26.0

 
27.1

    Total gross deferred tax assets
 
205.2

 
147.1

Valuation allowance
 
(67.2
)
 
(70.8
)
       Total deferred tax assets
 
138.0

 
76.3

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
38.4

 
40.1

Lease assets
 
46.4

 
—

Investments and intangible assets
 
1,001.4

 
540.6

        Total deferred tax liabilities
 
1,086.2

 
580.7

Net deferred tax liabilities
 
$
(948.2
)
 
$
(504.4
)


The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of December 31, 2019, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by $3.6 million in 2019.

As of December 31, 2019, our foreign and California net operating loss carryforwards were approximately $239.0 million and $52.7 million, respectively. Of our foreign net operating losses, $124.7 million may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of December 31, 2019, our California research tax credit carryforwards were approximately $35.7 million and may be carried forward indefinitely.

Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.

We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2019
 
2018
 
2017
Unrecognized tax benefits – January 1
 
$
29.8

 
$
54.9

 
$
21.1

Additions to tax positions related to prior years
 
7.6

 
0.6

 
1.3

Reductions to tax positions related to prior years
 
(0.7
)
 
(20.2
)
 
(1.0
)
Additions to tax positions related to the current year
 
3.0

 
4.6

 
34.8

Settlements
 
—

 
(6.8
)
 
(0.2
)
Lapse of statute of limitations
 
(0.4
)
 
(1.1
)
 
(3.4
)
Currency translation
 
(0.1
)
 
(2.2
)
 
2.3

Unrecognized tax benefits – December 31
 
$
39.2

 
$
29.8

 
$
54.9



Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of December 31, 2019, 2018 and 2017, respectively was $11.2 million, $9.5 million and $10.9 million. Bio-Rad accrued interest and penalties of $1.7 million, $(1.4) million, and $(0.9) million in 2019, 2018, and 2017, respectively. The total unrecognized tax benefits and interest and penalties of $50.4 million in 2019 was partially offset by deferred tax assets of $1.4 million and prepaid taxes of $5.4 million, for a net amount of $43.6 million.

As of December 31, 2019, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately $2.8 million. Substantially all such amounts will impact our effective income tax rate if recognized.

It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.
XML 69 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
10. Other Income and Expenses
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
Other Income and Other Expense Disclosure
10. OTHER INCOME AND EXPENSE, NET

Other (income) expense, net includes the following components (in millions):
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Interest and investment income
 
$
(30.5
)
 
$
(26.6
)
 
$
(19.1
)
Net realized gains on investments
 
(1.5
)
 
(1.6
)
 
(0.1
)
Other-than-temporary impairment losses on investments
 
5.8

 
0.8

 
7.0

Gain on sale of land
 
—

 
(4.1
)
 
—

Gain on divestiture of a product line
 
—

 
(5.1
)
 
—

Other expense
 
0.1

 
—

 
1.5

Other (income) expense, net
 
$
(26.1
)
 
$
(36.6
)
 
$
(10.7
)


Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition in the first and fourth quarters of 2019.
XML 70 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
ASSETS:    
Cash and cash equivalents $ 660,672 $ 431,526
Short-term investments 453,973 413,270
Restricted investments 5,560 5,560
Accounts receivable, less allowance for doubtful accounts 392,672 392,443
Inventories:    
Raw materials 109,570 108,008
Work in process 146,131 145,051
Finished goods 298,306 330,756
Total inventories 554,007 583,815
Prepaid expenses 102,331 187,249
Other current assets 10,940 9,615
Total current assets 2,180,155 2,023,478
Property, plant and equipment:    
Land and improvements 25,215 25,185
Buildings and leasehold improvements 341,598 331,563
Equipment 1,015,359 970,081
Total property, plant and equipment 1,382,172 1,326,829
Less: accumulated depreciation and amortization (882,833) (818,139)
Property, plant and equipment, net 499,339 508,690
Operating lease right-of-use asset 201,868 0
Goodwill, net 264,131 219,770
Purchased intangibles, net 145,525 133,123
Other investments 4,638,205 2,655,709
Other assets 79,636 70,298
Total assets 8,008,859 5,611,068
LIABILITIES AND STOCKHOLDERS' EQUITY:    
Accounts payable 107,014 122,450
Accrued payroll and employee benefits 180,084 143,510
Current maturities of long-term debt 426,172 493
Income taxes payable 8,763 27,513
Other taxes payable 27,522 28,675
Current operating lease liabilities 35,365 0
Deferred revenue 33,735 26,936
Other current liabilities 86,840 101,218
Total current liabilities 905,495 450,795
Long-term debt, net of current maturities 13,579 438,937
Deferred income taxes 997,787 553,239
Operating lease liabilities 176,018 0
Other long-term liabilities 160,923 147,766
Total liabilities 2,253,802 1,590,737
Commitments and contingent liabilities
Stockholders' equity:    
Preferred stock 0 0
Additional paid-in capital 410,020 394,342
Retained earnings 5,470,779 3,722,073
Accumulated other comprehensive (loss) income (87,348) (46,958)
Total stockholders' equity 5,755,057 4,020,331
Total liabilities and stockholders' equity 8,008,859 5,611,068
Common Class A [Member]    
Stockholders' equity:    
Common stock 2 2
Common Class B [Member]    
Stockholders' equity:    
Common stock 1 1
Treasury Class-A [Member]    
Stockholders' equity:    
Treasury Stock, Value (38,397) (49,040)
Treasury Class B [Member]    
Stockholders' equity:    
Treasury Stock, Value $ 0 $ (89)
XML 71 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Reporting
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Information 14. SEGMENT INFORMATION

Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than 9,000 different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.

The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.

The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.

Other Operations include the remainder of our Analytical Instruments segment.

Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.

Information regarding industry segments at December 31, 2019, 2018, and 2017 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2019
 
$
885.9

 
$
1,412.0

 
$
13.8

 
2018
 
861.7

 
1,411.8

 
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2019
 
$
7.4

 
$
15.9

 
$
0.1

 
2018
 
7.2

 
16.7

 
0.1

 
2017
 
7.0

 
14.9

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2019
 
$
29.4

 
$
71.7

 
$
0.9

 
2018
 
34.1

 
72.0

 
0.5

 
2017
 
36.2

 
80.2

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2019
 
$
72.1

 
$
148.5

 
$
(1.5
)
 
2018
 
28.7

 
(145.7
)
 
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
 
 
 
 
 
 
 
Segment assets
2019
 
$
496.1

 
$
1,075.8

 
$
9.2

 
2018
 
450.2

 
949.0

 
5.9

 
 
 
 
 
 
 
 
Capital expenditures
2019
 
$
16.6

 
$
58.9

 
$
0.6

 
2018
 
36.7

 
60.5

 
0.5




Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of $276.1 million (see Note 4 to the consolidated financial statements).

Segment assets at December 31, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 16 to the consolidated financial statements).

Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Total segment profit (loss)
$
219.1

 
$
(116.8
)
 
$
106.3

Foreign currency exchange losses, net
(2.2
)
 
(2.9
)
 
(9.1
)
Net corporate operating, interest and other expense not allocated to segments
(12.9
)
 
(10.4
)
 
(10.1
)
Change in fair market value of equity securities
2,031.0

 
606.2

 
—

Other income (expense), net
26.1

 
36.6

 
10.7

Consolidated income before income taxes
$
2,261.1

 
$
512.7

 
$
97.8



The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2019
 
2018
Total segment assets
 
$
1,581.1

 
$
1,405.1

Cash and other current assets
 
1,233.5

 
1,047.2

Property, plant and equipment, net, and operating lease right-of-use
 

 

  assets, excluding segment specific balances
 
66.8

 
79.9

Goodwill, net
 
264.1

 
219.8

Other long-term assets
 
4,863.4

 
2,859.1

Total assets
 
$
8,008.9

 
$
5,611.1



Other long-term assets at December 31, 2019 increased from December 31, 2018 balance due to increase in fair market value of equity securities (see Note 3 to the consolidated financial statements).

The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Europe
 
$
770.3

 
$
792.0

 
$
758.5

Asia
 
505.0

 
495.5

 
461.3

United States
 
899.1

 
863.6

 
800.2

Other (primarily Canada and Latin America)
 
137.3

 
138.3

 
140.0

Total net sales
 
$
2,311.7

 
$
2,289.4

 
$
2,160.2


The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2019
 
2018
Europe
 
$
198.3

 
$
129.1

Asia
 
51.5

 
20.7

United States
 
468.7

 
369.2

Other (primarily Canada and Latin America)
 
12.7

 
11.1

Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes
 
$
731.2

 
$
530.1




Prior year amounts have been adjusted to exclude Other investments.
XML 72 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Schedule II - Valuation and Qualifying Accoutns
 12 Months Ended
Dec. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]  
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
BIO-RAD LABORATORIES, INC.
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 2019, 2018, and 2017
(in thousands)

Allowance for doubtful accounts receivable
 
 
Balance at
Beginning
of Year
 

(Credited) Charged to Costs
and Expenses
 
Deductions
 
Balance at
End of Year
2019
 
$
26,713

 
$
(1,240
)
 
$
(5,268
)
 
$
20,205

2018
 
$
25,549

 
$
11,527

 
$
(10,363
)
 
$
26,713

2017
 
$
23,367

 
$
11,174

 
$
(8,992
)
 
$
25,549



Valuation allowance for long-term deferred tax assets
 
 
Balance at
Beginning
of Year
 
Charged
(Credited) to Income
Tax Expense
 
Deductions
 
Balance at 
End of Year 
2019
 
$
70,769

 
$
—

 
$
(3,579
)
 
$
67,190

2018
 
$
66,356

 
$
4,413

 
$
—

 
$
70,769

2017
 
$
66,403

 
$
(47
)
 
$
—

 
$
66,356
XML 73 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
4. Intangible Assets, Goodwill and Other (Tables)
 12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes to goodwill by segment

Changes to goodwill by segment were as follows (in millions):
 
 
2019
 
 
2018
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
 
 
Life
Science
 
Clinical
Diagnostics
 
Total
Balances as of January 1:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
$
234.5

 
$
320.5

 
$
555.0

 
 
$
234.7

 
$
324.6

 
$
559.3

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(35.9
)
 
(17.3
)
 
(53.2
)
Goodwill, net
 
192.7

 
27.1

 
219.8

 
 
198.8

 
307.3

 
506.1

Acquisitions
 
15.6

 
28.7

 
44.3

 
 
—

 
—

 
—

Divestiture
 
—

 
—

 
—

 
 
—

 
(1.4
)
 
(1.4
)
Impairment
 
—

 
—

 
—

 
 
(5.9
)
 
(276.1
)
 
(282.0
)
Currency fluctuations
 
—

 
—

 
—

 
 
(0.2
)
 
(2.7
)
 
(2.9
)
Balances as of December 31:
 
 
 
 
 
 
 
 
 
 
 
 
 
Goodwill
 
250.1

 
349.2

 
599.3

 
 
234.5

 
320.5

 
555.0

Accumulated impairment losses and write-offs
 
(41.8
)
 
(293.4
)
 
(335.2
)
 
 
(41.8
)
 
(293.4
)
 
(335.2
)
Goodwill, net
 
$
208.3

 
$
55.8

 
$
264.1

 
 
$
192.7

 
$
27.1

 
$
219.8
Schedule of Finite-Lived Intangible Assets by Major-Class
Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):
 
December 31, 2019
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
6.36
 
$
107.2

 
$
(74.3
)
 
$
32.9

Know how
5.71
 
188.5

 
(162.6
)
 
25.9

Developed product technology
8.31
 
144.2

 
(93.9
)
 
50.3

Licenses
8.74
 
76.0

 
(44.4
)
 
31.6

Tradenames
8.50
 
6.4

 
(3.6
)
 
2.8

Covenants not to compete
6.01
 
3.2

 
(1.4
)
 
1.8

Other
—
 
0.1

 
(0.1
)
 
—

     Total definite-lived intangible assets
 
 
525.6

 
(380.3
)
 
145.3

In-process research and development
 
 
0.2

 
—

 
0.2

     Total purchased intangible assets
 
 
$
525.8

 
$
(380.3
)
 
$
145.5


 
December 31, 2018
 
Weighted-Average Amortization Period (years)
 
Purchase
Price
 
Accumulated
Amortization
 
Net
Carrying
Amount
Customer relationships/lists
3.98
 
$
88.7

 
$
(68.3
)
 
$
20.4

Know how
6.64
 
190.6

 
(159.8
)
 
30.8

Developed product technology
8.34
 
130.4

 
(86.6
)
 
43.8

Licenses
9.72
 
76.3

 
(40.9
)
 
35.4

Tradenames
3.42
 
3.9

 
(3.3
)
 
0.6

Covenants not to compete
7.01
 
3.2

 
(1.1
)
 
2.1

     Total definite-lived intangible assets
 
 
$
493.1

 
$
(360.0
)
 
$
133.1
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Selling, general and administrative expense $ (824,625) $ (834,783) $ (806,790)
Realized Investment Gains (Losses) 1,500 1,600 $ 100
Other Postretirement Benefit Plan [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Selling, general and administrative expense 1,500 2,400  
Net Unrealized Investment Gain (Loss) [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]      
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]      
Realized Investment Gains (Losses) $ 400 $ (300)  
XML 75 R67.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
11. Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Other Significant Noncash Transactions [Line Items]                      
Net Income (Loss) Attributable to Parent $ 553,500 $ (258,800) $ 598,800 $ 865,200 $ (828,500) $ 269,300 $ 268,000 $ 656,800 $ 1,758,675 $ 365,614 $ 122,249
Depreciation and amortization                 134,200 138,100 148,700
Reduction in the carrying amount of right-of-use assets                 40,300 0 0
Share-based compensation                 35,600 27,800 23,400
Gains on disposition of securities                 (1,500) (1,600) (100)
Other than Temporary Impairment Losses on Investments                 5,800 800 7,000
Changes in fair market value of equity securities                 (2,031,000) (606,200) 0
Losses on dispositions of fixed assets                 1,200 2,000 8,100
Gain on sale of land                 0 (4,100) 0
Gain on divestiture of product line                 0 5,100 0
Payments for operating lease liabilities                 38,600 0 0
Changes in fair value of contingent consideration                 (1,600) (6,200) (18,100)
Decrease (increase) in accounts receivable, net                 1,600 59,700 (64,100)
Decrease (increase) in inventories, net                 24,200 (12,900) (47,700)
Decrease (increase) in Other Current Assets                 61,800 (15,300) (35,700)
Increase (decrease) in accounts payable and other current liabilities                 10,600 (45,600) 7,800
Decrease in Income Taxes Payable                 (4,200) (20,900) (22,400)
Increase (decrease) in deferred income taxes                 450,200 120,900 (82,000)
(Increase) decrease in other long term assets                 (1,700) 1,100 2,300
Increase (decrease) in Other Long Term Liabilities                 13,400 (10,000) 38,100
Impairment losses on goodwill and long-lived assets         $ 292,500       0 292,513 11,506
Increase (Decrease) in Other Operating Assets and Liabilities, Net                 1,100 (4,900) (5,100)
Net cash provided by operating activities                 457,897 285,494 104,137
Noncash purchased property, plant and equipment                 8,100 5,700 0
Noncash Purchased Marketable Securities and Investments                 1,400 800 2,800
Noncash or Part Noncash Acquisition, Accounts Receivable Acquired                 $ 1,300 $ 0 $ 300
XML 76 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
2. Acquisitions (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Oct. 01, 2019
Aug. 02, 2019
Mar. 04, 2019
Dec. 31, 2017
Business Acquisition [Line Items]                    
Business Combination, Consideration Transferred $ 4,200 $ 60,000 $ 20,000              
Payments to Acquire Businesses, Net of Cash Acquired 3,600 59,700 16,000 $ 4,000            
Business Combination, Contingent Consideration, Liability             $ 600      
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized 400                  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles             3,400 $ 26,800 $ 5,500  
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets 200       $ 200          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                 $ 200  
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net             $ 1,400 $ 4,200    
Goodwill 264,131     $ 219,770 264,131 $ 219,770       $ 506,100
Goodwill, Acquired During Period   $ 28,700 15,600   44,300 $ 0        
Business Combination, Consideration Transferred, Liabilities Incurred 800   $ 1,300              
Analytical Flow Cytometer Platform [Member]                    
Business Acquisition [Line Items]                    
Business Combination, Contingent Consideration, Liability $ 4,300       $ 4,300          
XML 77 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies Warranty rollforward (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Movement in Standard Product Warranty Accrual [Roll Forward]    
Warranty accrual, beginning of period $ 10.1 $ 18.7
Provision for warranty 9.9 25.5
Actual warranty costs (11.0) (34.1)
Warranty accrual, end of period $ 9.0 $ 10.1
XML 78 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
15. Restructuring Costs (Tables)
 12 Months Ended
Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]  
Restructuring and Related Costs [Table Text Block]
The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):

 
 
2019
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
—

 
$
—

 
$
—

Charged to expense
 
6.2

 
19.1

 
25.3

Cash payments
 
(0.4
)
 
(0.7
)
 
(1.1
)
Reserve transferred from European Reorganization restructuring costs reserve (see above)
 
0.3

 
0.4

 
0.7

Foreign currency translation losses
 
0.1

 
0.3

 
0.4

Balance as of December 31
 
$
6.2

 
$
19.1

 
$
25.3


The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):

 
 
2019
 
2018
 
 
Life Science
 
Clinical Diagnostics
 
Total
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1
 
$
0.6

 
$
1.0

 
$
1.6

 
$
2.2

 
$
4.1

 
$
6.3

Adjustment to expense
 
—

 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.1
)
 
(0.2
)
Cash payments
 
(0.3
)
 
(0.5
)
 
(0.8
)
 
(1.5
)
 
(2.9
)
 
(4.4
)
Reserve transferred to European and North American Reorganization restructuring costs reserve (see below)
 
(0.3
)
 
(0.4
)
 
(0.7
)
 
—

 
—

 
—

Foreign currency translation gains
 
—

 
—

 
—

 
—

 
(0.1
)
 
(0.1
)
Balance as of December 31
 
$
—

 
$
—

 
$
—

 
$
0.6

 
$
1.0

 
$
1.6


The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions):

 
 
2019
 
2018
Balance as of January 1
 
$
11.5

 
$
14.1

Charged to expense
 
—

 
5.8

Adjustment to expense
 
(0.4
)
 
0.3

Cash payments
 
(7.7
)
 
(8.4
)
Foreign currency translation gains
 
(0.2
)
 
(0.3
)
Balance as of December 31
 
$
3.2

 
$
11.5
XML 79 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Debt Securities, Available-for-sale [Table Text Block]
Available-for-sale investments consist of the following (in millions):

 
December 31, 2019
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
203.2

 
$
1.4

 
$
(0.1
)
 
$
204.5

Municipal obligations
11.5

 
0.1

 
—

 
11.6

Asset-backed securities
72.7

 
0.2

 
(0.1
)
 
72.8

U.S. government sponsored agencies
105.6

 
0.7

 
(0.2
)
 
106.1

Foreign government obligations
4.7

 
—

 
—

 
4.7

  Other foreign obligations
3.1

 
—

 
—

 
3.1

 
400.8

 
2.4

 
(0.4
)
 
402.8

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.1

 
—

 
—

 
0.1

 
0.1

 
—

 
—

 
0.1

Total
$
400.9

 
$
2.4

 
$
(0.4
)
 
$
402.9
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions):

December 31, 2018
$
8.4

Analytical flow cytometer platform:
 
Payment of sales milestone
(2.5
)
Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense
(1.6
)
 
 
Foreign distributor earn-outs:
 
Acquisition of foreign distributor
$
0.6

December 31, 2019
$
4.9
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

The following table provides quantitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of December 31, 2019. Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.
 
Valuation Technique
Unobservable Input
Percentage
Analytical flow cytometer platform
Probability-weighted income approach
Sales milestones:
 
 
 
      Discount rate
11.1
%
 
 
      Cost of debt
3.9
%
Schedule of Derivative Instruments [Table Text Block]
The following is a summary of our forward foreign currency exchange contracts (in millions):
 
December 31,
 
2019
Contracts maturing in January through March 2020 to sell foreign currency:
 
Notional value
$
52.0

Unrealized gain
$
0.3

Contracts maturing in January through March 2020 to purchase foreign currency:
 
Notional value
$
269.1

Unrealized loss
$
(0.3
)
Financial assets and liabilities carried at fair value on a recurring basis
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
42.9

 
$
—

 
$
42.9

Time deposits
31.2

 
10.0

 
—

 
41.2

Asset-backed securities
—

 
0.1

 
—

 
0.1

Money market funds
69.9

 
—

 
—

 
69.9

Total cash equivalents (a)
101.1

 
53.0

 
—

 
154.1

Restricted investment
5.6

 
—

 
—

 
5.6

Equity Securities (b)
4,664.4

 
—

 
—

 
4,664.4

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
204.5

 
—

 
204.5

U.S. government sponsored agencies
—

 
106.1

 
—

 
106.1

Foreign government obligations
—

 
4.7

 
—

 
4.7

Other foreign obligations
—

 
3.1

 
—

 
3.1

Municipal obligations
—

 
11.6

 
—

 
11.6

Asset-backed securities
—

 
72.9

 
—

 
72.9

Total available-for-sale investments (c)
—

 
402.9

 
—

 
402.9

Forward foreign exchange contracts (d)
—

 
0.9

 
—

 
0.9

Total financial assets carried at fair value
$
4,771.1

 
$
456.8

 
$
—

 
$
5,227.9

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
     Forward foreign exchange contracts (e)
$
—

 
$
1.0

 
$
—

 
$
1.0

     Contingent consideration (f)
—

 
—

 
4.9

 
4.9

Total financial liabilities carried at fair value
$
—

 
$
1.0

 
$
4.9

 
$
5.9


Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2018 are classified in the hierarchy as follows (in millions):

 
Level 1
 
Level 2
 
Level 3
 
Total
Financial assets carried at fair value:
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Commercial paper
$
—

 
$
77.8

 
$
—

 
$
77.8

Time deposits
22.7

 
10.0

 
—

 
32.7

Asset-backed securities
—

 
0.3

 
—

 
0.3

Money market funds
36.9

 
—

 
—

 
36.9

Total cash equivalents (a)
59.6

 
88.1

 
—

 
147.7

Restricted investment:
5.6

 
—

 
—

 
5.6

Equity securities (b)
2,672.9

 
—

 
—

 
2,672.9

Available-for-sale investments:
 
 
 
 
 
 
 
Corporate debt securities
—

 
215.0

 
—

 
215.0

U.S. government sponsored agencies
—

 
80.3

 
—

 
80.3

Foreign government obligations
—

 
3.6

 
—

 
3.6

Municipal obligations
—

 
11.0

 
—

 
11.0

Asset-backed securities
—

 
63.3

 
—

 
63.3

Total available-for-sale investments (c)
—

 
373.2

 
—

 
373.2

Forward foreign exchange contracts (d)
—

 
0.6

 
—

 
0.6

Total financial assets carried at fair value
$
2,738.1

 
$
461.9

 
$
—

 
$
3,200.0

 
 
 
 
 
 
 
 
Financial liabilities carried at fair value:
 
 
 
 
 
 
 
Forward foreign exchange contracts (e)
$
—

 
$
0.7

 
$
—

 
$
0.7

 Contingent consideration (f)
—

 
—

 
8.4

 
8.4

Total financial liabilities carried at fair value
$
—

 
$
0.7

 
$
8.4

 
$
9.1


(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.

(b)
Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
Short-term investments
$
51.0

 
$
40.2

Other investments
4,613.4

 
2,632.7

        Total
$
4,664.4

 
$
2,672.9



The year-to-date unrealized gains on our equity securities still held as of December 31, 2019 were $2,031.1 million and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income.

(c)
Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31,
2019
 
December 31, 2018
 
 
 
 
Short-term investments
$
402.8

 
$
373.0

Other investments
0.1

 
0.2

Total
$
402.9

 
$
373.2




(d)
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.

(e)
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.

(f)
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Other current liabilities
$
3.3

 
$
3.2

Other long-term liabilities
1.6

 
5.2

   Total
$
4.9

 
$
8.4
Schedule of available-for-sale investments
Available-for-sale investments consist of the following (in millions):
 
December 31, 2018
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Estimated
Fair
Value
Short-term investments:
 
 
 
 
 
 
 
Corporate debt securities
$
216.2

 
$
0.1

 
$
(1.3
)
 
$
215.0

Municipal obligations
11.1

 
—

 
(0.1
)
 
11.0

Asset-backed securities
63.5

 
—

 
(0.4
)
 
63.1

U.S. government sponsored agencies
80.9

 
0.2

 
(0.8
)
 
80.3

Foreign government obligations
3.6

 
—

 
—

 
3.6

 
375.3

 
0.3

 
(2.6
)
 
373.0

Long-term investments:
 
 
 
 
 
 
 
Asset-backed securities
0.2

 
—

 
—

 
0.2

 
0.2

 
—

 
—

 
0.2

Total
$
375.5

 
$
0.3

 
$
(2.6
)
 
$
373.2
Summary of investments with gross unrealized losses and the associated fair value
The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):

 
December 31,
2019
 
December 31, 2018
 
 
 
 
Fair value of investments in a loss position 12 months or more
$
19.9

 
$
117.9

Fair value of investments in a loss position less than 12 months
$
97.8

 
$
193.0

Gross unrealized losses for investments in a loss position 12 months or more
$
0.1

 
$
1.8

Gross unrealized losses for investments in a loss position less than 12 months
$
0.3

 
$
0.8
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at December 31, 2019 by contractual maturity date (in millions):

 
Amortized
Cost
 
Estimated Fair
Value
Mature in less than one year
$
174.5

 
$
174.6

Mature in one to five years
164.2

 
165.2

Mature in more than five years
62.2

 
63.1

Total
$
400.9

 
$
402.9
Estimated fair value of financial instruments
The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):

 
December 31, 2019
 
December 31, 2018
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
 
Carrying 
Amount 
 
Estimated 
Fair 
Value 
 
Fair Value Hierarchy Level
Total current maturities long-term debt, excluding leases
$
424.4

 
$
435.5

 
2
 
$
—

 
$
—

 
2
Total long-term debt, excluding leases
and current maturities
$
—

 
$
—

 
2
 
$
423.7

 
$
435.8

 
2
XML 80 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
13. Legal Proceedings
 12 Months Ended
Dec. 31, 2019
Legal Proceedings [Abstract]  
Legal Matters and Contingencies
13.    LEGAL PROCEEDINGS

On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded $10.92 million, plus prejudgment interest of $141,608, post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about $2.96 million plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the $7.96 million in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing en banc with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24,
2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on our 2019 results of operations and is now closed.

We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.


JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10k123119.htm": { "axisCustom": 3, "axisStandard": 30, "contextCount": 496, "dts": { "calculationLink": { "local": [ "bio-20191231_cal.xml" ] }, "definitionLink": { "local": [ "bio-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a10k123119.htm" ] }, "labelLink": { "local": [ "bio-20191231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bio-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bio-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 998, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 58, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 63 }, "keyCustom": 24, "keyStandard": 633, "memberCustom": 38, "memberStandard": 85, "nsprefix": "bio", "nsuri": "http://www.bio-rad.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.bio-rad.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - 3. Fair Value Measurements", "role": "http://www.bio-rad.com/role/A3FairValueMeasurements", "shortName": "3. Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - 4. Intangible Assets, Goodwill and Other", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther", "shortName": "4. Intangible Assets, Goodwill and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - 5. Notes Payable and Long-Term Debt", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt", "shortName": "5. Notes Payable and Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - 6. Income Taxes", "role": "http://www.bio-rad.com/role/A6IncomeTaxes", "shortName": "6. Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - 7. Stockholders' Equity", "role": "http://www.bio-rad.com/role/A7StockholdersEquity", "shortName": "7. Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - 8. Accumulated Other Comprehensive Income", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome", "shortName": "8. Accumulated Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - 9. Share-based Compensation", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensation", "shortName": "9. Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - 10. Other Income and Expenses", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses", "shortName": "10. Other Income and Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - 11. Supplemental Cash Flow Information", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation", "shortName": "11. Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - 12. Commitments & Contingent Liabilities", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities", "shortName": "12. Commitments & Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Balance Sheets", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - 13. Legal Proceedings", "role": "http://www.bio-rad.com/role/A13LegalProceedings", "shortName": "13. Legal Proceedings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - 14. Segment Reporting", "role": "http://www.bio-rad.com/role/A14SegmentReporting", "shortName": "14. Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125100 - Disclosure - 15. Restructuring Costs (Notes)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsNotes", "shortName": "15. Restructuring Costs (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127100 - Disclosure - 16. Leases (Notes)", "role": "http://www.bio-rad.com/role/A16LeasesNotes", "shortName": "16. Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128100 - Disclosure - 17. Quarterly Financial Data", "role": "http://www.bio-rad.com/role/A17QuarterlyFinancialData", "shortName": "17. Quarterly Financial Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130100 - Disclosure - Schedule II - Valuation and Qualifying Accoutns", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "shortName": "Schedule II - Valuation and Qualifying Accoutns", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - 1. Significant Accounting Policies (Policies)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies", "shortName": "1. Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2301302 - Disclosure - 1. Significant Accounting Policies (Tables)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables", "shortName": "1. Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - 3. Fair Value Measurements (Tables)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsTables", "shortName": "3. Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - 4. Intangible Assets, Goodwill and Other (Tables)", "role": "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables", "shortName": "4. Intangible Assets, Goodwill and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Consolidated Balance Sheets (Parentheticals)", "role": "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - 5. Notes Payable and Long-Term Debt (Tables)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables", "shortName": "5. Notes Payable and Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - 6. Income Taxes (Tables)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesTables", "shortName": "6. Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - 7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "shortName": "7. Stockholders' Equity Stockholders' Equity Shares Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - 8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - 9. Share-based Compensation (Tables)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationTables", "shortName": "9. Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - 10. Other Income and Expenses (Tables)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables", "shortName": "10. Other Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - 11. Supplemental Cash Flow Information (Tables)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables", "shortName": "11. Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - 12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables", "shortName": "12. Commitments & Contingent Liabilities Commitments & Contingent Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324301 - Disclosure - 14. Segment Reporting (Tables)", "role": "http://www.bio-rad.com/role/A14SegmentReportingTables", "shortName": "14. Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325301 - Disclosure - 15. Restructuring Costs (Tables)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsTables", "shortName": "15. Restructuring Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327301 - Disclosure - 16. Leases (Tables)", "role": "http://www.bio-rad.com/role/A16LeasesTables", "shortName": "16. Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328301 - Disclosure - 17. Quarterly Financial Data (Tables)", "role": "http://www.bio-rad.com/role/A17QuarterlyFinancialDataTables", "shortName": "17. Quarterly Financial Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedInvestmentsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - 1. Significant Accounting Policies Property, Plant and Equipment (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "shortName": "1. Significant Accounting Policies Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember", "decimals": null, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401404 - Disclosure - 1. Significant Accounting Policies Warranty rollforward (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails", "shortName": "1. Significant Accounting Policies Warranty rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2017Q4", "decimals": "-5", "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - 1. Significant Accounting Policies Earnings per share (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "shortName": "1. Significant Accounting Policies Earnings per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401406 - Disclosure - 1. Significant Accounting Policies Details (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "shortName": "1. Significant Accounting Policies Details (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - 1. Significant Accounting Policies Revenue Recognition (Details)", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "1. Significant Accounting Policies Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:RevenueRecognitionLeases", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "lang": null, "name": "bio:RevenueAllocationPercentToLeaseElements", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - 2. Acquisitions (Details)", "role": "http://www.bio-rad.com/role/A2AcquisitionsDetails", "shortName": "2. Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - 3. Fair Value Measurements (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "shortName": "3. Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - 3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails", "shortName": "3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - 3. Fair Value Measurements Available-for-Sale Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "shortName": "3. Fair Value Measurements Available-for-Sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_DebtSecuritiesMember", "decimals": "-5", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - 3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "shortName": "3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403406 - Disclosure - 3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "shortName": "3. Fair Value Measurements Fair Value and Gross Unrealized Losses with Unrealized Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "2", "first": true, "lang": null, "name": "bio:PriceChangeDebtSecurity", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403407 - Disclosure - 3. Fair Value Investments (Details)", "role": "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "shortName": "3. Fair Value Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2018Q1SD", "decimals": "-3", "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403408 - Disclosure - 3. Fair Value Measurements Contingent Consideration (Details)", "role": "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "shortName": "3. Fair Value Measurements Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2018Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2019Q1SD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2019Q1SD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2019Q4SD1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - 4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "role": "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "shortName": "4. Goodwill and other Purchased Intangible Assets Intangible Assets, Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - 5. Notes Payable and Long-Term Debt (Details)", "role": "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "shortName": "5. Notes Payable and Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - 6. Income Taxes (Details)", "role": "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "shortName": "6. Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "D2019Q4November", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - 7. Stockholders' Equity (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "shortName": "7. Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember", "decimals": "-3", "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2019Q4November", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - 7. Stockholders' Equity Treasury Shares (Details)", "role": "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "shortName": "7. Stockholders' Equity Treasury Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2019Q4November", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TreasuryStockShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - 8. Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - 8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "role": "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "shortName": "8. Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "bio:AccumulatedOtherComprehensiveIncomeTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - 9. Share-based Compensation (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "shortName": "9. Share-based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - 9. Share-based Compensation Restricted Stock (Details)", "role": "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails", "shortName": "9. Share-based Compensation Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - 10. Other Income and Expenses (Details)", "role": "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "shortName": "10. Other Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterestAndDividend", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - 11. Supplemental Cash Flow Information (Details)", "role": "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "shortName": "11. Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - 12. Commitments & Contingent Liabilities (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "shortName": "12. Commitments & Contingent Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - 12. Commitments & Contingent Liabilities Period Expense (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails", "shortName": "12. Commitments & Contingent Liabilities Period Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416404 - Disclosure - 12. Commitments & Contingent Liabilities Pensions (Details)", "role": "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "shortName": "12. Commitments & Contingent Liabilities Pensions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2018Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421401 - Disclosure - 13. Legal Proceedings Legal Proceedings (Details)", "role": "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "shortName": "13. Legal Proceedings Legal Proceedings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2018Q4YTD", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesSoughtValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424402 - Disclosure - 14. Segment Reporting (Details)", "role": "http://www.bio-rad.com/role/A14SegmentReportingDetails", "shortName": "14. Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "0", "first": true, "lang": null, "name": "bio:NumberOfProductsAndServices", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424403 - Disclosure - 14. Segment Information Segment Profit Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "shortName": "14. Segment Information Segment Profit Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424404 - Disclosure - 14. Segment Information Segment Asset Reconciliation (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "shortName": "14. Segment Information Segment Asset Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-5", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424405 - Disclosure - 14. Segment Information Segment Information by Geographical Location (Details)", "role": "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "shortName": "14. Segment Information Segment Information by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_RestructuringPlanAxis_bio_EuropeanReorganizationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425402 - Disclosure - 15. Restructuring Costs (Details)", "role": "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "shortName": "15. Restructuring Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_RestructuringPlanAxis_bio_EuropeanReorganizationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427402 - Disclosure - 16. Leases (Details)", "role": "http://www.bio-rad.com/role/A16LeasesDetails", "shortName": "16. Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherCommitment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrealizedGainOnSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428402 - Disclosure - 17. Quarterly Financial Data (Details)", "role": "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "shortName": "17. Quarterly Financial Data (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "us-gaap:QuarterlyFinancialInformationTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BusinessCombinationDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429402 - Disclosure - 18. Subsequent Event (Details)", "role": "http://www.bio-rad.com/role/A18SubsequentEventDetails", "shortName": "18. Subsequent Event (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - 1. Significant Accounting Policies", "role": "http://www.bio-rad.com/role/A1SignificantAccountingPolicies", "shortName": "1. Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430402 - Disclosure - Schedule II - Valuation and Qualifying Accoutns (Details)", "role": "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "shortName": "Schedule II - Valuation and Qualifying Accoutns (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - 2. Acquisitions", "role": "http://www.bio-rad.com/role/A2Acquisitions", "shortName": "2. Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a10k123119.htm", "contextRef": "I2018Q1SD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - a10k123119.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - a10k123119.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 127, "tag": { "bio_A2011EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2011 Employee Stock Purchase Plan [Member]", "label": "2011 Employee Stock Purchase Plan [Member]", "terseLabel": "2011 Employee Stock Purchase Plan [Member]" } } }, "localname": "A2011EmployeeStockPurchasePlanMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_AccumulatedOtherComprehensiveIncomeTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "accumulated other comprehensive income [Text Block]", "label": "accumulated other comprehensive income [Text Block]", "terseLabel": "accumulated other comprehensive income [Text Block]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeTextBlock", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "bio_AggregateTransitionTaxonForeignEarnings2017TaxAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act", "label": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act", "terseLabel": "Aggregate Transition Tax on Foreign Earnings, 2017 Tax Act" } } }, "localname": "AggregateTransitionTaxonForeignEarnings2017TaxAct", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_AnalyticalFlowCytometerPlatformMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Analytical Flow Cytometer Platform", "label": "Analytical Flow Cytometer Platform [Member]", "terseLabel": "Analytical Flow Cytometer Platform [Member]" } } }, "localname": "AnalyticalFlowCytometerPlatformMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_BalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Balance Sheet Parenthetical [Abstract]", "label": "Balance Sheet Parenthetical [Abstract]" } } }, "localname": "BalanceSheetParentheticalAbstract", "nsuri": "http://www.bio-rad.com/20191231", "xbrltype": "stringItemType" }, "bio_BiotestAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biotest AG [Member]", "label": "Biotest AG [Member]", "terseLabel": "Biotest AG [Member]" } } }, "localname": "BiotestAGMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_BusinessAcquisitionContingentConsiderationPotentialPercentagePayout": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "business acquisition contingent consideration percentage payout", "label": "Business Acquisition, Contingent Consideration, Potential Percentage Payout", "terseLabel": "Business Acquisition, Contingent Consideration, Potential Percentage Payout" } } }, "localname": "BusinessAcquisitionContingentConsiderationPotentialPercentagePayout", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_CapitalLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Leases and Other Debt [Member]", "label": "Capital Leases and Other Debt [Member]", "terseLabel": "Capital Leases and Other Debt [Member]" } } }, "localname": "CapitalLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_CapitalizedCloudComputingArrangements": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Capitalized Cloud Computing Arrangements", "label": "Capitalized Cloud Computing Arrangements", "terseLabel": "Capitalized Cloud Computing Arrangements" } } }, "localname": "CapitalizedCloudComputingArrangements", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "bio_CellsorterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CellSorter [Member] [Member]", "label": "CellSorter [Member]", "terseLabel": "CellSorter [Member]" } } }, "localname": "CellsorterMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_ClinicalDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Clinical Diagnostics [Member]", "label": "Clinical Diagnostics [Member]", "terseLabel": "Clinical Diagnostics [Member]" } } }, "localname": "ClinicalDiagnosticsMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_DiaMedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "DiaMed [Member]", "label": "DiaMed [Member]", "terseLabel": "DiaMed [Member]" } } }, "localname": "DiaMedMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_DiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount Rate", "label": "Discount Rate", "terseLabel": "Discount Rate" } } }, "localname": "DiscountRate", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bio_DistributorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributor [Member]", "label": "Distributor [Member]", "terseLabel": "Distributor [Member]" } } }, "localname": "DistributorMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Document and Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.bio-rad.com/20191231", "xbrltype": "stringItemType" }, "bio_EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "label": "Effective Income Tax Rate Reconciliation, Fines and Penalties, Percent", "terseLabel": "Fines and penalties" } } }, "localname": "EffectiveIncomeTaxRateReconciliationFinesandPenaltiesPercent", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act", "terseLabel": "U.S. tax reform" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsandJobsAct", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "bio_ElectionPercentageForBoardOfDirectors": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Election Percentage for Board of Directors", "label": "Election Percentage for Board of Directors", "terseLabel": "Election Percentage for Board of Directors" } } }, "localname": "ElectionPercentageForBoardOfDirectors", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "bio_EmployeeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employee Location [Axis]", "label": "Employee Location [Axis]", "terseLabel": "Employee Location [Axis]" } } }, "localname": "EmployeeLocationAxis", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "bio_EmployeeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Employee Location [Axis]", "label": "Employee Location [Domain]", "terseLabel": "Employee Location [Domain]" } } }, "localname": "EmployeeLocationDomain", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "domainItemType" }, "bio_EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Employees covered by collective bargaining agreements, percentage", "label": "Employees Covered By Collective Bargaining Agreements U.S., Percentage", "terseLabel": "Employees Covered By Collective Bargaining Agreements U.S., Percentage" } } }, "localname": "EmployeesCoveredByCollectiveBargainingAgreementsUSPercentage", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "bio_EuropeanReorganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "European Reorganization [Member]", "label": "European Reorganization [Member]", "terseLabel": "European Reorganization [Member]" } } }, "localname": "EuropeanReorganizationMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "bio_EuropeanandNorthAmericanReorganizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "European and North American Reorganization [Member]", "label": "European and North American Reorganization [Member]", "terseLabel": "European and North American Reorganization [Member]" } } }, "localname": "EuropeanandNorthAmericanReorganizationMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Finance Lease Cost", "label": "Finance Lease Cost", "totalLabel": "Finance Lease Cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "bio_FinanceLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease [Member]", "label": "Finance Lease [Member]", "terseLabel": "Finance Lease [Member]" } } }, "localname": "FinanceLeaseMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "domainItemType" }, "bio_FinanceLeaseObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease Obligations [Member]", "label": "Finance Lease Obligations [Member]", "terseLabel": "Finance Lease Obligations [Member]" } } }, "localname": "FinanceLeaseObligationsMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_FinanceLeasesandOtherDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Leases and Other Debt [Member]", "label": "Finance Leases and Other Debt [Member]", "terseLabel": "Finance Leases and Other Debt [Member]" } } }, "localname": "FinanceLeasesandOtherDebtMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_FinesandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fines and penalties [Axis]", "label": "Fines and penalties [Axis]", "terseLabel": "Fines and penalties [Axis]" } } }, "localname": "FinesandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_FinesandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Fines and penalties [Axis]", "label": "Fines and penalties [Domain]", "terseLabel": "Fines and penalties [Domain]" } } }, "localname": "FinesandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForeignTaxCreditCarryforwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign Tax Credit Carryforward [Member]", "label": "Foreign Tax Credit Carryforward [Member]", "terseLabel": "Foreign Tax Credit Carryforward [Member]" } } }, "localname": "ForeignTaxCreditCarryforwardMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttopurchaseforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to purchase foreign currency [Member]", "label": "Forward foreign exchange contract to purchase foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to purchase foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttopurchaseforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_ForwardforeignexchangecontracttosellforeigncurrencyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward foreign exchange contract to sell foreign currency [Member]", "label": "Forward foreign exchange contract to sell foreign currency [Member]", "terseLabel": "Forward foreign exchange contract to sell foreign currency [Member]" } } }, "localname": "ForwardforeignexchangecontracttosellforeigncurrencyMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "bio_IncentiveAwardPlan2017Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Award Plan 2017 [Member]", "label": "Incentive Award Plan 2017 [Member]", "terseLabel": "Incentive Award Plan 2017 [Member]" } } }, "localname": "IncentiveAwardPlan2017Member", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Axis]", "label": "Including accrued interest and penalties [Axis]" } } }, "localname": "IncludingaccruedinterestandpenaltiesAxis", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_IncludingaccruedinterestandpenaltiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Domain]", "label": "Including accrued interest and penalties [Domain]", "terseLabel": "Including accrued interest and penalties [Domain]" } } }, "localname": "IncludingaccruedinterestandpenaltiesDomain", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_IncludingaccruedinterestandpenaltiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Including accrued interest and penalties [Member]", "label": "Including accrued interest and penalties [Member]", "terseLabel": "Including accrued interest and penalties [Member]" } } }, "localname": "IncludingaccruedinterestandpenaltiesMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_Investmentownershippercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investment ownership percentage", "label": "Investment ownership percentage", "terseLabel": "Investment ownership percentage" } } }, "localname": "Investmentownershippercentage", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "percentItemType" }, "bio_KnowHowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Know how [Member]", "label": "Know How [Member]", "terseLabel": "Know how [Member]" } } }, "localname": "KnowHowMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LeaseTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Type [Axis]", "label": "Lease Type [Axis]", "terseLabel": "Lease Type [Axis]" } } }, "localname": "LeaseTypeAxis", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "stringItemType" }, "bio_LegalProceedingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Legal Proceedings [Abstract]" } } }, "localname": "LegalProceedingsAbstract", "nsuri": "http://www.bio-rad.com/20191231", "xbrltype": "stringItemType" }, "bio_LesseeOperatingAndFinanceLeasesRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Operating And Finance Leases Remaining Lease Term", "label": "Lessee Operating And Finance Leases Remaining Lease Term", "terseLabel": "Lessee Operating And Finance Leases Remaining Lease Term" } } }, "localname": "LesseeOperatingAndFinanceLeasesRemainingLeaseTerm", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "durationItemType" }, "bio_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_LesseeSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Supplemental Cash Flow Information [Table Text Block]", "label": "Lessee Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Lessee Supplemental Cash Flow Information [Table Text Block]" } } }, "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_LifeScienceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Life Sciences [Member]", "label": "Life Science [Member]", "terseLabel": "Life Science [Member]" } } }, "localname": "LifeScienceMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bio_LimitationsOnUseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Limitations On Use [Member]", "label": "Limitations On Use [Member]", "terseLabel": "Limitations On Use" } } }, "localname": "LimitationsOnUseMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_MarketPriceOfRiskMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market Price of Risk [Member]", "label": "Market Price of Risk [Member]", "terseLabel": "Discount rate [Member]" } } }, "localname": "MarketPriceOfRiskMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "label": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]", "terseLabel": "Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]" } } }, "localname": "MaturitiesOfLeaseLiabilitiesForOperatingandFinanceLeasesTableTextBlock", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesTables" ], "xbrltype": "textBlockItemType" }, "bio_NetofprepaidtaxesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Axis]", "terseLabel": "Net of prepaid taxes [Axis]" } } }, "localname": "NetofprepaidtaxesAxis", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "bio_NetofprepaidtaxesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Net of prepaid taxes [Axis]", "label": "Net of prepaid taxes [Domain]", "terseLabel": "Net of prepaid taxes [Domain]" } } }, "localname": "NetofprepaidtaxesDomain", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NetofprepaidtaxesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net of prepaid taxes [Member]", "label": "Net of prepaid taxes [Member]", "terseLabel": "Net of prepaid taxes [Member]" } } }, "localname": "NetofprepaidtaxesMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_NonCurrentIncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non Current Income Tax Expense", "label": "Non Current Income Tax Expense", "terseLabel": "Non-current tax expense (benefit)" } } }, "localname": "NonCurrentIncomeTaxExpense", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_NumberOfProductsAndServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number Of Products And Services", "label": "Number Of Products And Services", "terseLabel": "Number Of Products And Services" } } }, "localname": "NumberOfProductsAndServices", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "bio_ObligationsandFundedStatusAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Obligations and Funded Status [Abstract]", "label": "Obligations and Funded Status [Abstract]" } } }, "localname": "ObligationsandFundedStatusAbstract", "nsuri": "http://www.bio-rad.com/20191231", "xbrltype": "stringItemType" }, "bio_OperatingLossCarryforwardWithNoExpirationDate": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Operating Loss Carryforward With No Expiration Date", "label": "Operating Loss Carryforward With No Expiration Date", "terseLabel": "Operating Loss Carryforward With No Expiration Date" } } }, "localname": "OperatingLossCarryforwardWithNoExpirationDate", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_OperatingleaseassetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease assets [Member]", "label": "Operating lease assets [Member]", "terseLabel": "Operating lease assets [Member]" } } }, "localname": "OperatingleaseassetsMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_OperatingleaseobligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease obligations [Member]", "label": "Operating lease obligations [Member]", "terseLabel": "Operating lease obligations [Member]" } } }, "localname": "OperatingleaseobligationsMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_PasteurSanofiDiagnosicsS.A.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pasteur Sanofi Diagnosics S.A. [Member]", "label": "Pasteur Sanofi Diagnosics S.A. [Member]", "terseLabel": "Pasteur Sanofi Diagnosics S.A. [Member]" } } }, "localname": "PasteurSanofiDiagnosicsS.A.Member", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "domainItemType" }, "bio_PriceChangeDebtSecurity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price Change Debt Security", "label": "Price Change Debt Security", "terseLabel": "Price Change Debt Security" } } }, "localname": "PriceChangeDebtSecurity", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_Proceedsfromderivativeinstrumentsoperatingactivities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from derivative instruments, operating activities", "label": "Proceeds from derivative instruments, operating activities", "terseLabel": "Proceeds from (payments for) forward foreign exchange contracts, net" } } }, "localname": "Proceedsfromderivativeinstrumentsoperatingactivities", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bio_ProjectedVolatilityOfSalesMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Projected Volatility of Sales [Member]", "label": "Projected Volatility of Sales [Member] [Member]", "terseLabel": "Cost of debt [Member]" } } }, "localname": "ProjectedVolatilityOfSalesMemberMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member] -- excludes segment specific gross machinery and equipment and operating lease right-of-use assets", "label": "Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member]", "terseLabel": "Property, Plant and Equipment and Operating lease right-of-use assets excluding segment specific [Member]" } } }, "localname": "PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "bio_ReagentRentalEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reagent Rental Equipment [Member]", "label": "Reagent Rental Equipment [Member]", "terseLabel": "Reagent Rental Equipment [Member]" } } }, "localname": "ReagentRentalEquipmentMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "bio_RevenueAllocationPercentToLeaseElements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue Allocation Percent To Lease Elements", "label": "Revenue Allocation Percent To Lease Elements", "terseLabel": "Revenue Allocation Percent To Lease Elements" } } }, "localname": "RevenueAllocationPercentToLeaseElements", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "bio_SalesmilestoneminimumamountMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone minimum amount [Member]", "label": "Sales milestone minimum amount [Member]", "terseLabel": "Sales milestone minimum amount [Member]" } } }, "localname": "SalesmilestoneminimumamountMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices [Member]", "label": "Sales milestone percentage of annual invoices [Member]", "terseLabel": "Sales milestone percentage of annual invoices [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoicesMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SalesmilestonepercentageofannualinvoiceslowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales milestone percentage of annual invoices low [Member]", "label": "Sales milestone percentage of annual invoices low [Member]", "terseLabel": "Sales milestone percentage of annual invoices low [Member]" } } }, "localname": "SalesmilestonepercentageofannualinvoiceslowMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bio_SeniorNotes4.875due2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes 4.875% [Member]", "label": "Senior Notes 4.875% due 2020 [Member]", "terseLabel": "Senior Notes 4.875% due 2020 [Member]" } } }, "localname": "SeniorNotes4.875due2020Member", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "bio_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Contribution Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeContributionAmount", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "bio_ShorttermRestrictedInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Short-term Restricted Investments [Policy Text Block]", "label": "Short-term Restricted Investments [Policy Text Block]", "terseLabel": "Short-term Restricted Investments" } } }, "localname": "ShorttermRestrictedInvestmentsPolicyTextBlock", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bio_StockAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Award Plans [Member]", "label": "Stock Award Plans [Member]", "terseLabel": "Stock Award Plans [Member]" } } }, "localname": "StockAwardPlansMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_StockOptionAndAwardPlansMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Award Plans [Member]", "label": "Stock Option and Award Plans [Member]", "terseLabel": "Stock Option and Award Plans [Member]" } } }, "localname": "StockOptionAndAwardPlansMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bio_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefit", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase", "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase", "terseLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Increase" } } }, "localname": "TaxCutsandJobsActChangeinTaxRateIncomeTaxExpenseBenefitIncrease", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncomeTaxExpenseBenefitComposition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "", "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition", "terseLabel": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Composition" } } }, "localname": "TaxCutsandJobsActIncomeTaxExpenseBenefitComposition", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActIncomeTaxExpenseComposition": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act, Income Tax Expense, Composition", "label": "Tax Cuts and Jobs Act, Income Tax Expense, Composition", "terseLabel": "Tax Cuts and Jobs Act, Income Tax Expense, Composition" } } }, "localname": "TaxCutsandJobsActIncomeTaxExpenseComposition", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "bio_TaxCutsandJobsActMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tax Cuts and Jobs Act [Member]", "label": "Tax Cuts and Jobs Act [Member]", "terseLabel": "Tax Cuts and Jobs Act [Member]" } } }, "localname": "TaxCutsandJobsActMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project [Member]", "label": "Termination of a Diagnostics Research and Development Project [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "label": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]", "terseLabel": "Termination of a Diagnostics Research and Development Project and a Facility Closure [Member]" } } }, "localname": "TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "bio_TolerablevarianceLevel2debtsecuritypricing": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tolerable variance Level 2 debt security pricing", "label": "Tolerable variance Level 2 debt security pricing", "terseLabel": "Tolerable variance Level 2 debt security pricing" } } }, "localname": "TolerablevarianceLevel2debtsecuritypricing", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "percentItemType" }, "bio_TreasuryClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class A [Member]", "label": "Treasury Class-A [Member]", "terseLabel": "Treasury Class-A [Member]" } } }, "localname": "TreasuryClassAMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "bio_TreasuryClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Treasury Class B [Member]", "label": "Treasury Class B [Member]", "terseLabel": "Treasury Class B [Member]" } } }, "localname": "TreasuryClassBMember", "nsuri": "http://www.bio-rad.com/20191231", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "domainItemType" }, "country_DE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "GERMANY", "terseLabel": "GERMANY" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r711" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r710" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r713" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Entity Number of Employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r712" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r708" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r709" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "naics_ZZ541714": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]", "terseLabel": "541714 Research and Development in Biotechnology (except Nanobiotechnology) [Member]" } } }, "localname": "ZZ541714", "nsuri": "http://xbrl.sec.gov/naics/2017-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "domainItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continents of North and South America.", "label": "Americas [Member]", "terseLabel": "Other (primarily Canada and Latin America) [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region of Asia Pacific.", "label": "Asia Pacific [Member]", "terseLabel": "Asia [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r184", "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r199", "r343", "r347", "r696" ], "lang": { "en-US": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r196", "r343", "r345", "r693", "r694" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r714" ], "lang": { "en-US": { "role": { "documentation": "Information reported for future period.", "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r151", "r717" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r198", "r343", "r346", "r695", "r703", "r706", "r715", "r716" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r304", "r622" ], "lang": { "en-US": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]", "verboseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r151", "r717" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r494", "r495" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16 [Member]" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r34", "r201", "r202", "r344" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r25", "r645", "r677" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r14", "r16", "r52" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r74", "r81", "r82", "r389", "r533" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Other Postretirement Benefit Plan [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r46", "r282" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r71", "r72", "r73", "r81", "r82" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Net Unrealized Investment Gain (Loss) [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r77", "r80", "r81" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r76", "r81", "r82", "r533" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r70", "r81", "r82", "r533" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquisitionRelatedCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).", "label": "Acquisition-related Costs [Member]", "terseLabel": "Acquisition-related Costs [Member]" } } }, "localname": "AcquisitionRelatedCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortizationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Amortization [Abstract]" } } }, "localname": "AdjustmentForAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "terseLabel": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForErrorCorrectionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the types error corrections made to the financial statements.", "label": "Adjustments for Error Correction [Domain]", "terseLabel": "Adjustments for Error Correction [Domain]" } } }, "localname": "AdjustmentsForErrorCorrectionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r410", "r412", "r448", "r449" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other Segments [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r412", "r442", "r447" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r40", "r207", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r124", "r266", "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the computation of diluted EPS" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r225", "r380" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r124", "r280" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment losses on goodwill and long-lived assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r188", "r643", "r676" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r68" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r557" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial Assets Carried at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r215", "r240" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Total Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value", "terseLabel": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r223" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth fiscal year through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r219", "r223", "r666" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value", "terseLabel": "Mature in more than five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r222" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r219", "r222", "r665" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Mature in one to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r221" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r219", "r221", "r664" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Mature in less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r211", "r216", "r240" ], "calculation": { "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAmortizedCostAndFairValueOfDebtSecuritiesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale investments" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r413", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r543", "r546" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r662" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time Deposits [Member]" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and Building Improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r12", "r281" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and leasehold improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r506", "r507" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r518", "r519", "r521" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A18SubsequentEventDetails", "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r516", "r518", "r519", "r522" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Business Combination, Consideration Transferred, Liabilities Incurred" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r123", "r525" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Changes in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r526" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r524" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r524" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r517", "r520", "r523" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r527" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r460", "r509" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r509" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r509" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r508", "r509" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r508", "r509" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized": { "auth_ref": [ "r505" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The revenues and gains recognized recorded for each transaction with the acquiree that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.", "label": "Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized", "terseLabel": "Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r593" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Capital Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Five Years", "terseLabel": "Capital Leases, Future Minimum Payments Due in Five Years" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Four Years", "terseLabel": "Capital Leases, Future Minimum Payments Due in Four Years" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Three Years", "terseLabel": "Capital Leases, Future Minimum Payments Due in Three Years" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Two Years", "terseLabel": "Capital Leases, Future Minimum Payments Due in Two Years" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due Thereafter", "terseLabel": "Capital Leases, Future Minimum Payments Due Thereafter" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r575", "r576" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying (Reported) Amount, Fair Value Disclosure [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r42", "r126" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18", "r127", "r135" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r118", "r126", "r132" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodStartLabel": "Beginning Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r118", "r580" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Cash Flow, Supplemental Disclosures [Text Block]" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r669" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Domestic Time Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r336", "r337", "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r303", "r658", "r685" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingent liabilities" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r302", "r307" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingent Liabilities" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Common Class A [Member]", "verboseLabel": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Common Class B [Member]", "verboseLabel": "Common Class B [Member]" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r33", "r328" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r33" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Common Stock, Voting Rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r85", "r87", "r88" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Bio-Rad" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r267", "r271", "r514" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r174", "r671" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r135", "r531", "r534", "r535" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Axis]", "terseLabel": "Contract with Customer, Duration [Axis]" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract with Customer, Duration [Domain]", "terseLabel": "Contract with Customer, Duration [Domain]" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r380", "r407", "r697" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r98" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]", "terseLabel": "Cost of Goods and Service Benchmark [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r139", "r490", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "U.S. Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r145", "r492" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "International" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r490", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current Income Tax Expense (Benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r139", "r490", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r655", "r689" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "totalLabel": "Debt and Lease Obligation" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndEquitySecuritiesGainLoss": { "auth_ref": [ "r94", "r95" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities.", "label": "Debt and Equity Securities, Gain (Loss)", "negatedLabel": "Gains on disposition of securities" } } }, "localname": "DebtAndEquitySecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Debt, Current" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r23", "r25", "r26", "r644", "r648", "r673" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r585", "r587" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt sold" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r54", "r322", "r585" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r55", "r141", "r329", "r332", "r333", "r334", "r584", "r585", "r587", "r670" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r320", "r586" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r227", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Gross unrealized losses for investments in a loss position 12 months or more" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r227", "r242" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Gross unrealized losses for investments in a loss position less than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Debt Securities, Available-for-sale [Table Text Block]" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesMember": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "label": "Debt Securities [Member]", "terseLabel": "Debt Securities [Member]" } } }, "localname": "DebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "terseLabel": "Contribution expense" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPeriodExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r491", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "U.S. Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r491", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "verboseLabel": "International" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r483" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred Income Tax Assets, Net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r139", "r491", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred tax benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r29", "r30", "r479", "r646", "r672" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r41" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenuePeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred revenue.", "label": "Deferred Revenue, Period Increase (Decrease)", "terseLabel": "Deferred Revenue, Period Increase (Decrease)" } } }, "localname": "DeferredRevenuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueRevenueRecognized1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.", "label": "Deferred Revenue, Revenue Recognized", "terseLabel": "Deferred Revenue, Revenue Recognized" } } }, "localname": "DeferredRevenueRevenueRecognized1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r491", "r497" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetDomain": { "auth_ref": [ "r482" ], "lang": { "en-US": { "role": { "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.", "label": "Deferred Tax Asset [Domain]", "terseLabel": "Deferred Tax Asset [Domain]" } } }, "localname": "DeferredTaxAssetDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r480" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross", "verboseLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent": { "auth_ref": [ "r460", "r462", "r483" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Assets, Net, Noncurrent", "terseLabel": "Deferred Tax Assets, Net, Noncurrent" } } }, "localname": "DeferredTaxAssetsLiabilitiesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r481" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "verboseLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r460", "r461", "r462", "r463", "r480" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Long-term deferred tax assets" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r454", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Deferred Tax Assets, Other", "verboseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r485", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Tax credit and net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r485", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": { "auth_ref": [ "r453", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other", "terseLabel": "Other post-employment benefits, vacation and other reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": { "auth_ref": [ "r453", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies", "terseLabel": "Legal reserves" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r453", "r488", "r489" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Bad debt, inventory and warranty accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r482" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedTerseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r462", "r483" ], "calculation": { "http://www.bio-rad.com/role/A6IncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r454", "r488", "r489" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "terseLabel": "Deferred Tax Liabilities, Leasing Arrangements" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r460", "r462", "r463" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": { "auth_ref": [ "r454", "r488", "r489" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment.", "label": "Deferred Tax Liabilities, Other Finite-Lived Assets", "terseLabel": "Investments and intangible assets" } } }, "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r454", "r488", "r489" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r488" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "verboseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r502" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.", "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Deferred Tax Liability Not Recognized, Cumulative Amount of Temporary Difference" } } }, "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r372", "r407" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r386", "r403", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Defined Benefit Plan, Amortization of Gain (Loss)" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r387", "r404", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r392" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r393" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "terseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r368", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Benefits Paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r380", "r381", "r394", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r374", "r380", "r381", "r406", "r407" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r385", "r402", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r371", "r380", "r381", "r407" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "terseLabel": "Defined Benefit Plan, Plan Assets, Amount" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r359", "r378" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r364", "r384", "r401", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Defined Benefit Plan, Interest Cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r382", "r399", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r376", "r408" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Benefits Paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant" } } }, "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r373" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r388", "r405" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r362", "r383", "r400", "r407" ], "calculation": { "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Defined Benefit Plan, Service Cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r363" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "terseLabel": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedTerseLabel": "Defined Benefit Plan, Plan Assets, Payment for Settlement" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": { "auth_ref": [ "r363" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.", "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits" } } }, "localname": "DefinedBenefitPlanSpecialTerminationBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosuresTableTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan Disclosures [Table Text Block]", "terseLabel": "Defined Contribution Plan Disclosures [Table Text Block]" } } }, "localname": "DefinedContributionPlanDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r124" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Reduction in the carrying amount of right-of-use assets" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r124", "r186" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r544", "r545", "r549", "r551" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r538", "r540" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r146", "r537", "r539", "r540", "r541", "r542", "r547", "r549", "r552", "r554", "r556" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r135", "r147", "r537", "r539", "r541", "r542", "r553" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Forward Foreign Exchange Contracts" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r515" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r93", "r154", "r162", "r164", "r165", "r166", "r170", "r660", "r691" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic earnings per share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r93", "r154", "r162", "r164", "r165", "r166", "r170", "r660", "r691" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r135", "r167", "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r580" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r144", "r465", "r466" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for qualified production activity.", "label": "Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent", "negatedTerseLabel": "Domestic manufacturing deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Impact of foreign operations" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent", "terseLabel": "Nondeductible executive compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent", "negatedTerseLabel": "Stock-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent", "terseLabel": "Other reconciling items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "terseLabel": "Prior period adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "negatedTerseLabel": "Foreign dividends, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "Research tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.", "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent", "negatedTerseLabel": "Nontaxable subsidies" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r465", "r466", "r496" ], "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements and changes to unrecognized tax benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and employee benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r443" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation cost from stock options", "verboseLabel": "Total unrecognized compensation cost from restricted stock" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average fair value of options granted, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r442" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Share-based Payment Arrangement, Expense, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r445" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock [Member]", "verboseLabel": "Employee Stock [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesByIndustryAxis": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Axis]", "terseLabel": "Industry Sector [Axis]" } } }, "localname": "EquitySecuritiesByIndustryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesByInvestmentObjectiveAxis": { "auth_ref": [ "r379", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by investment objective.", "label": "Investment Objective [Axis]", "terseLabel": "Investment Objective [Axis]" } } }, "localname": "EquitySecuritiesByInvestmentObjectiveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r571" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Equity Securities, FV-NI" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Equity Securities, FV-NI, Unrealized Gain" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesIndustryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.", "label": "Industry Sector [Domain]", "terseLabel": "Industry Sector [Domain]" } } }, "localname": "EquitySecuritiesIndustryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesInvestmentObjectiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Objective of investment.", "label": "Investment Objective [Domain]", "terseLabel": "Investment Objective [Domain]" } } }, "localname": "EquitySecuritiesInvestmentObjectiveMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r19", "r24", "r230", "r654", "r674", "r702" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Marketable Equity Securities [Member]" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": { "auth_ref": [ "r156", "r157", "r158" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error correction.", "label": "Adjustments for Error Corrections [Axis]", "terseLabel": "Adjustments for Error Corrections [Axis]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r574" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimate of Fair Value, Fair Value Disclosure [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility Closing [Member]" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r557", "r558", "r559", "r567" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r560" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r557", "r575", "r576" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r557", "r575" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Estimated fair value of financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r380", "r381", "r407", "r558", "r624" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r557", "r568" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r557", "r558", "r561", "r562", "r569" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r380", "r381", "r407", "r558", "r625" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r380", "r381", "r407", "r558", "r626" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r380", "r381", "r407", "r558", "r627" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r563", "r567" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r564" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedLabel": "Net (decrease) increase in estimated fair value of contingent consideration included in selling, general and administrative expense" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r565" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r563" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "verboseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r566", "r569" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsContingentConsiderationDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r135", "r570", "r573" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r597", "r604", "r613" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "bio_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance Lease, Interest Expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r599", "r607" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Finance Lease, Interest Payment on Liability" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r596", "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "totalLabel": "Finance Lease, Liability" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r596" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current maturities of long-term debt and notes payable" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r596" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance Lease, Liability, Noncurrent" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Finance Lease, Liability, Payment, Due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Finance Lease, Liability, Payments, Due after Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "Finance Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "Finance Lease, Liability, Payments, Due Year Five" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "Finance Lease, Liability, Payments, Due Year Four" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "Finance Lease, Liability, Payments, Due Year Three" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "Finance Lease, Liability, Payments, Due Year Two" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Finance Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r598", "r607" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Finance Lease, Principal Payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r597", "r604", "r613" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "bio_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance Lease, Right-of-Use Asset, Amortization" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r610", "r613" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r609", "r613" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r234", "r235", "r236", "r237", "r238", "r241", "r243", "r244", "r245" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Schedule of Available-for-sale Securities, Major Types of Debt and Equity Securities [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Future Amortization Expense, Year One" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Future Amortization Expense, Year Five" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Future Amortization Expense, Year Four" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Future Amortization Expense, Year Three" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Future Amortization Expense, Year Two" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r267", "r269", "r272", "r276", "r629" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Acquired Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r272", "r629" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r267", "r271" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r272" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "verboseLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Finite-Lived Intangible Assets, Remaining Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Asset" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Forward foreign exchange contracts, Liability" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r550" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency Gain (Loss) [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r577", "r578", "r579" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange losses, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r135", "r579", "r582" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignGovernmentDebtMember": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.", "label": "Foreign Government Debt [Member]", "terseLabel": "Foreign Government Debt [Member]" } } }, "localname": "ForeignGovernmentDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r380", "r697" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign Government Obligations [Member]" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r124" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of land" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r544", "r548" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsForeignExchangeForwardContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r124" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 }, "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedTerseLabel": "Gain on divestiture of product line", "terseLabel": "Gain on divestiture of product line" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r124" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Losses on dispositions of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r252", "r254" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, net period end", "periodStartLabel": "Goodwill, net period start", "terseLabel": "Goodwill, net", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets Disclosure" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r135", "r262" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r259" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency fluctuations" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r255", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "periodEndLabel": "Goodwill period end", "periodStartLabel": "Goodwill period start" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r255", "r261" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedPeriodEndLabel": "Accumulated impairment loss period end", "negatedPeriodStartLabel": "Accumulated impairment loss period start" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r124", "r253", "r258", "r263" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r260", "r504" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "negatedTerseLabel": "Goodwill, Purchase Accounting Adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r257" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill, Written off Related to Sale of Business Unit" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r97" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r124", "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r213" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other than Temporary Impairment Losses on Investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r135", "r279", "r286" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "U.S.", "verboseLabel": "U.S." } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r142" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r469" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r470", "r476", "r478", "r493" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r139", "r187", "r499" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTerseLabel": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r89", "r135", "r458", "r459", "r477", "r478", "r484", "r501", "r705" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r128" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Income tax payments, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.", "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities", "terseLabel": "Increase (decrease) in accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Decrease (increase) in accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Decrease in Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Increase (decrease) in deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Decrease (increase) in inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Decrease (increase) in Other Current Assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "(Increase) decrease in other long term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedTerseLabel": "Increase (decrease) in Other Long Term Liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "terseLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r163", "r168" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of potentially dilutive stock options and restricted stock awards" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r268", "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r268", "r275" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Intangible Assets, Gross (Excluding Goodwill)" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r265", "r270" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible Assets, Net (Excluding Goodwill)", "verboseLabel": "Purchased intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r91", "r185", "r583", "r586", "r661" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r128" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "negatedTerseLabel": "Interest paid, net" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r62" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r65", "r247" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r17", "r66", "r135", "r171", "r248", "r249" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r64" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r63" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r100" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "negatedTerseLabel": "Interest and investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r687" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summary of amortized cost and estimated fair value of debt securities by contractual maturity date" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Land": { "auth_ref": [ "r11", "r45" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land and improvements" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r611" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r594" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases of Lessee Disclosure [Text Block]" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r603" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r601" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r602" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r612" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r614", "r615", "r616", "r617" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Lessor, Leases" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of Credit Outstanding, Amount", "verboseLabel": "Letters of Credit Outstanding Amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r51" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r39", "r650", "r683" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r557" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r513" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements [Member]" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Line of Credit Facility, Interest Rate at Period End" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit [Member]" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A18SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r23", "r644" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation.", "label": "Litigation Settlement Interest", "terseLabel": "Litigation Settlement Interest" } } }, "localname": "LitigationSettlementInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r26", "r321", "r648", "r679" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r26" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.", "label": "Long-term Debt and Lease Obligation", "terseLabel": "Long-term Debt and Lease Obligation", "verboseLabel": "Long-term debt, net of current maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-term Debt and Lease Obligation, Including Current Maturities", "terseLabel": "Long-term Debt and Lease Obligation, Including Current Maturities" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Total long-term debt, excluding leases and current maturities" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal after Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Five" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Four" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Three" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r149", "r318" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "Long-term Debt, Maturities, Repayments of Principal in Year Two" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Notes Payable and Long-term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r43" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Other investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A18SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r319" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A18SubsequentEventDetails", "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in loss contingency liability.", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "negatedTerseLabel": "Loss Contingency Accrual, Period Increase (Decrease)" } } }, "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r303", "r305", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r303", "r305", "r306" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss Contingency, Damages Sought, Value" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r12", "r281" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "verboseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r668" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Available-for-sale Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security, excluding other-than-temporary impairment (OTTI).", "label": "Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss", "negatedTerseLabel": "Changes in fair market value of equity securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r192", "r193" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maturities of Long-term Debt [Abstract]" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Obligations [Member]" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfErrorDomain": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of the error being corrected including when and how the error arose and the fact that the error had previously been considered immaterial.", "label": "Nature of Error [Domain]", "terseLabel": "Nature of Error [Domain]" } } }, "localname": "NatureOfErrorDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r118", "r122", "r125" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r83", "r86", "r92", "r125", "r168", "r659", "r690" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss) Attributable to Parent", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r153", "r155" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of accounts receivable that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Accounts Receivable Acquired", "terseLabel": "Noncash or Part Noncash Acquisition, Accounts Receivable Acquired" } } }, "localname": "NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Noncash purchased property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionInvestmentsAcquired1": { "auth_ref": [ "r129", "r130", "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of investments that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Investments Acquired", "terseLabel": "Noncash Purchased Marketable Securities and Investments" } } }, "localname": "NoncashOrPartNoncashAcquisitionInvestmentsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r511" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r197" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Other assets, property, plant and equipment, net and Operating lease right-of-use assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Notes and Loans Payable, Current", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (Loss)", "totalLabel": "Income from operations", "verboseLabel": "Segment profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r605", "r613" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r596" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r596" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r596" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r600", "r607" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r600", "r607" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "terseLabel": "Payments for operating lease liabilities" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r595" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r610", "r613" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r609", "r613" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "Operating Leases, Future Minimum Payments Due, Next Twelve Months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": { "auth_ref": [ "r591" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements.", "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals", "terseLabel": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Five Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Four Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "Operating leases, due in three years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "Operating Leases, Future Minimum Payments, Due in Two Years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r588", "r590" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Operating Leases, Future Minimum Payments, Due Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r589" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "terseLabel": "Operating Leases, Rent Expense, Net" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r485" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsExpirationDate": { "auth_ref": [ "r485" ], "lang": { "en-US": { "role": { "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.", "label": "Operating Loss Carryforwards, Expiration Date", "terseLabel": "Operating Loss Carryforwards, Expiration Dates" } } }, "localname": "OperatingLossCarryforwardsExpirationDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r455", "r482", "r486" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Operating Loss Carryforward, Valuation Allowance" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r184", "r194" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r152", "r176", "r536" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r67" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "terseLabel": "Unrecorded Unconditional Purchase Obligation" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r75", "r77", "r529", "r532" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedTerseLabel": "Other post-employment benefits adjustments, net of tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location in other comprehensive income.", "label": "Other Comprehensive Income Location [Axis]", "terseLabel": "Other Comprehensive Income Location [Axis]" } } }, "localname": "OtherComprehensiveIncomeLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in other comprehensive income.", "label": "Other Comprehensive Income Location [Domain]", "terseLabel": "Other Comprehensive Income Location [Domain]" } } }, "localname": "OtherComprehensiveIncomeLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r81", "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r69", "r581" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r84", "r87", "r90", "r328" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r84", "r87", "r529", "r530", "r532" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r78", "r498", "r500" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Tax" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r71", "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Net unrealized holding gains on available-for-sale investments, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r543", "r555" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets [Member]" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r354", "r451" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income and Other Expense Disclosure" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r43", "r686" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other Investments", "verboseLabel": "Other assets" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other Investments [Member]" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r52" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebt": { "auth_ref": [ "r26", "r648", "r679" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt classified as other.", "label": "Other Long-term Debt", "terseLabel": "Other Long-term Debt" } } }, "localname": "OtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r23", "r25" ], "calculation": { "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Current", "terseLabel": "Other Long-term Debt, Current" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermInvestmentsMember": { "auth_ref": [ "r697" ], "lang": { "en-US": { "role": { "documentation": "Long-term investments classified as other.", "label": "Other Long-term Investments [Member]", "terseLabel": "Other Long-term Investments [Member]" } } }, "localname": "OtherLongTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "terseLabel": "Other Expense" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r101" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net", "verboseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense) [Member]" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionNameDomain": { "auth_ref": [ "r129", "r130", "r131" ], "lang": { "en-US": { "role": { "documentation": "The name of other significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed to enable users of the financial information to fully understand the period cash flows of the Entity in relation to the statements of financial position, income statement, and statement of changes in shareholders' equity. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transaction, Name [Domain]", "terseLabel": "Other Significant Noncash Transaction, Name [Domain]" } } }, "localname": "OtherSignificantNoncashTransactionNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherSignificantNoncashTransactionsByUniqueDescriptionAxis": { "auth_ref": [ "r129", "r130", "r131" ], "lang": { "en-US": { "role": { "documentation": "Information by other significant noncash transactions.", "label": "Other Significant Noncash Transaction [Axis]", "terseLabel": "Other Significant Noncash Transaction [Axis]" } } }, "localname": "OtherSignificantNoncashTransactionsByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Significant Noncash Transactions [Line Items]", "terseLabel": "Other Significant Noncash Transactions [Line Items]" } } }, "localname": "OtherSignificantNoncashTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherSignificantNoncashTransactionsTable": { "auth_ref": [ "r129", "r130", "r131" ], "lang": { "en-US": { "role": { "documentation": "This table may contain information related to other significant noncash investing and financing activities that occurred during the accounting period and are not otherwise listed in the existing taxonomy. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.", "label": "Other Significant Noncash Transactions [Table]", "terseLabel": "Other Significant Noncash Transactions [Table]" } } }, "localname": "OtherSignificantNoncashTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r143", "r464", "r492" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other Tax Expense (Benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.", "label": "Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net", "terseLabel": "Other-than-temporary impairment losses on investments" } } }, "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Bio Rad [Member]", "verboseLabel": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payments of contingent consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [ "r148" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedTerseLabel": "Payments for (proceeds from) acquisitions and long-term investment" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromProductiveAssets": { "auth_ref": [ "r148" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.", "label": "Payments for (Proceeds from) Productive Assets", "terseLabel": "Recovery of (payments for) purchases of intangible assets" } } }, "localname": "PaymentsForProceedsFromProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payments for purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r117", "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Payments for Restructuring" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r113" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payments for credit agreement renewal fees" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r111" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Tax payments from net share settlement" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r107" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Payments for purchases of marketable securities and investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r108" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures", "terseLabel": "Payments to Acquire Property, Plant, and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRestrictedInvestments": { "auth_ref": [ "r109" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.", "label": "Payments to Acquire Restricted Investments", "negatedTerseLabel": "Payments for purchases of restricted investment" } } }, "localname": "PaymentsToAcquireRestrictedInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r115", "r116", "r121" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedTerseLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r25", "r359", "r360", "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedTerseLabel": "Liability, Defined Benefit Plan, Current" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r359", "r378", "r647", "r678" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.", "label": "Liability, Defined Benefit Plan", "negatedTerseLabel": "Liability, Defined Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r27", "r359", "r360", "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedTerseLabel": "Liability, Defined Benefit Plan, Noncurrent" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceGuaranteeMember": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "An agreement (contract) that requires the guarantor to make payments to a guaranteed party based on another entity's failure to perform under an obligating agreement. This may include the issuance of a performance standby letter of credit which requires the guarantor to make payments if a specified party fails to perform under a nonfinancial contractual obligation.", "label": "Performance Guarantee [Member]", "terseLabel": "Performance Guarantee [Member]" } } }, "localname": "PerformanceGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r413", "r444" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r572" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": { "auth_ref": [ "r357", "r358", "r657", "r688" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.", "label": "Postemployment Benefits Liability", "terseLabel": "Post-Employment Benefits Liability" } } }, "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r8", "r251" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r6", "r8", "r250", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "negatedTerseLabel": "Prepaid Taxes", "terseLabel": "Prepaid Taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r119" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Proceeds from Customers", "terseLabel": "Cash received from customers" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "verboseLabel": "Issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r110" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from Issuances of common stock for shared-based compensation" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r103", "r104", "r212" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of marketable securities and investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherOperatingActivities": { "auth_ref": [ "r120" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from operating activities classified as other.", "label": "Proceeds from Other Operating Activities", "terseLabel": "Investment proceeds and miscellaneous receipts, net" } } }, "localname": "ProceedsFromOtherOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r148" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "terseLabel": "Net (payments) borrowings on line-of-credit arrangements and notes payable" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepurchaseOfEquity": { "auth_ref": [ "r148" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow resulting from the entity's share transaction.", "label": "Proceeds from (Repurchase of) Equity", "terseLabel": "Proceeds from reissuances of treasury stock for shared-based compensation, net" } } }, "localname": "ProceedsFromRepurchaseOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities": { "auth_ref": [ "r105", "r212" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.", "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sales of marketable securities and investments" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from divestiture of a product line" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r106" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from dispositions of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r110", "r445" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Cash Received from Exercise of Stock Options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r313", "r314", "r656" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Warranty accrual, end of period", "periodStartLabel": "Warranty accrual, beginning of period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r310" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Actual warranty costs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for warranty" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesWarrantyRollforwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r46", "r283" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment by Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r45", "r281" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property, plant and equipment:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r20", "r21", "r283", "r684" ], "calculation": { "http://www.bio-rad.com/role/A16LeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r44", "r135", "r283" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r20", "r281" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "auth_ref": [ "r592" ], "lang": { "en-US": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease.", "label": "Property Subject to or Available for Operating Lease [Domain]", "terseLabel": "Property Subject to or Available for Operating Lease [Domain]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Purchase Commitment, Excluding Long-term Commitment [Line Items]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Line Items]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": { "auth_ref": [ "r28", "r649", "r680" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.", "label": "Purchase Commitment, Excluding Long-term Commitment [Table]", "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]" } } }, "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Information by type of error in the financial statements.", "label": "Nature of Error [Axis]", "terseLabel": "Nature of Error [Axis]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsByNatureOfErrorAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Quantifying Misstatement in Current Year Financial Statements [Line Items]", "terseLabel": "Quantifying Misstatement in Current Year Financial Statements [Line Items]" } } }, "localname": "QuantifyingMisstatementInCurrentYearFinancialStatementsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialDataAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Data [Abstract]" } } }, "localname": "QuarterlyFinancialDataAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Data [Text Block]" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialData" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealizedInvestmentGainsLosses": { "auth_ref": [ "r692" ], "calculation": { "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net realized gains or losses on investments during the period, not including gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity.", "label": "Realized Investment Gains (Losses)", "negatedTerseLabel": "Net realized gains on investments", "terseLabel": "Realized Investment Gains (Losses)" } } }, "localname": "RealizedInvestmentGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r81", "r82", "r90" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Member]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": { "auth_ref": [ "r191", "r193" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r191", "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Assets from Segment to Consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r190", "r193" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r190", "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profit to consolidated income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Recorded Unconditional Purchase Obligation" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueAfterFifthYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due after Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due after Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueAfterFifthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFifthYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fifth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fifth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFifthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInFourthYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Fourth Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Fourth Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInFourthYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInSecondYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Second Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Second Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInThirdYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Third Year", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Third Year" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInThirdYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueWithinOneYear": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months", "terseLabel": "Recorded Unconditional Purchase Obligation Due in Next Twelve Months" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r620" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r394", "r618", "r619" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r394", "r618", "r619", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r112" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r452", "r707" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r135", "r452" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r132", "r642", "r681" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r18", "r126", "r132", "r642", "r681" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted Cash and Cash Equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r18", "r132" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted Cash included in Other current assets" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r10", "r22", "r132", "r704" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted Cash included in Other assets" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsAtFairValue": { "auth_ref": [ "r699", "r700" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate value of all restricted investments.", "label": "Restricted Investments, at Fair Value", "terseLabel": "Restricted Investments, at Fair Value" } } }, "localname": "RestrictedInvestmentsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedInvestmentsCurrent": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.", "label": "Restricted Investments, Current", "terseLabel": "Restricted investments" } } }, "localname": "RestrictedInvestmentsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Treasury Class-A [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring and Related Activities Disclosure [Text Block]" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r124", "r287", "r292", "r297" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "localname": "RestructuringCostsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r288", "r294" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring Reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r287", "r293" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "terseLabel": "Restructuring Reserve, Accrual Adjustment" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAdjustment": { "auth_ref": [ "r288", "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.", "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Restructuring Reserve, Foreign Currency Translation (Gain) Loss" } } }, "localname": "RestructuringReserveTranslationAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "auth_ref": [ "r288", "r293" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).", "label": "Restructuring Reserve, Translation and Other Adjustment", "terseLabel": "Restructuring Reserve, Translation and Other Adjustment" } } }, "localname": "RestructuringReserveTranslationAndOtherAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r36", "r335", "r682" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanFundingStatusAxis": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Information by status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Axis]", "terseLabel": "Retirement Plan Funding Status [Axis]" } } }, "localname": "RetirementPlanFundingStatusAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanFundingStatusDomain": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Status of funding for defined benefit plan designed to provide retirement benefits.", "label": "Retirement Plan Funding Status [Domain]", "terseLabel": "Retirement Plan Funding Status [Domain]" } } }, "localname": "RetirementPlanFundingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanNameAxis": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Axis]", "terseLabel": "Retirement Plan Name [Axis]" } } }, "localname": "RetirementPlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanNameDomain": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.", "label": "Retirement Plan Name [Domain]", "terseLabel": "Retirement Plan Name [Domain]" } } }, "localname": "RetirementPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r396", "r398" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r396", "r398" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r355", "r356", "r395", "r396", "r409" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r355", "r356", "r395", "r396", "r409" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r342", "r343" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r342", "r343" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r136", "r353" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionDeferredRevenue": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.", "label": "Revenue Recognition, Deferred Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition, Deferred Revenue" } } }, "localname": "RevenueRecognitionDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionLeases": { "auth_ref": [ "r135", "r137" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor.", "label": "Revenue Recognition, Leases [Policy Text Block]", "terseLabel": "Revenue Recognition, Leases" } } }, "localname": "RevenueRecognitionLeases", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r608", "r613" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r608", "r613" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major-Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Defined Benefit Plan, Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r220", "r224", "r226", "r227", "r228", "r229", "r663", "r667" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r506", "r507" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A2AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r492" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for income taxes [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r55", "r141", "r329", "r332", "r333", "r334", "r584", "r585", "r587", "r670" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Principal components of long-term debt [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r483" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant components of deferred tax assets and liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r395", "r396", "r397", "r398", "r407" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesPensionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r146", "r537", "r539", "r540", "r541", "r542", "r547", "r549", "r552", "r554" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Derivative Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r557", "r558" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r262", "r264" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r262", "r264" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Changes to goodwill by segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4IntangibleAssetsGoodwillAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "U.S. and international components of income before taxes [Table Text Block]" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs [Table Text Block]" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesCommitmentsContingentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income (expense), net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r46", "r283" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Disclose the nature of each individual error being corrected in the correcting adjustment. This disclosure would also generally include when and how each error being corrected arose and assert that the errors were immaterial to the prior amounts reported.", "label": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]", "terseLabel": "Schedule of Quantifying Prior Year Misstatement Corrected in Current Year Financial Statements [Table]" } } }, "localname": "ScheduleOfQuantifyingPriorYearMisstatementCorrectedInCurrentYearFinancialStatementsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Data [Table Text Block]" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r290", "r291", "r295" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r290", "r291", "r295" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Restructuring and Related Costs [Table Text Block]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r96", "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Net sales and assets to external customers by geographic area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r183", "r188", "r189", "r192", "r262" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r183", "r188", "r189", "r192", "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Information regarding industry segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r413", "r444" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Employee Stock Purchase Plan, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Stock Options Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Resticted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r58", "r140", "r324", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r31", "r32", "r33", "r138", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Stock by Class [Table Text Block]" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r336", "r337", "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Class of Treasury Stock [Table Text Block]" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).", "label": "Schedule of Unrealized Loss on Investments [Table Text Block]", "terseLabel": "Summary of investments with gross unrealized losses and the associated fair value" } } }, "localname": "ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAssetReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Asset Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingAssetReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentAssetReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentInformationByGeographicalLocationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "localname": "SegmentReportingInformationProfitLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentsGeographicalAreasAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segments, Geographical Areas [Abstract]" } } }, "localname": "SegmentsGeographicalAreasAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r99", "r246" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "negatedTerseLabel": "Selling, general and administrative expense", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r123" ], "calculation": { "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A11SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Purchase Price Discount from Market Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Resticted Stock Units Cancelled/forfeited - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted Stock Units Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r428" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value - Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value", "terseLabel": "Resticted Stock Units Outstanding Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r427" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Nonvested shares - Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Restricted Stock Units - Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted Stock Units Vested - Weighted-Average Grant-Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r439" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk Free Interest Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r439" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Employee Contribution Rate - Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Number Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price - Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options, Exercises in Period, Total Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Options - Shares Forfeitures/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r426" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options Forfeitured/expired - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Restricted Stock Units - Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options - Shares Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r431" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Stock Options Activity" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value (in millions) - Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r421", "r444" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period", "periodStartLabel": "Outstanding beginning of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options - Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r433" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options Vested and Expected to Vest - Aggregate Intrinsic Value (in millions)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options - Shares Vested and Expected to Vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "auth_ref": [ "r411", "r444" ], "lang": { "en-US": { "role": { "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Options Granted Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r411", "r417" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails", "http://www.bio-rad.com/role/A9ShareBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options Exercised - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options Granted - Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r135", "r413", "r418" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation Plans" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r437", "r446" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options Exercisable Aggregate Intrinsic Value (in millions)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (in years) - Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options Vested and Expected to Vest - Weighted Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares, Issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShippingAndHandlingCostPolicyTextBlock": { "auth_ref": [ "r134", "r135" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.", "label": "Shipping and Handling Cost, Policy [Policy Text Block]", "terseLabel": "Shipping and Handling" } } }, "localname": "ShippingAndHandlingCostPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r24", "r651", "r652", "r654", "r675" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r701" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShorttermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.", "label": "Short-term Debt, Fair Value", "terseLabel": "Short-term Debt, Fair Value" } } }, "localname": "ShorttermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r468" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r135", "r312" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r309", "r316", "r528", "r698" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters of Credit [Member]", "terseLabel": "Standby Letters of Credit [Member]" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r188", "r262", "r285", "r289", "r298", "r693" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A14SegmentReportingDetails", "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherDetails", "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r31", "r32", "r33", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r61", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.bio-rad.com/role/A8AccumulatedOtherComprehensiveIncomeReclassificationOutOfAccumulatedOtherComprehensiveIncomeTables", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome", "http://www.bio-rad.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A10OtherIncomeAndExpensesDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsFairValueAndGrossUnrealizedLossesWithUnrealizedLossesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals", "http://www.bio-rad.com/role/ConsolidatedStatementsOfCashFlows", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.bio-rad.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r60", "r328", "r329", "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "negatedTerseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r32", "r33", "r328", "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r32", "r33", "r328", "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r32", "r33", "r328", "r335", "r424" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Options - Shares Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A9ShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": { "auth_ref": [ "r33", "r328", "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Shares, Treasury Stock Reissued", "negatedTerseLabel": "Stock Issued During Period, Shares, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": { "auth_ref": [ "r32", "r33", "r328", "r335", "r336" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.", "label": "Stock Issued During Period, Value, Treasury Stock Reissued", "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued" } } }, "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock Repurchase Program, Authorized Amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r33", "r37", "r38", "r209" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheets", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r341" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r606", "r613" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A16LeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A18SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A18SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r621" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A18SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r621" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A18SubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r621" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A13LegalProceedingsLegalProceedingsDetails", "http://www.bio-rad.com/role/A18SubsequentEventDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r623" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A18SubsequentEventNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r470", "r493" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Summary of income tax years currently under audit or open to examinations [Table Text Block]" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": { "auth_ref": [ "r468" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.", "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]", "terseLabel": "Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]" } } }, "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r485" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of the limitation related to use of the tax credit carryforward.", "label": "Tax Credit Carryforward, Limitations on Use", "terseLabel": "Tax Credit Carryforward, Limitations on Use" } } }, "localname": "TaxCreditCarryforwardLimitationsOnUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r487" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect", "terseLabel": "Tax Cuts and Jobs Act, Reclassification from AOCI to Retained Earnings, Tax Effect" } } }, "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing of Transfer of Good or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service [Axis]" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing of Transfer of Good or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service [Domain]" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r203", "r204", "r205", "r206", "r208", "r210" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A4GoodwillAndOtherPurchasedIntangibleAssetsIntangibleAssetsGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r628" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury Stock Acquired, Average Cost Per Share" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r59", "r336" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r59", "r336" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails", "http://www.bio-rad.com/role/ConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r33", "r328", "r335" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury Stock, Shares, Acquired" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityDetails", "http://www.bio-rad.com/role/A7StockholdersEquityTreasurySharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "Treasury Stock [Text Block]" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A7StockholdersEquityStockholdersEquitySharesDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r59", "r336", "r339" ], "calculation": { "http://www.bio-rad.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury Stock, Value" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r328", "r335", "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesPropertyPlantAndEquipmentDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesRevenueRecognitionDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A15RestructuringCostsDetails", "http://www.bio-rad.com/role/A15RestructuringCostsTables" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r380", "r653", "r697" ], "lang": { "en-US": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "US Government Sponsored Agencies [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A3FairValueMeasurementsAvailableForSaleInvestmentsDetails", "http://www.bio-rad.com/role/A3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainOnSecurities": { "auth_ref": [], "calculation": { "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease), resulting in a gain, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Gain on Securities", "negatedTerseLabel": "Unrealized Gain on Securities", "terseLabel": "Unrealized Gain on Securities" } } }, "localname": "UnrealizedGainOnSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A14SegmentInformationSegmentProfitReconciliationDetails", "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails", "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesDetailsDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedLossOnSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease), resulting in a loss, in the difference between the fair value and the carrying value, or in the comparative fair values, of securities held at each balance sheet date, that was included in earnings for the period.", "label": "Unrealized Loss on Securities", "terseLabel": "Unrealized Loss on Securities" } } }, "localname": "UnrealizedLossOnSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A17QuarterlyFinancialDataDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r456", "r471" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits period end", "periodStartLabel": "Unrecognized tax benefits period start" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r471" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation", "negatedTerseLabel": "Currency translation" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r472" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedTerseLabel": "Reductions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r474" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedTerseLabel": "Settlements" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r467" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r467" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Acquisitions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r473" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions to tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation.", "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation", "terseLabel": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions related to prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedTerseLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due in Next Twelve Months", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due in Twelve Months" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Four Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Four Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Two Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Two Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due within Three Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due within Three Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Unrecorded Unconditional Purchase Obligation" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears": { "auth_ref": [ "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the fixed and determinable portion of the unrecorded unconditional purchase obligation maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Unrecorded Unconditional Purchase Obligation, Due after Five Years", "terseLabel": "Unrecorded Unconditional Purchase Obligation, Due after Five Years" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationDueAfterFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A12CommitmentsContingentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebt": { "auth_ref": [ "r26", "r648", "r679" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Unsecured Debt", "terseLabel": "Unsecured Debt" } } }, "localname": "UnsecuredDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A5NotesPayableAndLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r457" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A6IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "auth_ref": [ "r150" ], "lang": { "en-US": { "role": { "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]" } } }, "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Valuation Allowances and Reserves, Balance Period End", "periodStartLabel": "Valuation Allowances and Reserves, Balance Period Start" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r151" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedTerseLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)" } } }, "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": { "auth_ref": [ "r151" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired", "terseLabel": "Other" } } }, "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r151" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutns", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsDetails", "http://www.bio-rad.com/role/ScheduleIiValuationAndQualifyingAccoutnsScheduleIiValuationAndQualifyingAccountsTables" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r161", "r166" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares - diluted", "totalLabel": "Diluted weighted average common shares" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r160", "r166" ], "calculation": { "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares - basic", "verboseLabel": "Basic weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.bio-rad.com/role/A1SignificantAccountingPoliciesEarningsPerShareDetails", "http://www.bio-rad.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 1.N)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e30840-122693" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=SL6283291-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=77896938&loc=d3e25383-109308" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=99404985&loc=d3e10037-110241" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118956092&loc=d3e12803-110250" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r323": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208821" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238119&loc=d3e30536-109315" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31928-109318" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31958-109318" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r503": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e961-128460" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r527": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r536": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164653&loc=d3e41551-112718" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r594": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL77919352-209981" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL117410129-209981" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119202524&loc=SL117410129-209981" }, "r617": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "14", "Topic": "842", "URI": "http://asc.fasb.org/section&trid=77888298" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r623": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f,g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.3(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.6(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.9(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r708": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r709": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r710": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r711": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r712": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r713": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r714": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r715": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r716": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r717": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL116659650-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 83 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
17. Quarterly Financial Data
 12 Months Ended
Dec. 31, 2019
Quarterly Financial Data [Abstract]  
Quarterly Financial Data [Text Block]
17. QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for 2019 and 2018 are as follows (in millions, except per share data):

 
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
2019
 
 
 
 
 
 
 
 
Net sales
 
$
554.0

 
$
572.6

 
$
560.6

 
$
624.5

Gross profit
 
311.8

 
307.8

 
307.0

 
330.4

Net income (loss)
 
865.2

 
598.8

 
(258.8
)
 
553.5

Basic earnings (loss) per share
 
$
29.03

 
$
20.08

 
$
(8.68
)
 
$
18.50

Diluted earnings (loss) per share
 
$
28.74

 
$
19.86

 
$
(8.68
)
 
$
18.31

 
 
 
 
 
 
 
 
 
2018
 
 
 
 
 
 
 
 
Net sales
 
$
551.5

 
$
575.9

 
$
545.1

 
$
616.9

Gross profit
 
302.2

 
301.7

 
286.7

 
332.6

Net income (loss)
 
656.8

 
268.0

 
269.3

 
(828.5
)
Basic earnings (loss) per share
 
$
22.05

 
$
8.99

 
$
9.02

 
$
(27.73
)
Diluted earnings (loss) per share
 
$
21.77

 
$
8.87

 
$
8.89

 
$
(27.73
)


As a result of the net losses for the three months ended September 30, 2019 and December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effects were anti-dilutive. Financial data for the fourth quarter of 2019 were negatively affected by the December 2019 Cyberattack, and restructuring costs for the European and North American reorganization, and are described in Item 7 and Note 15 to the consolidated financial statements, respectively. These negative effects were offset by a $646.0 million increase in fair market value of equity securities. The net losses for the three months ended September 30, 2019 and December 31, 2018 were primarily due to a $390.6 million and $814.1 million decrease in fair market value of equity securities, respectively. These changes in fair market value of equity securities mostly consisted of holding gains or losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of $292.5 million (see Note 4 to the consolidated financial statements).
XML 84 R62.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
8. Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive (loss) income $ (87,348) $ (46,958)  
Other comprehensive income, net of tax (40,390) (106,495) $ 321,028
Foreign currency translation adjustments [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive (loss) income (72,400) (35,500) 77,400
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (36,500) (112,900)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 0 0  
Other Comprehensive Income (Loss), Tax (400) 0  
Other comprehensive income, net of tax (36,900) (112,900)  
Other Postretirement Benefit Plan [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive (loss) income (22,200) (14,800) (22,300)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (10,000) 6,900  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 1,500 2,400  
Other Comprehensive Income (Loss), Tax 1,100 (1,800)  
Other comprehensive income, net of tax (7,400) 7,500  
Net Unrealized Investment Gain (Loss) [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive (loss) income 7,200 3,300 4,400
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 4,800 (1,400)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (400) 300  
Other Comprehensive Income (Loss), Tax (500) 0  
Other comprehensive income, net of tax 3,900 (1,100)  
Parent [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Accumulated other comprehensive (loss) income (87,400) (47,000) $ 59,500
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax (41,700) (107,400)  
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 1,100 2,700  
Other Comprehensive Income (Loss), Tax 200 (1,800)  
Other comprehensive income, net of tax $ (40,400) $ (106,500)  
XML 85 a10k123119_htm.xml IDEA: XBRL DOCUMENT 0000012208 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassBMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2020-02-24 0000012208 us-gaap:CommonClassBMember 2020-02-24 0000012208 us-gaap:CommonClassBMember 2019-06-30 0000012208 us-gaap:CommonClassAMember 2019-06-30 0000012208 2019-12-31 0000012208 2018-12-31 0000012208 us-gaap:CommonClassBMember 2019-12-31 0000012208 us-gaap:CommonClassAMember 2018-12-31 0000012208 us-gaap:CommonClassAMember 2019-12-31 0000012208 us-gaap:CommonClassBMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2018-12-31 0000012208 bio:TreasuryClassBMember 2019-12-31 0000012208 bio:TreasuryClassBMember 2018-12-31 0000012208 bio:TreasuryClassAMember 2019-12-31 0000012208 2017-01-01 2017-12-31 0000012208 2018-01-01 2018-12-31 0000012208 2016-12-31 0000012208 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2019-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0000012208 us-gaap:TreasuryStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000012208 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000012208 us-gaap:RetainedEarningsMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0000012208 us-gaap:TreasuryStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0000012208 us-gaap:TreasuryStockMember 2017-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0000012208 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000012208 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonStockMember 2017-12-31 0000012208 us-gaap:CommonStockMember 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2019-12-31 0000012208 us-gaap:TreasuryStockMember 2018-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonStockMember 2018-12-31 0000012208 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 0000012208 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0000012208 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonStockMember 2016-12-31 0000012208 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000012208 2018-01-01 0000012208 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:NewAccountingPronouncementMember 2019-12-31 0000012208 srt:MinimumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember us-gaap:EquipmentMember 2019-01-01 2019-12-31 0000012208 naics:ZZ541714 2019-12-31 0000012208 srt:MinimumMember bio:ReagentRentalEquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember bio:ReagentRentalEquipmentMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-12-31 0000012208 2019-01-01 2019-03-31 0000012208 2019-03-04 0000012208 2019-10-01 2019-12-31 0000012208 2019-10-01 0000012208 2019-07-01 2019-09-30 0000012208 2019-08-02 0000012208 2018-10-01 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2018-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:ProjectedVolatilityOfSalesMemberMember 2019-01-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:MarketPriceOfRiskMember 2019-01-01 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2018-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoicesMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2016-12-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestoneminimumamountMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-07-01 2019-09-30 0000012208 bio:DistributorMember 2019-10-01 2019-12-31 0000012208 bio:DistributorMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-12-31 0000012208 bio:DistributorMember 2019-01-01 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember bio:SalesmilestonepercentageofannualinvoiceslowMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-01-01 2019-03-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:OtherLongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 bio:AnalyticalFlowCytometerPlatformMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2019-01-01 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttopurchaseforeigncurrencyMember 2019-12-31 0000012208 bio:ForwardforeignexchangecontracttosellforeigncurrencyMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000012208 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2019-12-31 0000012208 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:AssetBackedSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000012208 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtMember 2019-12-31 0000012208 bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:LifeScienceMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:LifeScienceMember 2017-12-31 0000012208 bio:LifeScienceMember 2019-12-31 0000012208 us-gaap:LicensingAgreementsMember 2019-12-31 0000012208 us-gaap:TradeNamesMember 2019-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2019-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000012208 us-gaap:InProcessResearchAndDevelopmentMember 2019-12-31 0000012208 bio:KnowHowMember 2019-12-31 0000012208 bio:CellsorterMember us-gaap:DevelopedTechnologyRightsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:DiaMedMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-08-02 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-08-02 0000012208 bio:CellsorterMember us-gaap:NoncompeteAgreementsMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 us-gaap:TradeNamesMember 2019-08-02 0000012208 bio:BiotestAGMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-08-02 0000012208 bio:PasteurSanofiDiagnosicsS.A.Member bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:ClinicalDiagnosticsMember 2018-01-01 2018-03-31 0000012208 bio:KnowHowMember 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000012208 us-gaap:TradeNamesMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000012208 us-gaap:LicensingAgreementsMember 2018-01-01 2018-12-31 0000012208 us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000012208 us-gaap:TradeNamesMember 2018-01-01 2018-12-31 0000012208 bio:KnowHowMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:TradeNamesMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-12-31 0000012208 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-12-31 0000012208 us-gaap:NoncompeteAgreementsMember 2018-01-01 2018-12-31 0000012208 bio:KnowHowMember 2019-01-01 2019-12-31 0000012208 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2019-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2018-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2019-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2019-12-31 0000012208 bio:CapitalLeasesandOtherDebtMember us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000012208 bio:FinanceLeasesandOtherDebtMember bio:FinanceLeaseObligationsMember 2018-12-31 0000012208 bio:SeniorNotes4.875due2020Member us-gaap:UnsecuredDebtMember 2010-12-31 0000012208 us-gaap:LineOfCreditMember 2019-04-30 0000012208 us-gaap:LineOfCreditMember 2019-12-31 0000012208 us-gaap:PerformanceGuaranteeMember 2019-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2019-12-31 0000012208 us-gaap:ForeignCountryMember 2019-12-31 0000012208 bio:NetofprepaidtaxesMember 2019-12-31 0000012208 bio:IncludingaccruedinterestandpenaltiesMember 2019-12-31 0000012208 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0000012208 bio:TaxCutsandJobsActMember 2017-01-01 2017-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2018-01-01 2018-12-31 0000012208 bio:TaxCutsandJobsActMember 2019-01-01 2019-12-31 0000012208 us-gaap:DomesticCountryMember 2019-01-01 2019-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2017-01-01 2017-12-31 0000012208 bio:TaxCutsandJobsActMember 2018-01-01 2018-12-31 0000012208 us-gaap:DomesticCountryMember 2018-01-01 2018-12-31 0000012208 us-gaap:AcquisitionRelatedCostsMember 2019-01-01 2019-12-31 0000012208 us-gaap:DomesticCountryMember 2017-01-01 2017-12-31 0000012208 bio:OperatingleaseobligationsMember 2018-12-31 0000012208 bio:OperatingleaseassetsMember 2018-12-31 0000012208 bio:OperatingleaseassetsMember 2019-12-31 0000012208 bio:OperatingleaseobligationsMember 2019-12-31 0000012208 2018-11-30 0000012208 2018-11-01 2018-11-30 0000012208 2019-06-30 0000012208 2019-11-30 0000012208 2019-08-31 0000012208 2019-05-31 0000012208 2019-06-01 2019-06-30 0000012208 2019-08-01 2019-08-31 0000012208 2019-05-01 2019-05-31 0000012208 2019-11-01 2019-11-30 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000012208 us-gaap:CommonClassAMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassBMember 2017-01-01 2017-12-31 0000012208 us-gaap:CommonClassAMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2016-12-31 0000012208 us-gaap:CommonClassBMember 2018-01-01 2018-12-31 0000012208 us-gaap:CommonClassBMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2017-12-31 0000012208 us-gaap:CommonClassAMember 2016-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:ParentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:ParentMember 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000012208 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0000012208 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000012208 us-gaap:ParentMember 2018-12-31 0000012208 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000012208 us-gaap:ParentMember 2019-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0000012208 bio:A2011EmployeeStockPurchasePlanMember 2019-12-31 0000012208 bio:StockOptionAndAwardPlansMember bio:IncentiveAwardPlan2017Member 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeStockMember 2017-12-31 0000012208 us-gaap:EmployeeStockMember 2018-12-31 0000012208 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000012208 us-gaap:EmployeeStockOptionMember 2018-12-31 0000012208 bio:StockAwardPlansMember bio:IncentiveAwardPlan2017Member 2019-01-01 2019-12-31 0000012208 country:US 2019-12-31 0000012208 2019-02-26 2019-02-26 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNoncurrentAssetsMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherCurrentAssetsMember 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:GoodwillMember 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember bio:PropertyPlantandEquipmentandOperatingleaserightofuseassetsexcludingsegmentspecificMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2019-12-31 0000012208 srt:EuropeMember 2018-01-01 2018-12-31 0000012208 srt:EuropeMember 2017-01-01 2017-12-31 0000012208 country:US 2017-01-01 2017-12-31 0000012208 srt:AmericasMember 2019-01-01 2019-12-31 0000012208 srt:AmericasMember 2018-01-01 2018-12-31 0000012208 srt:AsiaPacificMember 2017-01-01 2017-12-31 0000012208 country:US 2019-01-01 2019-12-31 0000012208 srt:EuropeMember 2019-01-01 2019-12-31 0000012208 srt:AsiaPacificMember 2019-01-01 2019-12-31 0000012208 srt:AsiaPacificMember 2018-01-01 2018-12-31 0000012208 country:US 2018-01-01 2018-12-31 0000012208 srt:AmericasMember 2017-01-01 2017-12-31 0000012208 srt:EuropeMember 2018-12-31 0000012208 srt:AmericasMember 2018-12-31 0000012208 srt:AmericasMember 2019-12-31 0000012208 country:US 2019-12-31 0000012208 srt:AsiaPacificMember 2018-12-31 0000012208 srt:EuropeMember 2019-12-31 0000012208 country:US 2018-12-31 0000012208 srt:AsiaPacificMember 2019-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-12-31 0000012208 bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2019-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-12-31 0000012208 bio:LifeScienceMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllOtherSegmentsMember 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0000012208 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember 2017-01-01 2017-12-31 0000012208 us-gaap:MaterialReconcilingItemsMember us-gaap:ForeignCurrencyGainLossMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2017-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:LifeScienceMember 2019-12-31 0000012208 bio:EuropeanReorganizationMember bio:ClinicalDiagnosticsMember 2017-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2018-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2019-01-01 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember 2018-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:LifeScienceMember 2019-12-31 0000012208 bio:EuropeanandNorthAmericanReorganizationMember bio:ClinicalDiagnosticsMember 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2017-01-01 2017-12-31 0000012208 bio:EuropeanReorganizationMember 2016-05-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 us-gaap:FacilityClosingMember 2018-12-01 2019-12-31 0000012208 us-gaap:AccountsPayableAndAccruedLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherCurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:EmployeeSeveranceMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:OtherNoncurrentLiabilitiesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2019-01-01 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanandNorthAmericanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:ResearchAndDevelopmentExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember 2017-12-01 2019-12-31 0000012208 country:DE us-gaap:FacilityClosingMember 2018-06-01 2019-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-01-01 2017-12-31 0000012208 us-gaap:EmployeeSeveranceMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2018-01-01 2018-12-31 0000012208 us-gaap:CostOfGoodsTotalMember bio:EuropeanReorganizationMember 2017-01-01 2017-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2018-01-01 2018-12-31 0000012208 bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2017-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:OtherOperatingIncomeExpenseMember us-gaap:FacilityClosingMember bio:ClinicalDiagnosticsMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:EuropeanReorganizationMember 2019-01-01 2019-12-31 0000012208 us-gaap:SellingGeneralAndAdministrativeExpensesMember bio:TerminationofaDiagnosticsResearchandDevelopmentProjectandaFacilityClosureMember 2019-01-01 2019-12-31 0000012208 srt:MaximumMember 2019-01-01 2019-12-31 0000012208 srt:MinimumMember 2019-01-01 2019-12-31 0000012208 bio:FinanceLeaseMember 2019-12-31 0000012208 2019-04-01 2019-06-30 0000012208 2018-01-01 2018-03-31 0000012208 2018-04-01 2018-06-30 0000012208 2018-07-01 2018-09-30 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-01-01 2019-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-01-01 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2017-01-01 2017-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2018-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2016-12-31 0000012208 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2019-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2016-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-01-01 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-01-01 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2019-01-01 2019-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2018-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2017-12-31 0000012208 us-gaap:AllowanceForCreditLossMember 2019-12-31 iso4217:USD shares iso4217:USD pure shares false --12-31 FY 2019 0000012208 26713000 20205000 0.0001 0.0001 0.0001 0.0001 80000000 20000000 80000000 20000000 24884265 5096421 24966035 5089532 24704772 5095504 24835804 5089532 .10 1 P6Y P3Y P8Y P9Y P7Y P0Y P3Y P5Y P6Y P8Y P8Y P6Y P0Y P8Y 0 0.0001 0.0001 7500000 7500000 0 0 0 0 P12Y P3Y 5600000 0 0 0 0 P5Y P5Y 0 0 179493 917 130231 0 10-K true 2019-12-31 false 1-7928 BIO-RAD LABORATORIES, INC. DE 94-1381833 1000 Alfred Nobel Drive, Hercules, CA 94547 (510) 724-7000  Class A Common Stock Par Value $0.0001 per share BIO NYSE Class B Common Stock Par Value $0.0001 per share BIOb NYSE No No Yes Yes Large Accelerated Filer false false false false 6613310960 67954565 24839715 5085621 660672000 431526000 453973000 413270000 5560000 5560000 392672000 392443000 109570000 108008000 146131000 145051000 298306000 330756000 554007000 583815000 102331000 187249000 10940000 9615000 2180155000 2023478000 25215000 25185000 341598000 331563000 1015359000 970081000 1382172000 1326829000 882833000 818139000 499339000 508690000 201868000 0 264131000 219770000 145525000 133123000 4638205000 2655709000 79636000 70298000 8008859000 5611068000 107014000 122450000 180084000 143510000 426172000 493000 8763000 27513000 27522000 28675000 35365000 0 33735000 26936000 86840000 101218000 905495000 450795000 13579000 438937000 997787000 553239000 176018000 0 160923000 147766000 2253802000 1590737000 0 0 2000 2000 1000 1000 410020000 394342000 38397000 49040000 0 89000 5470779000 3722073000 -87348000 -46958000 5755057000 4020331000 8008859000 5611068000 2311659000 2289415000 2160153000 1054663000 1066264000 972450000 1256996000 1223151000 1187703000 824625000 834783000 806790000 202710000 199196000 250157000 0 292513000 11506000 229661000 -103341000 119250000 23416000 23962000 23014000 -2245000 -2861000 -9128000 2030987000 606230000 0 26094000 36593000 10697000 2261081000 512659000 97805000 502406000 147045000 -24444000 1758675000 365614000 122249000 58.93 12.25 4.12 29843000 29836000 29655000 58.27 12.10 4.07 30184000 30228000 30034000 1758675000 365614000 122249000 -36953000 -112857000 76050000 7363000 -7549000 3767000 3926000 -1187000 248745000 -40390000 -106495000 321028000 1718285000 259119000 443277000 2311925000 2326310000 2093948000 1818575000 1989685000 1916119000 22330000 22703000 22224000 45081000 62414000 52136000 31673000 26383000 18392000 285000 7603000 -17724000 457897000 285494000 104137000 98532000 129825000 111332000 129000 4315000 86000 0 6964000 0 79386000 -266000 76645000 -8818000 3000 3795000 0 0 1000000 371450000 371019000 282656000 104632000 77029000 97523000 226900000 225295000 202247000 -208889000 -186978000 -175572000 0 0 -36000 643000 2961000 316000 486000 0 0 13113000 14133000 14604000 8096000 8862000 7310000 3831000 0 0 28000000 48912000 2920000 2477000 2078000 3681000 -22758000 -48680000 341000 2237000 -655000 -1094000 228487000 49181000 -72188000 434164000 384983000 457171000 662651000 434164000 384983000 660672000 431526000 383824000 93000 111000 882000 1886000 2527000 277000 662651000 434164000 384983000 3000 332911000 -101000 1828581000 417766000 2579160000 122249000 122249000 391000 -256000 135000 200893000 200893000 -120135000 120135000 4490000 4490000 23439000 23439000 2920000 2920000 2804000 2804000 3000 361231000 -217000 1830439000 738794000 2930250000 1543747000 -679257000 864490000 -17591000 -17591000 -136000 -136000 365614000 365614000 -106495000 -106495000 5271000 5271000 27840000 27840000 48912000 48912000 3000 394342000 -49129000 3722073000 -46958000 4020331000 1758675000 1758675000 -40390000 -40390000 5017000 5017000 35593000 35593000 28000000 28000000 -24932000 38732000 -9969000 3831000 3000 410020000 -38397000 5470779000 -87348000 5755057000 <div style="line-height:120%;padding-left:0px;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;padding-right:48px;">1.</span><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Short-term Restricted Investments</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at both </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Available-for-Sale Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span><span style="font-family:inherit;font-size:11pt;">Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> years; and equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Lived Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  As a result, our lease income is heavily variable in nature.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements of these reagent rental arrangements represents approximately </span><span style="font-family:inherit;font-size:11pt;"><span>3%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue for </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, respectively, and is included as part of the Net sales in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$37.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$45.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> was primarily driven by </span><span style="font-family:inherit;font-size:11pt;"><span>$33.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$24.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We conduct extensive research and development activities in all areas of our business, employing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>780</span></span><span style="font-family:inherit;font-size:11pt;"> employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Forfeitures are recognized as they occur.  These plans are described more fully in Note 9.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,843</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, we capitalized </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements to be Adopted </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," </span><span style="font-family:inherit;font-size:11pt;color:#222222;">which </span><span style="font-family:inherit;font-size:11pt;">eliminates certain exceptions within ASC 740, Income Taxes</span><span style="font-family:inherit;font-size:11pt;font-style:italic;">,</span><span style="font-family:inherit;font-size:11pt;"> and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective </span><span style="font-family:inherit;font-size:11pt;color:#222222;">for fiscal years beginning after December 15, 2020 </span><span style="font-family:inherit;font-size:11pt;">and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect </span><span style="font-family:inherit;font-size:11pt;color:#222222;">of adopting this pronouncement </span><span style="font-family:inherit;font-size:11pt;">on our financial statements and disclosures.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements, however due to the generally short duration of our customers' trade receivables, we do not expect ASU 2016-13 to have a material impact. </span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The consolidated financial statements include the accounts of Bio-Rad Laboratories, Inc. and all of our wholly and majority owned subsidiaries (referred to in this report as “Bio-Rad,” “we,” “us” and “our”) after elimination of intercompany balances and transactions.  The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.  Actual results could differ from those estimates.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued.  The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading.  To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects for those events and conditions.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Cash and Cash Equivalents</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less which are readily convertible into cash.  Cash equivalents are stated at cost, which approximates fair value.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Short-term Restricted Investments</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term restricted investments of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at both </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> represent a money market fund that is renewed annually for collateral that secures worker's compensation and general liability insurance. Investment income accrues to Bio-Rad and is recorded in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div> 5600000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Available-for-Sale Investments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of corporate obligations, municipal securities, asset backed securities, U.S. government sponsored agencies and marketable equity securities.  Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date.  Investments with maturities beyond one year may be classified as short-term based on their liquid nature and because such marketable securities represent the investment of cash that is available for current operations.  Available-for-sale investments are reported at fair value based on quoted market prices and other observable market data.  Unrealized gains and losses are reported as a component of other comprehensive income, net of any related tax effect.  Effective January 1, 2018, changes in fair value for equity securities are reported in Change in fair market value of equity securities in the Consolidated Statements of Income due to the adoption of ASU 2016-01, "Recognition and Measurement of Financial Assets and Financial Liabilities." Unrealized losses are charged against income when a decline in the fair value of an individual security is determined to be other-than-temporary.  We review our available-for-sale debt securities for other-than-temporary losses on a quarterly basis. </span><span style="font-family:inherit;font-size:11pt;color:#007f00;"> </span><span style="font-family:inherit;font-size:11pt;">Realized gains and losses and other-than-temporary impairments on investments are included in Other (income) expense, net (see Note 10).</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash and cash equivalents, investments, foreign exchange contracts and trade accounts receivable.  Cash and cash equivalents and investments are placed with various highly rated major financial institutions located in different geographic regions. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The forward contracts used in managing our foreign currency exposures have an element of risk in that the counterparties may be unable to meet the terms of the agreements.  We attempt to minimize this risk by limiting the counterparties to a diverse group of highly-rated domestic and international financial institutions.  In the event of non-performance by these counterparties, the carrying values of our financial instruments represent the maximum amount of loss we would have incurred as of our fiscal year-end.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We perform credit evaluation procedures related to our trade receivables and with the exception of certain developing countries, generally do not require collateral.  As a result of increased risk in certain developing countries, some Bio-Rad sales are subject to collateral letters of credit from our customers.  Credit risk for trade accounts receivable is generally limited due to the large number of customers and their dispersion across many geographic areas.  However, a significant amount of trade receivables are with national healthcare systems in countries within the European Union.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Accounts Receivable</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments.  The amount of the allowance is determined by analyzing known uncollectible accounts, aged receivables, economic conditions in the customers’ country or industry, historical losses and our customers’ credit-worthiness.  Amounts later determined and specifically identified to be uncollectible are charged or written off against this allowance.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Inventory</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Inventories are valued at the lower of cost and net realizable value and include material, labor and overhead costs. The first-in, first-out method is used to relieve inventory for products sold.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Property, Plant and Equipment</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment are carried at cost, less accumulated depreciation and amortization.  Included in property, plant and equipment are buildings and equipment acquired under capital lease arrangements, reagent rental equipment and capitalized software, including costs for software developed or obtained for internal use. Property, plant and equipment are assessed for impairment quarterly or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets.  The estimated useful lives of property, plant and equipment are generally as follows: buildings and leasehold improvements, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>39</span></span><span style="font-family:inherit;font-size:11pt;"> years or the term of the leases or life of the improvements, whichever is shorter; reagent rental equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>5</span></span><span style="font-family:inherit;font-size:11pt;"> years; and equipment, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;">-</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>12</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div> P10Y P39Y P1Y P5Y P3Y P12Y <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Leases</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current operating lease liabilities, and Operating lease liabilities in our Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities in our Consolidated Balance Sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Where we act as lessee, we elected not to separate lease and non-lease components. <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Where we act as lessor in our reagent rental arrangements, we allocate the consideration in the contract to the separate lease components and non-lease components. After allocation, the amount of variable payments allocated to lease components will be recognized as income under the lease accounting standard ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Such reagent rental arrangements are more fully described below under the caption "Reagent Rental Agreements."</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill represents the excess of the cost over the fair value of net tangible and identifiable intangible assets of acquired businesses.  Goodwill is assessed for impairment by applying fair value based tests annually in the fourth quarter or whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We perform impairment tests of goodwill at our reporting unit level, which is one level below our operating segments.  Our reporting units are identified as components for which discrete financial information is available and is regularly reviewed by management.  Goodwill amounts are assigned to reporting units at the time of acquisition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The goodwill impairment amount will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. We use a projected discounted cash flow model to determine the fair value of a reporting unit.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Lived Assets</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For purposes of recognition and measurement of an impairment loss, a long-lived asset or assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.  We assess the impairment of long-lived assets (including identifiable intangible assets and operating lease right-of-use assets) quarterly or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.  Factors that we consider important that could trigger an impairment review include:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant under-performance relative to expected, historical or projected future operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant changes in the manner of use of the long-lived assets, intangible assets or the strategy for our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of at a loss before the end of its previously estimated useful life; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">significant negative industry, legal, regulatory or economic trends.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">When management determines that the carrying value of long-lived assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, we test for any impairment based on a projected undiscounted cash flow method.  Projected future operating results and cash flows of the asset or asset group are used to establish the fair value used in evaluating the carrying value of long-lived and intangible assets.  We estimate the future cash flows of the long-lived assets using current and long-term financial forecasts.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  If this is the case, an impairment loss would be recognized.  The impairment loss recognized is the amount by which the carrying amount exceeds the fair value. </span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities reflect the tax effects of net operating losses, tax credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. They are determined using enacted tax rates in effect for the year in which such temporary differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record deferred tax assets to the extent we believe these assets will more likely than not be realized.  In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. When we establish, or reduce the valuation allowance against our deferred tax assets, our provision for income taxes will increase or decrease, respectively, in the period that determination to change the valuation allowance is made.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement.  The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination.  We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in the provision for income taxes.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 70000000 -49000000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On January 1, 2018, we adopted Accounting Standards Codification ("ASC") 606, "Revenue from Contracts with Customers," using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018.  We recorded a net reduction to opening retained earnings of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606 with the impact primarily related to a customer loyalty program in the United States for which the resulting non-cash consideration is treated as variable consideration under the new revenue recognition accounting standard. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant.</span></div> 100000 <div style="line-height:174%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Reagent Rental Agreements </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As discussed further above under the caption “Leases” and below under the caption “Recent Accounting Pronouncements Adopted,” as well as in Note 16, Leases, we adopted ASC 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments.  As a result, our lease income is heavily variable in nature.  Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Hence, our reported lease income is primarily variable in nature and is recognized as the reagents are consumed by the customer or delivered.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Revenue allocated to the lease elements of these reagent rental arrangements represents approximately </span><span style="font-family:inherit;font-size:11pt;"><span>3%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> of total revenue for </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, respectively, and is included as part of the Net sales in our Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contract costs:</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force compensation programs and certain partner sales incentive programs, as we have determined that annual compensation is commensurate with annual selling activities. </span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Disaggregation of Revenue:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The disaggregation of our revenue by geographic region based primarily on the location of the use of the product service, and by industry segment sources, and the disaggregation of our revenues by industry segment sources are presented in our Segment Information footnote (see Note 14).</span></div> 0.03 0.05 <span style="font-family:inherit;font-size:11pt;">Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance extends over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The increase in our total deferred revenue balance from </span><span style="font-family:inherit;font-size:11pt;"><span>$37.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>$45.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> was primarily driven by </span><span style="font-family:inherit;font-size:11pt;"><span>$33.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, net, of cash payments received or due in advance of satisfying our performance obligations, partially offset by </span><span style="font-family:inherit;font-size:11pt;"><span>$24.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> of revenue recognized that were included in our deferred revenue balance as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span>. 37300000 45800000 33100000 24600000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year.  Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback.  A review is performed on a quarterly basis to assess the adequacy of our warranty accrual.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Components of the warranty accrual, included in Other current liabilities and Other long-term liabilities in the Consolidated Balance Sheets, were as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for warranty</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Actual warranty costs</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(11.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(34.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10100000 18700000 9900000 25500000 11000000.0 34100000 9000000.0 10100000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Shipping and Handling</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We classify all freight costs billed to customers as Net sales.  Related freight costs are recognized upon transfer of control of the promised products to customers as a fulfillment cost and included in Cost of goods sold.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We conduct extensive research and development activities in all areas of our business, employing approximately </span><span style="font-family:inherit;font-size:10pt;"><span>780</span></span><span style="font-family:inherit;font-size:11pt;"> employees worldwide in these activities, including degreed scientists and technical support staff.  Research and development has played a major role in Bio-Rad’s growth and is expected to continue to do so in the future.  Our research teams are continuously developing new products and new applications for existing products.  In our development of new products and applications, we interact with scientific and medical professionals at universities, hospitals and medical schools, and within our industry.  </span></div> 780 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance sheet accounts of international subsidiaries are translated at the current exchange rates as of the end of each accounting period.  Income statement items are translated at average exchange rates for the period.  The resulting translation adjustments are recorded as a separate component of stockholders’ equity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency transaction gains and losses are included in Foreign exchange losses, net in the Consolidated Statements of Income.  Transaction gains and losses result primarily from fluctuations in exchange rates when intercompany receivables and payables are denominated in currencies other than the functional currency of our subsidiary that recorded the transaction.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Forward Foreign Exchange Contracts</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes, nor do we seek hedge accounting treatment for any of our contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded as an asset or liability measured at their fair value at each balance sheet date. The resulting gains or losses offset exchange gains or losses, on the related receivables and payables, all of which are recorded in Foreign exchange losses, net in the Consolidated Statements of Income.  </span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation expense for all share-based payment awards granted is determined based on the grant-date fair value.  We recognize these compensation costs over the requisite service period of the award, which is generally the vesting term of the share-based payment awards.  Forfeitures are recognized as they occur.  These plans are described more fully in Note 9.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period.  Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding.  Potential common shares are excluded from the diluted earnings per share calculation if the effect would be anti-dilutive.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,843</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share and the anti-dilutive shares are as follows (in thousands):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic weighted average shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,843</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,836</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29,655</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Effect of potentially dilutive stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    and restricted stock awards</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>379</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted weighted average common shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,184</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Anti-dilutive stock options and restricted stock awards </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    excluded from the computation of diluted EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29843000 29836000 29655000 341000 392000 379000 30184000 30228000 30034000 98000 84000 13000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For certain financial instruments, including cash and cash equivalents, short-term investments, accounts receivable, marketable securities, notes payable, accounts payable and foreign exchange contracts, the carrying amounts approximate fair value.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of financial instruments is based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) using available market information or other appropriate valuation methodologies in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants.  Estimates are not necessarily indicative of the amounts that could be realized in a current market exchange as considerable judgment is required in interpreting market data used to develop estimates of fair value.  The use of different market assumptions or estimation techniques could have a material effect on the estimated fair value (see Note 3).</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements Adopted</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-15, "Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract." ASU 2018-15 amends the definition of a hosting arrangement and requires a customer in a hosting arrangement that is a service contract to capitalize certain implementation costs as if the arrangement was an internal-use software project. The internal-use software guidance states that only qualifying costs incurred during the application development stage can be capitalized. We prospectively adopted ASU 2018-15 effective January 1, 2019. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, we capitalized </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of implementation costs for cloud computing arrangements, net of accumulated amortization, primarily for business analytics software. These costs were recorded in Other current assets and Other assets in the Consolidated Balance Sheet.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the SEC issued Final Rule Release No. 33-10532, "Disclosure Update and Simplification" that extends to interim periods the annual disclosure requirement of presenting the changes in stockholders' equity, which was effective in the first quarter of 2019. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In February 2016, the FASB issued ASU 2016-02, "Leases," and related accounting standard updates, which requires, among other items, lease accounting to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures are enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. We adopted ASU 2016-02 on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. The practical expedients elected in transition included, among other items, for leases that existed prior to January 1, 2019, not reassessing whether any contracts are or contain embedded leases, not reassessing the classification of existing leases, and not reassessing whether previously capitalized initial direct costs qualify for capitalization. Where we act as a lessee, the adoption of the standard resulted in material additions to the balance sheet for right-of-use assets and the associated liabilities. See Note 16, Leases. Where we act as a lessee, we also elected not to separate lease and non-lease components. Where we act as a lessor in reagent rental arrangements, there was an insignificant impact to our Consolidated Financial Statements, which is more fully described above under the caption "Reagent Rental Agreements."</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Recent Accounting Pronouncements to be Adopted </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective January 1, 2021 and early adoption is permitted at the beginning of any interim period on a prospective basis. We are currently evaluating the effect of ASU 2020-01 and the consideration of early adoption.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," </span><span style="font-family:inherit;font-size:11pt;color:#222222;">which </span><span style="font-family:inherit;font-size:11pt;">eliminates certain exceptions within ASC 740, Income Taxes</span><span style="font-family:inherit;font-size:11pt;font-style:italic;">,</span><span style="font-family:inherit;font-size:11pt;"> and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective </span><span style="font-family:inherit;font-size:11pt;color:#222222;">for fiscal years beginning after December 15, 2020 </span><span style="font-family:inherit;font-size:11pt;">and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect </span><span style="font-family:inherit;font-size:11pt;color:#222222;">of adopting this pronouncement </span><span style="font-family:inherit;font-size:11pt;">on our financial statements and disclosures.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2018, the FASB issued ASU 2018-18, "Clarifying the Interaction between Topic 808 and Topic 606." Topic 808 is Collaborative Arrangements, and Topic 606 is Revenue from Contracts with Customers. ASU 2018-18 clarifies that certain transactions between collaborative partners should be accounted for as revenue under ASC 606 when the collaborative partner is a customer. We currently do not have any customers that are collaborative partners or anticipate any in the near future. ASU 2018-18 will be effective January 1, 2020.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2018, the FASB issued ASU 2018-13, "Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement." ASU 2018-13 eliminates, adds and modifies certain disclosures for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. We do not expect ASU 2018-13 to have a material impact to our fair value disclosures.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div>In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 will replace the current incurred loss approach with an expected loss model for instruments measured at amortized cost and require entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount under the current other-than-temporary impairment model. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We are currently evaluating the effect ASU 2016-13 will have on our consolidated financial statements, however due to the generally short duration of our customers' trade receivables, we do not expect ASU 2016-13 to have a material impact. 3100000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">2.    ACQUISITIONS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, which included cash payments at closing, net of closing cash, of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, the preliminary allocation of the payments was </span><span style="font-family:inherit;font-size:11pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> to customer relationships; a definite-lived intangible, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to deferred tax asset, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> to deferred tax liability related to the purchased intangible and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> to acquired net assets. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In August 2019, we acquired all the issued and outstanding membership interests of Exact Diagnostics, LLC for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:11pt;">. Cash payments at closing, net of closing cash, were </span><span style="font-family:inherit;font-size:11pt;"><span>$59.7 million</span></span><span style="font-family:inherit;font-size:11pt;">. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is deductible for income tax purposes. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The final allocation of the payments was </span><span style="font-family:inherit;font-size:11pt;"><span>$26.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> to purchased intangibles consisting primarily of customer relationships, developed product technology and tradenames, </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to acquired net assets, and </span><span style="font-family:inherit;font-size:11pt;"><span>$28.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> to goodwill.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe that the acquisition will accelerate market penetration in the areas of quality controls and assay verification panels in our Clinical Diagnostics operations. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2019, we completed the acquisition of all the issued and outstanding stock of a small U.S. private company for approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:11pt;">. Cash payments, net of closing cash, consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:11pt;">paid in November 2018 and the remaining </span><span style="font-family:inherit;font-size:11pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> paid in March 2019. The acquisition was included in our Life Science segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. The goodwill related to this acquisition is not deductible for income tax purposes. Pro forma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The final allocation of the payments was </span><span style="font-family:inherit;font-size:11pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:11pt;">to goodwill that included workforce and time-to-market advantage, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> to definite-lived intangibles, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> to in-process research and development, an indefinite-lived intangible asset, and a deferred tax liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the purchased intangibles.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe that the acquisition will expand our reagents suite of offerings in our Life Science operations.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4200000 3600000 600000 400000 3400000 200000 800000 1400000 60000000.0 59700000 26800000 4200000 28700000 20000000.0 4000000.0 16000000.0 15600000 5500000 200000 1300000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">3. FAIR VALUE MEASUREMENTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date.  The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability.  A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1: Quoted prices in active markets for identical instruments</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments)</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments)</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets carried at fair value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity Securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other foreign obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,771.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>456.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,227.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial liabilities carried at fair value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets carried at fair value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial liabilities carried at fair value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,613.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,632.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The year-to-date unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> were </span><span style="font-family:inherit;font-size:11pt;"><span>$2,031.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(f)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from </span><span style="font-family:inherit;font-size:11pt;"><span>39%</span></span><span style="font-family:inherit;font-size:11pt;"> to </span><span style="font-family:inherit;font-size:11pt;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> for the calendar years 2017 through 2020. The sales milestones could potentially range from </span><span style="font-family:inherit;font-size:11pt;"><span>$0</span></span><span style="font-family:inherit;font-size:11pt;"> to an unlimited amount. In the first and third quarters of 2019, we paid </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, per the purchase agreement. Since 2016 we have had a net decrease in the cumulative valuation of the sales milestones of </span><span style="font-family:inherit;font-size:11pt;"><span>$13.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> was paid by the acquisition date and the remaining payment is due in the second quarter of 2020. The maximum earn-out payment due is </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;">. The contingent consideration was accrued at its estimated fair value of </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Foreign distributor earn-outs:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition of foreign distributor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides q</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ua</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">      Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">      Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">To estimate the fair value of Level 2 debt securities, our primary pricing provider used Reuters as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and Securities Evaluations as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> as the primary pricing sources. Our pricing process allowed us to select a hierarchy of pricing sources for securities held. If Reuters or Securities Evaluations did not price a Level 2 security that we held, then the pricing provider utilized our custodian supplied pricing as the secondary pricing source. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For all commercial paper as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, our primary pricing provider used its leading pricing source in the hierarchy to determine pricing. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our primary pricing provider performed daily reasonableness testing of the Reuters and Securities Evaluations prices. Price changes of </span><span style="font-family:inherit;font-size:11pt;"><span>5%</span></span><span style="font-family:inherit;font-size:11pt;"> or greater were investigated and resolved. In addition, we performed a quarterly testing of the Reuters and Securities Evaluations prices to custodian reported prices. Price differences outside a tolerable variance of approximately </span><span style="font-family:inherit;font-size:11pt;"><span>1%</span></span><span style="font-family:inherit;font-size:11pt;"> were investigated and resolved.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>203.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  Other foreign obligations </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>164.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>165.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The unrealized losses on these securities are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others.  Because Bio-Rad has the ability and intent to hold these investments with unrealized losses until a recovery of fair value, or for a reasonable period of time sufficient for a forecasted recovery of fair value, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> or at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As part of distributing our products, we regularly enter into intercompany transactions.  We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables.  We do not use derivative financial instruments for speculative or trading purposes.  We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date.  The notional principal amounts provide one measure of the transaction volume outstanding as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties.  The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign exchange losses, net in the Consolidated Statements of Income. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign currency exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2020 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2020 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of our current maturities of long-term debt, excluding leases, as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and long-term-debt, excluding all lease and current maturities, as of December 31, 2018 that is not recognized at fair value in the Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total current maturities long-term debt, excluding leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>424.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>435.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Included in Other Investments in the Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over </span><span style="font-family:inherit;font-size:11pt;"><span>37%</span></span><span style="font-family:inherit;font-size:11pt;"> of the outstanding voting shares (excluding treasury shares) of Sartorius as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, due to the adoption of ASU 2016-01 and ASU 2018-03 as of </span><span style="font-family:inherit;font-size:11pt;">January 1, 2018</span><span style="font-family:inherit;font-size:11pt;">, we account for this investment at fair market value as determined at period end by a quoted price on an organized exchange.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets carried at fair value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>101.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>53.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>154.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity Securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other foreign obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.9</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,771.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>456.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,227.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial liabilities carried at fair value:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets and liabilities carried at fair value and measured on a recurring basis as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> are classified in the hierarchy as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial assets carried at fair value:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total cash equivalents (a)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted investment:</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Equity securities (b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total available-for-sale investments (c)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (d)</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,738.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3,200.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Financial liabilities carried at fair value:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts (e)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Contingent consideration (f)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total financial liabilities carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> Equity securities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.0</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,613.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,632.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,664.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,672.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The year-to-date unrealized gains on our equity securities still held as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> were </span><span style="font-family:inherit;font-size:11pt;"><span>$2,031.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> and were primarily due to our investment in Sartorius AG and are recorded in our Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(c)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(d)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(e)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.</span></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><span style="font-family:inherit;font-size:11pt;">(f)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">   Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 0 42900000 0 42900000 31200000 10000000.0 0 41200000 0 100000 0 100000 69900000 0 0 69900000 101100000 53000000.0 0 154100000 5600000 0 0 5600000 4664400000 0 0 4664400000 0 204500000 0 204500000 0 106100000 0 106100000 0 4700000 0 4700000 0 3100000 0 3100000 0 11600000 0 11600000 0 72900000 0 72900000 0 402900000 0 402900000 0 900000 0 900000 4771100000 456800000 0 5227900000 0 1000000.0 0 1000000.0 0 0 4900000 4900000 0 1000000.0 4900000 5900000 0 77800000 0 77800000 22700000 10000000.0 0 32700000 0 300000 0 300000 36900000 0 0 36900000 59600000 88100000 0 147700000 5600000 0 0 5600000 2672900000 0 0 2672900000 0 215000000.0 0 215000000.0 0 80300000 0 80300000 0 3600000 0 3600000 0 11000000.0 0 11000000.0 0 63300000 0 63300000 0 373200000 0 373200000 0 600000 0 600000 2738100000 461900000 0 3200000000.0 0 700000 0 700000 0 0 8400000 8400000 0 700000 8400000 9100000 51000000.0 40200000 4613400000 2632700000 4664400000 2672900000 2031100000 402800000 373000000.0 100000 200000 402900000 373200000 3300000 3200000 1600000 5200000 4900000 8400000 0.39 0.20 0 1400000 1100000 13900000 4300000 700000 1400000 600000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:66.796875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Analytical flow cytometer platform:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payment of sales milestone </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Foreign distributor earn-outs:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition of foreign distributor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8400000 2500000 1600000 600000 4900000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following table provides q</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ua</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">ntitative information about Level 3 inputs for fair value measurement of our analytical flow cytometer platform contingent consideration liability as of</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Significant increases or decreases in these inputs in isolation could result in a significantly lower or higher fair value measurement.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:17%;"/><td style="width:26%;"/><td style="width:41%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unobservable Input</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Percentage</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Analytical flow cytometer platform</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Probability-weighted income approach</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Sales milestones:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">      Discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">      Cost of debt</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.111 0.039 0.05 0.01 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>203.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>204.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  Other foreign obligations </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 203200000 1400000 100000 204500000 11500000 100000 0 11600000 72700000 200000 100000 72800000 105600000 700000 200000 106100000 4700000 0 0 4700000 3100000 0 0 3100000 400800000 2400000 400000 402800000 100000 0 0 100000 100000 0 0 100000 400900000 2400000 400000 402900000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of the amortized cost and estimated fair value of our debt securities at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> by contractual maturity date (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in less than one year</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>174.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in one to five years</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>164.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>165.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Mature in more than five years</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>62.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>400.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>402.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 174500000 174600000 164200000 165200000 62200000 63100000 400900000 402900000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Available-for-sale investments consist of the following (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Short-term investments:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>216.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>215.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Municipal obligations</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. government sponsored agencies</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign government obligations</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term investments:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>375.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>373.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 216200000 100000 1300000 215000000.0 11100000 0 100000 11000000.0 63500000 0 400000 63100000 80900000 200000 800000 80300000 3600000 0 0 3600000 375300000 300000 2600000 373000000.0 200000 0 0 200000 200000 0 0 200000 375500000 300000 2600000 373200000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of investments with gross unrealized losses and the associated fair value (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>117.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair value of investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>193.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position 12 months or more</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross unrealized losses for investments in a loss position less than 12 months</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 19900000 117900000 97800000 193000000.0 100000 1800000 300000 800000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a summary of our forward foreign currency exchange contracts (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2020 to sell foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>52.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Contracts maturing in January through March 2020 to purchase foreign currency:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Notional value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrealized loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 52000000.0 300000 269100000 -300000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The estimated fair value of our debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Estimated </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fair </span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Value </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value Hierarchy Level</span></div></td></tr><tr><td style="vertical-align:top;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total current maturities long-term debt, excluding leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>424.4</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>435.5</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total long-term debt, excluding leases </span></div><div style="padding-left:12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and current maturities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>435.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 424400000 435500000 0 0 0 0 423700000 435800000 300000 600000 0.37 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">4.    GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Divestiture</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(276.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(282.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>349.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>599.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>208.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Customer relationships, a definite-lived intangible assets.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding membership interests of Exact Diagnostics, LLC in August 2019 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$28.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill and </span><span style="font-family:inherit;font-size:11pt;"><span>$26.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> of definite-lived intangible assets: </span><span style="font-family:inherit;font-size:11pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Customer relationships, </span><span style="font-family:inherit;font-size:11pt;"><span>$8.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Developed product technology, </span><span style="font-family:inherit;font-size:11pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Tradenames and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Backlog.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In conjunction with the purchase of all the issued and outstanding stock of a small U.S. private company in March 2019 (see Note 2, "Acquisitions"), we recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill that included workforce and time-to-market advantage, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> of Developed product technology, a definite-lived intangible asset, and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of In-process research and development, an indefinite-lived intangible asset.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In March 2018, we wrote off </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> of goodwill from our Clinical Diagnostics segment as a result of a divestiture of a product line.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2018, we impaired goodwill associated with our 1999 acquisition of Pasteur Sanofi Diagnostics S.A., 2007 through 2012 acquisitions of DiaMed Holding AG, DiaMed Fennica Oy, DiaMed (G.B.) Limited, and DiaMed Benelux (collectively DiaMed), 2010 acquisition of Biotest AG, and 2013 acquisition of AbD Serotec in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$18.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$247.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$10.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$5.9 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. Goodwill for DiaMed, Biotest AG and AbD Serotec was fully impaired at December 31, 2018. Impairments for the Pasteur Sanofi Diagnostics S.A., DiaMed and Biotest AG were included in our Clinical Diagnostics segment's results of operations, and the impairment for AbD Serotec was included in our Life Science segment's results of operations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-Average Amortization Period (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.36</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(74.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">5.71</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>188.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(162.6</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(93.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>50.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.74</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(44.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.50</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>525.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(380.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>525.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(380.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-Average Amortization Period (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3.98</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.64</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(159.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.34</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(86.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">9.72</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3.42</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7.01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>493.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In 2018, we impaired developed product technology and fully impaired covenants not to compete in the amounts of </span><span style="font-family:inherit;font-size:11pt;"><span>$8.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, associated with our 2012 acquisition of a cell sorting system from Propel Labs, Inc. These impairments were included in our Life Science segment's results of operations. The impairments were based upon a revision of our Level 3 valuation inputs, i.e., expected future cash flows.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization expense related to purchased intangible assets for the years ended December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$23.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$28.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$30.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  Estimated future amortization expense (based on existing purchased intangible assets) for the years ending December 31, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2021</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2022</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2023</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2024</span><span style="font-family:inherit;font-size:11pt;"> and thereafter is </span><span style="font-family:inherit;font-size:11pt;"><span>$23.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$22.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$19.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$18.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$16.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$44.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to goodwill by segment were as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.8515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Life<br/>Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical<br/>Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of January 1:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>324.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>559.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(17.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(53.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>198.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>307.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>506.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>44.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Divestiture</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(276.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(282.0</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Currency fluctuations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balances as of December 31:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>349.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>599.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>234.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>320.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated impairment losses and write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(41.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(293.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(335.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>208.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>192.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 234500000 320500000 555000000.0 234700000 324600000 559300000 41800000 293400000 335200000 35900000 17300000 53200000 192700000 27100000 219800000 198800000 307300000 506100000 15600000 28700000 44300000 0 0 0 0 0 0 0 1400000 1400000 0 0 0 5900000 276100000 282000000.0 0 0 0 -200000 -2700000 -2900000 250100000 349200000 599300000 234500000 320500000 555000000.0 41800000 293400000 335200000 41800000 293400000 335200000 208300000 55800000 264100000 192700000 27100000 219800000 3400000 28700000 26800000 16100000 8100000 2500000 100000 15600000 5500000 200000 1400000 18100000 247200000 10800000 5900000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-Average Amortization Period (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.36</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>107.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(74.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">5.71</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>188.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(162.6</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>144.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(93.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>50.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.74</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(44.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.50</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>525.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(380.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In-process research and development</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total purchased intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>525.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(380.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>145.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-Average Amortization Period (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchase</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Carrying</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Customer relationships/lists</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3.98</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>88.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(68.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Know how</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">6.64</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(159.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Developed product technology</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">8.34</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>130.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(86.6</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>43.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Licenses</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">9.72</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(40.9</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tradenames</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">3.42</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.3</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Covenants not to compete</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">7.01</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">     Total definite-lived intangible assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>493.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(360.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>133.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 107200000 74300000 32900000 188500000 162600000 25900000 144200000 93900000 50300000 76000000.0 44400000 31600000 6400000 3600000 2800000 3200000 1400000 1800000 100000 100000 0 525600000 380300000 145300000 200000 200000 525800000 380300000 145500000 88700000 68300000 20400000 190600000 159800000 30800000 130400000 86600000 43800000 76300000 40900000 35400000 3900000 3300000 600000 3200000 1100000 2100000 493100000 360000000.0 133100000 8800000 1700000 23500000 28300000 30800000 23500000 22800000 19600000 18700000 16600000 44100000 <div style="line-height:120%;padding-left:0px;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;padding-right:48px;">5.</span><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">NOTES PAYABLE AND LONG-TERM DEBT</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had </span><span style="font-family:inherit;font-size:11pt;"><span>$207.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> available for borrowing and usage as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, which was reduced by </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>424.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Finance leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(426.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Senior Notes due 2020</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2010, Bio-Rad sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$425.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> principal amount of Senior Notes due December 2020 (</span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes).  The sale yielded net cash proceeds of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$422.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> at an effective rate of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.946%</span></span><span style="font-family:inherit;font-size:11pt;">.  The </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes pay a fixed rate of interest of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> per year.  We have the option to redeem any or all of the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>4.875%</span></span><span style="font-family:inherit;font-size:11pt;"> Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Credit Agreement</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In April 2019, Bio-Rad entered into a </span><span style="font-family:inherit;font-size:11pt;color:#000000;font-style:normal;text-decoration:none;"><span>$200.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">; however, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> was utilized for domestic standby letters of credit that reduced our borrowing availability as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. The Credit Agreement matures in </span><span style="font-family:inherit;font-size:11pt;">April 2024</span><span style="font-family:inherit;font-size:11pt;">. If we had borrowed against our Credit Agreement, the borrowing rate would have been </span><span style="font-family:inherit;font-size:11pt;"><span>3.035%</span></span><span style="font-family:inherit;font-size:11pt;"> at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of long-term debt at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> were as follows: </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$426.8 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">thereafter</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$9.7 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 207500000 4200000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The principal components of long-term debt are as follows (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">4.875% Senior Notes due 2020, net of discount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>425.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.6</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt less unamortized discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>424.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>423.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Finance leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>15.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital leases and other debt</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>439.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Less current maturities</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(426.2</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>438.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 425000000.0 425000000.0 600000 1300000 424400000 423700000 15400000 0 0 15700000 439800000 439400000 426200000 500000 13600000 438900000 425000000.0 0.04875 422600000 0.04946 0.04875 0.04875 0.04875 0.04875 0.04875 0.04875 200000000.0 200000 0.03035 426800000 1600000 1500000 400000 400000 9700000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">6. INCOME TAXES</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The U.S. and international components of income before taxes are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,034.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,227.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The provision for income taxes consists of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>409.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit) </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>502.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25.0</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">On December 22, 2017, the U.S. enacted comprehensive tax legislation (the “Tax Act”). The Tax Act made broad and complex changes to the U.S. tax code, including the imposition of a one-time mandatory deemed repatriation tax (“Transition Tax”) on certain earnings accumulated offshore since 1986 and the reduction of the corporate tax rate from 35% to 21% for U.S. taxable income, resulting in a one-time remeasurement of U.S. federal deferred tax assets and liabilities. In 2017, we recorded an income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> related to the Transition Tax and remeasurement of our U.S. federal deferred tax assets and liabilities. We completed our accounting for the Tax Act under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) in 2018, which resulted in an additional income tax benefit of </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our effective income tax rate was </span><span style="font-family:inherit;font-size:11pt;"><span>22.2%</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>28.7%</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>(25.0)%</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The effective tax rate for 2018 was driven by detriments due to non-deductible impairment charges and the taxation of our foreign operations, partially offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$49 million</span></span><span style="font-family:inherit;font-size:11pt;"> benefit recorded as a result of the completion of our accounting for the Tax Act under SAB 118. The effective tax rate for 2017 was driven by a </span><span style="font-family:inherit;font-size:11pt;"><span>$70 million</span></span><span style="font-family:inherit;font-size:11pt;"> benefit recorded as a provisional estimate of the accounting for the Tax Act. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Many jurisdictions in which we operate have statutory tax rates that differ from the U.S. statutory tax rate of 21%. Our effective tax rate is impacted, either favorably or unfavorably, by many factors including, but not limited to the jurisdictional mix of income before tax, changes to statutory tax rates, changes in tax laws or regulations, tax audits and settlements, and generation of tax credits.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lease obligations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(67.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,001.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>540.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,086.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>580.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(948.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(504.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, and have maintained a valuation allowance on such deferred tax assets. The valuation allowance against our deferred tax assets in California and certain foreign jurisdictions decreased by </span><span style="font-family:inherit;font-size:11pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, our foreign and California net operating loss carryforwards were approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$239.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">$52.7 million</span><span style="font-family:inherit;font-size:11pt;color:#0000ff;text-decoration:underline;">,</span><span style="font-family:inherit;font-size:11pt;"> respectively. Of our foreign net operating losses, </span><span style="font-family:inherit;font-size:11pt;"><span>$124.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> may be carried forward indefinitely. The majority of the remaining foreign net operating losses, if not utilized, will begin to expire in 2025. Our California net operating loss carryforwards, if not utilized, will begin to expire in 2028. As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, our California research tax credit carryforwards were approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$35.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> and may be carried forward indefinitely.</span></div><div style="line-height:174%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our income tax returns are audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. The tax years open to examination include the years 2012 and forward for the U.S. and certain foreign jurisdictions including France, Germany, India and Switzerland. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues of the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. Related to the unrecognized tax benefits noted above, the cumulative amount of accrued interest and penalties as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively was </span><span style="font-family:inherit;font-size:11pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$9.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.9 million</span></span><span style="font-family:inherit;font-size:11pt;">. Bio-Rad accrued interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$(1.4) million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.9) million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The total unrecognized tax benefits and interest and penalties of </span><span style="font-family:inherit;font-size:11pt;"><span>$50.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> was partially offset by deferred tax assets of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and prepaid taxes of </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, for a net amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$43.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitation for certain jurisdictions, we believe that within the next twelve months it is reasonably possible that our previously unrecognized tax benefits could decrease by approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:11pt;">. Substantially all such amounts will impact our effective income tax rate if recognized.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">It is generally our intention to repatriate certain foreign earnings to the extent that such repatriations are not restricted by local laws or accounting rules, and there are no substantial incremental costs. The determination of the amount of the unrecognized deferred tax liability for foreign earnings that are indefinitely reinvested is not practicable to estimate.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The U.S. and international components of income before taxes are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S.</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,034.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>363.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,227.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>149.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Income before taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1034000000.0 363400000 72800000 1227100000 149300000 25000000.0 2261100000 512700000 97800000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The provision for income taxes consists of the following (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>32.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Current tax expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>41.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. Federal</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>409.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(69.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.3</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax expense (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(84.8</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-current tax expense (benefit) </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.4</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>502.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(24.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13000000.0 8800000 6700000 4400000 2200000 3400000 23500000 30500000 32000000.0 40900000 41500000 42100000 409700000 114000000.0 -69800000 24400000 6600000 4300000 16100000 300000 -19300000 450200000 120900000 -84800000 11300000 -15400000 18300000 502400000 147000000.0 -24400000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U. S. statutory tax rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impact of foreign operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Research tax credits</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nontaxable subsidies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Nondeductible executive compensation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. taxation of foreign income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Acquisition-related</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">U.S. tax reform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(71.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">State taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Provision for (benefit from) income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(25.0</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.210 0.210 0.350 -0.097 -0.041 0.060 0.002 0.007 0.038 0.001 0.002 0.022 0 0.056 0.012 0.001 0.010 0.053 0.001 0.002 0.020 0.103 0.155 0.027 0 -0.002 0.101 0 -0.096 -0.710 0.010 0.017 0.029 -0.001 0.005 -0.026 0.222 0.287 -0.250 70000000 -49000000 0.222 0.287 -0.250 -49000000 70000000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax assets:</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bad debt, inventory and warranty accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other post-employment benefits, vacation and other reserves</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Tax credit and net operating loss carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>75.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lease obligations</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:Times_New_Roman;font-size:11pt;"><span>48.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">    Total gross deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>205.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>147.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(67.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(70.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">       Total deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>76.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Deferred tax liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lease assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>46.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Investments and intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,001.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>540.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">        Total deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,086.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>580.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(948.2</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(504.4</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 23900000 21700000 23000000.0 23000000.0 83700000 75300000 48600000 0 26000000.0 27100000 205200000 147100000 67200000 70800000 138000000.0 76300000 38400000 40100000 46400000 0 1001400000 540600000 1086200000 580700000 948200000 504400000 3600000 239000000.0 124700000 35700000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reductions to tax positions related to prior years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.0</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Additions to tax positions related to the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.8</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Lapse of statute of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(3.4</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Currency translation</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Unrecognized tax benefits – December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>39.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>54.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 29800000 54900000 21100000 7600000 600000 1300000 700000 20200000 1000000.0 3000000.0 4600000 34800000 0 6800000 200000 400000 1100000 3400000 100000 2200000 2300000 39200000 29800000 54900000 11200000 9500000 10900000 1700000 -1400000 -900000 50400000 1400000 5400000 43600000 2800000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">7.    STOCKHOLDERS' EQUITY</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad’s issued and outstanding stock consists of Class A Common Stock (Class A) and Class B Common Stock (Class B).  Each share of Class A and Class B participates equally in the earnings of Bio-Rad, and is identical in all respects except as follows. Class A has limited voting rights.  Each share of Class A is entitled to one tenth of a vote on most matters, and each share of Class B is entitled to one vote.  Additionally, Class A stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>25%</span></span><span style="font-family:inherit;font-size:11pt;"> of the Board of Directors and Class B stockholders are entitled to elect </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>75%</span></span><span style="font-family:inherit;font-size:11pt;"> of the directors. Cash dividends may be paid on Class A shares without paying a cash dividend on Class B shares but no cash dividend may be paid on Class B shares unless at least an equal cash dividend is paid on Class A shares.  Class B shares are convertible at any time into Class A shares on a one-for-one basis at the option of the stockholder.  The founders of Bio-Rad, the Schwartz family, collectively hold a majority of Bio-Rad’s voting stock.  As a result, the Schwartz family is able to exercise significant influence over Bio-Rad.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to Bio-Rad's issued common stock shares are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,884</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,096</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,966</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;">Treasury Shares</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November, 2017, the Board of Directors authorized a new share repurchase program, granting Bio-Rad authority to repurchase, on a discretionary basis, up to </span><span style="font-family:inherit;font-size:11pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of outstanding shares of our common stock. Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:48%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number of Shares Purchased</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average Price per Share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Shares Repurchased To Date</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining Authorized Value </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 1, 2018 - November 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,911</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,150</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">May 1, 2019 - May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>25,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>291.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>218,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">June 1, 2019 - June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>25,977</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>292.01</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>244,548</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>186.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">August 1, 2019 - August 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>14,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>339.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>259,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>181.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">November 1, 2019 - November 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>22,343</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>358.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>281,636</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>173.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">In 2019, we used </span><span style="font-family:inherit;font-size:11pt;"><span>118,910</span></span><span style="font-family:inherit;font-size:11pt;"> of the repurchased shares in connection with the vesting of restricted stock units and </span><span style="font-family:inherit;font-size:11pt;"><span>19,755</span></span> shares in connection with ESPP stock purchases. The Credit Agreement may limit our ability to repurchase our stock. 0.25 0.75 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes to Bio-Rad's issued common stock shares are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:56%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class A Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Class B Shares</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at January 1, 2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,454</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,124</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,679</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,884</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,096</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">B to A conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24,966</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,090</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 24454000 5124000 34000 34000 191000 18000 24679000 5108000 30000 30000 175000 18000 24884000 5096000 24000 24000 58000 18000 24966000 5090000 250000000.0 The share repurchase activity under the share repurchase program through open market transactions in 2018 and 2019 is summarized as follows:<div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:48%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number of Shares Purchased</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average Price per Share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Shares Repurchased To Date</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining Authorized Value </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 1, 2018 - November 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>178,911</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.39</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>193,150</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">May 1, 2019 - May 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>25,421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>291.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>218,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>193.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">June 1, 2019 - June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>25,977</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>292.01</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>244,548</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>186.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">August 1, 2019 - August 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>14,745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>339.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>259,293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>181.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#000000;">November 1, 2019 - November 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>22,343</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>358.04</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>281,636</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>173.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 178911 273.39 193150 201100000 25421 291.70 218571 193700000 25977 292.01 244548 186100000 14745 339.05 259293 181100000 22343 358.04 281636 173100000 118910 19755 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">8.    </span><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains (losses) on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:2%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains (losses) on equity securities and available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reclassification adjustments are calculated using the specific identification method.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Accumulated other comprehensive income (loss) included in our Consolidated Balance Sheets and Consolidated Statements of Changes in Stockholders' Equity consists of the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign other post-employment benefits adjustments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net unrealized holding gains (losses) on available-for-sale investments</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Accumulated other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of January 1, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(112.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(35.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified from Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax effects</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive (loss) income, net of income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balances as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(87.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 77400000 -22300000 4400000 59500000 -112900000 6900000 -1400000 -107400000 0 2400000 300000 2700000 0 1800000 0 1800000 -112900000 7500000 -1100000 -106500000 -35500000 -14800000 3300000 -47000000.0 -36500000 -10000000.0 4800000 -41700000 0 1500000 -400000 1100000 400000 -1100000 500000 -200000 -36900000 -7400000 3900000 -40400000 -72400000 -22200000 7200000 -87400000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The amounts reclassified out of Accumulated other comprehensive income into the Consolidated Statements of Income, with presentation location, were as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.65625%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:24%;"/><td style="width:5%;"/><td style="width:2%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of Comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of foreign other post-employment benefit items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net holding gains (losses) on equity securities and available for sale investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -1500000 -2400000 400000 -300000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Description of Share-Based Compensation Plans</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We believe our share-based compensation plans align the interests of our employees with those of our shareholders.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Equity Award Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have two equity award plans for officers and certain other employees: the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2007 Plan. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of </span><span style="font-family:inherit;font-size:11pt;"><span>2,095,049</span></span><span style="font-family:inherit;font-size:11pt;"> shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, there were </span><span style="font-family:inherit;font-size:11pt;"><span>1,507,489</span></span><span style="font-family:inherit;font-size:11pt;"> shares available to be granted.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>10</span></span><span style="font-family:inherit;font-size:11pt;"> years and vest in increments of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>20%</span></span><span style="font-family:inherit;font-size:11pt;"> per year over a </span><span style="font-family:inherit;font-size:11pt;">five</span><span style="font-family:inherit;font-size:11pt;">-year period on the yearly anniversary date of the grant.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span><span style="font-family:inherit;font-size:11pt;font-style:italic;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>10%</span></span><span style="font-family:inherit;font-size:11pt;"> of their compensation up to </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$25,000</span></span><span style="font-family:inherit;font-size:11pt;"> annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>85%</span></span><span style="font-family:inherit;font-size:11pt;"> of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;text-decoration:none;"><span>1,300,000</span></span><span style="font-family:inherit;font-size:11pt;"> shares of Class A common stock under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, we recognized share-based compensation expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$35.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$27.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$23.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  The income tax benefit related to share-based compensation expense was </span><span style="font-family:inherit;font-size:11pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> for </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. We did not capitalize any share-based compensation expense in inventory.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The tax benefit from share-based compensation vested or exercised during </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;"><span>$6.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,640</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138.81</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,490</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98.00</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,300</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>344,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.23</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.76</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94,172</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.93</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.45</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$12 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$10 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash received from stock options exercised during </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively.  </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, there was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.69</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>93.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,400</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,782</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332.38</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134,525</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,715</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243.76</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.08</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total fair value of restricted stock units vested in </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$44.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$40.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$27.7 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively. As of </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, there was approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$119.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3</span></span><span style="font-family:inherit;font-size:11pt;"> years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plans</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We sold </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>58,717</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$14.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:Times New Roman;font-size:11pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:none;"><span>63,464</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>74,409</span></span><span style="font-family:inherit;font-size:11pt;"> shares for </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> under the 2011 ESPP to employees in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively.  At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>599,531</span></span><span style="font-family:inherit;font-size:11pt;"> shares remain authorized and available for issuance under the 2011 ESPP.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.</span></div> 2095049 1507489 P10Y 0.20 0.10 25000 0.85 1300000 35600000 27800000 23400000 5600000 4400000 5800000 5400000 5400000 6300000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes stock option activity:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Value</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,640</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138.81</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(55,490</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98.00</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited/expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,300</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>231.71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>344,522</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.23</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.76</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94,172</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>273.93</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.45</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250,350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.46</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 373640 138.81 34672 328.48 55490 98.00 8300 231.71 344522 162.23 P4Y9M3D 71.6 94172 273.93 P8Y5M12D 9.1 250350 120.22 P3Y5M15D 62.5 12000000 8000000 10000000 2600000 500000 1600000 7000000.0 P3Y <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:340px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:87px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:83px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:94px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.69</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.87</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>93.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>105.94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.22 0.22 0.20 0.0169 0.0285 0.0187 P7Y6M P7Y7M6D P7Y2M12D 0 0 0 93.96 105.94 58.65 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes restricted stock unit activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:654px;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:186px;"/><td style="width:5px;"/><td style="width:106px;"/><td style="width:4px;"/><td style="width:10px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:110px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:96px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted Stock</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Grant-Date</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-Average</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remaining</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual Term</span></div><div style="text-align:center;vertical-align:top;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aggregate</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intrinsic Value</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(in millions)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>474,400</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>235.58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,782</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332.38</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134,525</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44,715</span></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243.76</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>279.14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.08</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 474400 235.58 174782 332.38 134525 206.44 44715 243.76 469942 279.14 P2Y29D 173.9 44800000 40000000.0 27700000 119500000 P3Y <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:529px;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:245px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/><td style="width:5px;"/><td style="width:33px;"/><td style="width:5px;"/><td style="width:8px;"/><td style="width:46px;"/><td style="width:12px;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.25</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.83</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Expected dividend</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Weighted-average fair value</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">of purchase rights</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>55.04</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.31 0.27 0.19 0.0225 0.0182 0.0083 P0Y2M26D P0Y2M26D P0Y2M26D 0 0 0 60.39 55.04 38.86 58717 14300000 63464 13600000 74409 13000000.0 599531 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">10. OTHER INCOME AND EXPENSE, NET</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on equity method investments were recorded in light of the investees' financial condition in the first and fourth quarters of 2019.</span></div> <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net includes the following components (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Interest and investment income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(19.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net realized gains on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(26.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 30500000 26600000 19100000 1500000 1600000 100000 5800000 800000 7000000.0 0 4100000 0 0 5100000 0 100000 0 1500000 26100000 36600000 10700000 <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">11. SUPPLEMENTAL CASH FLOW INFORMATION</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96956977964324%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:51%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,758.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>134.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reduction in the carrying amount of right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2,031.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payments for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in inventories, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(45.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other long term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>457.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>285.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Sold marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">11. SUPPLEMENTAL CASH FLOW INFORMATION</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The reconciliation of net income to net cash provided by operating activities is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.96956977964324%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:51%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,758.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>365.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>122.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustments to reconcile net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">to net cash provided by operating activities </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>134.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reduction in the carrying amount of right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>40.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>35.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>23.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gains on dispositions of securities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other-than-temporary impairment losses on investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair market value of equity securities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2,031.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Losses on dispositions of fixed assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on sale of land</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gain on divestiture of a product line</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Payments for operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(38.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Changes in fair value of contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(18.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in accounts receivable, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(64.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in inventories, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(47.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease (increase) in other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>61.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(35.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">and other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(45.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Decrease in income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(20.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(22.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>120.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(82.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(Increase) decrease in other long term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Increase (decrease) in other long term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>38.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Impairment losses on goodwill and long-lived assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>292.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>457.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>285.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>104.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Non-cash investing activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchased property, plant and equipment</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Purchased marketable securities and investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Sold marketable securities and investments</span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#d6ffd2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#d6ffd2;border-top:3px double #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#d6ffd2;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1758700000 365600000 122200000 134200000 138100000 148700000 40300000 0 0 35600000 27800000 23400000 1500000 1600000 100000 5800000 800000 7000000.0 2031000000.0 606200000 0 -1200000 -2000000.0 -8100000 0 4100000 0 0 5100000 0 38600000 0 0 -1600000 -6200000 -18100000 -1600000 -59700000 64100000 -24200000 12900000 47700000 -61800000 15300000 35700000 10600000 -45600000 7800000 -4200000 -20900000 -22400000 -450200000 -120900000 82000000.0 1700000 -1100000 -2300000 -13400000 10000000.0 -38100000 0 292500000 11500000 1100000 -4900000 -5100000 457900000 285500000 104100000 8100000 5700000 0 1400000 800000 2800000 1300000 0 300000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">12. COMMITMENTS AND CONTINGENT LIABILITIES</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Deferred Profit Sharing Retirement Plan</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have a profit sharing plan covering substantially all U.S. employees.  Contributions are made at the discretion of the Board of Directors.  Bio-Rad has no liability other than for the current year’s contribution.  Contribution expense was </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$15.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Purchase Obligations </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, we had purchase obligations that have not been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$35.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, which include agreements to purchase goods or services that are enforceable and legally binding to Bio-Rad and that specify all significant terms and exclude agreements that are cancelable without penalty. Recognition of purchase obligations occurs when products or services are delivered to Bio-Rad. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our purchase obligations that have not been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> are as follows: </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$34.0 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:10pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Long-Term Liabilities</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, we had obligations that have been recognized on our balance sheet of </span><span style="font-family:inherit;font-size:11pt;"><span>$118.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, which primarily represent recognized long-term obligations for other post-employment benefits as indicated below that are mostly due in more than 5 years, and long-term deferred revenue. Excluded are tax liabilities for uncertain tax positions and contingencies. We are not able to reasonably estimate the timing of future cash flows of these tax liabilities, therefore, our income tax obligations are excluded. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The annual future fixed and determinable portion of our obligations that have been recognized on our balance sheet as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> were as follows: </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$5.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$12.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and after </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$88.3 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Letters of Credit/Guarantees</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In the ordinary course of business, we are at times required to post letters of credit/guarantees.  The letters of credit/guarantees are issued by financial institutions to guarantee our obligations to various parties. We were contingently liable for </span><span style="font-family:inherit;font-size:11pt;"><span>$4.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> of standby letters of credit/guarantees with financial institutions as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Other Post-Employment Benefits </span></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In several foreign locations we are statutorily required to provide retirement benefits or a lump sum termination indemnity to our employees upon termination for virtually any reason. These plans are accounted for as defined benefit plans and the associated net benefit obligation at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> of </span><span style="font-family:inherit;font-size:11pt;"><span>$81.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$70.4 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets. Most plans are not required to be funded, and as such, there is no trust or other device used to accumulate assets or settle these obligations. However, some of these plans require funding based on local laws in which there is a trust or other device administered by an external plan manager that is used to accumulate assets to assist in settling these obligations. The following disclosures include such plans, which are located in France, Switzerland, Germany, Korea, India, Thailand, Italy, Dubai and Japan.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Obligations and Funded Status</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$137.3</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$136.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(81.5)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(81.5)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Components of Net Periodic Benefit Cost</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$7.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Assumptions</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">In some foreign locations we have service award plans that are paid based upon the number of years of employment.</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;">Under these plans, the liability at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> was </span><span style="font-family:inherit;font-size:11pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:11pt;">, respectively, and has been included in Accrued payroll and employee benefits and Other long-term liabilities in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Concentrations of Labor Subject to Collective Bargaining Agreements</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">At </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, approximately </span><span style="font-family:inherit;font-size:11pt;"><span>seven</span></span><span style="font-family:inherit;font-size:11pt;"> percent of Bio-Rad's approximately </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>3,180</span></span> U.S. employees were covered by a collective bargaining agreement, which will expire on November 14, 2023.  Many of Bio-Rad's non-U.S. full-time employees, especially in France, are covered by collective bargaining agreements. 16100000 15900000 16000000.0 35800000 34000000.0 1000000.0 200000 200000 200000 200000 118400000 5200000 12800000 4500000 4300000 3300000 88300000 4200000 81500000 70400000 <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Obligations and Funded Status</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table sets forth the change in benefit obligations, fair value of plan assets and amounts recognized in the Consolidated Balance Sheets for the plans (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Change in benefit obligation:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at beginning of year</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$137.3</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$136.6</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actuarial (gain) loss</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Change in plan assets:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at beginning year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual return on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employer contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plan participants' contributions</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change attributable to foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under funded status of plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(81.5)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Amounts recognized in the consolidated balance sheets: </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities (Accrued payroll and employee benefits) </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(1.1)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Noncurrent liabilities (Other long-term liabilities)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(80.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net liability, end of fiscal year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(81.5)</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$(70.4)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 137300000 136600000 6900000 7500000 1500000 1100000 3500000 3100000 11900000 -5400000 2100000 3100000 200000 -500000 -3800000 0 -1600000 -2000000.0 153800000 137300000 66900000 61700000 900000 300000 4700000 4000000.0 3800000 3100000 800000 1500000 3800000 0 600000 -700000 72300000 66900000 -81500000 -70400000 1100000 1100000 80400000 69300000 81500000 70400000 <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Components of Net Periodic Benefit Cost</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The following sets forth the net periodic benefit cost (income) for the periods indicated (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:36%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$7.5</span></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$6.5</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected returns on plan assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of actuarial losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of prior service costs </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic benefit costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$8.9</span></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$9.1</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 6900000 7500000 6500000 1500000 1100000 1100000 1200000 1100000 1100000 -1000000.0 -1300000 -1400000 0 100000 0 -900000 0 -1200000 9100000 8900000 9100000 <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Assumptions</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the benefit obligations are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:50%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation rate increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;background-color:#ffffff;">The weighted-average assumptions used in computing the net periodic benefit costs are as follows:</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:44%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount rate</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected long-term rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.005 0.011 0.017 0.018 0.011 0.008 0.009 0.018 0.018 0.019 3500000 3100000 0.07 3180 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">13.    LEGAL PROCEEDINGS</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">On May 27, 2015, our former general counsel, Sanford S. Wadler, filed a lawsuit in the U.S. District Court, Northern District of California, against us and four of our then current directors and one former director. The plaintiff’s suit alleged whistleblower retaliation in violation of the Sarbanes-Oxley Act and the Dodd-Frank Act for raising FCPA-related concerns. Mr. Wadler also alleged wrongful termination in violation of public policy, non-payment of wages and waiting time penalties in violation of the California Labor Code. The plaintiff sought back pay, compensatory damages for lost wages, earnings, retirement benefits and other employee benefits, compensation for mental pain and anguish and emotional distress, waiting time penalties, punitive damages, litigation costs (including attorneys’ fees) and reinstatement of employment. On July 28, 2015, we filed a motion to dismiss the plaintiff's complaint and specifically requested dismissal of the claims alleged against us under the Dodd-Frank Act and California Labor Code 1102.5 and the claims against the directors under the Sarbanes-Oxley Act and the Dodd-Frank Act. On October 23, 2015, the District Court granted our motion with respect to the alleged violations of the Sarbanes-Oxley Act against all the director defendants except Norman Schwartz with prejudice. The Court denied our motion to dismiss the claims under the Dodd-Frank Act as against both us and the director defendants. The trial commenced on January 17, 2017 and concluded on February 6, 2017. Mr. Wadler was awarded</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;"><span>$10.92 million</span></span><span style="font-family:inherit;font-size:11pt;">, plus prejudgment interest of </span><span style="font-family:inherit;font-size:11pt;"><span>$141,608</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-size:11pt;">post-judgment interest, and Mr. Wadler’s litigation costs, expert witness fees, and reasonable attorneys’ fees as approved by the Court. We previously accrued for the judgment, interest and Mr. Wadler's litigation costs. On June 6, 2017, we filed a notice of appeal with the United States Court of Appeals for the Ninth Circuit. Oral arguments occurred on November 14, 2018. On February 26, 2019, the United States Court of Appeals for the Ninth Circuit issued its decision, reversing in part, vacating in part, and affirming in part. Specifically, the court: (1) reversed the Dodd-Frank claim, which amounts to about</span><span style="font-family:inherit;font-size:11pt;"> </span><span style="font-family:inherit;font-size:11pt;"><span>$2.96 million</span></span><span style="font-family:inherit;font-size:11pt;"> plus interest, and directed the district court to enter judgment in Bio-Rad’s favor on that claim; (2) vacated the SOX claim due to instructional error and remanded for further proceedings, including whether a new trial is needed; and (3) affirmed the California public policy claim and the </span><span style="font-family:inherit;font-size:11pt;"><span>$7.96 million</span></span><span style="font-family:inherit;font-size:11pt;"> in damages attributable to it. On March 12, 2019 we filed a petition for panel rehearing or rehearing </span><span style="font-family:inherit;font-size:11pt;font-style:italic;">en banc</span><span style="font-family:inherit;font-size:11pt;"> with the United States Court of Appeals for the Ninth Circuit, and this petition was denied on April 8, 2019. On September 24, </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019, Mr. Wadler filed a dismissal with prejudice of all remaining claims under the lawsuit with the U.S. District Court, Northern District of California as a result of a Confidential Settlement Agreement and Satisfaction of Judgment that the parties entered into that was last executed on September 6, 2019. This matter did not have a material impact on our 2019 results of operations and is now closed.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-size:11pt;">We are also party to various other claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 10920000 141608 2960000 7960000 14. SEGMENT INFORMATION<div style="line-height:120%;padding-left:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Bio-Rad is a multinational manufacturer and worldwide distributor of its own life science research products and clinical diagnostics products.  We have two reportable segments:  Life Science and Clinical Diagnostics.  These reportable segments are strategic business lines that offer more than </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;"><span>9,000</span></span><span style="font-family:inherit;font-size:11pt;"> different products and services and require different marketing strategies. We do not disclose quantitative information about our different products and services as it is impractical to do so based primarily on the numerous products and services that we sell and the global markets that we serve.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. These products are sold to university and medical school laboratories, pharmaceutical and biotechnology companies, food testing laboratories and government and industrial research facilities.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. These products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories and insurance and forensic testing laboratories.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other Operations include the remainder of our Analytical Instruments segment.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. The accounting policies of the segments are the same as those described in Significant Accounting Policies (see Note 1).  Segment profit or loss includes an allocation of corporate expense based upon sales and an allocation of interest expense based upon accounts receivable and inventories.  The difference between total segment allocated interest expense, depreciation and amortization, and capital expenditures and the corresponding consolidated amounts is attributable to our corporate headquarters.  Segments are expected to manage only assets completely under their control.  Accordingly, segment assets include primarily accounts receivable, inventories and gross machinery and equipment.  Goodwill balances have been included in corporate for segment reporting purposes.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>885.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,412.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>861.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment profit (loss)</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(145.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>496.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,075.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>949.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics segment loss for 2018 was due to impairment losses taken on goodwill of </span><span style="font-family:inherit;font-size:11pt;"><span>$276.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> (see Note 4 to the consolidated financial statements).</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets at December 31, 2019 increased from December 31, 2018 balances due to inclusion of operating lease right-of-use assets in segment assets (see Note 16 to the consolidated financial statements).</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating expense consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. The following reconciles total segment profit to consolidated income before taxes (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(116.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,031.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following reconciles total segment assets to consolidated total assets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,581.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,405.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,233.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,047.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, and operating lease right-of-use </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  assets, excluding segment specific balances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,863.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8,008.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,611.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets at December 31, 2019 increased from December 31, 2018 balance due to increase in fair market value of equity securities (see Note 3 to the consolidated financial statements).</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>792.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asia</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>505.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>899.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>863.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,311.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,289.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>129.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asia</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>468.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>369.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>731.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>530.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been adjusted to exclude Other investments.</span></div> 9000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Information regarding industry segments at </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:none;">2017</span><span style="font-family:inherit;font-size:11pt;"> and for the years then ended is as follows (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:81.0546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:33%;"/><td style="width:13%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Science</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other</span></div><div style="text-align:center;vertical-align:top;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operations</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment net sales </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>885.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,412.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>861.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,411.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>785.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,360.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Allocated interest expense</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Depreciation and amortization</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>71.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>34.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>80.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment profit (loss)</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>72.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>148.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(145.7</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>114.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Segment assets</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>496.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,075.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>450.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>949.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Capital expenditures</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>58.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>60.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div> 885900000 1412000000.0 13800000 861700000 1411800000 15900000 785200000 1360800000 14200000 7400000 15900000 100000 7200000 16700000 100000 7000000.0 14900000 0 29400000 71700000 900000 34100000 72000000.0 500000 36200000 80200000 0 72100000 148500000 -1500000 28700000 -145700000 200000 -9900000 114800000 1400000 496100000 1075800000 9200000 450200000 949000000.0 5900000 16600000 58900000 600000 36700000 60500000 500000 276100000 he following reconciles total segment profit to consolidated income before taxes (in millions):<div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:90.4296875%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment profit (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(116.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>106.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency exchange losses, net</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.2</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(9.1</span></span></div></td><td style="vertical-align:top;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net corporate operating, interest and other expense not allocated to segments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(12.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(10.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Change in fair market value of equity securities</span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,031.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>606.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>26.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Consolidated income before income taxes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,261.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>512.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>97.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 219100000 -116800000 106300000 -2200000 -2900000 -9100000 -12900000 -10400000 -10100000 2031000000.0 606200000 0 26100000 36600000 10700000 2261100000 512700000 97800000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following reconciles total segment assets to consolidated total assets (in millions):</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:87.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total segment assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,581.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,405.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,233.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1,047.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Property, plant and equipment, net, and operating lease right-of-use </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">  assets, excluding segment specific balances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>66.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>79.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Goodwill, net</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>264.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>219.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4,863.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,859.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8,008.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5,611.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1581100000 1405100000 1233500000 1047200000 66800000 79900000 264100000 219800000 4863400000 2859100000 8008900000 5611100000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.1171875%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>770.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>792.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>758.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asia</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>505.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>495.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>461.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>899.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>863.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>800.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>137.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>138.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>140.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,311.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:8px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,289.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2,160.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:85.3515625%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">December 31,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>198.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>129.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Asia</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>51.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>468.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>369.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Other (primarily Canada and Latin America)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>12.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>731.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>530.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Prior year amounts have been adjusted to exclude Other investments.</span></div> 770300000 792000000.0 758500000 505000000.0 495500000 461300000 899100000 863600000 800200000 137300000 138300000 140000000.0 2311700000 2289400000 2160200000 198300000 129100000 51500000 20700000 468700000 369200000 12700000 11100000 731200000 530100000 RESTRUCTURING COSTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for European Reorganization</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In May 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance enterprise resource planning ("ERP") platform, were incurred through and completed in December 2019. We recorded approximately </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in restructuring charges and adjustments related to severance and other employee benefits for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. From May 2016 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$12.7 million</span></span><span style="font-family:inherit;font-size:11pt;">. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.2) million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Selling, general and administrative expense of zero, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The amounts adjusted were primarily for additional positions identified for elimination, partially offset by employees finding other positions within Bio-Rad or leaving prematurely. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reserve transferred to European and North American Reorganization restructuring costs reserve (see below)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#006ebf;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#006ebf;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for Termination of a Diagnostics Research and Development Project and Facility Closures</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2017, we announced the termination of a diagnostics research and development project in Europe. We recorded restructuring charges and adjustments related to severance and employee benefits of less than </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> and asset write-offs and exit costs of zero, </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. From December 2017 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:11pt;">. This restructuring plan was completed in December 2019.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In June 2018, we announced the closure of a small manufacturing operation in Munich, Germany. We recorded restructuring charges and adjustments related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, respectively. From June 2018 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:11pt;">. This restructuring plan was completed in November 2019.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. We recorded restructuring charges and adjustments related to severance and employee benefits of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.9 million</span></span><span style="font-family:inherit;font-size:11pt;"> and exit costs of zero and </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, respectively. From December 2018 to </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, total expenses were </span><span style="font-family:inherit;font-size:11pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Restructuring charges for the termination of a diagnostics research and development project and the facility closures are all included in our Clinical Diagnostics segment's results of operations. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.3) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$5.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, in Selling, general and administrative expense of zero, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:11pt;">, and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$(0.1) million</span></span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$15.5 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the years ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;">, respectively. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> consisted of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Accrued payroll and employee benefits, </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other current liabilities, and </span><span style="font-family:inherit;font-size:11pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:11pt;"> recorded in Other long-term liabilities in the Consolidated Balance Sheets.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">Restructuring Costs for European and North American Reorganization</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. We recorded </span><span style="font-family:inherit;font-size:11pt;"><span>$25.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> of expense in restructuring charges related to severance and employee benefits for the year ended December 31, 2019. The liability of </span><span style="font-family:inherit;font-size:11pt;"><span>$25.3 million</span></span><span style="font-family:inherit;font-size:11pt;"> as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;"> was recorded in Accrued payroll and employee benefits in the Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of </span><span style="font-family:inherit;font-size:11pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:11pt;">, in Selling, general and administrative expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$14.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and in Research and development expense of </span><span style="font-family:inherit;font-size:11pt;"><span>$6.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> in the Consolidated Statements of Income for the year ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reserve transferred from European Reorganization restructuring costs reserve (see above)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -100000 -200000 500000 12700000 -100000 -100000 -200000 -100000 700000 600000 1000000.0 1600000 2200000 4100000 6300000 0 -100000 -100000 -100000 -100000 -200000 300000 500000 800000 1500000 2900000 4400000 -300000 -400000 -700000 0 0 0 0 0 0 0 100000 100000 0 0 0 600000 1000000.0 1600000 -100000 400000 11000000.0 -100000 10100000 21400000 -300000 1700000 1400000 -100000 3900000 200000 4000000.0 -300000 5400000 2300000 400000 3300000 100000 300000 15500000 3200000 1800000 200000 1200000 11500000 14100000 0 5800000 -400000 300000 7700000 8400000 200000 300000 3200000 11500000 25300000 25300000 4800000 14400000 6100000 <div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:37%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reserve transferred from European Reorganization restructuring costs reserve (see above)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation losses</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>25.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Life Science</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Clinical Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>6.3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(2.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Reserve transferred to European and North American Reorganization restructuring costs reserve (see below)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#006ebf;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;color:#006ebf;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#c5ffc2;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#c5ffc2;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The following table summarizes the activity for the termination of the diagnostics research and development project and the facility closures restructuring reserves for severance and exit costs (in millions): </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:50%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>14.1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Charged to expense</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Adjustment to expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Cash payments</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(7.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Foreign currency translation gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Balance as of December 31</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 0 6200000 19100000 25300000 400000 700000 1100000 300000 400000 700000 -100000 -300000 -400000 6200000 19100000 25300000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">16.    LEASES</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. Our leases have remaining lease terms of </span><span style="font-family:inherit;font-size:11pt;"><span>1</span></span><span style="font-family:inherit;font-size:11pt;"> year to </span><span style="font-family:inherit;font-size:11pt;"><span>19</span></span><span style="font-family:inherit;font-size:11pt;"> years, which includes our determination to exercise renewal options.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The components of lease expense were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Amortization of right-to-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">        Total finance lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The sublease is for a building with a term that ends in 2025, with no options to extend or renew.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating lease cost includes original reduction in the carrying amount of right-of-use assets, the impact of remeasurements, modifications, impairments and abandonments.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Historically, our short-term leases, reflecting leases with a lease term of one year or less, are predominantly comprised of leases with a lease term of one month or less, which are not significant. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Property, plant and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current maturities of long-term debt and notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Long-term debt, net of current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:77%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Lease Term</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases - in years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases - in years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of lease liabilities were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December 31,</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles and other equipment with shorter terms and higher-turn over.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">As of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, we have an additional lease for a facility in Texas that has not commenced of </span><span style="font-family:inherit;font-size:11pt;"><span>$1.6 million</span></span><span style="font-family:inherit;font-size:11pt;">. The operating lease will commence in either the second or third quarter of 2020 with a lease term of </span><span style="font-family:inherit;font-size:11pt;"><span>four years</span></span><span style="font-family:inherit;font-size:11pt;">. </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Operating and Capital Lease Commitments Under ASC 840, Leases</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Rents and Leases</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Rental expense under operating leases was </span><span style="font-family:inherit;font-size:11pt;"><span>$47.4 million</span></span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$43.6 million</span></span><span style="font-family:inherit;font-size:11pt;"> in </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> and 2017, respectively.  Leases were principally for facilities and automobiles.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Annual future minimum lease payments at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> under operating leases were as follows: </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$44.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$37.8 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$27.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$19.7 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$13.9 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;">2024</span><span style="font-family:inherit;font-size:11pt;"> and beyond - </span><span style="font-family:inherit;font-size:11pt;"><span>$25.6 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The total minimum rentals to be received in the future for the sublease as of </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> were </span><span style="font-family:inherit;font-size:11pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:11pt;"> and ends in 2025.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of our capital lease obligations at </span><span style="font-family:inherit;font-size:11pt;">December 31, 2018</span><span style="font-family:inherit;font-size:11pt;"> were as follows: </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2020</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2021</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2022</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; </span><span style="font-family:inherit;font-size:11pt;">2023</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:11pt;">; and </span><span style="font-family:inherit;font-size:11pt;">thereafter</span><span style="font-family:inherit;font-size:11pt;"> - </span><span style="font-family:inherit;font-size:11pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:11pt;">.</span></div> P1Y P19Y <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">The components of lease expense were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Amortization of right-to-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Interest on lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">        Total finance lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sublease income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 51400000 600000 900000 1500000 3000000.0 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Supplemental cash flow information related to leases was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 47200000 900000 600000 28700000 200000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Supplemental balance sheet information related to leases was as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating lease right-of-use assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>201.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Finance Leases</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Property, plant and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Current maturities of long-term debt and notes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Long-term debt, net of current maturities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">      Total finance lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:77%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Remaining Lease Term</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases - in years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases - in years</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Discount Rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">  Finance leases</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 201900000 35400000 176000000.0 211400000 11400000 4200000 7200000 500000 11200000 11700000 P9Y P18Y 0.042 0.065 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Maturities of lease liabilities were as follows (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ending December 31,</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Leases</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>103.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">   Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>255.4</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(44.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 41000000.0 1100000 35800000 1300000 28600000 1200000 24500000 1100000 21800000 1100000 103700000 15200000 255400000 21000000.0 44000000.0 9300000 211400000 11700000 1600000 P4Y 47400000 43600000 44400000 37800000 27400000 19700000 13900000 25600000 17800000 500000 200000 500000 400000 400000 9900000 <div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">17. QUARTERLY FINANCIAL DATA (UNAUDITED)</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Summarized quarterly financial data for </span><span style="font-family:inherit;font-size:11pt;">2019</span><span style="font-family:inherit;font-size:11pt;"> and </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;"> are as follows (in millions, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>554.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>572.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>560.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>624.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>311.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>330.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>865.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>598.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(258.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>553.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.86</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.68</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.31</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>551.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>616.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>332.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>656.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>268.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(828.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.99</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:11pt;">As a result of the net losses for the three months ended September 30, 2019 and December 31, 2018, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effects were anti-dilutive. Financial data for the fourth quarter of 2019 were negatively affected by the December 2019 Cyberattack, and restructuring costs for the European and North American reorganization, and are described in Item 7 and Note 15 to the consolidated financial statements, respectively. These negative effects were offset by a </span><span style="font-family:inherit;font-size:11pt;"><span>$646.0 million</span></span><span style="font-family:inherit;font-size:11pt;"> increase in fair market value of equity securities. The net losses for the three months ended September 30, 2019 and December 31, 2018 were primarily due to a </span><span style="font-family:inherit;font-size:11pt;"><span>$390.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:11pt;"><span>$814.1 million</span></span><span style="font-family:inherit;font-size:11pt;"> decrease in fair market value of equity securities, respectively. These changes in fair market value of equity securities mostly consisted of holding gains or losses on our investment in Sartorius AG. The net loss for the three months ended December 31, 2018 also included impairment losses on goodwill and long-lived assets in the amount of </span><span style="font-family:inherit;font-size:11pt;"><span>$292.5 million</span></span> (see Note 4 to the consolidated financial statements). <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">First</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Second</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Third</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Fourth</span></div><div style="text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>554.0</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>572.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>560.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>624.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>311.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>307.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>330.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>865.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>598.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(258.8</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>553.5</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>29.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>20.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>28.74</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>19.86</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(8.68</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>18.31</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">2018</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>551.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>575.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>545.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>616.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>302.2</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>301.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>286.7</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>332.6</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>656.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>268.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>269.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(828.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Basic earnings (loss) per share</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>22.05</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.99</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>9.02</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Diluted earnings (loss) per share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>21.77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.87</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>8.89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><span>(27.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 554000000.0 572600000 560600000 624500000 311800000 307800000 307000000.0 330400000 865200000 598800000 -258800000 553500000 29.03 20.08 -8.68 18.50 28.74 19.86 -8.68 18.31 551500000 575900000 545100000 616900000 302200000 301700000 286700000 332600000 656800000 268000000.0 269300000 -828500000 22.05 8.99 9.02 -27.73 21.77 8.87 8.89 -27.73 646000000.0 390600000 814100000 292500000 <div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">BIO-RAD LABORATORIES, INC.</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">Years Ended </span><span style="font-family:inherit;font-size:11pt;">December 31, 2019</span><span style="font-family:inherit;font-size:11pt;">, </span><span style="font-family:inherit;font-size:11pt;">2018</span><span style="font-family:inherit;font-size:11pt;">, and </span><span style="font-family:inherit;font-size:11pt;">2017</span><span style="font-family:inherit;font-size:11pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;">(in thousands)</span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Allowance for doubtful accounts receivable</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.7890625%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Credited) Charged to Costs</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and Expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,713</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,240</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,268</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,205</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,363</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,367</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,174</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,992</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,549</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;text-decoration:underline;">Valuation allowance for long-term deferred tax assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:83.203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charged</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Credited) to Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance at </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of Year </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,769</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,579</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67,190</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;border-top:1px solid #000000;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>70,769</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,403</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;background-color:#ccffcc;"><div style="text-align:left;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66,356</span></span></div></td><td style="vertical-align:bottom;background-color:#ccffcc;"><div style="text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 26713000 -1240000 5268000 20205000 25549000 11527000 10363000 26713000 23367000 11174000 8992000 25549000 70769000 0 3579000 67190000 66356000 4413000 0 70769000 66403000 -47000 0 66356000 Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets. Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets. (a)Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets. Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions): December 31, 2019 December 31, 2018    Other current liabilities$3.3 $3.2Other long-term liabilities1.6 5.2   Total$4.9 $8.4 XML 86 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
10. Other Income and Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Interest and investment income $ (30,500) $ (26,600) $ (19,100)
Net realized gains on investments (1,500) (1,600) (100)
Other-than-temporary impairment losses on investments 5,800 800 7,000
Gain on sale of land 0 (4,100) 0
Gain on divestiture of product line 0 (5,100) 0
Other Expense 100 0 1,500
Other (income) expense, net $ (26,094) $ (36,593) $ (10,697)
XML 88 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
1. Significant Accounting Policies Earnings per share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Accounting Policies [Abstract]      
Basic weighted average shares outstanding 29,843 29,836 29,655
Effect of potentially dilutive stock options and restricted stock awards 341 392 379
Diluted weighted average common shares 30,184 30,228 30,034
Anti-dilutive shares excluded from the computation of diluted EPS 98 84 13
XML 89 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
16. Leases (Tables)
 12 Months Ended
Dec. 31, 2019
Leases [Abstract]  
Lease, Cost [Table Text Block]
The components of lease expense were as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Operating lease cost
$
51.4

 
 
Finance lease cost:
 
  Amortization of right-to-use assets
$
0.6

  Interest on lease liabilities
0.9

        Total finance lease cost
$
1.5

 
 
Sublease income
$
3.0
Lessee Supplemental Cash Flow Information [Table Text Block]
Supplemental cash flow information related to leases was as follows (in millions):
Twelve Months Ended December 31,
2019
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
  Operating cash flows from operating leases
$
47.2

  Operating cash flows from finance leases
$
0.9

  Financing cash flows from finance leases
$
0.6

 
 
Right-of-use assets obtained in exchange for lease obligations:
 
  Operating leases
$
28.7

  Finance leases
$
0.2
Lessee Supplemental Balance Sheet Information [Table Text Block]
Supplemental balance sheet information related to leases was as follows (in millions):
 
December 31, 2019
 
 
Operating Leases
 
  Operating lease right-of-use assets
$
201.9

 
 
  Current operating lease liabilities
$
35.4

  Operating lease liabilities
176.0

     Total operating lease liabilities
$
211.4


 
December 31, 2019
 
 
Finance Leases
 
  Property, plant and equipment, gross
$
11.4

  Less: accumulated depreciation and amortization
(4.2
)
      Property, plant and equipment, net
$
7.2

 
 
  Current maturities of long-term debt and notes payable
$
0.5

  Long-term debt, net of current maturities
11.2

      Total finance lease liabilities
$
11.7


 
December 31, 2019
 
 
Weighted Average Remaining Lease Term
 
  Operating leases - in years
9

  Finance leases - in years
18

 
 
Weighted Average Discount Rate
 
  Operating leases
4.2
%
  Finance leases
6.5
%
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]
Maturities of lease liabilities were as follows (in millions):
Year Ending December 31,

Operating Leases
 
Finance Leases
 
 
 
 
2020
$
41.0

 
$
1.1

2021
35.8

 
1.3

2022
28.6

 
1.2

2023
24.5

 
1.1

2024
21.8

 
1.1

Thereafter
103.7

 
15.2

   Total lease payments
255.4

 
21.0

Less imputed interest
(44.0
)
 
(9.3
)
    Total
$
211.4

 
$
11.7
XML 90 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Oct. 01, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity Securities, FV-NI, Unrealized Gain $ 2,031.1    
Debt Securities, Available-for-sale 402.9    
Business Combination, Contingent Consideration, Liability   $ 0.6  
Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 5.6   $ 5.6
Equity Securities, FV-NI 4,664.4   2,672.9
Debt Securities, Available-for-sale 402.9   373.2
Forward foreign exchange contracts, Asset [1] 0.9   0.6
Financial Assets Carried at Fair Value 5,227.9   3,200.0
Forward foreign exchange contracts, Liability [2] 1.0   0.7
Business Combination, Contingent Consideration, Liability [3] 4.9   8.4
Liabilities, Fair Value Disclosure 5.9   9.1
Fair Value, Recurring [Member] | Foreign Government Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 3.1    
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 204.5   215.0
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 106.1   80.3
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 4.7   3.6
Fair Value, Recurring [Member] | Municipal Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 11.6   11.0
Fair Value, Recurring [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 72.9   63.3
Fair Value, Recurring [Member] | Time Deposits [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 41.2   32.7
Fair Value, Recurring [Member] | Money Market Funds [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 69.9   36.9
Fair Value, Recurring [Member] | Commercial Paper [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 42.9   77.8
Fair Value, Recurring [Member] | Cash Equivalents [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 154.1   147.7
Fair Value, Recurring [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents 0.1   0.3 [4]
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 5.6   5.6
Equity Securities, FV-NI 4,664.4   2,672.9
Debt Securities, Available-for-sale 0.0   0.0
Forward foreign exchange contracts, Asset [1] 0.0   0.0
Financial Assets Carried at Fair Value 4,771.1   2,738.1
Forward foreign exchange contracts, Liability [2] 0.0   0.0
Business Combination, Contingent Consideration, Liability [3] 0.0   0.0
Liabilities, Fair Value Disclosure 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Sponsored Agencies [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Foreign Government Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Municipal Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Time Deposits [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 31.2   22.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 69.9   36.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Commercial Paper [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Cash Equivalents [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 101.1   59.6
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 0.0   0.0
Equity Securities, FV-NI 0.0   0.0
Debt Securities, Available-for-sale 402.9   373.2
Forward foreign exchange contracts, Asset [1] 0.9   0.6
Financial Assets Carried at Fair Value 456.8   461.9
Forward foreign exchange contracts, Liability [2] 1.0   0.7
Business Combination, Contingent Consideration, Liability [3] 0.0   0.0
Liabilities, Fair Value Disclosure 1.0   0.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 3.1    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 204.5   215.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Sponsored Agencies [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 106.1   80.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Foreign Government Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 4.7   3.6
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Municipal Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 11.6   11.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 72.9   63.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Time Deposits [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 10.0   10.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 42.9   77.8
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Cash Equivalents [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 53.0   88.1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents 0.1   0.3
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Restricted Investments, at Fair Value 0.0   0.0
Equity Securities, FV-NI 0.0   0.0
Debt Securities, Available-for-sale 0.0   0.0
Forward foreign exchange contracts, Asset [1] 0.0   0.0
Financial Assets Carried at Fair Value 0.0   0.0
Forward foreign exchange contracts, Liability [2] 0.0   0.0
Business Combination, Contingent Consideration, Liability [3] 4.9   8.4
Liabilities, Fair Value Disclosure 4.9   8.4
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0    
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Sponsored Agencies [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Foreign Government Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Municipal Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Time Deposits [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Commercial Paper [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Cash Equivalents [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents [4] 0.0   0.0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash equivalents 0.0   0.0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability 3.3   3.2
Short-term Investments [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity Securities, FV-NI 51.0   40.2
Debt Securities, Available-for-sale 402.8   373.0
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Debt [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 3.1    
Short-term Investments [Member] | Fair Value, Recurring [Member] | Corporate Debt Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 204.5   215.0
Short-term Investments [Member] | Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 106.1   80.3
Short-term Investments [Member] | Fair Value, Recurring [Member] | Foreign Government Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 4.7   3.6
Short-term Investments [Member] | Fair Value, Recurring [Member] | Municipal Obligations [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 11.6   11.0
Short-term Investments [Member] | Fair Value, Recurring [Member] | Asset-backed Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Debt Securities, Available-for-sale 72.8   63.1
Other Investments [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Equity Securities, FV-NI 4,613.4   2,632.7
Debt Securities, Available-for-sale 0.1   0.2
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Business Combination, Contingent Consideration, Liability $ 1.6   $ 5.2
[1]
Forward foreign exchange contracts in an asset position are included in Other current assets in the Consolidated Balance Sheets.
[2]
Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Consolidated Balance Sheets.
[3]
Contingent consideration liabilities are included in the following accounts in the Consolidated Balance Sheets (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
Other current liabilities
$
3.3

 
$
3.2

Other long-term liabilities
1.6

 
5.2

   Total
$
4.9

 
$
8.4
[4]

(a)
Cash equivalents are included in Cash and cash equivalents in the Consolidated Balance Sheets.
XML 91 R9999.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Label Element Value
Retained Earnings [Member]  
Equity Securities without Readily Determinable Fair Value, Amount us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount $ 1,543,747,000
AOCI Attributable to Parent [Member]  
Equity Securities without Readily Determinable Fair Value, Amount us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount (679,257,000)
Accounting Standards Update 2014-09 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (136,000)
Accounting Standards Update 2016-16 [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (17,591,000)
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
16. Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Lessee, Lease, Description [Line Items]      
Unrecorded Unconditional Purchase Obligation $ 1,600    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 4 years    
Deferred Tax Assets, Other $ 26,000 $ 27,100  
U.S. 1,034,000 363,400 $ 72,800
Operating Leases, Rent Expense, Net   47,400 $ 43,600
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 41,000    
Finance Lease, Liability, Payments, Remainder of Fiscal Year $ 1,100    
Operating Lease, Weighted Average Remaining Lease Term 9 years    
Property, Plant and Equipment, Gross $ 1,382,172 1,326,829  
Operating lease right-of-use asset 201,868 0  
Operating Lease, Payments 47,200    
Capital Leases, Future Minimum Payments Due in Three Years   500  
Operating Leases, Future Minimum Payments Due, Next Twelve Months   44,400  
Operating Leases, Future Minimum Payments, Due in Two Years   37,800  
Operating leases, due in three years   27,400  
Operating Lease, Cost 51,400    
Finance Lease, Right-of-Use Asset, Amortization 600    
Finance Lease, Interest Expense 900    
Finance Lease Cost 1,500    
Sublease Income 3,000    
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals   17,800  
Operating Leases, Future Minimum Payments, Due in Four Years   19,700  
Operating Leases, Future Minimum Payments, Due in Five Years   13,900  
Operating Leases, Future Minimum Payments, Due Thereafter   25,600  
Capital Leases, Future Minimum Payments Due, Next Twelve Months   500  
Capital Leases, Future Minimum Payments Due in Two Years   200  
Capital Leases, Future Minimum Payments Due in Four Years   400  
Capital Leases, Future Minimum Payments Due in Five Years   400  
Capital Leases, Future Minimum Payments Due Thereafter   9,900  
Finance Lease, Interest Payment on Liability 900    
Finance Lease, Principal Payments 600    
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 28,700    
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 200    
Current operating lease liabilities 35,365 0  
Operating lease liabilities 176,018 0  
Less: accumulated depreciation and amortization (882,833) (818,139)  
Current maturities of long-term debt and notes payable 500    
Finance Lease, Liability, Noncurrent 11,200    
Property, plant and equipment, net 499,339 508,690  
Operating Lease, Liability $ 211,400    
Finance Lease, Weighted Average Remaining Lease Term 18 years    
Operating Lease, Weighted Average Discount Rate, Percent 4.20%    
Finance Lease, Weighted Average Discount Rate, Percent 6.50%    
Lessee, Operating Lease, Liability, Payments, Due Year Two $ 35,800    
Finance Lease, Liability, Payments, Due Year Two 1,300    
Lessee, Operating Lease, Liability, Payments, Due Year Three 28,600    
Finance Lease, Liability, Payments, Due Year Three 1,200    
Lessee, Operating Lease, Liability, Payments, Due Year Four 24,500    
Finance Lease, Liability, Payments, Due Year Four 1,100    
Lessee, Operating Lease, Liability, Payments, Due Year Five 21,800    
Finance Lease, Liability, Payments, Due Year Five 1,100    
Lessee, Operating Lease, Liability, Payments, Due after Year Five 103,700    
Finance Lease, Liability, Payments, Due after Year Five 15,200    
Lessee, Operating Lease, Liability, Payments, Due 255,400    
Finance Lease, Liability, Payment, Due 21,000    
Lessee, Operating Lease, Liability, Undiscounted Excess Amount (44,000)    
Finance Lease, Liability, Undiscounted Excess Amount (9,300)    
Finance Lease, Liability $ 11,700    
Maximum [Member]      
Lessee, Lease, Description [Line Items]      
Lessee Operating And Finance Leases Remaining Lease Term 19 years    
Minimum [Member]      
Lessee, Lease, Description [Line Items]      
Lessee Operating And Finance Leases Remaining Lease Term 1 year    
Finance Lease [Member]      
Lessee, Lease, Description [Line Items]      
Property, Plant and Equipment, Gross $ 11,400    
Less: accumulated depreciation and amortization (4,200)    
Property, plant and equipment, net 7,200    
Operating lease obligations [Member]      
Lessee, Lease, Description [Line Items]      
Deferred Tax Assets, Other $ 48,600 $ 0  
XML 93 R73.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Information Segment Profit Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Goodwill, Impairment Loss   $ 0 $ 282,000  
Income before income taxes   2,261,081 512,659 $ 97,805
Unrealized Gain on Securities $ 646,000 2,030,987 606,230 0
Operating Segments [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes   219,100 (116,800) 106,300
Segment Reconciling Items [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Unrealized Gain on Securities   2,031,000 606,200 0
Corporate, Non-Segment [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes   (12,900) (10,400) (10,100)
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes   (2,200) (2,900) (9,100)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Income before income taxes   26,100 36,600 $ 10,700
Clinical Diagnostics [Member]        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Goodwill, Impairment Loss   $ 0 $ 276,100  
XML 95 R58.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
5. Notes Payable and Long-Term Debt (Details) - USD ($)
Dec. 31, 2019
Apr. 30, 2019
Dec. 31, 2018
Dec. 31, 2010
Debt Instrument [Line Items]        
Debt and Lease Obligation $ 439,800,000   $ 439,400,000  
Other Long-term Debt, Current 426,200,000   500,000  
Long-term Debt and Lease Obligation 13,579,000   438,937,000  
Maturities of Long-term Debt [Abstract]        
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 426,800,000      
Long-term Debt, Maturities, Repayments of Principal in Year Two 1,600,000      
Long-term Debt, Maturities, Repayments of Principal in Year Three 1,500,000      
Long-term Debt, Maturities, Repayments of Principal in Year Four 400,000      
Long-term Debt, Maturities, Repayments of Principal in Year Five 400,000      
Long-term Debt, Maturities, Repayments of Principal after Year Five 9,700,000      
Line of Credit Facility, Remaining Borrowing Capacity 207,500,000      
Letters of Credit Outstanding, Amount 4,200,000      
Performance Guarantee [Member]        
Maturities of Long-term Debt [Abstract]        
Letters of Credit Outstanding, Amount 4,200,000      
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]        
Debt Instrument [Line Items]        
Unsecured Debt 425,000,000.0   425,000,000.0  
Long-term debt 424,400,000   423,700,000 $ 422,600,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net 600,000   1,300,000  
Debt Instrument, Interest Rate, Effective Percentage       4.946%
Face amount of debt sold       $ 425,000,000.0
Debt Instrument, Interest Rate, Stated Percentage       4.875%
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]        
Debt Instrument [Line Items]        
Other Long-term Debt 15,400,000   0  
Capital Lease Obligations [Member] | Capital Leases and Other Debt [Member]        
Debt Instrument [Line Items]        
Long-term Debt and Lease Obligation, Including Current Maturities 0   $ 15,700,000  
Line of Credit [Member]        
Maturities of Long-term Debt [Abstract]        
Line of Credit Facility, Maximum Borrowing Capacity   $ 200,000,000.0    
Long-term Line of Credit $ 0      
Line of Credit Facility, Interest Rate at Period End 3.035%      
Letters of Credit Outstanding, Amount $ 200,000      
XML 96 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements Foreign Exchange Forward Contracts (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2019
USD ($)
Forward foreign exchange contract to purchase foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments $ (0.3)
Derivative, Notional Amount 269.1
Forward foreign exchange contract to sell foreign currency [Member]  
Derivatives, Fair Value [Line Items]  
Gain (loss) on foreign currency derivative instruments not designated as hedging instruments 0.3
Derivative, Notional Amount $ 52.0
XML 97 R54.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Investments (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Jan. 01, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Equity Securities without Readily Determinable Fair Value, Amount $ 300 $ 600 $ 864,490
Investment ownership percentage 37.00%    
Carrying (Reported) Amount, Fair Value Disclosure [Member]      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Debt, Current $ 424,400 0  
Total long-term debt, excluding leases and current maturities 0 423,700  
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Short-term Debt, Fair Value 435,500 0  
Total long-term debt, excluding leases and current maturities $ 0 $ 435,800  
XML 98 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
9. Share-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Stock Options Activity

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
 
 
 
Granted
 
34,672

 
$
328.48

 
 
 
 
Exercised
 
(55,490
)
 
$
98.00

 
 
 
 
Forfeited/expired
 
(8,300
)
 
$
231.71

 
 
 
 
Outstanding, December 31, 2019
 
344,522

 
$
162.23

 
4.76
 
$
71.6

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2019
 
94,172

 
$
273.93

 
8.45
 
$
9.1

Exercisable, December 31, 2019
 
250,350

 
$
120.22

 
3.46
 
$
62.5
Stock Options Valuation Assumptions

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Expected volatility
 
22
%
 
22
%
 
20
%
Risk-free interest rate
 
1.69
%
 
2.85
%
 
1.87
%
Expected life (in years)
 
7.5

 
7.6

 
7.2

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
93.96

 
$
105.94

 
$
58.65
Resticted Stock Activity

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2018
 
474,400

 
$
235.58

 
 
 
 
Granted
 
174,782

 
$
332.38

 
 
 
 
Vested
 
(134,525
)
 
$
206.44

 
 
 
 
Forfeited
 
(44,715
)

$
243.76

 
 
 
 
Outstanding, December 31, 2019
 
469,942

 
$
279.14

 
2.08
 
$
173.9
Employee Stock Purchase Plan, Valuation Assumptions
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2019
 
 
 
2018
 
 
 
2017
Expected volatility
31
%
 
 
 
27
%
 
 
 
19
%
Risk-free interest rate
2.25
%
 
 
 
1.82
%
 
 
 
0.83
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.24

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
60.39

 
 
 
$
55.04

 
 
 
$
38.86
XML 99 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
6. Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
U.S. and international components of income before taxes [Table Text Block]
The U.S. and international components of income before taxes are as follows (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U.S.
 
$
1,034.0

 
$
363.4

 
$
72.8

International
 
1,227.1

 
149.3

 
25.0

Income before taxes
 
$
2,261.1

 
$
512.7

 
$
97.8
Provision for income taxes [Table Text Block]
The provision for income taxes consists of the following (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Current tax expense:
 
 

 
 

 
 

U.S. Federal
 
$
13.0

 
$
8.8

 
$
6.7

State
 
4.4

 
2.2

 
3.4

International
 
23.5

 
30.5

 
32.0

Current tax expense
 
40.9

 
41.5

 
42.1

Deferred tax expense (benefit):
 
 

 
 
 
 

U.S. Federal
 
409.7

 
114.0

 
(69.8
)
State
 
24.4

 
6.6

 
4.3

International
 
16.1

 
0.3

 
(19.3
)
Deferred tax expense (benefit)
 
450.2

 
120.9

 
(84.8
)
Non-current tax expense (benefit)
 
11.3

 
(15.4
)
 
18.3

Provision for (benefit from) income taxes
 
$
502.4

 
$
147.0

 
$
(24.4
)
Reconcilation of effective tax rate on inocme before taxes and statutory rate [Table Text Block]
The reconciliation between our effective tax rate on income before taxes and the statutory tax rate is as follows:

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
U. S. statutory tax rate
 
21.0
 %
 
21.0
 %
 
35.0
 %
Impact of foreign operations
 
(9.7
)
 
(4.1
)
 
6.0

Research tax credits
 
(0.2
)
 
(0.7
)
 
(3.8
)
Nontaxable subsidies
 
(0.1
)
 
(0.2
)
 
(2.2
)
Goodwill impairment
 
—

 
5.6

 
1.2

Share-based compensation
 
(0.1
)
 
(1.0
)
 
(5.3
)
Nondeductible executive compensation
 
0.1

 
0.2

 
2.0

U.S. taxation of foreign income
 
10.3

 
15.5

 
2.7

Acquisition-related
 
—

 
(0.2
)
 
10.1

U.S. tax reform
 
—

 
(9.6
)
 
(71.0
)
State taxes
 
1.0

 
1.7

 
2.9

Other
 
(0.1
)
 
0.5

 
(2.6
)
Provision for (benefit from) income taxes
 
22.2
 %
 
28.7
 %
 
(25.0
)%
Significant components of deferred tax assets and liabilities [Table Text Block]
Deferred tax assets and liabilities reflect the tax effects of losses, credits, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of deferred tax assets and liabilities are as follows (in millions):

 
 
December 31,
 
 
2019
 
2018
Deferred tax assets:
 
 

 
 

Bad debt, inventory and warranty accruals
 
$
23.9

 
$
21.7

Other post-employment benefits, vacation and other reserves
 
23.0

 
23.0

Tax credit and net operating loss carryforwards
 
83.7

 
75.3

Lease obligations
 
48.6

 
—

Other
 
26.0

 
27.1

    Total gross deferred tax assets
 
205.2

 
147.1

Valuation allowance
 
(67.2
)
 
(70.8
)
       Total deferred tax assets
 
138.0

 
76.3

Deferred tax liabilities:
 
 
 
 
Property and equipment
 
38.4

 
40.1

Lease assets
 
46.4

 
—

Investments and intangible assets
 
1,001.4

 
540.6

        Total deferred tax liabilities
 
1,086.2

 
580.7

Net deferred tax liabilities
 
$
(948.2
)
 
$
(504.4
)
Tabular reconcilation of total amounts of unrecognized tax benefits [Table Text Block]

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits (in millions):
 
 
2019
 
2018
 
2017
Unrecognized tax benefits – January 1
 
$
29.8

 
$
54.9

 
$
21.1

Additions to tax positions related to prior years
 
7.6

 
0.6

 
1.3

Reductions to tax positions related to prior years
 
(0.7
)
 
(20.2
)
 
(1.0
)
Additions to tax positions related to the current year
 
3.0

 
4.6

 
34.8

Settlements
 
—

 
(6.8
)
 
(0.2
)
Lapse of statute of limitations
 
(0.4
)
 
(1.1
)
 
(3.4
)
Currency translation
 
(0.1
)
 
(2.2
)
 
2.3

Unrecognized tax benefits – December 31
 
$
39.2

 
$
29.8

 
$
54.9
XML 100 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
14. Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Information regarding industry segments

Information regarding industry segments at December 31, 2019, 2018, and 2017 and for the years then ended is as follows (in millions):

 
 
 
Life
Science
 
Clinical
Diagnostics
 
Other
Operations
Segment net sales 
2019
 
$
885.9

 
$
1,412.0

 
$
13.8

 
2018
 
861.7

 
1,411.8

 
15.9

 
2017
 
785.2

 
1,360.8

 
14.2

 
 
 
 
 
 
 
 
Allocated interest expense
2019
 
$
7.4

 
$
15.9

 
$
0.1

 
2018
 
7.2

 
16.7

 
0.1

 
2017
 
7.0

 
14.9

 
—

 
 
 
 
 
 
 
 
Depreciation and amortization
2019
 
$
29.4

 
$
71.7

 
$
0.9

 
2018
 
34.1

 
72.0

 
0.5

 
2017
 
36.2

 
80.2

 
—

 
 
 
 
 
 
 
 
Segment profit (loss)
2019
 
$
72.1

 
$
148.5

 
$
(1.5
)
 
2018
 
28.7

 
(145.7
)
 
0.2

 
2017
 
(9.9
)
 
114.8

 
1.4

 
 
 
 
 
 
 
 
Segment assets
2019
 
$
496.1

 
$
1,075.8

 
$
9.2

 
2018
 
450.2

 
949.0

 
5.9

 
 
 
 
 
 
 
 
Capital expenditures
2019
 
$
16.6

 
$
58.9

 
$
0.6

 
2018
 
36.7

 
60.5

 
0.5
Reconciliation of segment profit to consolidated income before taxes he following reconciles total segment profit to consolidated income before taxes (in millions):
 
 
 
Year Ended December 31,
 
2019
 
2018
 
2017
Total segment profit (loss)
$
219.1

 
$
(116.8
)
 
$
106.3

Foreign currency exchange losses, net
(2.2
)
 
(2.9
)
 
(9.1
)
Net corporate operating, interest and other expense not allocated to segments
(12.9
)
 
(10.4
)
 
(10.1
)
Change in fair market value of equity securities
2,031.0

 
606.2

 
—

Other income (expense), net
26.1

 
36.6

 
10.7

Consolidated income before income taxes
$
2,261.1

 
$
512.7

 
$
97.8
Reconciliation of Assets from Segment to Consolidated
The following reconciles total segment assets to consolidated total assets (in millions):

 
 
December 31,
 
 
2019
 
2018
Total segment assets
 
$
1,581.1

 
$
1,405.1

Cash and other current assets
 
1,233.5

 
1,047.2

Property, plant and equipment, net, and operating lease right-of-use
 

 

  assets, excluding segment specific balances
 
66.8

 
79.9

Goodwill, net
 
264.1

 
219.8

Other long-term assets
 
4,863.4

 
2,859.1

Total assets
 
$
8,008.9

 
$
5,611.1
Net sales and assets to external customers by geographic area
The following presents net sales to external customers by geographic region based primarily on the location of the use of the product or service (in millions):

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Europe
 
$
770.3

 
$
792.0

 
$
758.5

Asia
 
505.0

 
495.5

 
461.3

United States
 
899.1

 
863.6

 
800.2

Other (primarily Canada and Latin America)
 
137.3

 
138.3

 
140.0

Total net sales
 
$
2,311.7

 
$
2,289.4

 
$
2,160.2


The following presents Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes, by geographic region based upon the location of the asset (in millions):

 
 
December 31,
 
 
2019
 
2018
Europe
 
$
198.3

 
$
129.1

Asia
 
51.5

 
20.7

United States
 
468.7

 
369.2

Other (primarily Canada and Latin America)
 
12.7

 
11.1

Total Property, plant and equipment, net, Operating lease right-of-use assets and Other assets, excluding deferred income taxes
 
$
731.2

 
$
530.1




Prior year amounts have been adjusted to exclude Other investments.
XML 101 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net Income (Loss) Attributable to Parent $ 1,758,675 $ 365,614 $ 122,249
Foreign currency translation adjustments (36,953) (112,857) 76,050
Other post-employment benefits adjustments, net of tax (7,363) 7,549 (3,767)
Net unrealized holding gains on available-for-sale investments, net of tax 3,926 (1,187) 248,745
Other comprehensive income, net of tax (40,390) (106,495) 321,028
Comprehensive income attributable to Bio-Rad $ 1,718,285 $ 259,119 $ 443,277
XML 102 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
5. Notes Payable and Long-Term Debt
 12 Months Ended
Dec. 31, 2019
Debt Disclosure [Abstract]  
Notes Payable and Long-term Debt
5.NOTES PAYABLE AND LONG-TERM DEBT


Under domestic and international lines of credit, standby letters of credit and guarantee arrangements, we had $207.5 million available for borrowing and usage as of December 31, 2019, which was reduced by $4.2 million that was utilized for standby letters of credit and guarantee arrangements issued by our banks to support our obligations.

The principal components of long-term debt are as follows (in millions):
 
December 31, 2019
 
December 31, 2018
 
 
 
 
4.875% Senior Notes due 2020, net of discount
$
425.0

 
$
425.0

Less unamortized discount and debt issuance costs
(0.6
)
 
(1.3
)
Long-term debt less unamortized discount and debt issuance costs
424.4

 
423.7

Finance leases and other debt
15.4

 
—

Capital leases and other debt
—

 
15.7

 
439.8

 
439.4

Less current maturities
(426.2
)
 
(0.5
)
Long-term debt
$
13.6

 
$
438.9



Senior Notes due 2020

In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 (4.875% Notes).  The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946%.  The 4.875% Notes pay a fixed rate of interest of 4.875% per year.  We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date.  Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness.  Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of December 31, 2019. There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios.
 
Credit Agreement

In April 2019, Bio-Rad entered into a $200.0 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of December 31, 2019; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of December 31, 2019. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 3.035% at December 31, 2019.

The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens.  We were in compliance with all of these ratios and covenants as of December 31, 2019.

Maturities of long-term debt at December 31, 2019 were as follows: 2020 - $426.8 million; 2021 - $1.6 million; 2022 - $1.5 million; 2023 - $0.4 million; 2024 - $0.4 million; and thereafter - $9.7 million.
XML 103 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
9. Share-based Compensation
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments

9. SHARE-BASED COMPENSATION/EQUITY AWARD AND PURCHASE PLANS

Description of Share-Based Compensation Plans

We believe our share-based compensation plans align the interests of our employees with those of our shareholders.

Equity Award Plans
We have two equity award plans for officers and certain other employees: the 2007 Incentive Award Plan (2007 Plan) and the 2017 Incentive Award Plan (2017 Plan).  The 2007 Plan authorized the grant of stock options, restricted stock, restricted stock units, stock appreciation rights and other types of equity awards to employees.  We no longer grant equity under the 2007 Plan.

The 2017 Plan authorizes the grant to employees of stock options, stock appreciation rights, restricted stock, restricted stock units, and other types of equity awards. A total of 2,095,049 shares have been reserved for issuance of equity awards under the 2017 Plan and may be of either Class A or Class B common stock. At December 31, 2019, there were 1,507,489 shares available to be granted.

Under the above plans, Class A and Class B options are granted at prices not less than fair market value of the underlying common stock on the date of grant.  Generally, options granted have a maximum term of 10 years and vest in increments of 20% per year over a five-year period on the yearly anniversary date of the grant.  

Employee Stock Purchase Plans
Our 2011 Employee Stock Purchase Plan (2011 ESPP) provides that eligible employees may contribute up to 10% of their compensation up to $25,000 annually toward the quarterly purchase of our Class A common stock.  The employees’ purchase price is 85% of the lesser of the fair market value of the stock on the first business day or the last business day of each calendar quarter.  

The 2011 ESPP includes two components: a Code Section 423 Component that we intend to qualify as an “employee stock purchase plan” under Section 423 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and a Non-423 Component, which authorizes the grant of purchase rights that does not qualify as an “employee stock purchase plan” under Section 423 of the Code. We have authorized the sale of 1,300,000 shares of Class A common stock under the 2011 ESPP.

Share-Based Compensation

Included in our share-based compensation expense is the cost related to stock option grants, ESPP stock purchases and restricted stock unit awards.  Share-based compensation expense is allocated to Cost of goods sold, Research and development expense, and Selling, general and administrative expense in the Consolidated Statements of Income.

For 2019, 2018 and 2017, we recognized share-based compensation expense of $35.6 million, $27.8 million and $23.4 million, respectively.  The income tax benefit related to share-based compensation expense was $5.6 million, $4.4 million and $5.8 million for 2019, 2018 and 2017, respectively. We did not capitalize any share-based compensation expense in inventory.

The tax benefit from share-based compensation vested or exercised during 2019, 2018 and 2017 was $5.4 million, $5.4 million, and $6.3 million, respectively.

For options and awards, we amortize the fair value on a straight-line basis.  All stock compensation awards are amortized over the requisite service periods of the awards, which are generally the vesting periods. We recognize forfeitures as they occur.

Stock Options
The following table summarizes stock option activity:

 
 
Shares
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (in years)
 
Aggregate
Intrinsic
Value
(in millions)
Outstanding, December 31, 2018
 
373,640

 
$
138.81

 
 
 
 
Granted
 
34,672

 
$
328.48

 
 
 
 
Exercised
 
(55,490
)
 
$
98.00

 
 
 
 
Forfeited/expired
 
(8,300
)
 
$
231.71

 
 
 
 
Outstanding, December 31, 2019
 
344,522

 
$
162.23

 
4.76
 
$
71.6

 
 
 
 
 
 
 
 
 
Unvested, December 31, 2019
 
94,172

 
$
273.93

 
8.45
 
$
9.1

Exercisable, December 31, 2019
 
250,350

 
$
120.22

 
3.46
 
$
62.5




Intrinsic value for stock options is defined as the difference between the current market value and the exercise price. The total intrinsic value on the date of exercise of stock options exercised during 2019, 2018 and 2017 was approximately $12 million, $8 million and $10 million, respectively.

Cash received from stock options exercised during 2019, 2018 and 2017 was $2.6 million, $0.5 million and $1.6 million, respectively.  

As of December 31, 2019, there was $7.0 million of total unrecognized compensation cost from stock options. This amount is expected to be recognized in the future over a weighted-average period of approximately 3 years.

The weighted-average fair value of stock options granted was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:

 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
Expected volatility
 
22
%
 
22
%
 
20
%
Risk-free interest rate
 
1.69
%
 
2.85
%
 
1.87
%
Expected life (in years)
 
7.5

 
7.6

 
7.2

Expected dividend
 
—

 
—

 
—

Weighted-average fair value of options granted
 
$
93.96

 
$
105.94

 
$
58.65



Volatility is based on the historical volatilities of our common stock for a period equal to the stock option’s expected life.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the number of years that we estimate, based primarily on historical experience, that the options will be outstanding prior to exercise.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

Restricted Stock Units
Restricted stock units, which are rights to receive shares of company stock, were granted from 2009 through 2016 under the 2007 Plan and since 2017 under the 2017 Plan.  The fair value of a restricted stock unit is the market value as determined by the closing price of the stock on the day of grant.

The following table summarizes restricted stock unit activity:
 
 

Restricted Stock
Units
 
Weighted-
Average
Grant-Date
Fair Value
 
Weighted-Average
Remaining
Contractual Term
(in years)
 
Aggregate
Intrinsic Value
(in millions)
Outstanding, December 31, 2018
 
474,400

 
$
235.58

 
 
 
 
Granted
 
174,782

 
$
332.38

 
 
 
 
Vested
 
(134,525
)
 
$
206.44

 
 
 
 
Forfeited
 
(44,715
)

$
243.76

 
 
 
 
Outstanding, December 31, 2019
 
469,942

 
$
279.14

 
2.08
 
$
173.9



The total fair value of restricted stock units vested in 2019, 2018 and 2017 was $44.8 million, $40.0 million and $27.7 million, respectively. As of December 31, 2019, there was approximately $119.5 million of total unrecognized compensation cost related to restricted stock units.  This amount is expected to be recognized over a remaining weighted-average period of approximately 3 years.

Employee Stock Purchase Plans
The fair value of the employees’ purchase rights under the 2011 ESPP was estimated using a Black-Scholes model with the following weighted-average assumptions:

 
Year Ended December 31,
 
2019
 
 
 
2018
 
 
 
2017
Expected volatility
31
%
 
 
 
27
%
 
 
 
19
%
Risk-free interest rate
2.25
%
 
 
 
1.82
%
 
 
 
0.83
%
Expected life (in years)
0.24

 
 
 
0.24

 
 
 
0.24

Expected dividend
—

 
 
 
—

 
 
 
—

Weighted-average fair value
 
 
 
 
 
 
 
 
 
of purchase rights
$
60.39

 
 
 
$
55.04

 
 
 
$
38.86



The major assumptions are primarily based on historical data.  Volatility is based on the historical volatilities of our common stock for a period equal to the expected life of the purchase rights.  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant.  We do not anticipate paying any cash dividends in the future and therefore use an expected dividend yield of zero.

We sold 58,717 shares for $14.3 million, 63,464 shares for $13.6 million and 74,409 shares for $13.0 million under the 2011 ESPP to employees in 2019, 2018 and 2017, respectively.  At December 31, 2019, 599,531 shares remain authorized and available for issuance under the 2011 ESPP.

We currently issue new shares or treasury shares, if available, to satisfy stock option exercises, restricted stock issuances and ESPP stock purchases.
XML 104 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Allowance for doubtful accounts $ 20,205 $ 26,713
Preferred stock par value $ 0.0001 $ 0.0001
Preferred stock authorized 7,500,000 7,500,000
Preferred stock issued 0 0
Preferred stock outstanding 0 0
Common Class A [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 80,000,000 80,000,000
Common stock issued 24,966,035 24,884,265
Common stock outstanding 24,835,804 24,704,772
Common Class B [Member]    
Common stock par value $ 0.0001 $ 0.0001
Common stock authorized 20,000,000 20,000,000
Common stock issued 5,089,532 5,096,421
Common stock outstanding 5,089,532 5,095,504
Treasury Class-A [Member]    
Treasury Stock, Shares 130,231 179,493
Treasury Class B [Member]    
Treasury Stock, Shares 0 917

4I'H5#&E 2*1HR"67/PK$5PWC0FBTX2G#F4X& M['VGM";6K'(QRH35 'QIC_+9W,(#IW8AMRK"V(NIXP7/]W6RH,N&-(,^X8*@ MT?(4ADK1WA%J-9@GB4L1K@%9*49]"G9 @-1Z'Q&9'L=(RV.T&+ZRY +W MW3+='E=&-.XCW0X&N!>=4S:,\I!(TT(3QYC,S<&^G%(Z[0C4NAGI=?N[C,83 MO/$&0QQG9SJF3M[GVIBP01WM4!^"O=0GR0AX'&XM$$*?\W@1 MZ;-/J8%LYN><@ <1M'F20YVF@X.BO67K/DTB+<*ZT9@ ,:3?R/PQWS#R8A@ M8QJ:&V(:Z/?Z8S2A'^C"X^K0+L/:E_[HS#C$9DQF9/1R?%0G ;;*8D3I G+Z M_/1(-P:>X?+&N[LR79#&RYX+'\%C V*LP\[BI2+@]HVI5$\F8[BC&(926AR0 MK;HS(3J"ODWYCN0KB),B09LW%4-OJ#"H.-PJ\(SLV "I=$#AS(@_VU"XI!*< M-.AK!BTM?T)X)^Z9&1LSSGC0?$Z8&O 3-'.C[XH=/S)!/+F2EGHX^0YQ@;_G ML*_OX77<\N/OHVMK,Q@2 9VQM$4CAGMVOI5U!G$?%DSI>)70*X M[_^$%\[Y?$M_#7X2&X%\"/+ 0F'^^2+'6CU?7:BSZ'5NK>;Y(K$YE.+)S:T) M'^Z7$]+5UUCFDJ@<\7=;155 MC/)ZP,-:$J+98#8]-:!81&(>%LKK .[,,13 ML]3U<#LI7 /.TT$ M(4F_-BH(77LS-,PY2)VG2RE^)&,49U@+D1&SV9%T@K3I"[U*?!";;1SS]L), M+Q1"6[#[X4(GM"VA>5E.43LY+5/:DW D235_"E".5&#XP%OZ9Q0Z;QQ M@M"4;&:T!YJ0IER5H<8B9A9B+E3>#F#=W^Q*(H;3L,0OHI?Q0JP1:#S(:->Y MPAQZQ= ,A1;P>$6*VH@A=@8.'P@FLSV!55[E;)B69(NA+@5& M/ U1C:)_;AT)T'/DP7*)*93=23LDR;%E-$77$4&64"WN$,EH:C!.>'A#%)Y) M">5 #,8(:5K@81_#Q%'=&!C4/<)Z(RM)Y_2,A>134L!DL\I"B4SJ3OE7)G#F[C8*I#NDF M(<<+1US@60D9@L&F" 4UQ]01@&R#@B8E[:%UA0QHZO.0(GTDV7CH!QQ!659- M=I)$+/FJS4?.E?>"R^9+ U6DP$DI#94@4U;I9PQ3);03BK/!:Z+$X1.O0(PW M=H9U?9YLO5_2R?#U.UU718JC::AP+DONJ^VUM,>1R1CL148^[X=GV5[R&X7$R4VJJ]3KT&E?R>6R>R1<.4X*AG:/Z?;O2;&"WZTWF25/ES*\@<4T6K *TJS4&TF:/%,6*L>F\R[2 M&,9OL%!T("B("$#/BQEH=85*1OM"MM:OP+[ MX!0*"_L+UHMAE)@_)A*?L)$BJ4T!H]@ ^KI0F,Y=-DD68*"2(UGN=50!:Z(Y M@F4YJ RC^P=P[KM,-YJ$<>W,YFCKI854Z"EU(V&++0WP(>?T[LB5%8X7<$66 MJO2JU]"X\!:-!8QA\U<(=X W=N8:(5#5G=.\L\0AM;FSTC8XLI \:6(TTDQU MI*F8HQ4SI[$@-9T9EV#=B&D#TA+*7"WX[1PS832M]CUK331F6WOK>R0D#W[R MB<6HKLS(73,9J_(RB,X7BOB&$DZP6#9(%\NH"@LY(VA5M(J/HH_^C!SZNAKI MAV*"9Q/T8<,@/55\+127@XH39D"/T!=SXW5L;^D^Y218[NQMO.%T05;KZ5<; MN"/HDQ*UWN&\69<;3(YI-3Z+U9\="$-8BN=WPEQMZ"Z<4;J(W1*-!W -^5H# MSB]/B$U)!N>"S0#F0+?USZE&>H6)?ZH'>Q>L:_O[&:$&$')-5[; UQ#KKM6W5N3N\H$+FLP8;*XF(7B?F0UN&IY:& MJVT&EV]=\Q(T)6PZPUB#[6.R0@V(P3A9+W-XD50+JB1K@E/+-I@9 3<]26QM M>\HE#UR-"[3@5K0'$]G1BVYV=Q@A)=N)FBEI6WHY.,?D?%MQ[%9M]2!O^R&! MGDS3\3""7.",:OAH9*JXJI*:T.=<4<(<8+$87@_5^!WY'+R;R\=M:F@02\4H M+ZV<==18H8L=PYMZ,JTQLD8+#A>[ MJ<^5(">+)% !8$X<2H1\I)0"!!B=-"=U?^M+/-1B9(5?Y "?]7' MFIZ)SK<<^*B=?(CITFN/I&ELA;+7;2#.G@@;'.WM]<4??[Y^^^KRXPVT\:=/ M5[=_469*E]C93^7^#'L;B7*!I6"C7GM&J,AYLMD: MDW+/=8PH"RAH M2Y&_9&QK:.UE4VO81,\)3SCYKNN\-!1!9&U?YEH=PXF+)W^I\$JO%%XI6.<# M&COSC3F(IAZ7Q?11O:)TT_T#4W=C94P0!3?;Q.R)X*A^?=N_\%)?8$]/Y;'& M/MPKNXS14K<4A,U9 11='C:2EBV#[%4;)$4^!QY1L'?2AO)30&-EDKFZUQ$F M'C=1(H.W-G% %M(LNVH99"D(:1J?O)D_@#Z__;L =F$$N<$+$-@N:RFJGFL+ MFU;'IJVV3TJ.,L #<+:DMYZ%6?+PK,)3YLP&F)68U:VX=Y!&2B!.5(=T;6_X M:=T:^5.A]&!M0XBMLV@X[HXGXVC2'0S'\ (,YUQVL:0K;83YT@0KI(D[*+K8 M 0YFF,]M^ZB*0]3+Z=D,>^E/&WOI0R_]O;V<39[I98J]3*=Z-[]+I19(7*\V+*$:>%OM'E(X4Y5P4YY'&?Z5!UH]T&GSU"W"5O MKR4701,@$1LE_+J@DN3R%3SJ]X*6B,&N)=76=RYN<#S]*#SA3Q&&R4*G0.J% M@P\1%!HX4UER#X>0E;( BYLRGJKKA-]^H2*8+HB_;2U=7W8(09RUA)2H,C/# M\\VPO.I&<%& [QW@O&S^!Y?R6LNDYR1Y3)&B9\4#)^_YM5U@J:Q7*(A^=+;K MWB?=\9"-)J D]J/A8-J=G VDQ,!9](<=L&[_+OTI'=/+LS,"SYH- M,1=^.!YW)V.J3S E9#0&>O*ORP>N]\&X>S8FY#?T-$R@P5EW.!M1 SCPRO1G M#=.?86C=:$Q56R?37G\<#:>#[BF#59SYA'HN%TDN>HQ:F@WZWI'@-T@."07, M9UE2@6+ZXNLR&1V >?:)TCC?"XN/KW[]/;\]E*1!R^NWWWX M>/GSY?N;JS]?:BA[Y^WUS%CV-I5!_: MX\I-F$;%/OFZ"MIMK686?E8?S/=&3P2OX Z:2A /@JW$>.<==FM11&6\OQ0/ MF"(P!Q^)KE>H. MQ VTB89.:REP.(>?SS]>GKPDH&&\ M^.'6/[^]NG[_HYC4SG\Y__B*@$D4D#CZ\/;\_0W0)V@1J;, <'H7V(SKGK-.4NB M&P6C'CSF2H0Q?W)O6P64PNY0R63O D&$;L1U4!5CZY^P8*N)[6CB3^;B MY66KH(GWW#YM6,.T*T1&$+< Y'G/L=BXW0F'KKE!<'>/=^3@6& LBHKBWXXBE82'1]M1^ M+WJC/J"NZUU[=N$/7]/U;AU1MC(AC8BW'D>.]T5$%>3$)4.;/.Q[[!.V\<5< M+?.$/M%::YD+/D+G5I:E:)6B.'23H2#CO!1:%4> A]HC3G+-@&J#O8_1R8=' M;CY\./9EU\FS ZR28X/]D4"BH5(&Z&I)Q%@T<" K:1$R4F=,ZO;[?9P,NQNV M.3$>G(B/TK'@Q(PDRJ00TB E@NAPQ!0;&>L-6D_2,IIZTSH2!UM?2"-K(Y" M')9I4:M%Q=3:6*2*O ]PG2=8]5JGY/@-+ZZJH27Q?:\.O@ JN,@7"99CIC4; M#T=>THJT1#?Y(^URR%7%%M$J M@J@,FY:2.X5U*'W\B;V7>"6!>1*9A2NBT8$--Y&[;5H3=BNCDC M4Y<$6M7U6<95*%(G$U.$#.?Y.,C:6TF\#N0C0)X)DB&SH!!$--7+T'$-,Q%UOIB4"5NS!+G&26B2' M0&M*A&I&,4VL^IAAXH(P=$BN>* //;$FXC Q18@9]WR9I%L)C,47X"J:@RXK M,131MARG8VZI^,^P6M,>]-!]$;$ MM!'Z$8>$*3WMC:=NV'!]32;=\8QA)'CK"'9Z;(_AE->#1 M'.J]XYA!=^/N9(C](5(UW#7CWAFZ#:3A,,TO3@;=P8YAFJ-#0;25DT2A=)YLDKQL!%]:&4%%T'8O5I6L;V 1E2"Q01#R6 4B[K>R M"@JXX!J?:I3\M2,Z&H9><$:9#*R(" M_*N-L_\:@, >6['L(N' M@[55C6GX^61:)MQQQO"'L_@R?Z4TG\&/0FR+& MAVMOA9C4AD6BD1]#Q]%B[!YRX39MI99^V;_(U>4%5@-\A^'X)[T9.6"FO=-) M]&<_.Z"/($852 =+NV$LF%N#M#D>0$)CM:X:A0V)J=INMXNI2>QB2!G?EL6L MCHJT&!=F04BGR+O(-JUI%!(RQ#$&@29]:V-O:2=,R*X6-%RGG-]*[/G:IU#RO(,B"4P!,M)#--,$X#P[BU9?V4'5WQPL$T_YX4.89S.-6!Q8I/Y)S^V&+;\K*,*G.YLE:C M2&GY(#&4D>E("9*8U;#?GT6F6LQIDT&/80((Y(4.9H.A2T+ @A,0MZA#HFGM M*1!XQW(9FKYE@^;-Y@,Q"QC2VB. M2AG3A)KV8&ZX$6BSPD%A9@RL;4(DW^I M?#8^&W?'?2[ -^E-IDX^&\ 79U,2T$;#WF@:_9EUA,Y@A)+41"HYG/;&8R^? M8<6.[ME OAR/4,9Z1C ;G\ZZLS$+6"!4(=9:?RKQ'#,CKH0TTA*2H5'-+2 N M=$&/QR&6_+A?S7L%A;(][_40(: J]PQF8?6K@X0"HY VS_8;9 21"GP:[;?+ M!_LMF?53O-UK!Q3FTV";.4B>^-<+$*,!R@4H#@QF>P0(4"U$:*HRMW^E"/)?<+M#EX0Y/YD"6SW3&QJ7[&@P#JPKIZ/N^'0A&Q&;K9I,NK4@@$&_ M%[E2Z9QDC:^RX:[F;F]]<(_#O_8.?Z"1 NU5A7%H',\G$7SHP[_\#W3P7W:C M]Y>W>T,HO,ODP%BZ SGPE+U&?N4X@_GP)1 /-@>] M! M"NH)#A@,U2$1+RA],=OP\SSC;Q[%,\NXQIL.N@$M>/';BI85] MKI'Q $[8#=:SUPP[,AJ]!H*TA?YJ(3?/OK'GS+GGNV'/_K#M!X#&,=]\^O#A M[>6[R_>WYV^CB_.;GZ/7;Z]_@;/X^OKC.XJP:4+%A560TY=S3+XM%X(7"9>X M\47@65=)GZM'>.#I?)^8DSCHGDVXP-OH=$*E50842G=N@JE8QZ09)+]ZY*\2 M$]0AN!8^;@VT$H3X&DT)DQH'Y!+YE:HJ<'"D1I G(5^>[ P>5[^AEG>K"XZ< M4>2!(J?3&V4WB.*1F^*I)HKMG\1]3.ASHP^]'D[7&7;[(P'Y/>USV1R=\%O7 M7W4F7#Y&T<@$[!>7_5_&_C1.C2.Q/& /Y29;Z)#.:$IK7-W-ZE*Y-<+("6B* M8#@Q4GRA^&6Z65);B(K)(K:V)$1W*) $?B,D4\D++L6PPJ(&%9B'1B:(_]PY M'>]K0/UX*0H@^.*0JF5*;#&& I^UORQ1J.(4D'TZQ;!F!.P>$0K$A!JXRK0! MS>P.A[\Q)<2]YWKMPZ+,P8>.@8A,;!0+(D'0Y\QC#D(<&H-_9>?3F8.9YX#:8F MSG/5=&"#VN5408$K1P>J<,1[*%./) MT70\I@R;[(1:8!82OO7")#UM!,"P2_$:VPJ.X1&=]B,L_PK_ND/IWF;&PU:T M,'8W#-0=4*!NG\!"$#_@!A6=PU\>F[>4]23OBM.5U%AQ2":&UB;\0840;$E(6\V;77VG1O4]5+-U=J]K T[:;A.4XCP^=,Z\ M14X&VAF&IJ*(46^RRZ1&(:<_E9C^I.$OUG[)!GU7"4=+\I2V$*D$ J&+F2,= M##)$@K+N/'&,?I7<$P'SE\%G-8L) O R*@1=D#Y,AC1Q2L#6_UL>C/.Z41 %*!H/2:;B0C@W0F9+D,D6; QUJ=J4S4%! MCFJ6$6F&8J($AX/Q,PN+@_U;[5];)DIK0DCE4A\7OM:^84_ETR%5PAN&G MH\9/Q]5/29:F4CE-W_9,W5/#MYZG^>:E.IC,$55\7*-S;Y=TWC_;FJ]/9'OW ME<7:<_)0&%RD'$%WEZ 2Z.@5P2R@0P1N1W6),+6134W8C-OU][I41A*V7'"< M9B^Z_"HQA7&1U'!W&=ZN&=N-:SN8F\?!+)(14J*V#;R/PTG?>@A %-FK-8R% M0Y>UX72]C;(K\#HN4LXN*7$.F=:O/U;_ (FTG:36ZE.3ZCG@DQ06%M:C- [* M#^M1"@VN>EA&E2K,X5&:VB+-<)9\P3@NHO;C&RT;1I #Y'.FLHX%QG'O"@[ MT7AF#H\K^,Y-UV1#IX+!@ER57&^C0>1;4-,< MH)VO=E;;R-R!1Q*436**DWG]"HAUE3HK;U#OEW&QFNOKV:&2^Z=EA.T%S5BV M_H",X-(S@I?*"& /2JHEMW)YT](99;1FAHE%Q .@'C@ @B:%KNF1)^ M6&)&/79/DY,\R>KTPAB+A3&1JNA*(&R29>2C5#2J'9I7>%Z#Q6NP>O\(IS46 MR-XN=(<^'GS@:ALCM;W:W<4I;>4?X@W&G5CY'3]^3;M- >R[EIC6PF$\]KQ)*:[$\>T#/U#%B(FB8KR]V#,>"[+ZLO%L$X9U M)O("I3L=#49GJ&0/R$UP(R'2%)J *==G',2JI341^@/-%Z!TD=+I4,Q@EC\$ M2EL94=D\A S!R!:"J.V@F^:8(;<' S3I<&FY-U32P9U[@J_J#!7*%']PG!$F MOK"6@:*K9)5;\%0IH!8: &'>(22=P\_[*INK9C^V+S6O',%XR9H-)M@/+YS? M#[/Y+SCRIYDN["Y0XT*<#*H]&04 ,UAWE09L1VL#0:"TA&D5EN1&!'?6( M _9E2OO2N.I<&4-LU[_!TI+5D-U.>Y?$+N\9&NIH43@[D3DTW\>EO@NZ?P>O MHF/XB1=0@&U0.6P!7',@8,).7308.SL'75#'!+LZ<#\P<;NIL3UW&"SU5*![ M3[F0(]K_G+FDJ^NR!$X*A,$GMC+O$ X W_] 41;IW)$R90J%S*["YE H"<6NKYR' MSD!QF ?^1Q7E(';,1RRU7"9P1&;)ZL,R[P5'JW[)#6OW$A M2X3_'8#\A//'W\Y-,$YC6+:-UJ&[68K^[K:*4M!P)348&5SM(" B]_[2A;:6O?8(ETPA'S6/LT%%QV&W+E#I?6 MZVKFH3P/_1>;0$T 1;%&-8"KAPD]6' 9S4@KLERFBN(4PU11J^T4),7*68-4(P2%8GGITR68$L':/Y M=X'5;7^)%RO4/Y8I8J#&I%3LTJWN(CD#7J4<# 6#W16$2%+@_F?^"S1LN+HF M75Z< XU_FS1?JO7XB* :$4(41FQ?L$:!)R*%$%7ELX=0$,$;3BYQU04 MC#M<)7? ,J@B&:9/JI(->G.^"C"6;^+B+LZ2\N3ZZRIYHJ*&J@Z_RA>+$]0W M/M/'>,$5<4JAJ*\O/IR["K48TP#31W6RT!6$T92Y'U(!1V.Y6U54_G TFQVP MZ7FT@5,RAV.)M2$W @ #WS[&6@[R,4Z9=V)LHH=5;YJ<*2[#!XJ3JH-%!/ZV MP]B0BAI,S!#"JB]N"S5^-*]"%%3ZFO@G)T8(D!"99G!13B;(4[7I2,HF0:ZI>Q4R"2?+5#E42SL]QC?E7D(8,7<^BL0B*9) M\D 729:&XZSLL*QA^V;X];V#@Z&LL&6 DJ%9<%S<>HWY2&3I;JT>PRSE65+2 T#GPV'7EV(D/(VD^G)%F57SQ:3ZT/V1; M-C4,M$"&ZB0ZVFY8D\*/]H?Z..6@PR5TJM"_YIQG0 6<5@0#2F*3AH!Y/V)" M0N!F(A^$B*/'O/7F?8IXZ1=I,8>["_HBF(7B?B>P"7.Z$VE'/23JF/W2-#*W MST,>WJS[JWM74S\R[@6P(P17[I+CJBBE;C8:#+3@I_V$71W+M%B;CWO1C>%J M4EH%1_("U+!C:3BI<0XZ0L[J)]HZFA;OT#E\-,3\1Z56HM60]/@8)7JFA,]0 MOQ2^C@]'AFQK0.%4@Y=S!$#$IM'\%'6&QSQM:?CF^C_X*RWAC$>ZV&GMW:0H MT-!.M(PEU(4&E[N"/8]>*K25V!\?$OJ:@:/YV*-Q&1Y-%C]1A:4%-3[O&J:29EMOR-TD,'0.=( M"L/]=";^<@T9/IUF*IF@"5(UKJ[BL)_:KQ"(JQ5A$%DH6S*2(*)(._.!5V\8 MEH62%!C9&M_[@Q*S2U055QL3.REQ=(-B"BR6>$!0I.1K,M]M>07]>IWJ*E(R M&==L>#L 5XVMAL MRRZ:B?/CWURWS)522I:!JIXWXGRH FPIKRM7KNNSUEO>*:>3!Z26(I?:%V8$ M=Q#S_%BN0!=[ ^*$8_#GF;6D\;@>:(6Q^"6DWGH5%&G=N+=#"M4%MRU6[E2) M0H #OES\:[>8H]GQT:[H[8(+Z8&=!UTS4.0PV\S%NF.GHBHEA4;-#&NQT67P MJ.(08M/S/-@[ZB(>90KHX(02>&C:QA)U9%2*N2@QLBFBEB4 '\% .*[!-UUV MHXK>/S!76DYG[4*J@E>R",H/-!6UX6<;DA*PS[/?(/[/2P20,"ST[-TC261\ M^9@+9P?LP1 MW4&/Z\UR_@C.:+H/K\%?C?.&/7]<44I=,<-\=U=^U(93X9E; M&E:(Z7Z+['9E!*/%K+!/=#V43"J8SEXRG&#Q-OH 75QR%X07R V^&.P9P"MAZ MF&\PK"+8IN =%#D;[#!S<;F^1OJ N>EG-M]8R_%VB9=>\,$,0U"4!?":INU2 MMX:7WG)ARP=S M$30^&Z(!W11J+U%X[:M5'CUKL (C@ MB@NNI6XD('RWF-VMU^#V-GIM)G'R#W>9V8A9OJ/5A.=-=]M\=K>"3I\8U "? MO5FO3?L< ZV;P==N(21V92_?Q6J^*T@TLP?%+ E;.5E7#)#V4$I]A M=%'Q5 #,D=0NJ6F M$&+_9@?Z2'5_#&GQA4,VQ4V.Z >A_91XG\].--$5A$G>F^?6*'EBN.D3$="Y M(F#>27<7R-U#N=(8A^B\BD5V#\N[6N48>?-H']$7& V%HBX0<=.\\4>NKC?1 MQSA@@,K-"+"E@8W-$9KZF85^J*-X3U^07 M:;)3Y#G57DN.W"IP/#G9!^W*(@ZDJRU,>34;2&G:.O! Y1F!?"&>9/D]J[,' M7@MDV=@\@97L_E4-;!8",,CY=-B)Y?Y0@JC/.B--A8'ZZ)VY(+Z)A6V] >%P M35*(YV\617=15SIG+A[*)C7I):;F"<&#QA&?&>NZ=W,9_: ^5FC\AH]MB)A/6P,]]#KK67K.D$4&;:3^H4A+U$Y9*GS%)P M\P1(R(R-D%4;LR>]FS1X(51XD1PD<(32,>#"!)/)$!-XDGB00/ )P.=U)S38 M"4:$P#?@KL2\!ASY> (QKDG<'X$G-(&0RI-:RI:.J,1'0KV!*QN[ $2K9&1Z MX4_&F&&8#)1+NSD=DUM/I]C\.,%4H5Z77;A]R$8:P[S UXSM]R&S;@+1.\Z7 M[C$9K@4APTXQ!0DR/8>N" 'YAR'YLY,,*,<-6L0..E-,-DNPK@;X^"]]& M!],1M1SWQD-,39I2"Q-..9L.IF;&,W/."XD#+^5OAE)R,;;0&XBZCT:'S >3Z"QK<7W+J=#U M@9#+/6PEH45MLG7R@UZ ZB/R2%35'Z %R6FZL>-V7;DB:R5,$!O7KZ%\O8L< M[6]. F"A@/QO5 W7<-W\)B!$H'"Q*8=AVJ3LHG0C\IG;KOU%9:69"\QP 99G MI9!?A;KC(PYEW#$@!LKIC+@*#A31Z5=+,=EP,CH*E"W+)-TE%#F9I(B0YY"NFY+DG !OQY)T$-R*GU:J"& JU"[P'&' MDX1Y[Z '&:\(L%!-/I:(G3CM0[2+X=0#N*^^-"6MXM)Q98?]#"?FW!8*AZ-Q MVKHOEIN-@#;'<*V(4",;!-<;T/"D$AXC& /Q9 3)PVD\&0)Y7NE5-+=_W.O1 MS3&,1PDL2DT[+^+'BAW;7.FVR &6_?8/X;X^J5GT1B?]()@B1Z+/C/QFR-<( M8(:WW>90]?'ASJR_D?& H=482;3V@$;(PB%',;2 BN1['O,ZVP&I88&T'J8A MCZ@@I$1>UP!K(Z;T:FY M*.89TNP'(-CHQ*R&D1>.., 8P"[,_XA?1P3D%A).>S\AL>K3>5NX_#?.7XE4G M"A:F72WXB[/+JXNOIU=?+\X__1:=?KZ\N@P.'$0L(I8,:F6M-[?92I2:BU 'K=%H50Y6A#0F!"KQ#[/(9-:DH_0"T?UK7)! M_V*[ *>5>LKVYG:Q(BF*C2#6>[.C*8&=&6,GW.U7-B5Q_5UT V'/$+T&SBVX M':R6EW\3#XWD<.H5DO7,V6E'SKFMM 2G=G$O2$FZ%;93@V,/"[I! N L)V^F M.73H("C,@S.*C$6S8N>GLXLO/QW!!UN8">/4+E8<0"'PM-9_F+.-SO((IW\ZFVC'3C,U+_C' \<\&6/CD- MM;DC^^UL=/&V?<[6B/?+X++=Y@TFAKQ!["; J4FQ#BY\"PJI0SFC>Y,(S^)6 MD5)8]P.45-1Q'@30BJM6<@*;GW,EZNP %F/1F_, MCX$IL3'-YODT\F@TJN@:2J]T WI[<] UF"9JQAPSY2\Z)A6!N;9)Y#CG^%(8 M:X V5.W6+"KN(3+->8Z1A8L+ =K^N#.<[W2EVG[7;*YBT% MM\@NSV%2RO-VQ\;9VMW1^_6L';H1G@ 5(R .YPO$K<6>=Y+*7]9[;_ZM M" ?8O8+@W/<8\+#,@%,/H^;9 G.%L?>]=ED8WU=3,"SL]TJ .0#--OPK97$% M0@?X:AH:JP9&AMU$.>U*HC"$-/)QJRS*V#]O^OW/GMG;0VEBGMOTWO-S,@^1 M]&M.'T7BO\KY:Z4LE-A9K>Y0+^LC\"9XE,'Q@*QE'A+IP2<<%OI90 ;J+@GU M!-?:F>#W+21D5@U8\&Z2@/NHCN#0]QJS]FL$YZ6;L'3O83E4"HU\.IYO%M_R MLA+Q@!5]?I>P%/:3>A"!"@%LRQG@!2J;PC%MG/.V[O;F4DR;G&- D.;18H5; M@I8F!.TS71DR7JSMJ+E81+5-%[D$D;-_("*B>4X!2-,RAC)M*-D.K,&QA+V7 M"K%4+%* 2>:+ &_2H>**%(,N53W#XL$!XH#FE'6,,L0)O3'5 JYEQ>%,KS4; M>OY5Z5?Y.?PBA/H:_AW8]L+381?/NLUJ+[.7&6$"#."U[#(O-[4TZ?(!=@S. M<@P20!JM&%&4I8+A/T+V$F0S=<;^O>:1[-KP2N+WT"'TULC;.5@'5%IYIXFU MCXBU4R $S++B>AD!) &6D*[QMO"W32 $^ " +D -]KRM,P6[/CNY/+NT60 E MKSH'0*X!1X#*NX-?UQP4\@SG_%1,4>&[Q9(SX[[E=XN9A(.JL,'/NXTTC-VY M1"URF!'RK)E(0B<(BMY/!9_3@\@M*$ _UP*+JN%G6E[ECY!]_: D]IF'I$-= M6K1A'W&R?#ZN'O.E&?#']6I[5]0ZE\L.0 38@4 -0R7O]9+A-V\K #7D,-RN MM<.03& 61P=(L(*0#R%Y=#1O*KV@W6P(2!Q+#@_@D@]0,@A6I;#?ZX25QFVAFO%AA2/ZSRCS$ MXHS**$+,_ M+'TSI?.EI8X(+Y*C8&39*[X$T X/F <<8SY? [TBA#=I$2SZHI#,+3TA7)/>",P3._^>H>)O5RLD M\F5X@$0TBK%:$ MW2?(\NRA]J+Y]=@6]Y+WU?6+JU@,6R_S1@E#LAQ94ZANNT/)U\J",30E7%O9 M 8"&%-TXYJ#.V%NUK@J!%R^?"M=\$V$L4_T;/O_DH%KB$"T?'T47@>B"]35X MJVE6-JCN9LU<5^-(O2W3"4:;0*C$^VIGJ;][/H;O2W:PB87RM=8FJ )*6 +< MDV"]-543>0/%7@:59KV*$..1#<9I;BI-@+579R%KR'/8$SQ"_G_4 =XA[]5 M&)WSYN0%*<.Q/SX%P\13NT;H$K3U_#3P]36]O0)IQ%;[>(.QSA^\QZA92 RI MMIF 62-T)_D+B,%-U?63RHB!:O>XI%1'M4+!QY%498RF93I6WR63:@<6BNP" M DLK+<,B_UQN0(03!"\3X'72ZT/-M#=HVM?W!GB 3J M.2'2W#>(O-Z#EX^YU-KC3_,AL9'0 M@B(O(<-?;.\8YJ" ^%\4P[9WB\U<*J]!RT@V03$#8;WHA&@I@BPCE"1!AT_7 M1"&TNY/+TV@RZ,5"FQ=6Q%(?.,< IS%5[DVJ[#LN6ZT'N@(FE?APMN"R*9@[ ME$",.M)!/@IIFNMK"),V.^LAWX,]X7YW7R;_0*3NI'8R50Q[0RC'6+K83?"7 MR%:)&"M;QR^18-NGX_+3B&V?3)6K[I=(P.T3[1WZA1?)G'7,H\V?@"B.T214 MIBYRW,BT-[A=A2M!G&.M([\6JA@[K (1-BY-Q*NGYX?7DU(FNB4VBED03'05 MV26\#;7KK4.[W')K<[U;[G_^Z>33Z?G)A^C= MR=5)U/GZZ>3KN_.KLW='1AID6Y7E+$M=90 *"TO2D_(J9O7W8"R(7N8049%7 M;,14Y5)^1,[_Z1BJ8?# 5Z5PW%*:5TC"BX9 MX;5(<,F(#]HC/@HUYUOMU![6G[TF=).NM0]CI]Y27O,)]8G0N6V09KF/,:C>5 MR:9JQBY46PJOB)\$7&TT47Y4T':W;+K:N6!;NQ1N#5"<@+1@0HB1^\<,YQC; M70!4Q/OJ&46&[M5G)2E!JK"L\MN,[E; KR)[/4.W>>$PT>G3-=R VVSVAZ#! M56VOTF-[[G9ENB,;\."83#UBDL >=QX>;IKY^+P,RB-Z.!7VOL MT(0;NFE?E_#*$:><#61&VY_V2H7#WTS0+RH?Z>J*[2807KG9P25+N1:3YW^_ M6Y/-D4L];U3I1:I@I,I' VPDF.IV173RF[^J36M:73R$L7*FH&?4?>3SZ:R4 M;Z@")"]R!3AH=I?/=X8KG)\;$>$?9HF<6O\? /=Q@T9/!&_8KBK8Q)=GIY$T M$4=)>MR;QGM: ;%5.P0^0$E6.#U%%=4HU+H=L9G;83TU2!J_GG\^OCAY%WTX M^?7SQOA)L$)12-GIYZ]06O$_46&I,_Y5D0$ZN&/K76$^,9<(Y-8_HEH-A#-?[ZZW@/,;@J6P M?AXH-*3J;* &WZ%"4/G\2#NZR($/?=OJ[^_$TEWH!L]6<]N49-V/XG'2Q_S9 M.!WTJ,3W,$[Y=D][<=H;TO3 M10/!YBRGL3#=$S5P./^J$_/4E,X_S> Z-H? MC>G9!&6'SB2>3E-ZE!I2.^TM4*! &A05X\/0N$*R+&JES JQX_3*-&++W+== MH7$O'H^FGK.QTX^'XRG.9#2.DVE/%F@TBOM#D(\&\2#QBXYR,[PZYL$!"F6= MP1C;<0]2&Q6IN;L?=T5^JSCW0#A"A><+I>\%H<2"#[%':\]=Y^'D6*)VN.F$ M*FP!>\QN=.F^)?@!X+R/AC,O&;DI^R_S(#BE'\'(#+5&%_-%AJ@AG4WN MCQ MC&'@!YAR0#:!54Q[OW"W,?Z9_"(?/^;E3W:%? =\X=F./SI$1=H4XD3%FF& M$**>7(HOJF;@P^7,* ;0-H/+-O;5FM6#)0;[M@4)1,!(#CX@-!6XJ><>A ^9 M'9:Y+?E4:+P 0D2T$(+#63K+%#$#2']N=M%EE,IXJ$Q8V,S7@08#AIRNZ[X M#$4T$C0?H>J(" J 0G94% +T#1D!*OD%H%M#E,0WVP\,(H=J:7!(S1]/MGH: MH:B!ML;Y*?F?"RY6S C57,@!?J\4!7Q$]+-"O\]H#3!$VOKJB]CD]6YK(W1L M/_6+90OE$5&(\(=H1W[?. '8Z&U=U]DF#U2G"?7;C<[<(JJ.!!5S[PP%O&'_ MO A@B+<1#Z=XS7, QG0UO**%7X?PCSQ_J.\ *>8Z1RB,1;',,Q#>S!J2#,YA M E@,+ _.%%Y>K;UC.1:*2A\"TC-43 9-3)^=RY)LXQGTWC2?4LC-8 M^5LWL TD6'_+-]O%-69A MB#Z;9+(]0#DS*(1-6@H5GOK)_91@5:RE0?"J2 M"GD8LP"+@;9@-AK/S/4'7FS =L2RR:#'@'UW;1K8<$$ 6PX!\WDY-,W%X5GO M>%=-54PH!'9>E<+_R(O'KR:A&%5]Z%DV]06,^0Q[&9X3%8AIKVS'_ZLO1T M%&A,[Y:F?H?EBI*VC9DK*)>9CZO< MN^LM'9YU=<391&^C1^ZS)S# VQ%2"4MW0&P%23+],#=ACDDV_UD&CG(1 MI$2 (Y?=^AIB]W 0_ @8LJ#HDN%]A)I)!@32UE&)][L%2Z -!$,9E^+S(10F MOP,,RF\2)&7]VU2BE4,;C*9"MXRYQ/$GO&"#(,4<6#:*T#0QU[=B#O$&"$?] M4/BAUO&I;!U"F7).85L(Y'[Y%7/)CWMF_#_IZNVPC!_]T!AG0SQQD!;N0U5= MO/N3WA>U&S-6!:6B!C-"K 6?@5UJB=()RT]>74$,\YXOC(RY<_P"K*U.K)& M;=S88_ &F\-R#XQG(VEUWQ;Y(RHW695B,0!"+:ZM.UYJ2MF(,N4&N09E#;*< M:LE1B+G)K#!:U5'5P' M+EU!$;').QLL2>=F(AX!5";1MD)%PL$U,LA';WQK-[0'MP;BHQ[2HJ1O@C3O7Z#WV9_H0G<6831+6U@9W!.;2Y*IMFT) MT.-\1946>+QR2ECF@*.#A4CFG%EE8^ZP(-N&5"@A<*XY)L MY&>5T\?H-IP# M06Z:'123A85P1@[&3A>T=2<1=\N>-8=:)H36W ?69A2IER&$-[GE&L@RK/A= MJ2//X9<0*R P8UUA4M@_JH%U1Q\N#3='I% @-7=%+N&64N4>'989JZ +P(@O M'@#;'&Z!&>/XK#P8+ B?U97!_4PJ1R:!C=OD'&,MQ*Z OQD_G$Q4O)X" N)Y MV+ZNS+M5#4#6X\)VV.(1($J,!*9*;R7C<-5ZCO*.5=/Y JQDB,%Y4!E+WGY: M:YDU34@PCDXMLFS)CL<7"+ \>K9\^F_H]8\5E$[8K69$2Y M^HG4/<93H"<%C7CEYQ2H#$E I3DJRW.C2L(%:(Y9Y3H MI]HOHG,-)+WA.#]K-*.2CJ@),E0G2"PD(B)]D9Q'7)X,UQ)!'A,B/"V=.4@ MIRV%OO"VA$"1X\4JYM_ _'B?;^_6J$GCS8E8^%BX)5K8 2,:J\#F0]Y99=8N MM/:+#:T]D]#!@QYNCM*E#3(WST+;8]#$TSH<&.X])R8^[.W.)NV4OYOQ::/@ M-C\4RPP11"SK3,?2$1PSIMM8651UE(2+]0' Q"ID>SO:BX'@.4GDSS&S%L';4>Z[)W?.-+<".?YII W<% M_[,3Q% '8^-U[9/["4%Y-%0(G4\>N/O@IQ<@.J: ! +J^E,IA^Q2R660'!&) M-8ANK-7?;P3MCK@1BT)"<7^I)2[3J>ES2%W^4HYVA_"\)*4O*\>9 D1KDNB@ M4(PVC\,=YZB=BO;P(4"UE62I2M)-0&-K2F/HL'_KXO-7Y]_B!*<6.0WDW6[* M:!"PBUH386UB<+<<]%Z>V)[$@S;I!C3^]KD%+YA-==N+8KV1N.7RM[]#/">F MSU,%T"4^+?V7:-/GBH^YQ9RV44GF?G9X/_PA:G8.(AP]DBY]S^8K4D+&ZKC\ MA1$/;@AD4G!5XU(\BDW_.K*P0"XTJI$>'P#D]@4?.05VE M6/ 43_0R/VPTH2DVCVA!)40V<]Q]E)9A #$'5V"T;-AE\CC!'XTPRQ!S;$! M9@B:IF9KKC'5EBNC^*3 MO2%\"QF<&[,7MPM;2H7%PHS=0?8[SAF[<;>]5.<""[D="9;+"-^D(%<_/"R? M""NI9,V%2CZ%\Z6(.:\4:_BC;F"E3JL)T!@9=X#"O+9\N*5&"=2DIHIS-@>Y M0 L]5:$C4O&S6 1@GC*>_::8@SI1G6&LF-AO<$&@%W"-;O)M[ED=7*J=9Y"W M_J);*)R'E:C!Q$F:CPL]4)MJD2M)3K*@M97!^EX0I!2"G"29PZZ;6E3>"3FW MB@.8T;!_L=01N-$\FPL2? X) EOM@(RI6,.:OZY+%991X;9CHJ! U.18FYML M/G.5AWJ_GN=+WSL>,#Z71EVM-(B7V <,$"3K>*O37WD+, AL<1Q*SO5M\J5T M5;"*^\&+8&EO15\%A2A>OQ%I:Y"'VA" MP<-/11QSIZNK)ZT7)MP_F1BI=);D>_-419;P8C)5C?@]O ^5R?T)ID??164@ MLJKC5^\SJM\NH-0B0,#LH<:BE(VE.)ZM&?4M5HW4J\..#A;7WE(8U>@7SP"% MEYQG&46#(CBU&*D##HUGQ""-F4\3)P-5"GK^$NQ-K1,92[&\FME%A?!?V= X M=&MQ[A%C I&7!ICP-U1C[$WFAI%949(FQ: 19@UC$@*6BS^ 5#%]T.Q(\ 0) M3R. &G8,/0+B!!@"UYQ*CWA):/95<3HY!3 "/U.5S@,ZVTVN@MY*ZV>CU)UU M"Q66TWD&8%%6SSE0Y"LVRNJ*7,X-D*DVL9Y)]BI594DAGN MRC77]Q2M%5!7Y&RLR:3KZ!:E9RR+*$5AM<@AGF+-T@T1!YDZVG^Z O/:0*W. M 60YDM6N+=MDYP3P-;$GF4&:^2^*N_)M(:X:L=F+ZZ-QB%)?6.5 M?E<=;76W=AA-9DNN2 0[:EE.K 2-:V)&2%PGP9.PJ)@GX C@@50M[VX*370 MV@#"6^2C;+$?P9J%=QQN@7QVAS5L"U?16&U1-SJ_(>/EHI#+!:HS5ZY%=L)X MV@3-NOR@#N0K@C),2/;0DU=A4Q4YP84]5[5._1W>?*1DL0E,589P^@EMB;XV MGYCX16:U@:CPN)8FS#*&0KG+(H"D5=CM8BJ$5^!JPMC0&0DK?"UR=G.H+F!] M7.17GA-4,><)M!D>P[*0K&HC- K1A]0=SQ6F<-QH;&?SB?/#NTJ3A2LU6=UK MTISJ5\O-KUKOT,8P2E.VMJ[;8%4<\0HB:\DV:JW_=+3S53:3J)0-AB,!SZ'( M80^,S'Q,A("10.')EDM10HV*39'KR%AB!C,;H.+ZQ82B_1NU\$_62NGQ,%:J MX,TA1X(21+>GF2C=7!A%96'W@KUNO3#4QUP*MK/+EY_"RSQT]1-_(+,U>I+O MLS]0KX.U\T"G8D\T \'#*67$J;[E[.>0]#(.E]96\()S;.:\Y)!Z73Z7GKVO M(GZ9)UC$I< EI!\IL>$J87/P&L1@*/K4(5PH)SSF[F*+"$R579#@)3PLCP0M"(/49&"J3DTX$GD5/3_(2S.$0E%0PP)LZZL0)CR>:. M@I 2+=]@:$.Z@C+T$K+_&E?4WCU0G96N.V@O1$)6JO)>M/*C$=[(L;&&F)7, M3H!3*\U+R&EVA@5*;*"*]8NP(#8*XY UN;4B@'3$2?UN1N5C5QO839(5!$/, MP);@#Q\-9J1ZSOT!H:)7;.T"6FB+S$A->4;A[&!-CX:]GVFQ%G=0O]L,G,+( M;: 8E1/.M]LE&RU\/^]NI6;BS7"A"G% SQ##_+!92/E9+R1/ H,\;2VF$PXQ MEIZ+WHC0'-ZT=GD,>"BS1S!4/XKTC;YA\509*7_+']7N*KVM[3K6XS7G@DET MGSD2X0-9J H^F4=#)=+&T.B,\3R],HE&(<^6-(I'M'2K%8MU7$G#DO.!K#W; MW>BSQF%/8P;M@+S \^PE@5RQD]E6/"5$'_PA)1!< M;]8<1$T \7_:O>>+ 7LFT67N<6(V+R@9,P/]Y1CM7_=@X48-:PY67^"D#QF4 ME"?68YH31\X59!M1$V9@UJ>S=N$P-H-;NW8AV_@.F$D!KB6H&!_7U\7 MV)&0SN7)K]"@I1G&NW%R/.P<\7 ?:JAF@0<-("077(1,1?RV> 1.="7>^9$C MBL&$Z:9_R4ZA(CI52(Q1YZ>3R].?CL!+@_'&U 52[ZD-=D2SY*D$R,0_L<2+ M9B-L# _@=K,6 4'"/< CL1 Z6AG5Y-'RRJ_!,RY25IV=S$85 M&67GR3!X3,J[W63WPJU]Y&MGR"4V(YP!?'&HIY=-04NJ1]RFBE= MCK3!GA&[ZCDLW5L;319.1(UT!^>=@YB#3;2BS.1+7+$84>F$IV,RN MK4LY\S)AV;J#5KL"C#5F?V=;K]BU2OQQ^^"OM$JZ(/6 @]ARADIQB]GA>K/9 MG[%$CLWGQ/SC*-_.ND=ZJ"Z%%0_,/82_X8E1N41*-"/GG5NS4M_KFZTS:@@% MD( A1'(/)^EAF8=7T3^K$")$B@P"[][EZ \)OXAQ8DPHY,]J7&?:;2-8L.7+ MWRB).3!K JHGQNG?4N]@ZY687RT0_]=N?DMV6LJS0HNS&(:9-;'3D $ AS M[;ZYIM<0&B6N*!>8Q.>#+56'8D9$MDT\)1EY1'A]"03"GND MW&T"K5WI@<0RZ0WV'6!K? MY-&,X=;_MI2$_"=S=+\M-@1/'%LYT.O2D@1Y@=A^"AD"^KIEN<.-'P)8-LBA MC3ZSPN3?VL%"FB/J(1AE@3?PVH6=>H*-75COS$D@MSF@$*N#=R=ZW9&C\LZH M8>H)2AA_)>C0,VH&*8-4C'D.-NO-4W4-@NN)0Y8@G%JV]3N#+Y;,!PYA@/+6 M_- 6OWTYRCB<].VVSO^0,S& MX (W:\I'F-URZ"=%Q12Y*'@?*;V'<2)(R0@SY;*2_:K=,81+'R.1B M7;F3JQ1D7Y'L1V KZYWDNS01G&*R*#Z05!78(W\19U!?96NO:+BZ!-I 5?-2 M8^M&)RJP8A.Z!V/R<+%>[5^1?ER]E$0W;S"S82*>:Q4')VF*;GAAHL>!@K70PH2Y@3HC3FG(W>B2:[G;WM NMB7@ MID<\_-LGG=3E8RV8:9A9/;F8*!UH*G7B;=(298&BW'D,.?-/-6>]BW$87LB8 MMDQ3)NFUPA^I$97=\FM((]YI](X[P8*Y^+IP-:$+MCCM%1/80:%XB7M\ ML?JV7LRP&HR@[^HDT#L.Y7)$4\EHC?3CC?$X&7LC90^[$)KU<3@0+2^5K=*2Q-YFR\]EYZ.@#4_&0N?(X($V)&'^Y MCD,+0TQ=V')MD&IT40J&==\@/U+%WFR "6?E,7Y%GDA5HTM(\]; <3>_0[L^858ED'8X"Y]4(J;4DRAC=S5CA)EET$SC[TN M5\Z)'A--'..1 1Y \J)C.-@]C."67;6IH0\'G0%SZAK(2UG'/';!\W M:$=TI(EQY#F]4_6(J"TNV: BY%<@;X#0C)0O+'9AO#>J7$A4.Y=7H/K,B5N M\0!$@LYWD#OF"S))P)SGBSF;H]"C3@3.50D-@UUOY+RQ$TI"HJSU187!JBO5 MPU9T8(I+N=R7XDL %#DSLCM;O2$M*X&<4^OG,545 M/ATBY8_(,AF7UF._LMJ%C38F-T"M>N/'>? :54=C37-BI+3RB#.KLW'Y9O%G M/O^;E#QP$JZC,X?0J%.7RIKSCT_ ^I^38O7U@?&9?3@A'!Z[+J>T(%IL4TX: MB"MU?BT1%6,N;?98-0X%:(D +IXY RPO+P%MY)_QB]#2N)"J+)R2W0"$\LL$ MTT",N1I9V]\9G>N,EGC.:6O):,=7=V=QY P)6FF@ M8$>TW9*>V5DT/4I_*\'">E6J1?V:) MGPF@HU667BSF%>G;H&770<1'.E1E*CL$6F6.7<*O.O M$N^B\U3DC4NM91?]G'/7P9VR'SSO[MBOU5\K!E#Q?RS*R N/^Y(A7 M^,5>>+FNC=X@7(>W1(D!<2D6U_:*R@99/"3"@P"#%7D;E,'7!N&[VG6Q%"'DD2G$]:?1KOUL4 M\HJD-85EPDNB*A#9/#K!:H-S,<+0=#K#?.16)]'(IO=*-J7W[, M1I,'10-X2.M60\Z*LIV7AU*$73!J6.9^4D#R-W[0N*4RAG, TO9N%/YDW05A"WI,,=VXZZZHS9MTH'"4JQZ8 M_Q:V@S%S6KALW+6:0G 5> UVZU4^S\7CY\)EG5>;A2,C'87.ML;F:=S>Q)M=UA1#D@ )YZ5=7AG?(SL4!#/T+^;_^"R;O40&I"(-5(8 MQLT&:]KR@/C"\&(/S;)8H0XD5 IN\-\K^=6;HA[Y&B]%/I9[S !S']K2*R1#%)KQL,5.BMC]/B[G.#NE_-'\#$O;$B6[4&G4,QS<-X9B60&DOY" M"B"YC*5B]X!580H(J@(^2]!5V*<0S>_Y?^ C MSF?*56V3A.11=(;1G>DFB,FII>9T4^S7 O#3F=0HID6]82C<>P@@,$L*]1K- M7F(B ,)U[%:(I\N;<[H89/&6IX MW_>6.W-A%U5_R ?Q]2H)P?(CRUE*90K2LP6\@8UUE'::V5N'\140=U\7XV$/ MRWG)P!4M$#ZUVEG&%<%+'U=><'RT@1*@)B#YH5+< H!1AU)>*$'0F\8 MYNP/@-936*"$\XXQ2#[ L[9Z!]'N-7-]7P;&E@SH5;X-WJAAS?ZJJ4\V #H) M%Z5G,84M&#"UM*#(^KR"36708JX]+]; U9KS5CLK(K MQCS/DME3Q*'%O#,E7T+E^GG/4-RRF&KY4PN;&X#9S&TAR#>-!ZUQ\"*4"[&)85*/M MFZLWG]_6!$(('HF$!LEBE6RN6S8W\;=:_= 5/YXPEQV/V;1G?G]R-7WH+G2K MXXY6B?9OA%TOT"ID@;4KC&?EP$PT1@3G\A*376PTA$E3$1.?^U5J=I*":4FA M]'TL]B&)KZW;[ECBBW6)(U<2YY586U7<-AT=DP)VJNUL@.@;*&@$3_]:\W2D M&_.,=F+]1)(RLRS4@Q(=ECUB[MPM:!KYO(QIK>,S\9%C+ ^F84?*.>Y%R3[) MRJ=8;-#-980&9_#Q0V=P/ H%SY$U^C=R3HS6AJ/:6>&]=I,OMK;V5\7P_D2! M[F*^?< %]2L!*_1&"0J85KCWF:3E?8%43AC1_B?*9:M=H66-WGL- !K?%G.2 M#%U%IRTQ;JFA( #W[#)X1(4+ILFBAH*8]XI%KW=;](J[Q-1L:P602EEL-\1M M]@=*_:#*,W@,2D@6PD,J0FM>J9+?01CAZ!$)A+>%N/!+DAEW!8-SR#RH=W+$ M^_(2F6G\B"\W:ULPI#1_KOF7,YPY)W>M]RUB=?6ZT9>:+D@;JZO$'5A;(SG/ M=I)9=*/7U4(+E8IN7SUWRR646[JD\)091YK4CM!BR^AAZ/F6S".N&NY;*J]: M5TP7[298)I4.1V52@3FDTW@RZ../_@A^C(9#KIOD[3QH67:H>^E/.&-_D$3] M:1KUQU-['BJC\A>XWXN3R0!^I.D$?O3Z@^C$7ZK6_5KF^5;91+CU+((T83XF>@JTY!Y#>*T4/UQHVS),(.7)P@S&!GJ8I<5Y2 MF@TA8DQ75,[4U;+EY/I5#H#%(K,BT!\*X#RS=.6:N"5=K]=E8U%( M,EBZ_K6S:9E4ALFZ)^P]S,06(E7G=^Q7W8Z?\L?ZN,FJY;1=G"48J$YVMQ!+ M3H@.,+;W)Y>_2AU9+A(W.4Z&Y70!'GH$U)2I@HQ]V?]!@(EH?DCWE^LU@IQ):[-9<:5NT2 M&^?@0)6%@ ,*O6#+'E:]GW@G2V$+RV07_L39VEN(E*#;?B2-3 (($&K6%L!@ M<"]Q6X8>L0&=Q=9IV9A3^J^=&11Y VD -K2"\81P*,[(Z!DDBRW>E]D*BTZZ MTAV$GNW"9"'QT\;:NAVI#9M%]3C@$9Q&A)^FBH2\T0[1]4UX43$;"&EH9FG( MSP\6# $%KJ,C1V)MJUH[8WB$58(,7ROL6GO!(^1>TCJH[\U2B#/T!7^PUW/5 M#1Z_R[-3.7WO,<_I8K>$: .*(0+HF7[_..D-^ZDYD>]<)>>O#U2/V@SC$A;0 MIDO\Q(Y,=M6+Q6AQ;_, 2'!<,=BF-*CB'RG-$<,5+*BI ];2=LQ_8PNF*(Q M](Y$+ 89A!A;-/@;IA>S&N_SZPT2$52FK&5'H^,>3)Y#O'_RTG9#U0EVN#3E M#'(09^XA$I4N7#0-Q]4:!UN5?4RWJQ3%*.KP#IG)>S:4;O0?<$JWF44'-/,W M/? 'Y9K8^>H.WN6B3E "C<* <4[J-HTE-1)U,P&NV[HRB@++337&462E\1/ MMG^B86'_AX3*7Z%@4VT(HNBX.#1)*G0%B/4[N*XQN8 .Z"?C\PYBABO8-@<:JL2^UAN!<^-G\H$S@OQ&^F0R;H!*!1IS4$E MEXVSLHAO\;5 G%,>%K2X4I432:#A0'85V(T6'3E).N39BC:2[V61UGSC(70? MP%=W*JN# O$0NRYM%);-^&@:-Q9?*=:6/CAQJ51>I;ZF2KAEJOS26/5E2R_* M[:[#5@4795V-I73ZFS-0*BM;L$))73I.4X62:*\L2'86)1'*:4A[::^.!Z<] MK!M\NC2.Z<_9:4Q,ZZP]7Z83&+^FFBJV"CORO]Y8S*&E\JM5$>[]<_ M_I$QOQ!*#7 N_F&>V6WD[% +$R.I(, M-4'/L4BO*A]>NUDBC5BC7G>)VIAT24F3A?--W]D:Y9QG2[*+[!)MLUL-:UL+ M97-BLH6"R-FHZQ% 0-VKIRANWOYIX!OTE M96R)LBFP!,!GS1:5"KCH'9"@>6>B*>\3H;O17L6689: 15%MXVS%6*1TE0VG M:D _AK&3W/$K[9[G1UESC3"]-/4WI]D(A#Q'UYYEOA2VQ9!5[!&_S@T!KQ@+ M 5'R/5G.8N3[-S;=]1OK4 <'HH]1[\S$WF8RBZZD4ODC1='-X7W:])^ Z#8] M3D!T8PG5TFY9G51HZ$:^XR13R*IIC(P2EL*VM@@I).N-!+_::B(@O.*J4 MPB,/@A>N@PVLGD5X#O?K+2\ 5C=X8@'#X7N#4$PWEIJCO]D$#6YK_19J&S/, M)+.+!WHVK/Y>>N"D$-E^-$NA!$^$$$NP[),7FL"X<_EN618+MC!$^_*]UZ$AUO!67;U6,O7CLT;US>+#'GFC85S M"8I:>#?,3:,!N=Q!Q))TD6>!!LGPX=*H?M=;S0YXKB[^I(OUBL.F9I1(FF0V MW.9,M.0+ @*3D"R]-)+75\V'-.4P5 U]-?K_)[G.,MCN.3GV 8/74A<[] M@R5]!]8F4. 9914=O9YQ:J 9%&63S!VGTOH=EDWF]@2U%?V<7:^Y9@[":69U M[(--S27U#8W*V>QN_U'6XX6L8=Y^1J;4PS2+5[9U^F)ORZFWW]'^J^RH_6 M<-EZ%O NO]YZYH 3\98>F^-PC-C/_\1WHRO 0?IU:0;]?\JM!%Y2;FR1YJV\ MBR0#>UHZK%5".2%_ H9]F0:^KJSW\C<,=U,??*"PN#/KZ5-+<1ETK[\UC0J\ M/Y1#ULKH&]-_OYO"*>X.S/^='AYS^'A@F,+'W6K!+F %H&9XPC""!]E\ A^, MJ-KD,:0(P::[+L:IX3X]TP>W;?Z>$-"^PDH&R()BC=&#MQR.F/2&IM6>>;D# M;Q^9#T:F 0G44R_KL0W,\S(L^0F?$?^5N #]1E]-1'["9X->SPPT-TM<=WL>X'6X;.ZSZ\PE? -]CZ%?9!M&>"VP!BF]1$FK6?LE%*/:?ARN/RK<,Z9?T2Z+G =+1[$8+="0J1#0@L91+QE+:'6V=_/W$^-3 M0U5[+9=*:G"A2T^)B(=4@X,&%[\1]L01[0-N>PBBYIZ'6KF8@7QG+NJ\;K;= MT&Z$COF7? .F>[CI]Q\+D!NO>0F.K:0@L:FL]T67_GDQM/B."S12,1ES0231 MSS8Y#V^AON%O/S?)C<[*[L6B'4I>%':QNT>T5::(Z;:)@:$5O=_A#]CH>X_ZQN M+5A;BZ[3T=1LFNH;2UGB7=2/*@*6\SO5.*\AY&Y!C%PSRQ7=$WPWH57YE9JF M]#1W U;ZJ3W1:,%P2 &LGMTM#$\PR_?4H(81:TKX9VI9%=WJE8D$!V[$M5+< M) AP]_?@7 [; :*RQLK-!C.G:*D4/K@"L# YSF6GS)"3F)$**.H]9Q0!)_4 M22U:(M&_?S2'^\E&_NT@[F,$&F19DL$/:=+E(-"HDX$H!PQAV%?C28:@85XX MO<&)5Q$(@N4NX+.*FR_J7!LY+1Z-!N;.KXB!_'FS%-\D+4M+)!S[?[60:.U4 M49#U_]HCUFI1MIU8JT59_7M8I/\?FJ$K?9I"#P-SWL\KJ, ;(4H;>M'\(]YW\_XW[ MCLL$/?.Z;@@KL<=\^?+*?^_:]WP/;[=A_W+7SNF\8CCR58+LF?OP+W389J)>FO [CO1"\K_M&2]_;5.L#O>SEI MS_]CWW:/^FI@^,?!G+0_!F.._]?!G'3D_7X@)TWC<7]"G'24E.22?ISVX!!\ M;TX*-J/RWP=Q4K 8P+^7<5(:Q@0-."!*P]$K,Y=*BOUI7?),"R]!%P]@]5B6 M^_"-DS:!9G\'^W6A*CL/VR3A^"(.MZN*6EUYZM+A40&Y)6%*;;@$;[+E_-:70#]+F_2N-=/= U&0+G( M-[D&XB)<$*[A(9(KV'FR#8 N[8KHY#>R\93"OEOB(<(YWV. _C$;?< >D\GT M#7*B7F"7R1*:*JLGZ3+$N8 MM3C^E&9$^4=>=>EZ[US;4'HX4GGK02AC4_$&^ MG,E?ZLM)1NC+(;=O)P%##7X,(E*M+\>)@>RA:916C& RU"^ 7V($BF4+$6P" MJAF[@B;FO3;25S\@?<)G_?'0O P-=%(TCA./.=@]DU9:A\_J/A>"A-Z';(A[ M(R-@OE6A46=[U!2&05RW&S"J[7PC6QX,8G=2QF'VSM?I\\ ;X;WG#]%#($8) M([ \,DFC>\/4[@I*-(4+-TJF>.23!%7O0UI;$MQ@IMLU ABI:#Q\I1%J:#%S0<'C;1ESDM#425689C$?'J'%-EEG'MTDX@^,/#DCF,RK8. M3[G-0 B^S!],$.VT:81EFBQQWB!;_4CXW N]X!;DU6SB>(#G&GZ.U,/P"$ = M@3."(JD2(X:FYG^XIMQS]U2^)5OI1T>I>09Y9-F[&W3GGAV2;Q[:I;V+[BJR M4.J'G/PE&DSDRG/O.N,+1X&Y.C5=HCR>-9="'2R/UE$1K MQN >]C9'H*R5883;A+[[J(9"WY.H^G/?PY' Y1,X7/Q_@Y\ +X?&JX\8E* X9 QL4&AZ[NT$>S)?DQX%9%G4&" M@DXGG?914NKT^T,,9NGTP;AJ?B9CE-(ZPSY^+N.BM.-D"KIO.C:L(S4WXL1\ M,.E"$!:\-$3'@7+Z&Z8$=KD4POT& V5,*O]\MT!\)61:=<]8$2^A@=./YK[6+M-_X^0CS5!*_RX1#ED'0T(*$!-_@-;?$;VN0F'><] M9&3FQQ\0-*1R1.2X]0U #I*,^:,!7F\SL2W:/3PQ[9I #0V#4J:&B4W-U M0[640G)2$8[-[(-I*$$5FP\MT"AQ<>W+965//KH2#'NBL"526)4 ABFPF$X? M53?3] "TL//5L9DV8+340PAKCA/J\%<@ V'8;IWH\<7B$\V\4'U? MA&H9+_30KK&7"[*#[F0\_#FZS%< $D"3!]LQ944SULAE$0UZ4P@W2&!?.R.Z M7FA(>';AZAC@I>WM\0A=,>;N2*;(*9J[C 9#N,23%,;9F0RPDT_KU?$L,!GW M5I)@#T,22^!V](E!GL3TD"-_:PU1]2@:'J(5>FAV16$I@%*&8>5H01%VLU00*_U$3[8CR5*HNR38HMNQIO? P68SC!N!?<,3J@\X MY)&ABT!S*5CX?Y8?_2'^.*>T/!4YSF7W0$WK3$D/HS0P$%5MK05H=68H94&W M#;-E?+HO=&&>(2!'0DW/"Q$_G9JGM2:MD^F0$XA9K$5!EA8Y8VV(9&SZ-JMD M1"F43_(_\QFE+'EOBALRE4@2&&XYC)YW+(%#DJ A!T)XG/9]+%!1)0T6D_"D MU0@K/-^[9Z9T.X]IT'1,B1K@DP2T?W/"V 9#$P3&P1Z']JNXY??@ M$-L\65Q%,!#H2L(5M$\PFH<[IX19L;,Z, :+CN+#9!64)3:\U$QF>TS56_!$,IF9 M]?^6,=Z4$^BX0$$![?3HORO+(+C*R587] 0O".X0!^4;91>$2W3O(3R3G]\U M4?Y &EX*W @%%%)/R+\56N"T!\89N#X2E2P!934?49#MC,;$C<;DG[SRZ[JI MEA(C6/9(V?(67&W?6SB=9II;6FI7=:P/(4$#.,LT/6YR,%+R\KF.ZEB%="PC MN?5 O1\.7)36O&8H\/ $!.;A!!@SI3'5/&JNU:E9Y!1UMLZP%[QBS4&'@A'V MVG,)7A2QYLZ95WX0^A+B>5X>Q[;4L9]:=D#OM:9ENCAKW\,-2G[QTJS3*8I^ MPX$LQ48KUP3"P( .2$ZB,28[PA77-U?9#K+BW(D3/6=D9D]J3./F0/!&Q+D@;^"@ '6Y$=>F)" M3D@H&&AKL"YW(UG:,!36U*FJK%ARQZRI&01!#^D'.AW M^39;+.N=(&!MQ7QVS'7^YX?%*H_. 22P0M/VT:L-NLN>Y)U]IR%9*ZB+ M7256+:ZE]:0PI2K/<(%8FR=D.)6%8_:P8A8K#LNFTK]3.(?D]Y7J"E8J+>?U M6SO;O&J>(\O;@RV10 R,W[O(G5WP:AV] Z'H(H>:Y6B(VVWOV*_XCVIH@L/U M$8O+L?NHW^//DO$DGB9X>,?];G\*@0%Q,D2W#^:F?,P<^N0Q_N6NV6$\2.G< MFSO27#W))!Z.$XXN&$=_WYG==^_BG]PQOCP=H\5_FH*!+1T,XN$ 0Q,FZ,XA MK!+W.G]@>T\&\7B [BI#ZCTCA0ZG<3KM8P,P\-+TIX'IFU&D<7^ @5A## T%V:1N,I]-*;!'LQ2GF_U]C+>+BGEPGT,IG 7'K34:@7,T.C M'3?U,ISLZ60*G4Q'(^RD5][42=WK$$MW MU,AZ-1$?V.I^9 C5'LG!,Z\]U@XZ2VRO7/RV*?X2^&Y#=/"IPTL.7F#U!C&E MCY2$H7"1N$!%.GEPW:@F>*^ [*GBHV"XKNI3AQ2\(TP8:H[/I/OBL&6OBP:P M2 'C,:$MI"G[;2AN8S@U&O?G0/-N.TTOL1ASC,#B@?$BB@[YKR$QQSK4>V/\ MY>3>EKYP64\(C])R=C;M8WX9D5 M[,S&Z!)E TQOA%;Y>F^]7?$.AL2@JI&0$5%"A#MHY L/K/6Z]VD@G82<4- # MN.S'K[GL8*1E"1?F'UAY]2W[*US.0^/$@BN.V5V@HY*C&"AJ0!WL6>\I.K93 M1A+II"DK>>SRGHQ#FEY[/G^1ES&H=]M#6&T-_Z\T>V*YR8$]--T-+QS\"Z3W M+$2'@=X;*!&+A@:@ K;7L MEO:G:]-RTY7!]50QA)VY Y'M(9@I<-/47R_59"!LRM;0P6*/Y4L'(G$9CJ=O M65.')G\D'=.Q+1/8M.L9KKWJ?K6X=2BH?698K1/6ZIJ?"D&K6'7-+\=F]<2W M(CQ;+E K,YW\S&X;U?3J3N-^C1])^ B$^C>.8FNZ,TI8B:A;$]O8A%1^4IS%$ M[7Q%@H&2 =47IX,XP7&"UFF4-C/8(6<'\I"IJ%5 %A_VXC[JI^!S2]&M"%V: M_H?-%.$,G2>NS% 3Y-ZQX,#YT<,^R)O4D<1"'#:65N!!?UUFLS^.C<"]!EP8 M>N<8JE5A^:3U/%\2(_(ETLH 5%VDUCZO,RG8_0WA=3 ;*T77!_X'CJZ+1?'' M\&9[F1H?ABY"%PEMKTEQ)W;K19; MQ2=4ACCU\W4% GZ5+>#!/$;#C0JJKEB!?BCW&(P'\:!'D;U&ZIQ8[I&8+\83 M9!]](_E/HG_@ 3:W3Q_.^9!#N$;=PP@-Z$[:Y5+, \%8T-$H+[4+6C(P7MS_4/GDAFC8W;&N#6YL@5M,HE-70 MC-HPILLO7UH=\Q]_KOL *I7"*4VF#>?:L&@^T, ">MU)O^E<&^XZ4/^]VM$N M+[/AW3VP/&),< ].-MQIHPKN;:\;L:3!PB8(*F7RIW& 8.2V+-BX(@S[2!,)6%(OFJZMX>/D+ . M2)YV\C#@/(\A4>?8^8^K@>"EIB :%3R#H)E",B=\CT(B.#PR11H<)B%_RK-S M%7>/Q>4DS',)FHD*H-Y 2:4N"(G@/L' Z<+P-P=DW8[_%=PK0>K]-+4F["+VRX-7_7]G]PR\Z_5EC M7;9^L&[\GY63&;;R_0X)%[2HG1GMR76!]U.C51&(49#"9BF" MV5Q\NOV2M(]^8;-3S("!!![D-=&L,#//DHM?6!FLB%A<$VZW1O_HI:UB")-\ M Q:)-R /O0%[BSW/]"U0*9@^$A1RF9EN"\3]Z.L0J*4 M@$#B?$HI4J:/$+;EA\E'6GCC#:&;:2^G!I." 7VJ6T@S=>!";R8P_VG ;Z*L MLU^H$F/NL/X5Q<5:2@*4BZE M>T_M+^K8SN A?MT6, 264K%P>XDZ3QO&HVGWU\JWX/CP"I50'FC2AP0K\P.8 MIB9VM.".RT1N:1QW15>S_3?*7@7T50I@&GI6[=-AF^K!YE?4 9"* W=$Y@1@QR$W)GC9K3@X5 M9<(N&71M3H+]\6F]"@&!=!K0/\Q23SAB9$2QR," +;9*+.NBZPF5YQT(/*S4 M68FU[O1<7JJ;"!I1=&WG'24ZJ4JS5"BIPD-+/G#-PWQ@73CN/T>"KJMLBA0U MS&#$&$>*"I#Y_YFCK)4FF@:+PD()"AC'VL.AP.G5FIBE!HJ2OJDY]#0/^1^: MJ(B. ZCS2$G%%S:(LT[T"^=%&EEH9V0^FYW<,IVR\EK8M\XVB5CB:L:V\,KV M3G #ME!6*<=SWIA4B9G/E[,%1+ZZ#.AWB^QV!;6H9P5K"9]=.++)$MT(^ M=ZJX:##<$;E:$^H-)#'L8HR8"E@P(.'&0;@;*(GL76Y.WVSAXDYU,69I/9U2 M,DN"62B]+M,C5C$9P[S@X&#[?8B+G.CL1%D;HYP!C;-/3H:=4M[N8(*YXGPI M$+%#;'4'$A3'[.+##CI3]-UQ%/'-9TU,.Z#0'C83F8LO"7 +,"U741 M2%XHM^D)D1*MB4% ,/+#VW^F;>$JU!WO**5;$U)2,F+G,_BN^]4("'MW2P@Z M'!P.4^3<](XS2,PL1I.-,[Z(']QN(XKD/ MV?L X;@==%"IL/K>F1+_^L88,D7%"H39P;8N< M5X D:9@M<"8?J(!P"0AKHBRB29QZ/!D1,N-D.+5!]W8I)G&O1\QG&(\ 7:R\ M9Y_LE8/,VVX-%)+?8 :D+0%X_13=YA"G^G '59R,+--, .S7+M2UUJ9AQZ;.=D &(%$B$_C*5V^XR'<,R?% M(HN&/58 QD9 M]]#;RJYO\!1,O0MKJ%A'/=3^@^-2=\,F40SF2$V?SA?6A#UY_W MT[3"H:D2NR6 20+AM^FL/ZT50E*%]UQ:8L& M(Q 1^J/I@9N#\-&)/6M_V:H"06(E 7.X^W 1?;$9"-:L@\7^KB'UBL+^Z$+C MNE]5"-!JG;]AE]R,@!&S(=<@YK'7Q@>5G\5Y79""MB?H1[]*;U&P34OC[3YW M*M*4!.,S !?134:BZR;8W,JVD@ #,@7*4BED;>'=]T#5E%SV!R>HD$U7M@O]9&.S"L%KO]R+J*1A+%X+Z#B)ZE8^Y7/-)#2GSMO>J;&Y,_&V"W[?8=YB[>LR7YKA\)/C2.KFW M+)N@"P4!X0<^I@Q^\[;BTR-99KO6L@S1M_7*(* JM*"-SN7",+G?/Y#&Y>YZ MR=7]./B@WZWDO@ J#03F['>6[U]PKQ'$_,="; O/MF@S-1D^!Z)Q7KH)3+T+ M+NU^+X#@/F9XJ9I>94W?JLVTHV<=OJ2L(BP4*+OU;]SX@$)DN.-J$>T>'T47 M 4%W?0WUM&E6UI(#TUZ6\\O?EHD3%9])%>P(.JN@:88(P_-COH0X/!_-BPBD MZ40R-VFC/E"JY-0ZB\K&B1+P.[@UR\UZ.>H(@$?GL[FI- %.49V%;!'/88^: M1# !R%<):.HMH"#8>/MYHYFY,T#FO5\3X_R*TRJ&50!<#, 1$!#L@='0WJ"= M^D,)$Y;30@*X6$EBD?5\%N!N0BK P,S* 3F.)'@NFI:/B?I. M@?39#JQKZ *,I966!XA94FH20DPJP"4?W1I\ON'1ZJ@?6_8?Q MH[]UE67=+Y@!3)_I<"B"!W' M_-4'G*>A/#D 0(()_F4N]TV>W4!YSZ0'F?8N4(4>3**PBK(R[T7\829=NL55A9[&0X)1&XY3 MX5Y06 &['_KH/@,,7_J_%_41U?%3;F,>V4,Q073Q(6+^=M+A!-6?X1 LQU10 MWA:SYQ=<37MT@?7ZR*0IRMA(IB/V<2":J)1_;VP#D4E1[YV,RFWTV6?G+P,) MV,,Q.?:&@R'IA@F$+OC+T$-TM!YB'$W /P71UZ/ ,HRP)E\Z LB5%$,".I-T MPBF&>Y;3M&IUL-LM]2(ZPASUF85S!"IE-.$?TQ5$Q4R]V%_3JC6 M"ISO+^OE NM@N&OCB[TVSBP^3(?0)LP@CJ.OE^^BSAM8<,--KB0+/H"HU]!> MDPGLRR9'&? JY,-S*(D2;QQU.("B,NN/YIZXW]U'__R(G.W_1/\WNES?;!]A M!>6S@X8=1U^+_&9'9HORFWVZ4UH,XM?=@E+ H''[Q_D]8 AR%$_=\))>ZUXN M\NR68@U05%-K7]P&'KIEML MQOX3^[L 94'DDU2/KCVH'_G:KXR.EXRR]_5 M*\SH(/RCB1W2I6"+E4N,$[^Y=DDZE9P;3-C&21@QW PO6T)E-[@B(+/4SX"# M\U#)E\H0P:P2?<:73&5(@LB!(ZML@QG L>N<1L^.%+:6;]E#U5@O??//T/3-#->INUK7J!9^0IFJ/"*KS'$!IZV>Q,@EOR=,=>M;^OKS%A-U8MP@.@YL31(?=J$-3CI!1A M^B7;!(IM6& ZZ,B6]@ 1K/;)0T;V2A/&;S%*L4+_"C8$V%73[M7R=HZ5HJI MR_6.4J\IK/$$.-AM'@SN&PZ2<3)P(*#9.^9DY@_;Z%.V M6E_K;XYJQW9F)F)VT\%F2AW^WU*KK^,/2A)6'N M;M_WL=0$$.J#Q:+? JRE_&YIL?^[ROK4%LE-7T1?'[!LE5G;P7%O6DL7:=>O MZG+X-E[F#UV+]E65D3:.*U?2H&9;2P"5+T]VM^;+M*'9WB#\Y:^0,@J&!#6Q M1JJQ+YCC>LTNIQACP5S!RROGZZL(.F+( &0LZ-(($](D1(=\(A,:&L'Y^TH; MM4.0M#)O-+&U-U7DJ7!#9H\RB!$T$H8C(YH38^]9.B,>2^4CZTDNW(UJ^UQ7 M>>%H.YD\Q9THC^Y;T'+K$?-.]S6]BFKMS.#QK(IVJ: MK@O:LZ^_(\_IEZ#T?>!IBKV!G%,&1Y7%K;+ETQ:#"-#Q=?H$T75@'3/J_!9A MKFLUPZY7D\\YF1J879U2Y1J*94W+2\D=S".B2#,;46@_K0%?E#\ O:%HY$J" M"FKC:LWQ^,?QI_.X7.:U>H5<;[W7JN5GF^;E!EVWH@J906$'QY!\X!IJ.YW* M4/;6/^:E+[_XSZ0R4&>ZY?:644_^Q7/E($XZ5CNJ3E MPW8H^K\V"N W5]H6":%N$_T^D:.^S6P[,7F>> M/KM=5\CX59KS2@._QHI>+>YA?Q!JN;X9%#W 5_C-G/V Z/O/P3-69KW*H0(< M)@- 5N\+9@$)]8!(!/&F&5ADGM\2S/3,S?0%%*4>.%\9+0Y./9;G3+YOH]_C M++?L]SL<^98]?T?.\.PE?Y43W[+[5^8S+7M]=7;4LM]V7.O5UO85.57K@_1: M#*UMAS^ [Z7?M]$?R_?2OXSOI7\UW]NWY-^9 Z5_"=]+_R*^E_Y0OI?^>+Z7 M_FB^E_YHOM?_OHW^6+[7_\OX7O^OYGO[EOP[]0H]'\8L7Z'#0_FD0*:^PF&@IA22U:L=S"&!B/Z)>)?&ZY7@<$%?;(>D@^6>,2SE<9Y[#JEPJLYR[Y)(;,W+& MM^G^.27=ZZN!(W0?8]:X6*?+ELOSH-.^M[)R\!XEASTH-]M"W_PU?7]O9W^?W4^A92W7?2Z)_5\\O,-_N[?#6Z)4G!97W^*%IJV6_;>3;= M+QZKIGQ,#P"[W$=+.0)S-#'X> G13H#O;R[Q/)QL8Y^%)P"G%^[TFJP2>?0> M 0FAV?JGN31AXVUT9FMIU,>\-$E>[G.,# SQ?TA)A5H [A;=\ WIK26,E"C"G.C$CX%'$QH/+[22BV-R LZ-N1%(3=>E=9 M@N@+:RAQ"11A362>;^*&]7^-;C]8,O0&T-0M;::JD'IG_'2<<:*K_<+\3?=^:2<.& R@&@Q5Z--QXX_JS.#J1-'T7[ I&5 M4PA/0%;5NMY5X$.9:UGL^;'0'@9&Y3Y,NDF5]5QBMOT](-UN07AQK OKHZQ6 MD+YI^/EZ,?,ME"\89BB#HRD;XHMD4$JV#XSN2_:TWE58'!2R?^DD83:O,U' M2]@_FGM.U2;@I-=>X^=PA MD"&9I/N^VD&Y7Q'*P/ZP?JT;5 EG&7.M$+QM\ MOSNM+MN@:P&&%1JR%+,+Y%14/XG]%A@W]6"!0F<]53+;; ^'IR2]0IY)9<(T M1Q2V9&3U(V[,$K>/458VU O95,Z?-B65:J UON=#1[=[\GEZUK9#FC7/?#0K\-S7 M,4_6L)N3WY[=Q/=B(]7W#FU^Z>EP_XZ6[3?Z,O@!5Z1EOF64Z= 7#S1$8UK,;!2FVOC*@YAZZ M^Y L;)7)L/?'&WU#C_JQ&C&W9AJ=,ZM1RCD)U,D)$V:KET\9?)^X/C!DHW0W M&"OW++V#IO,F'4Y_'(4-=?][922<.R4X5A5S3/B'[%.7Z']!Y5OKWIF$^_I@ MI-05ELT]N35'I=F=4H.;<[7)YGGT*;MO,+I"E +4@3+J28N.QN&.ZIAC73,U M0$G!"PY8OU'2+M>(H^:9E0]?;"4'&.$A0"8JB7>)I-2&5 \;]V$K?HZ5(&<@ MXM1B2]2_6YI,X/IJ,;UA%YS- $/&*),HFH*!Z4IL-:%KL,)L'C;U& ,:C:6" MGXL]G%NW^'[/+PX0[0/.>Q2F6>>\:#2J^8^U:M^'?RPU4,^2RP-RS0 /LWB+ M4-&38&90J34L^<^M;S)^I8;KKO@7-1>Z_%_28$@L>%%[@;O].>WM$1>0C,$. M9Z3!!60SS]@0YBZK7]>;#<4DG68/YONJ1>Y#;O2C3:':\:K*A^4#<^TA'# P MK-]V&=:UK]_AS-=SEAD+9KKGZ=YX%O M2ZP \N@SZSBSEK'.ETU^O]C='S&KA'>,^HS3Q5(=09"$2ML6'9Q0B0CM"RR" M7VI-_X/N=#"J6#7,SN9B^1$C2K%>!O"OFD> ;HMY8_>P!0'9R '$!AWJX #W M462=SM/H!@]QT:KC@\K/-7;O/=2Z^Q9\&?&B^(J3$.J/M0Z/TI&L[;?NY J> M8(MS:X?N-]:Z*X\V V! 8K.JI:#?K?7KY+%J*N MIKUD)/L0U(4M;5C&!P0O1^QS,H97O\&2%S4+; M@U#.[*2VYFDN>QJ0N8_%]P:/V5H1US6-XLBQ=.]VO7G"=S:!\:9!;W@_B'\% MDC!!%TK\W]I6^RP_VYEVQ[V?*Z/J#,#74/EX%.K.RJXP]AF2R/8ZHU-E-%>2L#Q/VMCGO8[8=78IX#4BC*^_F?YL[%RZNIAU[(>]0+C3D- M.CW@%(7K>R:PB=5& BX 9/O5,0RK3YH-&P4FGJ;! 4]"(^BDP^":_IK-V7,. M80XK/'9PNSR64$QK5.$'(V0<4ZUKU%BDVG4$U%?;='A9#^ M$M)!#PKY;R M[=5N[H+=$HD8,6DE\M(Z8:YR71SIX+P.NE>9AR^7_)3=2!:6/K.9. M_N(Z]Z_:YEG8&*M!/5U$1VU/4 ;\PJRYD8:NET\09E; \8I5# B]NX%PB%_# MTHKL#TIIN^W=&N/Q:A4"5YT"&,^IXE#1[Q D\FD-DUNP2_I=0(QY!\[H[6+6 MMD=FHAQG AD4((-6+J >W)*53X>ABR4-715!_-IZ)1=$-A34(*C^/B!2A:ZN MSCA\Q=/%2G8W\(']W:@OQ7PQ(_O^X5L1DN191\J(FOWRTP^62NLZLP(>+A/= M6M[F:ZO!NZ0Q-,C2>"L-TT2C'&[]Z9TW'25 H8D#0!ZZ'0.5.]^]$ MI8!4ZW>R9I.ZMSP>-!THQ/O0B\?=* @<7<53KZQ.8XSILOHL/6XW7$2C9P2 -U70S!0T_!Z4A>!HX (]L@ER%_D," <%,09>YNL@ MD#I7?IB$WG;+8/U1=E_J^VDQ_-JWC&"XW>3;!0?SLB"(57;J'<=F)"J/087( M4T8L]MD0>;1I\ERV)Y3*\JYWN$+?C7TPM'MT0F)H$VL/O>4:CHWB @ QI ]_ M?N!$(:=OM1YMG7:WOW^.0VKHU(@]253BQU_LW=)XHFU=";YLW044OCIH"5"0 MI\6%YCVOCJ$&"'$U=.$>P*(L!PQ"LJI0#/D-K&]-HZGG[PW5*@5_ "+$,::A M(U4H@1:5/[70\JGXTSYZJ5AJN@@''8VON62@W1*DK'GI$D^<8-01.6GJ3*FI]')O7;;HEUQ6)&ANMHXXHG550B M.33_6(,2$DJF2X-.M(M%\4?T?I/GOH>_ZE ;30.&RTG5SY]T)^/*AW9X2PA> MK&<;'/$9C6IR>.7[L1R<4?#)]VM6\BMVS3HQH*.;:P-36)K ME53D863ZD(B)!82 #Q]+'$[ EAMR6[]\NR7N)SRHL/G&/NOFB9>@#6-#[LL8 MF$'Y81*TI?6#82!I,"D]":92IMTTR$;20&S I%]]70YY&F8&K[#>UJA5E8YH M$9T"8;-^PA3Y:II+DVJKJNU0KUK7K7R))LRHOD+S%XOL**LT'V7&&8 MJ;1#R^Y8;%223'T6?WL1I%PWM>H10(,&?$WK$I":D3VBP[%A2#]NH=R0FV^% M&NJH8?8U3Q_SOK1^G#E_]8UVRVI:.&R 3#8!W1;;.=ZS;1?H,"XW>@I!+,NE M41EO9#K/[N%UE+!4Q*!ID#&&IZ&OV&?J&NYBS3??%@B-$J9S39V$90&3%5_WR% M*0#-V"BM*H96?+!_WZWJOZ0!ZT@6R(B"8>E:EGN2?![,G;%P@7190[JD#;(2 M--.9Y$ZZB/P-'.[C]AI_FBL&!($#]5Z^Y5M\.5I:Y2 MQCI1UWD]=5$T$ H$J!'=D]AH%:.<;J7Z4;A>U,#1.7JS^!/TK7"DG^2]P(E? MET(6&@+NRL/=B]I2)0$)%!T:QL8-^$$EUZWK ()KQ[-8^;'\G*K7;"P \[O%U:Y>%M7D*DXARS E_>V-7= M8O-:;4$6Y?;NM1I;W+Q.6Y1#6=^<"F ]F" .>3>V2]Y$#H>W",AIV.H:I_>* M+4*6[2NW"23RVDV"C>65FA1:J6NQ,5=VCY4.8)R,Z@=QTD_FU^620_4W3AJ!MX+9TY-0A\&DIZ>,5)YU#L$34,,]U%MIMU[8DD(H16'W[!*>OM7 M0G/4M%F +0XI F0GA&:OGN#V39^ $6<#&(0J*NKYS5E9YDNV".1ZMVTF)/F" MNH7S/C&';QX23]NWKP1[JT] ^RXKZ/EM-R7W'+[(-&.'T!1@URU>K%O/$S+A M7>3;W>8%XZK0)]\@%P"H(?8 &>2 9[N_F.]W/%PR2 M[1G3A1\%'*ZO(B@TB#26F)S>+D-D\FJFJR0DRR3];O0AOP5!'9"K)]W^?7W2@=A=. **M-Y,T9G*KL/@.KXN5Z=WNWC<.>G ]&(F7]TM&-%4XJ M9M_==9'_:P>/G'W;9\PHCXA20[.E]8L$KI[VLT)_##A9@M-*!ETSGUN<# ', M(]:\7P>CP9Q??E.[!YKFS(%?G^'THY?"#'0U%R90V]'#9AT(7K;F9'.HV;X5 M?;%&.2!$LZOH*ZJSRITLEVP3Y)X:$OO4BNG9RF=?<(@E!/-GN4I*:QN[-F&A MS;+B9>J,F-PS,SGT@$LC9F&\:FQ-6^,:W+L6;HS^P.K?L/67\,8[E@8:JA?Z MEWU-WL'A ['5%IW[09([6/]]80?[Z 19XWQYP1;QL^J7SYQ\_ M FHJ^7T"WC15@*+@$13FZ@$/X,M&YW"M7X6&9J^X[A# MD&-(C&ZFHSI["4TE8QF[T:-!@-,M=[!B%]M!T[63/RD6V9[E[CQL%O=&W5X^ M0:1&-L_(:P/C +5V8Q:B/H$L&78I< H NS<4AE$\I]1@TF_,8$ZFC5^GP\:O M!X/&KVD-,X@/6V]NLY5%[*U/LE<3OB#M^WY%A9D&H= &LA]YUH-$9XGMV! M9[UVAUHT?RDE1WY3)4=._)(C-A3F!?VT@HMOLQR' *\+/)UY:UTT5C.N>W!? MC[;NW.?]U_UK=JI"J" "K&E1P97-]1ZP](C79"V*K[EG_\LH8Q3/$GE#;:J: M]%T[>^%I^-YC>Y6C]+T'6=N$>&?^JH'9H *-Z\Q@1L&2Y3]Z@+XL^S]G1'LJ MN[_NH+YOJ]^3V_ZP$1[ FNU]!]U^6D.\ XN:K86P9S3Q6D+%03V^KIQQ4-?/ M9GG/Z^XP2>>P;3M$^/GM[.+CR:?_!##EMF)0,NH*Y/'A%@,H%IKGA/"$>+K% M;+-XV&NQD]<4/A@U0-#)$M8-OGU844A&!<,P%PR$2/>*FA,&)PQ"=@7A/4M# M0?PN1R[!Z+WZ63@OBR@K@LTS)V2!]XL"MC043>2A8+^PK:2C^5GF7P%2.>A[H-3C0,.?_(Q>JLLF>CS6I#BJH[V-!6W"*PKG6#*C"K M)H2J9-TP;\SIC2W.)US2I+R$H:"%$K582? *&U8?3?:,MFJ#O@YLZ\JPIQP#R5YP6-H0 M^*%GKXZZ#VRG?M$/;:AVQ0]IJ'ZYZTZ'Q!^86ZZ^3*W_KJO(4<<(JT_3DCM%7?3T,GL3Y2^8!&_<-=V^1II60SIA)Y-3,(+1I+W9/Z\^Z]9*:LEC[[U0O!,Z&8%8DEA!$^+Z!MVMZ%$*4/4Q:@8-1 M6UNOA832]/YS1Q(LV'?06()5?YXWFF =P$,&$ZP8],RQA L!'C"64&F@@\>R MOS1AJQ'M*UETZ+@.'D?PK3;=?EW-^7SF$/F,)=/",8+U8WAY&^7G!!BBMI(, MSDPG,*WFY5H\K1AF30U N70;ZB:J>Z=631UWH__895#*;OG$PX,PV7?9-CL0 MD[56FS7M0S5DS,S\N"@ ;S[G)%YK V2ZE.XOY9GF=-&J[2H8XT:U*<.!*0H[ M$0-TT(U;ETJ93+I1)6[H8,?DY>PNG^^69E+GD+_ORC,8 C%KM>2E0BONMBFR MOC[BX.PTDE[B*$F/>],X:EFJISZ2I&6C9 1C?UYQ2(14L(>/ZV^66O;VM@=R MH<5H?\V6>&QXU)>A\A#O;'6'EW<0*.H47 :U9YSA@N3ZVIMERT[$[$RFN"1. MP*_17S]DUWFE\-)9.&XS&.*V*XYO_[\E)A;$0T[80.0_T+T"P#P0E)J8DIE3 MZ0*Z?AXT\ QL^(+.

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end XML 23 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
3. Fair Value Measurements Amortized Cost and Fair Value of Debt Securities (Details)
$ in Millions
Dec. 31, 2019
USD ($)
Fair Value Disclosures [Abstract]  
Mature in less than one year $ 174.5
Mature in one to five years 164.2
Mature in more than five years 62.2
Total Amortized Cost 400.9
Mature in less than one year 174.6
Mature in one to five years 165.2
Mature in more than five years 63.1
Estimated Fair Value $ 402.9

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